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Abstract 
 
After 100 years of exploring microbial metabolites, there is genetic evidence of a potential silent 
secondary metabolism that may yield different classes of bioactive secondary metabolites. 
Secondary metabolite production is often limited by factors that have a great impact on the 
metabolic turnover such as culture conditions, including temperature, pH, media and salinity as well 
as strain improvement, optimization of media composition, variation in the culture conditions and 
exposure to chemical signalling such as in the case of microbial co-culture. As well as low 
molecular weight signalling molecules can play an important role in the regulation of secondary 
metabolite production, and in accessing silent genetic potential. We believe that silent genes may 
remain dormant and do not produce any metabolites until they become activated. They can be 
activated by chemical stimuli produced by other competing microbes. Such molecular tools could 
be used to unlock the silent secondary metabolism and more leading to next generation antibiotics. 
In recent years, microtiter plates have been presented as an alternative technique traditional shake 
flasks for optimizing cultivation of different microorganisms. For example, Duetz et al. developed a 
cultivation system employing 24 or 96-well square-shape microtiter plates (MTP).  
 
The aims of my research were to focuses on the isolation and structure elucidation of microbial 
natural products derived from marine or terrestrial microbes. At the same time, it focuses on finding 
new autoregulators that act as triggers to improve cellular development and activate the production 
of new secondary metabolites. 
 
Chapter 1 – Introduction: Activation of microbial secondary metabolites 
This chapter will outline an overview on the activation of secondary metabolites and the historical 
impact of microbial biodiscovery and the challenges for the discovery of new metabolites.  
 
Chapter 2 - Developing a micro-bioreactor technique for cultivation of microbes 
This chapter will explain and illustrates the new strategy for cultivating microbes in the micro-
bioreactor through developing a high-throughput (HTP) microbial biodiscovery methodology based 
on this system, testing and validating a number of critical hypotheses –efficacy, reproducibility, 
HTP practicality and HTP versatility. 
  
Chapter 3 - Activation of microbial secondary metabolites 
This chapter seeks to address the questions of how to activate silent secondary metabolites by 
looking for nature chemical cues that stimulate metabolism. This study explored two different 
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sources of chemical cues; (1) microbial crude extracts, (2) lipopolysaccharide (LPS) from the 
Gram-negative bacteria (Escherichia coli).  
 
Chapter 4 - Beach warefare: An Aspergillus stimulates antifungal defences in a Streptomyces 
sp.  
The chapter outlines the effect of nitric oxide synthase (NOS) on secondary metabolites production, 
heronapyrrole production in Streptomyces sp. as well as it illustrates for the first instance a co-
evolution between a Streptomyces sp. and an Aspergillus sp. and the discovery and quantification of 
the potency of two new classes of small molecule bNOS activators.  
 
Chapter 5 – Rare marine-derived fungal alkaloids reveal diketomorpholines as inhibitors of 
P-glycoprotein mediated multi-drug resistance in cancers, and a promising new scaffold for 
medicinal chemistry 
The chapter illustrates the isolation of new diketomorpholine shornephine A, its methanolysis 
artifact seco-shornephine A, and two known and one new diketopiperazine, 15b-β-hydroxyl-5-N-
acetyladreemin, 5-N-acetyladreemin and 15b-β-methoxy-5-N-acetyladreemin respectively in which 
two of these metabolites were inhibitors of P-glycoprotein, a critical determinant in many multidrug 
resistant cancers, responsible for efflux of many clinically important chemotherapeutics. The 
positive results towards P-gp inhibition promoted the synthesis of different diketomorpholines 
analogues to probe the structure activity relationship. 
 
Chapter 6 – Desotamides: New cyclic hexapeptides with anti-tuberculosis activity 
This chapter illustrates the structural elucidation of known desotamide and six new analogues in 
which all of the desotamides showed antibacterial activity against Gram positive bacteria while only 
two metabolites showed good activity against Mycobacterium tuberculosis.  
 
Chapter 7 – Aranciamycins: New Anthraquinones antibiotics 
This chapter illustrates the isolation and structural elucidation of two new and two known 
aranciamycins metabolites from Streptomyces sp. in which they possesses antibacterial activity 
against Gram positive bacteria. 
 
Chapter 8 – Citrinaline X: Importance of physicochemical characterization 
This chapter illustrates the isolation and structural elucidation of new citrinaline B and known 
citrinin metabolites in which citrinaline B possess moderate metallo-β-lactamase activity supported 
by molecular modelling studies. 
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Chapter 9 – Additional microbial chemical diversity 
The chapter briefly illustrates the structural elucidation of the known metabolites that have been 
isolated during PhD study. 
 
Chapter 10 – Microbial community isolation and analysis 
The chapter explains the collection of different terrestrial samples from different regions in 
Australia and outlines the methods used for the isolation of microbes and the preservation 
techniques. It also outlines the chemical and biological analysis of microbial crude extracts. 
 
Chapter 11 – Publications 
This chapter shows the screening process in the biodiscovery paradigm for the discovery of new 
antibiotics against Gram negative/positive bacteria and fungi. 
 
 
 v 
Declaration by author 
 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my research higher degree 
candidature and does not include a substantial part of work that has been submitted to qualify for 
the award of any other degree or diploma in any university or other tertiary institution. I have 
clearly stated which parts of my thesis, if any, have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the General Award Rules of The University of Queensland, immediately made available 
for research and study in accordance with the Copyright Act 1968. 
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
 
 vi 
Publications during candidature 
 
Peer-reviewed papers 
Salim, A. A.; Khalil, Z.; Capon, R. J. Structural and stereochemical investigations into 
bromotyrosine-derived metabolites from southern Australian marine sponges, Pseudoceratina spp. 
Tetrahedron 2012, 68, 9802-9807. 
 
Zhang, H.; Khalil, Z.; Conte, M. M.; Plisson, F; Capon, R. J. A search for kinase inhibitors and 
antibacterial agents: bromopyrrolo-2-aminoimidazoles from a deep-water Great Australian Bight 
sponge, Axinella sp. Tetrahedron Letters 2012, 53, 3784-3787. 
 
Plisson, F.; Huang, XC.; Zhang, H.; Khalil, Z.; Capon, R. J. Lamellarins as Inhibitors of P-
Glycoprotein-Mediated Multidrug Resistance in a Human Colon Cancer Cell Line. Chemistry-An 
Asian Journal 2012, 7, 1616-1623. 
 
Plisson, F.; Conte, M.; Khalil, Z.; Huang, XC.; Piggott, A. M.; Capon, R. J. Kinase Inhibitor 
Scaffolds against Neurodegenerative Diseases from a Southern Australian Ascidian, Didemnum sp. 
ChemMedChem 2012, 7, 983-990. 
 
Raju, R.; Piggott, A. M.; Khalil, Z.; Bernhardt, P. V.; Capon, R. J. Heronamycin A: a new 
benzothiazine ansamycin from an Australian marine-derived Streptomyces sp. Tetrahedron Letters 
2012, 53, 1063-1065. 
 
Zhang, H.; Xiao, X.; Conte, M.; Khalil, Z.; Capon, R. J. Spiralisones A-D: acylphloroglucinol 
hemiketals from an Australian marine brown alga, Zonaria spiralis. Organic & Biomolecular 
Chemistry 2012, 10, 9671-9676. 
 
Zhang, H.; Conte, M.; Khalil, Z.; Huang, XC.; Capon, R. J. New dictyodendrins as BACE 
inhibitors from a southern Australian marine sponge, Ianthella sp. RSC Advances, 2012, 2, 4209-
4214. 
 
Zhang, H.; Conte, M.; Huang, XC.; Khalil, Z ; Capon, R. J. A search for BACE inhibitors reveals 
new biosynthetically related pyrrolidones, furanones and pyrroles from a southern Australian 
marine sponge, Ianthella sp. Organic & Biomolecular Chemistry 2012, 10, 2656-2663. 
 
 vii 
Ajala, O. S.; Piggott, A. M.; Plisson, F.; Khalil, Z.; Huang, XC.; Adesegun, S. A.; Coker, H. A. B.; 
Capon, R. J. Ikirydinium A: a new indole alkaloid from the seeds of Hunteria umbellata (K. 
Schum). Tetrahedron Letters 2011, 52, 7125-7127.  
 
Zhang, H.; Khalil, Z.; Capon, R. J. Fascioquinols A-F: bioactive meroterpenes from a deep-water 
southern Australian marine sponge, Fasciospongia sp. Tetrahedron 2011, 67, 2591-2595. 
 
Fremlin, L.; Farrugia, M.; Piggott, A. M.; Khalil, Z.; Lacey, E.; Capon, R. J. Reveromycins 
Revealed: New polyketide spiroketals from Australian marine-derived and terrestrial Streptomyces 
spp. A case of natural products vs. artifacts. Organic & Biomolecular Chemistry 2011, 9, 1201-
1211. 
 
Raju, R.; Piggott, A. M.; Diaz, L. X. B. ; Khalil, Z.; Capon, R. J. Heronapyrroles A-C: Farnesylated 
2-Nitropyrroles from an Australian Marine-Derived Streptomyces sp. Organic Letters 2010, 12, 
5158-5161. 
 
Peng, C.; Gunaherath, G. M. K. B.; Piggott, A. M.; Khalil, Z.; Conte, M.; Capon, R. J. 9-(5'-
Deoxy-5'-thio-beta-D-xylofuranosyl)adenine Disulfide from the Southern Australian Marine 
Sponge Trachycladus laevispirulifer: the First Natural Occurrence of a Nucleoside Disulfide. 
Australian Journal of Chemistry 2010, 63, 873-876. 
 
Salim, A. A.; Rae, J.; Fontaine, F.; Conte, M.; Khalil, Z.; Martin, S.; Parton, R. G.; Capon, R. J. 
Heterofibrins: inhibitors of lipid droplet formation from a deep-water southern Australian marine 
sponge, Spongia (Heterofibria) sp. Organic & Biomolecular Chemistry 2010, 8, 3188-3194. 
 
Conferences Abstracts 
Poster Presentation “Shornephine A: A Novel diketomorpholine from a marine derived fungus 
inhibits P-glycoprotein” at the 2nd Division of Chemistry and Structural Biology Symposium – 
Brisbane, Australia (November 2012). 
  
Oral and Poster Presentation “ Exploring the chemical diversity of Microbes” at the 2nd Division of 
Chemistry and Structural Biology Symposium – Brisbane, Australia (November 2011). 
 
 viii 
Poster Presentation, “Exploring the chemical diversity of terrestrial and marine microbes” at 27th 
international symposium of discovery of natural products (ISCNP27/ICOB7) at Southbank, 
Brisbane, Queensland, Australia (July 2011). 
 
Poster Presentation, “The development of new metallo-beta-lactamase inhibitor leads from natural 
and synthetic compounds”  at 27th international symposium of discovery of natural products 
(ISCNP27/ICOB7) at Southbank, Brisbane, Queensland, Australia (July 2011). 
 
Oral Presentation, “Strategies for reinvigorating new microbial drug discovery” at Brisbane 
Biological & Organic Chemistry Symposium (BBOCS) – Brisbane, Australia (November 2011). 
 
Poster presentation, “Microbial biodiscovery” at 11th International Symposium on the Genetics of 
Industrial Microorganisms (GIM2010) at Melbourne, Australia (July 2010). 
 
  
Publications included in this thesis 
 
Salim, A. A.; Khalil, Z.; Capon, R. J. Structural and stereochemical investigations into 
bromotyrosine-derived metabolites from southern Australian marine sponges, Pseudoceratina spp. 
Tetrahedron 2012, 68, 9802-9807. Incorporated in Chapter 11 
Contributor Statement of contribution 
Salim, A. A.  Designed experiments (80%) 
Data analysis (80%) 
Wrote the paper (40%) 
Khalil, Z. Designed experiments (20%) 
Data analysis (20%) 
Wrote and edited paper (10%) 
Capon, R.  J. Wrote and edited paper (50%) 
 ix 
Zhang, H.; Khalil, Z.; Conte, M. M.; Plisson, F; Capon, R. J. A search for kinase inhibitors and 
antibacterial agents: bromopyrrolo-2-aminoimidazoles from a deep-water Great Australian Bight 
sponge, Axinella sp. Tetrahedron Letters 2012, 53, 3784-3787. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Zhang, Hua Designed experiments (60%) 
Data analysis (80%) 
Wrote the paper (30%) 
Khalil, Z. Designed experiments (20%) 
Data analysis (10%) 
Wrote and edited paper (10%) 
Conte, Melissa Designed experiments (10%) 
Data analysis (5%) 
Wrote and edited paper (5%) 
Plisson, Fabien Designed experiments (10%) 
Data analysis (5%) 
Wrote and edited paper (5%) 
Capon, Robert J. Wrote and edited paper (50%) 
 
Plisson, F.; Huang, XC.; Zhang, H.; Khalil, Z.; Capon, R. J. Lamellarins as Inhibitors of P-
Glycoprotein-Mediated Multidrug Resistance in a Human Colon Cancer Cell Line. Chemistry-An 
Asian Journal 2012, 7, 1616-1623. Incorporated in Chapter 11 
Contributor Statement of contribution 
Plisson, F. Designed experiments (50%) 
Data analysis (60%) 
Wrote the paper (30%) 
Hunag, X.  Designed experiments (30%) 
Data analysis (30%) 
Wrote and edited paper (10%) 
Zhang, H. Designed experiments (10%) 
Khalil, Z. Designed experiments (10%) 
Data analysis (10%) 
Wrote and edited paper (10%) 
Capon, R.  J. Wrote and edited paper (50%) 
 x 
Plisson, F.; Conte, M.; Khalil, Z.; Huang, XC.; Piggott, A. M.; Capon, R. J. Kinase Inhibitor 
Scaffolds against Neurodegenerative Diseases from a Southern Australian Ascidian, Didemnum sp. 
ChemMedChem 2012, 7, 983-990. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Plisson, F. Designed experiments (50%) 
Data analysis (60%) 
Wrote the paper (60%) 
Conte, M. Designed experiments (10%) 
Khalil, Z. Designed experiments (10%) 
Data analysis (15%) 
Wrote and edited paper (15%) 
Huang, X. Designed experiments (30%) 
Piggott, A. M. Wrote and edited paper (10%) 
Capon, R.  J. Wrote and edited paper (30%) 
 
Raju, R.; Piggott, A. M.; Khalil, Z.; Bernhardt, P. V.; Capon, R. J. Heronamycin A: a new 
benzothiazine ansamycin from an Australian marine-derived Streptomyces sp. Tetrahedron Letters 
2012, 53, 1063-1065. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Raju, R. Designed experiments (60%) 
Data analysis (60%) 
Piggott, A. Wrote and edited paper (40%) 
Khalil, Z. Designed experiments (20%) 
Data analysis (20%) 
Wrote and edited paper (10%) 
Bernhardt, P. V. Designed experiments (20%) 
Data analysis (20%) 
Capon, R.  J. Wrote and edited paper (50%) 
 xi 
Zhang, H.; Xiao, X.; Conte, M.; Khalil, Z.; Capon, R. J. Spiralisones A-D: acylphloroglucinol 
hemiketals from an Australian marine brown alga, Zonaria spiralis. Organic & Biomolecular 
Chemistry 2012, 10, 9671-9676. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Zhang, H. Designed experiments (60%) 
Data analysis (60%) 
Wrote the paper (40%) 
Xiao, X. Designed experiments (25%) 
Data analysis (30%) 
Wrote the paper (10%) 
Conte, M. Designed experiments (10%) 
Khalil, Z. Designed experiments (5%) 
Data analysis (10%) 
Wrote and edited paper (5%) 
Capon, R.  J. Wrote and edited paper (50%) 
 
Zhang, H.; Conte, M.; Khalil, Z.; Huang, XC.; Capon, R. J. New dictyodendrins as BACE 
inhibitors from a southern Australian marine sponge, Ianthella sp. RSC Advances, 2012, 2, 4209-
4214. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Zhang, H. Designed experiments (60%) 
Data analysis (40%) 
Wrote the paper (60%) 
Conte, M. Designed experiments (20%) 
Data analysis (20%) 
Khalil, Z. Designed experiments (10%) 
Data analysis (20%) 
Wrote and edited paper (5%) 
Huang, XC. Designed experiments (10%) 
Data analysis (20%) 
Wrote and edited paper (5%) 
Capon, R.  J. Wrote and edited paper (40%) 
 xii 
Zhang, H.; Conte, M.; Huang, XC.; Khalil, Z ; Capon, R. J. A search for BACE inhibitors reveals 
new biosynthetically related pyrrolidones, furanones and pyrroles from a southern Australian 
marine sponge, Ianthella sp. Organic & Biomolecular Chemistry 2012, 10, 2656-2663. 
Incorporated in Chapter 11. 
Contributor Statement of contribution 
Zhang, H. Designed experiments (60%) 
Data analysis (40%) 
Wrote the paper (60%) 
Conte, M. Designed experiments (20%) 
Data analysis (20%) 
Huang, XC. Designed experiments (10%) 
Data analysis (20%) 
Wrote and edited paper (5%) 
Khalil, Z.  Designed experiments (10%) 
Data analysis (20%) 
Wrote and edited paper (5%) 
Capon, R.  J. Wrote and edited paper (40%) 
 
Fremlin, L.; Farrugia, M.; Piggott, A. M.; Khalil, Z.; Lacey, E.; Capon, R. J. Reveromycins 
Revealed: New polyketide spiroketals from Australian marine-derived and terrestrial Streptomyces 
spp. A case of natural products vs. artifacts. Organic & Biomolecular Chemistry 2011, 9, 1201-
1211. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Fremlin, L. Desigened experiments (60%) 
Farrugia, M. Designed experiments (20%) 
Piggott, A. M. Wrote and edited paper (40%) 
Khalil, Z.  Designed experiments (10%) 
Data analysis (10%) 
Wrote and edited paper (10%) 
Lacey, E. Designed experiments (10%) 
Capon, R.  J. Wrote and edited paper (50%) 
 xiii 
Ajala, O. S.; Piggott, A. M.; Plisson, F.; Khalil, Z.; Huang, XC.; Adesegun, S. A.; Coker, H. A. B.; 
Capon, R. J. Ikirydinium A: a new indole alkaloid from the seeds of Hunteria umbellata (K. 
Schum). Tetrahedron Letters 2011, 52, 7125-7127. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Ajala, O. S. Designed experiments (60%) 
Data analysis (40%) 
Piggott, A. M. Data analysis (20%) 
Wrote and edited paper (20%) 
Plisson, F. Designed experiments (20%) 
Data analysis (20%) 
Wrote and edited paper (10%) 
Khalil, Z.  Designed experiments (10%) 
Data analysis (10%) 
Wrote and edited paper (10%) 
Huang, XC. Designed experiments (10%) 
Data analysis (10%) 
Wrote and edited paper (10%) 
Capon, R.  J. Wrote and edited paper (50%) 
 
Zhang, H.; Khalil, Z.; Capon, R. J. Fascioquinols A-F: bioactive meroterpenes from a deep-water 
southern Australian marine sponge, Fasciospongia sp. Tetrahedron 2011, 67, 2591-2595. 
Incorporated in Chapter 11. 
Contributor Statement of contribution 
Zhang, H. Designed experiments (80%) 
Data analysis (75%) 
Wrote the paper (40%) 
Khalil, Z.  Designed experiments (20%) 
Data analysis (15%) 
Wrote and edited paper (10%) 
Capon, Robert J. Wrote and edited paper (50%) 
 xiv 
Raju, R.; Piggott, A. M.; Diaz, L. X. B. ; Khalil, Z.; Capon, R. J. Heronapyrroles A-C: Farnesylated 
2-Nitropyrroles from an Australian Marine-Derived Streptomyces sp. Organic Letters 2010, 12, 
5158-5161. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Raju, R. Designed experiments (60%) 
Data analysis (60%) 
Piggott, A. M. Wrote and edited paper (40%) 
Data analysis (30%) 
Diaz, L. X. B. Designed experiments (10%) 
Khalil, Z.  Designed experiments (30%) 
Data analysis (10%) 
Wrote and edited paper (10%) 
Capon, R.  J. Wrote and edited paper (50%) 
 
Peng, C.; Gunaherath, G. M. K. B.; Piggott, A. M.; Khalil, Z.; Conte, M.; Capon, R. J. 9-(5'-
Deoxy-5'-thio-beta-D-xylofuranosyl)adenine Disulfide from the Southern Australian Marine 
Sponge Trachycladus laevispirulifer: the First Natural Occurrence of a Nucleoside Disulfide. 
Australian Journal of Chemistry 2010, 63, 873-876. Incorporated in Chapter 11. 
Contributor Statement of contribution 
Peng, C. Designed experiments (70%) 
Data analysis (50%) 
Gunaherath, G. Wrote and edited paper (10%) 
Data analysis (10%) 
Piggott, A. M. Wrote and edited paper (40%) 
Data analysis (30%) 
Khalil, Z.  Designed experiments (20%) 
Data analysis (10%) 
Wrote and edited paper (10%) 
Conte, M. Designed experiments (10%) 
Capon, R.  J. Wrote and edited paper (40%) 
 xv 
Salim, A. A.; Rae, J.; Fontaine, F.; Conte, M.; Khalil, Z.; Martin, S.; Parton, R. G.; Capon, R. J. 
Heterofibrins: inhibitors of lipid droplet formation from a deep-water southern Australian marine 
sponge, Spongia (Heterofibria) sp. Organic & Biomolecular Chemistry 2010, 8, 3188-3194. 
Incorporated in Chapter 11. 
Contributor Statement of contribution 
Salim, A. A. Designed experiments (50%) 
Data analysis (60%) 
Wrote the paper (50%) 
Rae, J. Designed experiments (10%) 
Fontaine, F. Designed experiments (20%) 
Data analysis (20%) 
Conte, M. Designed experiments (10%) 
Data analysis (10%) 
Khalil, Z. Designed experiments (10%) 
Data analysis (10%) 
Wrote and edited paper (5%) 
Martin, S. Designed experiments (20%) 
Parton, R. G. Designed experiments (10%) 
Capon, R.  J. Wrote and edited paper (45%) 
 
 
Contributions by others to the thesis  
 
The multidrug resistance assays in Chapter 5 (cytotoxicity MTT assays, MDR reversal assay and 
flow cytometry) were optimised and performed in-house with support of Dr Xiao-Cong Huang (as 
part of his PhD studies). Dr Andrew Piggott acquired high-resolution mass spectral (HRESIMS) 
data and contributed to this thesis for critical analysis. Dr Angela Salim for her help in the structure 
elucidation of citrinaline X. Dr Antje Blumenthal, Diamantina Institute, The Univeristy of 
Queensland for screening the desotamides against Mycobacterium bovis. Dr Waleed Hussein 
brought technical advice for use of Molegero software, synthetic procedures. Dr Katheryn Green for 
technical help and acquiring the electron microscope images. John Griffin for his help and acquiring 
the Confocol and BD microscope images. Prof. Robert Capon contributed to this thesis for critical 
analysis and help on practical work and drafting. 
 
 
 
xvi 
Statement of parts of the thesis submitted to qualify for the award of another degree 
 
None. 
 
Acknowledgements 
 
I wish to express my deepest appreciation to my research supervisor, Professor Robert J. Capon for 
the many years of endless enthusiasm, brilliant guidance and continuous encouragement and 
support I am forever grateful for him providing me with an opportunity to learn and work under his 
perfect guidance leading to the successful completion of this thesis. 
 
My appreciation goes out to all the members of Capon research group, especially Dr. Andrew M. 
Piggott for acquiring and teaching high resolution mass spectra, his assistance with the NMR and in 
sorting out the technical problems faced with the equipment and Dr Angela Salim for teaching the 
semi-preparative HPLC and for answering all my questions in the beginning of my PhD and 
teaching me how to perform structure elucidation. Dr Ernest Lacey (MST) for providing continuous 
help and support. Thanks also to the following people, Dr. Xiao-cong Huang for in vitro screening 
of the compounds isolated, Melissa Conte for teaching me the cytotoxicity assay and Dr Ian Lane 
(floor manger) for his help and support. 
 
A special thanks to Dr. Amanda Carozzi for handling all the paperwork and enquiries relating to 
postgraduate studies and for providing continuous support. I also acknowledge University of 
Queensland for the provision of a University of Queensland Research Scholarship (UQRS) 
scholarship and UQ International Research Tuition Awards (UQIRTA). A special thanks for 
Institute of Molecular Bioscience for the provision of writing scholarship award with additional 
financial support provided by Prof. Robert J. Capon  
 
Finally, a very special thanks to my dear husband, Dr Waleed Hussein, for his incalculable and 
unwavering support during my whole study and my two lovely boys, Yassin and Youssef for 
bearing me during my tough times. My parents, Dr GalalElDeen Khalil and Mrs Aziza Mowafi for 
their words of encouragement and love. My little brother, Salah who always cheers me up with his 
jokes. My lovely grandma Salwa whose prayers for me and her words were quite important. My 
sister in law, Hager and my little nephew Moazz, their smiles made a big difference in my life. 
 
 
 
xvii 
Keywords 
microbial natural products, nitric oxide synthase, P-glyoprotein, lipopolysaccharide, 
microbioreactor. 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 030502, Natural Products Chemistry, 50% 
ANZSRC code: 060503, Microbial Ecology, 15% 
ANZSRC code: 030401, Biologically Active Molecules, 35% 
 
Fields of Research (FoR) Classification 
FoR code: 0304, Medicinal and Biomolecular Chemistry, 50% 
FoR code: 0605, Microbiology, 50% 
  
  
 
xviii 
Table of contents 
Abstract                            ii 
Declaration by the author                            v 
Publications and Presentations                vi 
Acknowledgments                         xvi 
Table of Contents                     xvii  
Figures and Tables                      xxiv 
List of Figures                       xxiv 
List of Tables                   xxxvi 
List of Schemes                 xxxix 
Abbreviations                   xl 
1 Chapter 1. Introduction to Microbial Biodiscovery ................................................................. 1 
1.1 Historical impact of microbial natural products ............................................................................ 1 
1.2 Therapeutic fields responsive to natural products ......................................................................... 2 
1.2.1 Bacterial pathogens ....................................................................................................................... 2 
1.2.2 Fungal pathogens .......................................................................................................................... 3 
1.2.3 Viral pathogens ............................................................................................................................. 4 
1.3 Resistance to microbial natural products ........................................................................................ 4 
1.3.1 Antibiotics and the resistance in nature ........................................................................................ 4 
1.3.2 Anticancer resistance .................................................................................................................... 5 
1.4 Silent resources ................................................................................................................................... 5 
1.4.1 Detection of silent secondary gene cluster .................................................................................... 5 
1.5 Activating of silent genes ................................................................................................................... 7 
1.5.1 Effect of culturing conditions on secondary metabolite production ............................................. 7 
1.5.2 Novel metabolites in co-cultures .................................................................................................. 8 
1.5.3 Autoregulators ............................................................................................................................... 9 
1.6 Genomics-inspired screening for novel natural products ............................................................ 12 
1.7 Focus of this thesis ........................................................................................................................... 13 
2 Chapter 2. Developing a Micro-bioreactor technique for Microbial cultivation ................ 16 
2.1 Introduction ...................................................................................................................................... 16 
2.1.1 Progression from shake flasks to micro-bioreactors ................................................................... 16 
2.1.2 Different types of micro-bioreactors ........................................................................................... 17 
2.1.3 Applikon system ......................................................................................................................... 17 
2.1.4 Chapter outlines .......................................................................................................................... 18 
2.2 Results and discussion ..................................................................................................................... 19 
2.2.1 Efficacy ....................................................................................................................................... 19 
  
 
xix 
2.2.2 Reproducibility ........................................................................................................................... 23 
2.2.3 Practicality .................................................................................................................................. 25 
2.2.4 Versatility .................................................................................................................................... 26 
2.3 Conclusion ........................................................................................................................................ 29 
2.4 Experimental section ....................................................................................................................... 31 
2.4.1 Cultivation of strains for chemical profiling ............................................................................... 31 
2.4.2 Growth phase studies .................................................................................................................. 31 
3 Chapter 3. Activation of Microbial Secondary Metabolites .................................................. 34 
3.1 General outlines ............................................................................................................................... 34 
3.1.1 Microbial crude extracts ............................................................................................................. 34 
3.1.2 Lipoplysaccharide ....................................................................................................................... 34 
3.2 Results and discussion ..................................................................................................................... 38 
3.2.1 Assembly of an integrated set of microbial diversity libraries ................................................... 38 
3.2.2 Activation of silent microbial secondary metabolites ................................................................. 38 
3.2.3 Activation of silent metabolites using microbial crude extracts ................................................. 39 
3.2.4 Activation of silent metabolites using LPS ................................................................................. 41 
3.2.5 Streptomyces pseudoechinosporeus (ACM-2573) ...................................................................... 45 
3.2.6 CMB-TF411 ................................................................................................................................ 52 
3.2.7 CMB-M81F ................................................................................................................................. 58 
3.2.8 Streptomyces afghaniensis (ACM-4008) .................................................................................... 62 
3.3 Conclusion ........................................................................................................................................ 71 
3.4 Experimental section ....................................................................................................................... 73 
4 Chapter 4: Beach warfare: Aspergillus stimulates antifungal defenses in a Streptomyces . 75 
4.1 Heronapyrroles ................................................................................................................................ 75 
4.2 Future of heronapyrroles ................................................................................................................ 77 
4.3 Nitric oxide synthase (NOS) ............................................................................................................ 78 
4.3.1 Mammlian NOS .......................................................................................................................... 79 
4.3.2 Bacterial NOS (bNOS) ............................................................................................................... 80 
4.3.3 Structural differences between nitric oxide synthases ................................................................ 81 
4.3.4 Nitric oxide synthase inhibitors .................................................................................................. 82 
4.3.5 Bacterial nitric oxide synthase and their importance .................................................................. 83 
4.4 Results and discussion ..................................................................................................................... 86 
4.4.1 Cultivation of Streptomyces sp. (CMB-M0423) in the micro-bioreactor ................................... 86 
4.4.2 Cultivation of Streptomyces sp. (CMB-M0423) ......................................................................... 86 
4.4.3 Quantification of heronapyrrole B production ............................................................................ 87 
4.4.4 Cultivation of Streptomyces sp. (CMB-M0423) in the presence of NOS inhibitors .................. 88 
4.4.5 Pseurotin A2 (4.30) ...................................................................................................................... 90 
  
 
xx 
4.4.6 Gliotoxin (4.31) ........................................................................................................................... 93 
4.4.7 Bisdethiobis(methylthio)gliotoxin (4.32) ................................................................................... 96 
4.4.8 Fumitremorgin C (4.33) .............................................................................................................. 99 
4.4.9 cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) ............................................................................ 102 
4.4.10 cyclo-(L-Phe-L-Pro) (4.35) ..................................................................................................... 107 
4.4.11 Summary for impact of NOS inhibitors .................................................................................. 110 
4.4.12 Detection of an Aspergillus in the Streptomyces (CMB-M0423) ........................................... 110 
4.4.13 Cultivation of Aspergillus sp. (CMB-M0423) ........................................................................ 112 
4.4.14 Cultivation of the pure Streptomyces sp. (CMB-M0423) ....................................................... 112 
4.4.15 Co-cultivation of Streptomyces sp. and Aspergillus sp. (CMB-M0423) ................................ 113 
4.4.16 Effect of Aspergillus chemistry on Streptomyces sp. (CMB-M0423) .................................... 114 
4.4.17 Detecting the presence of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) in the crude extract of 
Aspergillus/ Streptomyces. sp (CMB-M0423) ....................................................................................... 117 
4.4.18 Quantify cyclo-(L-Phe-trans-4-hydroxy-L-proline) (4.34) ..................................................... 118 
4.4.19 Effect of Streptomyces chemistry on Aspergillus sp. (CMB-M0423) .................................... 118 
4.4.20 The effect of heronapyrrole B on Aspergillus sp. (CMB-M0423) ......................................... 120 
4.4.21 Synthesis of diketopiperazine analogue library ...................................................................... 121 
4.4.22 Synthesis of methyl esters (4.38a – e) and diketopiperazines (4.39a – l) .............................. 121 
4.4.23 Synthesis of cyclo-(Phe-4-hydroxy-Pro) stereoisomers ......................................................... 123 
4.4.24 cyclo-(Phe-Phe) (4.39e) .......................................................................................................... 139 
4.4.25 Synthesis of cyclo-(Tyr-4-hydroxy-Pro) stereoisomers .......................................................... 142 
4.4.26 Synthesis of cyclo-(L-Tyr-Pro) stereoisomers ........................................................................ 159 
4.4.27 Summary for the different synthetic diketopiperazines analogues ......................................... 172 
4.4.28 Effect of DKPs on Streptomyces sp. (CMB-M0423) secondary metabolism ........................ 172 
4.4.29 Effect of 4.34 on the activation of bNOS in Streptomyces sp. (CMB-M0423) ...................... 173 
4.4.30 The relationship between NO and heronapyrrole B production ............................................. 175 
4.4.31 Precursor directed biosynthesis .............................................................................................. 179 
4.4.32 Synthesis of 2 and 3- nitropyrrole .......................................................................................... 179 
4.4.33 Assembly of an analogue library for precursor directed biosynthesis .................................... 181 
4.4.34 Addition of 2-nitropyrrole to Streptomyces sp. (CMB-M0423) ............................................. 182 
4.4.35 Addition of 3-nitropyrrole to Streptomyces sp. (CMB-M0423) ............................................. 182 
4.4.36 Addition of other nitroaromatics to pure Streptomyces sp. (CMB-M0423) culture ............... 183 
4.4.37 Endogenous nitroaromatic activates bNOS ............................................................................ 185 
4.4.38 Quantify the amount of 2,4-DNP levels in the microbial culture ........................................... 186 
4.4.39 Study on the effect of 2,4-DNP on Streptomyces sp. (CMB-M0423) .................................... 187 
4.4.40 Heronapyrrole co-metabolites ................................................................................................ 190 
4.5 Conclusion ...................................................................................................................................... 197 
4.6 Future Directions ........................................................................................................................... 199 
  
 
xxi 
4.7 Experimental section ..................................................................................................................... 200 
5 Chapter 5: Rare marine-derived fungal alkaloids reveal diketomorpholines as inhibitors 
of P-glycoprotein-mediated multi-drug resistance in cancers, and a promising new scaffold for 
medicinal chemistry ....................................................................................................................... 212 
5.1 Introduction .................................................................................................................................... 212 
5.2 Results and discussion ................................................................................................................... 215 
5.2.1 Prior chemistry .......................................................................................................................... 215 
5.2.2 Analytical cultivation and chemical analysis ............................................................................ 215 
5.2.3 Preparative cultivation and isolation ......................................................................................... 216 
5.2.4 Structure Elucidation of fungal metabolites ............................................................................. 217 
5.2.5 Plausible biosynthetic pathway linking shornephine A and ardeemins .................................... 235 
5.2.6 Synthesis of diketomorpholines (DKMs) derviatives ............................................................... 236 
5.2.7 General method for the preparation of the morpholine compounds 5.5a – h ........................... 247 
5.2.8 Biological assays ....................................................................................................................... 256 
5.2.9 The stability of the diketomorpholines ..................................................................................... 263 
5.3 Conclusion ...................................................................................................................................... 265 
5.4 Future Directions ........................................................................................................................... 265 
5.5 Experimental section ..................................................................................................................... 266 
5.5.1 Isolation and identification of strain CMB-M081F .................................................................. 266 
5.5.2 Chemical profiling: ................................................................................................................... 266 
5.5.3 Analytical cultivation and chemical analysis ............................................................................ 266 
5.5.4 Large-scale cultivation and extraction of strain CMB-M81F ................................................... 267 
5.5.5 Cell Lines and Cell Culture ....................................................................................................... 267 
5.5.6 MDR Reversal (Vinblastine, doxorubicin and taxol) Assay .................................................... 268 
5.5.7 Flow Cytometry (Calcein AM assay) ....................................................................................... 268 
5.5.8 Mosher ester derivatives of shornephine A (5.17) .................................................................... 269 
6 Chapter 6: Desotamides: New cyclic hexapeptides with inhibitory activity against 
Mycobacterium bovis ...................................................................................................................... 273 
6.1 Introduction .................................................................................................................................... 273 
6.2 History ............................................................................................................................................. 273 
6.3 Desotamides from MST ................................................................................................................. 273 
6.4 Desotamides .................................................................................................................................... 273 
6.4.1 Desotamide (6.01) ..................................................................................................................... 276 
6.4.2 Desotamide B (6.02) ................................................................................................................. 285 
6.4.3 Desotamide C (6.03) ................................................................................................................. 289 
6.4.4 Desotamide D (6.04) ................................................................................................................. 298 
  
 
xxii 
6.4.5 Desotamide E (6.05) ................................................................................................................. 306 
6.4.6 Desoatmide F (6.06) .................................................................................................................. 314 
6.4.7 Amino acid residues correlations for deostamides (6.01 – 6.06) .............................................. 318 
6.4.8 Biological screening .................................................................................................................. 320 
6.4.9 Conclusion for the desotamides ................................................................................................ 323 
6.4.10 Future work for the desotamides ............................................................................................ 324 
6.5 Experimental section ..................................................................................................................... 325 
7 Chapter 7. Aranciamycins: New Anthraquinones antibiotics ............................................ 327 
7.1 Introduction .................................................................................................................................... 327 
7.2 Results and discussion ................................................................................................................... 327 
7.2.1 Analytical cultivation and chemical analysis ............................................................................ 327 
7.2.2 Preparative cultivation .............................................................................................................. 328 
7.2.3 Antimicrobial assay .................................................................................................................. 347 
7.3 Conclusion for the aranciamycins ................................................................................................ 348 
7.4 Experimental section ..................................................................................................................... 350 
8 Chapter 8. Citrinaline X and the importance of physicochemical characterization ........ 353 
8.1 Introduction .................................................................................................................................... 353 
8.2 Results and discussion ................................................................................................................... 356 
8.2.1 Isolation and taxonomy ............................................................................................................. 356 
8.2.2 Analytical cultivation and chemical analysis ............................................................................ 356 
8.2.3 Preparative cultivation and isolation ......................................................................................... 357 
8.2.4 Highlight- Plausible Biosynthesis of citrinaline X ................................................................... 367 
8.2.5 Citrinin (8.31) ........................................................................................................................... 368 
8.3 Diketopiperazines stimulates the production of microbial metabolites .................................... 370 
8.3.1 cyclo-(L-Trp-L-Phe) and the secondary metabolites production of CMB-TF438 .................... 371 
8.3.2 Biological assays ....................................................................................................................... 376 
8.4 Conclusion ...................................................................................................................................... 378 
8.5 Future work .................................................................................................................................... 378 
8.6 Experimental section ..................................................................................................................... 379 
9 Chapter 9. Additional Microbial Chemical Diversity .......................................................... 382 
9.1 Introduction .................................................................................................................................... 382 
9.2 Streptomyces sp. (CMB-M0137) .................................................................................................... 382 
9.2.1 Streptonigrin (9.01) ................................................................................................................... 383 
9.2.2 1-N-methylalbonourisin (9.02) and lansai D (9.03) .................................................................. 385 
9.3 Streptomyces sp. (CMB-TB376) .................................................................................................... 387 
9.3.1 Undecyl prodigiosin (9.04) ....................................................................................................... 387 
  
 
xxiii 
9.4 Streptomyces sp. (CMB0-TB385) .................................................................................................. 389 
9.4.1 6,8-dihydroxy-3-methylisocoumarin (9.05) .............................................................................. 389 
9.4.2 Trindoline (9.06) ....................................................................................................................... 390 
9.5 Streptomyces sp. (CMB-TB350) .................................................................................................... 392 
9.5.1 Actinomycin Z1 (9.07) .............................................................................................................. 392 
10 Chapter 10. Microbial Community isolation and analysis ................................................ 396 
10.1 Introduction ................................................................................................................................. 396 
10.2 Sampling ....................................................................................................................................... 396 
10.3 Transportation and storage conditions ...................................................................................... 396 
10.4 Isolation of microbes ................................................................................................................... 396 
10.4.1 Stamping ................................................................................................................................. 397 
10.4.2 Dilution and heat-shock .......................................................................................................... 397 
10.5 Primary cultivation and preservation of pure microbial isolates ........................................... 400 
10.6 Cultivation of isolates for chemical profiling ............................................................................ 401 
10.6.1 Actinomycetes ........................................................................................................................ 401 
10.6.2 Fungi ....................................................................................................................................... 401 
10.7 Biological assays ........................................................................................................................... 401 
10.8 Isolation of secondary metabolites ............................................................................................. 402 
10.8.1 Cultivation of actinomycetes on large scale-broth based media ............................................. 402 
10.8.2 Cultivation of actinomycetes on large scale-agar based media .............................................. 402 
11 Chapter 11. List of Publications during Candidature ....................................................... 404 
12 General Experimental Details .............................................................................................. 405 
12.1 Chiroptical measurements .......................................................................................................... 405 
12.2 High Performance Liquid Chromatography (HPLC) ............................................................. 405 
12.3 Ultraviolet-visble .......................................................................................................................... 405 
12.4 NMR .............................................................................................................................................. 405 
12.5 Electrospray ionization mass spectra ........................................................................................ 405 
12.6 High-resolution mass spectra ..................................................................................................... 406 
12.7 Antibacterial assay: ..................................................................................................................... 406 
12.8 Antifungal assay ........................................................................................................................... 406 
12.9 Cytotoxicity assay ........................................................................................................................ 407 
12.10   Chemicals ...................................................................................................................................... 407 
13 References .............................................................................................................................. 409 
14 Appendix ................................................................................................................................ 424 
  
 
xxiv 
List of Figures 
Figure 1.1. General figure for the PhD projects includes isolation of microbes ............................... 14 
Figure 2.1. Applikon bioreactor system ............................................................................................ 18 
Figure 2.2. Study showing a comparison between the microbioreactor and shake flask .................. 22 
Figure 2.3. Picture for the micro-bioreactor showing the growth of different microbes ................... 22 
Figure 2.4. HPLC-DAD chromatogram for the crude extract from strain CMB-TB365 .................. 23 
Figure 2.5. Time course of secondary metabolite production for strain CMB-TB365 ..................... 24 
Figure 2.6. HPLC-DAD chromatogram of the crude extract from strain CMB-TB385 over 
incubation period from 1 to 7 days in (a) micro-bioreactor and (b) shake flask ....................... 24 
Figure 2.7. Time course of secondary metabolite production for strain CMB-TB385 ..................... 24 
Figure 2.8. Micro-bioreactor showing the growth of different fungi and actinomyetes ................... 25 
Figure 2.9. HPLC-DAD chromatograms of the crude extracts from CMB-TB365 .......................... 27 
Figure 2.10. HPLC-DAD chromatograms of the crude extracts from CMB-TB385 ........................ 29 
Figure 3.1. A Gram-negative bacterium. Electron micrograph of Escherichia coli .......................... 35 
Figure 3.2. HPLC-DAD chromatogram of the activation of microbial secondary metabolites for 
strain CMB-TB365 in the presence and absence of crude extract from CMB-TE225 .............. 40 
Figure 3.3. HPLC-DAD chromatogram of the activation of microbial secondary metabolites for 
strain CMB-TB365 in the presence and absence of crude extract from CMB-TE464 .............. 40 
Figure 3.4. HPLC-DAD chromatogram of the crude extract from ACM-165F in the presence and 
absence of LPS .......................................................................................................................... 43 
Figure 3.5. HPLC-DAD chromatogram of the crude extract from ACM-194F in the presence and  
absence of LPS .......................................................................................................................... 43 
Figure 3.6. HPLC-DAD chromatogram of the crude extract from ACM-4993F in the presence and  
absence of LPS .......................................................................................................................... 43 
Figure 3.7. Antibacterial assay results showing the effect of the crude extract with LPS ................ 44 
Figure 3.8. Streptomyces pseudoechinosporeus (ACM-2573) .......................................................... 45 
Figure 3.9. HPLC-DAD chromatogram of the crude extract from ACM2573F in the presence and  
absence of LPS .......................................................................................................................... 45 
Figure 3.10. Key 2D NMR correlations of resistoflavin (3.01) ........................................................ 47 
Figure 3.11. 1H NMR (600 MHz, CDCl3) spectrum of resistoflavin (3.01) ..................................... 48 
Figure 3.12. Key 2D NMR correlations of resistomycin (3.02) ........................................................ 49 
Figure 3.13. NMR (MeOH-d4) spectrum of resistomycin (3.02) ...................................................... 50 
Figure 3.14. Picture of CMB-TF411 ................................................................................................. 52 
  
 
xxv 
Figure 3.15. HPLC-DAD  chromatogram of the crude extract from CMB-TF411 in the presence and  
absence of LPS .......................................................................................................................... 52 
Figure 3.16. Key 2D NMR correlations of rugulosin (3.03) ............................................................. 54 
Figure 3.17. NMR (DMSO-d6) spectrum of rugulosin (3.03) ........................................................... 55 
Figure 3.18. Key 2D NMR correlation of skyrin (3.04) .................................................................... 56 
Figure 3.19. NMR (MeOH-d4) spectrum of skyrin (3.04) ................................................................. 57 
Figure 3.20. Picture of fungus CMB-M81F ...................................................................................... 58 
Figure 3.21. HPLC-DAD chromatogram of the crude extract from CMB-M81F in the (a) presence 
and (b) absence of LPS .............................................................................................................. 59 
Figure 3.22. Key 2D NMR correlations of neoasterriquinone (3.05) ................................................ 60 
Figure 3.23. NMR (CDCl3) spectrum of neoasterriquinone (3.05) ................................................... 61 
Figure 3.24. Streptomyces afghaniensis (ACM-4008) ...................................................................... 62 
Figure 3.25. HPLC-DAD  chromatogram of the crude extract from ACM4008 in the (a) presence 
and (b) absence of LPS .............................................................................................................. 62 
Figure 3.26. Key 2D NMR correlations of julichrome Q3.5 (3.07) .................................................... 64 
Figure 3.27. NMR (CDCl3) spectrum of julichrome Q3.5 (3.07) ....................................................... 65 
Figure 3.28. Key 2D NMR correlations of ACM-4008-1-2-1 (3.06) ................................................ 68 
Figure 3.29. NMR (CDCl3) spectrum of ACM-4008-1-2-1 (3.06) ................................................... 68 
Figure 3.30. Comparison between ACM4008-1-2-1 (3.06) and julichrome Q3.5 (3.07) ................... 70 
Figure 3.31. NMR (CDCl3) spectrum of both julichrome Q3.5 (3.07) and (3.06) .............................. 71 
Figure 4.1. HPLC-DAD chromatogram of crude extract from Streptomyces sp. (CMB-M0423) .... 75 
Figure 4.2. Structures of the heronapyrroles ..................................................................................... 75 
Figure 4.3. Plausible biosynthesis of heronapyrroles ........................................................................ 77 
Figure 4.4. New possible biosynthesis of heronapyrrole C (4.03) .................................................... 78 
Figure 4.5. Two-step oxidation of L-arginine to L-citrulline and NO ............................................... 79 
Figure 4.6. Structures of the N-terminal heme oxygenase domains of  B. subtilis ........................... 81 
Figure 4.7. Domain structure of NO synthases from different sources ............................................. 82 
Figure 4.8. Structures of some bNOS inhibitors ............................................................................... 82 
Figure 4.9. Selective nNOS inhibitors ............................................................................................... 83 
Figure 4.10. Fenton’s reaction ........................................................................................................... 84 
Figure 4.11. Summary of physiological functions of nitric oxide (NO) ........................................... 85 
Figure 4.12. Production of heronapyrrole B (4.02) in the micro-bioreactor and shake flask ............ 86 
Figure 4.13. HPLC-DAD chromatogram heronapyrrole B standard and crude extract from 
Streptomyces sp. (CMB-M0423) ............................................................................................... 87 
  
 
xxvi 
Figure 4.14. Calibration curve of 4.02 of micro-bioreactor  and shake flask .................................... 87 
Figure 4.15. Streptomyces sp. (CMB-M0423) .................................................................................. 88 
Figure 4.16. HPLC-DAD chromatogram of the crude extract from Streptomyces sp. (CMB-M0423) 
in the presence of AG ................................................................................................................ 89 
Figure 4.17. HMBC (CDCl3) spectrum and 2D NMR correlations of pseurotin A (4.30) ................ 90 
Figure 4.18. NMR (CDCl3) and UV-vis  spectra of pseurotin A2 (4.30) .......................................... 91 
Figure 4.19. HMBC (CDCl3) spectrum and key 2D NMR correlations of gilotoxin (4.31) ............. 93 
Figure 4.20. NMR (CDCl3) and UV-vis spectra of gliotoxin (4.31) ................................................. 94 
Figure 4.21. HMBC (CDCl3) spectrum of bisdethiobis(methylthio)gliotoxin (4.32) ....................... 96 
Figure 4.22. NMR (CDCl3) and UV-vis  spectra of bisdethiobis(methylthio)gliotoxin (4.32) ......... 97 
Figure 4.23. HMBC (CDCl3) spectrum of fumitremorgin C (4.33) .................................................. 99 
Figure 4.24. NMR (CDCl3) and UV-vis  spectra of fumitremorgin C (4.33) ................................. 100 
Figure 4.25. HMBC (CDCl3) spectrum of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) ............... 102 
Figure 4.26. NMR (CDCl3) and UV-vis spectra of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) .. 103 
Figure 4.27. Reaction scheme between D/L amino acid with D/L-FDAA ....................................... 105 
Figure 4.28. C3 Marfey’s analysis of the selected amino acids derivatized with D-FDAA ............ 105 
Figure 4.29. HPLC-DAD C3 Marfey’s analysis of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) .. 106 
Figure 4.30. COSY (CDCl3) spectrum of cyclo-(L-Phe-L-Pro) (4.35) ............................................ 107 
Figure 4.31. NMR (CDCl3) and UV-vis spectra of cyclo-(L-Phe-L-Pro) (4.35) ............................. 108 
Figure 4.32. C3 Marfey’s analysis for the selected amino acids derivatized with D-FDAA ........... 109 
Figure 4.33. HPLC-DAD C3 Marfey’s analysis of cyclo-(L-Phe-L-Pro) (4.35) .............................. 110 
Figure 4.34. Pictures showing the isolation of Aspergillus sp. from Streptomyces sp. ................... 112 
Figure 4.35. Graph of production of Aspergillus sp. secondary metabolites production ................ 112 
Figure 4.36. Picture showing micro-bioreactor culture of Aspergillus/Streptomyces sp. ............... 113 
Figure 4.37. HPLC-DAD chromatogram (a) authentic heronapyrrole B, (b) crude extract from 
Streptomyces sp. (CMB-M0423). ............................................................................................ 113 
Figure 4.38. HPLC-DAD chromatogram of the crude extract in MeOH from mixing the Aspergillus 
sp. (CMB-M0423) and the Streptomyces sp. (CMB-M0423) ................................................. 114 
Figure 4.39. HPLC-DAD chromatogram showing metabolite profile of a micro-bioreactor culture of 
Streptomyces sp. (CMB-M0423) (a) in the presence of 4.34 .................................................. 114 
Figure 4.40. Graph showing the effect of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) ................. 115 
Figure 4.41. Picture of micro-bioreactor showing the effect of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) 
(4.34) on the production of heronapyrrole B by Streptomyces sp. (CMB-M0423) ................. 115 
Figure 4.42. Picture shows the effect of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) Streptomyces sp. .. 116 
  
 
xxvii 
Figure 4.43. Chromatograms showing Aspergillus/Streptomyces sp. ............................................. 117 
Figure 4.44. Graph of standard calibration curve of cyclo-(L-Phe-trans-4-hydroxy-L-Pro)  .......... 118 
Figure 4.45. Pictures of co-culture of both the Aspergillus sp. and Streptomyces sp. ..................... 119 
Figure 4.46. Streaking of Aspergillus sp. (CMB-M0423) ............................................................... 119 
Figure 4.47. Graph of the effect of (a) heronapyrrole A – C on the growth of Aspergillus sp. ....... 119 
Figure 4.48. Graph of peak height of 4.34 of the crude extract from Aspergillus sp. (CMB-M0423) 
in the presence of heronapyrrole B (10 µM) ........................................................................... 120 
Figure 4.49. Graph of the fungistatic effect of heronapyrrole B (4.02) on Aspergillus sp. (CMB-
M0423) .................................................................................................................................... 120 
Figure 4.50. Structures of amino acids (4.37a – d) and their methyl esters (4.38a – b) ................. 121 
Figure 4.51. HPLC-DAD-MS reaction product of cyclo-(L-Phe-4-hydroxy-Pro) .......................... 123 
Figure 4.52. HPLC-DAD chromatogram of the reaction mixture highlighting 4.39a .................... 124 
Figure 4.53. Semi-preparative HPLC-DAD chromatogram of 4.39a – d ....................................... 124 
Figure 4.54. ROESY (CDCl3) spectrum of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.39a) ............ 125 
Figure 4.55. NMR (CDCl3) of  natural/synthetic cyclo-(L-Phe-trans-4-hydroxy-L-Pro) ................ 126 
Figure 4.56. HPLC-DAD chromatogram of the reaction mixture, highlighting 4.39b ................... 127 
Figure 4.57. ROESY (CDCl3) spectrum of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39b) ............... 128 
Figure 4.58. NMR (CDCl3) spectrum of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39b) ................... 128 
Figure 4.59. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA ............................................................................................................. 129 
Figure 4.60. HPLC trace from HPLC-MS C3 Marfey’s analysis of cyclo-(L-Phe-cis-4-hydroxy-D-
Pro) (4.39b) ............................................................................................................................. 130 
Figure 4.61. Semi-preparative HPLC-DAD chromatogram of 4.39c .............................................. 131 
Figure 4.62. ROESY (CDCl3) spectrum of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39c) ................ 132 
Figure 4.63. NMR (CDCl3) spectrum of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39c) .................... 132 
Figure 4.64. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA. ............................................................................................................ 133 
Figure 4.65. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Phe-cis-4-
hydroxy-L-Pro) (4.39c) ........................................................................................................... 134 
Figure 4.66. HPLC-DAD chromatogram of the reaction mixture highlighting 4.39d .................... 135 
Figure 4.67. ROESY (600 MHz, CDCl3) spectrum showing the absence of key correlations of 
cyclo-(L-Phe-trans-4-hydroxy-D-Pro) (4.39d) ........................................................................ 136 
Figure 4.68. NMR (CDCl3) of cyclo-(L-Phe-trans-4-hydroxy-D-Pro) (4.39d) ............................... 136 
  
 
xxviii 
Figure 4.69. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA ............................................................................................................. 137 
Figure 4.70. HPLC trace from HPLC-MS C3 Marfey’s analysis of cyclo-(L-Phe-trans-4-hydroxy-D-
Pro) (4.39d) ............................................................................................................................. 138 
Figure 4.71. HPLC-DAD chromatogram of the reaction mixture highlighting 4.39e .................... 139 
Figure 4.72. NMR (CDCl3) comparison of cyclo-(Phe-4-hydroxy-Pro) stereoisomers .................. 140 
Figure 4.73. HPLC-DAD-MS reaction product of cyclo-(Tyr-4-hydroxy-Pro). ............................. 142 
Figure 4.74. HPLC-DAD chromatogram of the reaction mixture, highlighting 4.39f .................... 143 
Figure 4.75. ROESY (MeOH-d4) spectrum of cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) ........ 144 
Figure 4.76. NMR (MeOH-d4) spectrum of cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) ............ 144 
Figure 4.77. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA ............................................................................................................. 145 
Figure 4.78. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-trans-4-
hydroxy-D-Pro) (4.39f) ............................................................................................................ 146 
Figure 4.79. HPLC-DAD chromatogram of the reaction mixture, highlighting (4.39g) ................. 147 
Figure 4.80. ROESY (MeOH-d4) spectrum of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) ........... 148 
Figure 4.81. NMR (MeOH-d4) spectrum of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) ............... 148 
Figure 4.82. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA ............................................................................................................. 149 
Figure 4.83. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-cis-4-
hydroxy-D-Pro) (4.39g) ........................................................................................................... 150 
Figure 4.84. HPLC-DAD chromatogram of the reaction mixture, highlighting 4.39h ................... 151 
Figure 4.85. COSY (DMSO-d6) spectrum of cyclo-(L-Tyr-L-Tyr)  (4.39h) ................................... 152 
Figure 4.86. NMR (DMSO-d6) and UV-vis spectra of cyclo-(L-Tyr-L-Tyr) (4.39h) ...................... 152 
Figure 4.87. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-L-Tyr) 
(4.39h) ..................................................................................................................................... 153 
Figure 4.88. HPLC-DAD chromatogram of the reaction mixture, highlighting 4.39i .................... 154 
Figure 4.89. HMBC (DMSO-d6) spectrum of cyclo-(L-Tyr-D-Tyr) (4.39i) .................................... 155 
Figure 4.90. NMR (DMSO-d6) and UV-vis spectra of cyclo-(L-Tyr-D-Tyr) (4.39i) ...................... 155 
Figure 4.91. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-D-Tyr) 
(4.39i). ..................................................................................................................................... 156 
Figure 4.92. NMR (MeOH-d4) spectrum of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) and cyclo-
(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) ................................................................................... 157 
Figure 4.93. NMR (DMSO-d6) of cyclo-(L-Tyr-L-Tyr) (4.39i) and cyclo-(L-Tyr-D-Tyr) (4.39h) .. 157 
  
 
xxix 
Figure 4.94. HPLC-DAD-MS reaction product of cyclo-(Tyr-Pro) ................................................ 159 
Figure 4.95. HPLC-DAD chromatogram of the reaction mixture, highlighting 4.39j .................... 160 
Figure 4.96. ROESY (CDCl3) spectrum of cyclo-(L-Tyr-D-Pro) (4.39j) ........................................ 161 
Figure 4.97. NMR (MeOH-d4) and UV-vis spectra of cyclo-(L-Tyr-D-Pro) (4.39j) ....................... 161 
Figure 4.98. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA ............................................................................................................. 162 
Figure 4.99. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-D-pro) 
(4.39j). ..................................................................................................................................... 163 
Figure 4.100. HPLC-DAD chromatogram of the reaction mixture, highlighing 4.39k .................. 164 
Figure 4.101. ROESY (MeOH-d4) spectrum of cyclo-(L-Tyr-L-Pro)  (4.39k) ................................ 165 
Figure 4.102. NMR (MeOH-d4) and UV-vis spectra of cyclo-(L-Tyr-L-Pro) (4.39k) .................... 165 
Figure 4.103. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA ............................................................................................................. 166 
Figure 4.104. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-L-Pro) 
(4.39k) ..................................................................................................................................... 167 
Figure 4.105. NMR (MeOH-d4) of cyclo-(L-Tyr-D-Pro) (4.39j) and cyclo-(L-Tyr-L-Pro) (4.39k) 167 
Figure 4.106. HPLC-DAD chromatogram of the reaction mixture, highlighting 4.39l .................. 168 
Figure 4.107. HMBC (MeOH-d4) spectrum of cyclo-(L-Pro-L-Pro) (4.39l) ................................... 169 
Figure 4.108. NMR (MeOH-d4) and UV-vis spectra of cyclo-(L-Pro-L-Pro) (4.39l) ...................... 169 
Figure 4.109. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Pro-L-Pro) 
(4.39l) ...................................................................................................................................... 170 
Figure 4.110. HPLC-DAD chromatogram of (a) standard heronapyrrole B (4.02). (b) Streptomyces 
sp. (CMB-M0423) exposed to 4.34 plus AG ........................................................................... 174 
Figure 4.111. HPLC-DAD-MS chromatograms and  fluorescence images .................................... 175 
Figure 4.112. HPLC-DAD chromatograms of the microbial extract from Streptomyces sp. in the 
absence/presence of 4.34, CPTIO (4.26) and DEANO (4.27) ................................................. 177 
Figure 4.113. Aspergillus/Streptomyces sp. in the presence of AG ................................................. 177 
Figure 4.114. Visualization of NO production in Aspergillus/ Streptomyces sp. (CMB-M0423) .. 177 
Figure 4.115. Electron microscope images ...................................................................................... 178 
Figure 4.116. HPLC-DAD-MS chromatogram of the nitration of pyrrole to yield 2-nitropyrrole 
(4.40) and 3-nitropyrrole (4.41) ............................................................................................... 179 
Figure 4.117. NMR (CDCl3) spectrum of 2-nitropyrrole (4.40) ..................................................... 180 
Figure 4.118. NMR (CDCl3) spectrum of 3-nitropyrrole (4.41) ..................................................... 181 
Figure 4.119. Structures of the different nitro aromatics substrates ................................................ 181 
  
 
xxx 
Figure 4.120. HPLC-DAD chromatogram of the crude extract from Streptomyces sp. (CMB-
M0423) in the presence of 2-nitropyrrole (4.40) ..................................................................... 182 
Figure 4.121. HPLC-DAD chromatogram of the crude extract from Streptomyces sp. (CMB-
M0423) in the presence of 3-nitropyrrole (4.41) ..................................................................... 183 
Figure 4.122. HPLC-DAD chromatograms of crude extracts from Streptomyces sp. treated with 
nitroaromatics .......................................................................................................................... 184 
Figure 4.123. HPLC-DAD-MS of the crude extract from Aspergillus/Streptomyces sp. ................ 186 
Figure 4.124. Calibration curve for 2,4-DNP .................................................................................. 187 
Figure 4.125. Graph of the effect of 2,4-DNP (4.50) on the production of heronapyrrole B in 
Streptomyces sp. (CMB-M0423) ............................................................................................. 188 
Figure 4.126. HPLC-DAD chromatogram of the crude extract from Aspergillus/Streptomyces sp. 
(CMB-M0423) ......................................................................................................................... 190 
Figure 4.127. HPLC-DAD chromatogram of crude extract from Aspergillus/Streptomyces sp. .... 190 
Figure 4.128. HPLC-DAD chromatogram natural/synthetic heronapyrrole D (4.52) ..................... 191 
Figure 4.129. COSY, HMBC and ROESY (CDCl3) key correlations of debromomarinone (4.53) 192 
Figure 4.130. ROESY (CDCl3) spectrum of debromomarinone (4.53) .......................................... 193 
Figure 4.131. NMR (CDCl3) and UV-vis spectra of debromomarinone (4.53) .............................. 193 
Figure 4.132. NMR (600 MHz, DMSO-d6) spectrum of debromomarinone (4.53) ........................ 195 
Figure 4.133. HMBC (DMSO-d6) spectrum of debromomarinone (4.53) ...................................... 196 
Figure 4.134. Different structures of marinone analogues .............................................................. 197 
Figure 4.135. General Scheme for the NOS project ........................................................................ 198 
Figure 5.1. Proposed methanolysis of a putative natural product 5.16 ............................................ 214 
Figure 5.2. CMB-M081F ................................................................................................................. 215 
Figure 5.3. HPLC-DAD chromatogram of the crude extract from CMB-M81F ............................. 215 
Figure 5.4. Key 2D NMR (DMSO-d6) correlations of seco-shornephine A (5.15) ......................... 218 
Figure 5.5. NMR (DMSO-d6) and UV-vis spectra of seco-shornenine A (5.15) ............................ 218 
Figure 5.6. Key 2D NMR (CDCl3) correlations of shornephine A (5.16) ...................................... 220 
Figure 5.7. HMBC (CDCl3) spectrum of shornephine A (5.16) ...................................................... 221 
Figure 5.8. ROESY (CDCl3) spectrum of shornephine A (5.16) .................................................... 221 
Figure 5.9. NMR (CDCl3) and UV-vis spectra of shornephine A (5.16) ........................................ 222 
Figure 5.10. Key 2D NMR (CDCl3) correlations of shornephine A (5.16) .................................... 222 
Figure 5.11. Chromatogram showing Mosher analysis of 5.16. ...................................................... 225 
Figure 5.12. Key 2D NMR correlations of 15b-β-hydroxy-5-N-acetylardeemin (5.17) ................. 226 
Figure 5.13. HMBC (CDCl3) spectrum of 15b-β-hydroxy-5-N-acetylardeemin (5.17) .................. 227 
  
 
xxxi 
Figure 5.14. NMR (CDCl3) and UV-vis spectra of 15b-β-hydroxy-5-N-acetylardeemin (5.17) .... 227 
Figure 5.15. Key 2D NMR correlations of 5-N-acetylardeemin (5.18) ........................................... 229 
Figure 5.16. ROESY (CDCl3) spectrum of 5-N-acetylardeemin (5.18) .......................................... 230 
Figure 5.17. NMR (CDCl3) and UV-vis spectra of 5-N-acetylardeemin (5.18) .............................. 230 
Figure 5.18. Key 2D NMR correlations of 15b-β-methoxy-5-N-acetylardeemin (5.19) ................ 232 
Figure 5.19. HMBC (CDCl3) spectrum of 15b-β-methoxy-5-N-acetylardeemin (5.19) ................. 232 
Figure 5.20. NMR (CDCl3) and UV-vis spectra of 15b-β-methoxy-5-N-acetylardeemin (5.19) .... 233 
Figure 5.21. NMR (CDCl3) spectra of 15b-β-hydroxy-5-N-acetylardeemin (5.17) and 15b-β-
methoxy-5-N-acetylardeemin (5.19) ........................................................................................ 234 
Figure 5.22. A plausible biosynthetic pathway linking shornephine A and ardeemins .................. 235 
Figure 5.23. Structures of amino acids and their methyl esters ....................................................... 236 
Figure 5.24. Diagram that shows the synthesis of 8 different dioxomorpholine derivatives .......... 238 
Figure 5.25. NMR (CDCl3) spectrum of 5.4a ................................................................................. 239 
Figure 5.26. NMR (CDCl3) spectrum of 5.4b ................................................................................. 240 
Figure 5.27. NMR (CDCl3) spectrum of 5.4c .................................................................................. 241 
Figure 5.28. NMR (CDCl3) spectrum of 5.4d ................................................................................. 242 
Figure 5.29. NMR (CDCl3) spectrum of 5.4e .................................................................................. 243 
Figure 5.30. NMR (CDCl3) spectrum of 5.4f .................................................................................. 244 
Figure 5.31. NMR (CDCl3) spectrum of 5.4g ................................................................................. 245 
Figure 5.32. NMR (CDCl3) spectrum of 5.4h ................................................................................. 246 
Figure 5.33. NMR (CDCl3) spectrum of 5.5a ................................................................................. 247 
Figure 5.34. NMR (CDCl3) spectrum of 5.5b ................................................................................. 249 
Figure 5.35. NMR (CDCl3) spectrum of 5.5c .................................................................................. 250 
Figure 5.36. NMR (CDCl3) spectrum of 5.5d ................................................................................. 251 
Figure 5.37. NMR (CDCl3) spectrum of 5.5e .................................................................................. 252 
Figure 5.38. NMR (CDCl3) spectrum of 5.5f .................................................................................. 253 
Figure 5.39. NMR (CDCl3) spectrum of 5.5g ................................................................................. 254 
Figure 5.40. NMR (CDCl3) spectrum of 5.5h ................................................................................. 255 
Figure 5.41. cyclo-(L-Trp-L-Phe) ..................................................................................................... 258 
Figure 5.42. Cell flow cytometry of DKMs inhibiting P-gp in SW20 Ad300 ................................ 262 
Figure 5.43. Cell flow cytometry of the other synthetic DKMs inhibiting P-gp in SW20 Ad300 .. 262 
Figure 5.44. HPLC-DAD chromatograms of 5.5c, 5.5e, 5.5f, 5.16 and 5.17 in MeOH .................. 263 
Figure 5.45. Diagram showed the hydrolysis of the synthetic products .......................................... 264 
Figure 6.1. Desotamides (6.01 – 6.06) ............................................................................................ 274 
  
 
xxxii 
Figure 6.2. HPLC-DAD chromatogram of the crude extract from Streptomyces sp. (MST-1150688) 
of the desotamides (6.01 – 6.06) .............................................................................................. 275 
Figure 6.3. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA ............................................................................................................. 277 
Figure 6.4. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of desotamide (6.01) .......... 277 
Figure 6.5. NMR (DMSO-d6) and UV-vis spectra of desotamide (6.01) ........................................ 278 
Figure 6.6. NMR (DMSO-d6) spectrum of desotamide (6.01) ........................................................ 278 
Figure 6.7. NMR (DMSO-d6) spectrum of desotamide (6.01) ........................................................ 278 
Figure 6.8. NMR (DMSO-d6) spectrum of desotamide (6.01) ........................................................ 279 
Figure 6.9. Key 2D NMR correlations of desotamide (6.01) .......................................................... 279 
Figure 6.10. Key 2D NMR correlations of desotamide (6.01) ........................................................ 280 
Figure 6.11. Key 2D NMR correlations of desotamide (6.01) ........................................................ 280 
Figure 6.12. Key 2D NMR correlations of desotamide (6.01) ........................................................ 281 
Figure 6.13. Key 2D NMR correlations of desotamide (6.01) ........................................................ 281 
Figure 6.14. ROESY (DMSO-d6) spectrum of desotamide (6.01) .................................................. 282 
Figure 6.15. Key 2D NMR correlations for amino acids residues of desotamide B (6.02) ............ 285 
Figure 6.16. NMR (DMSO-d6) of desotamide B (6.02) .................................................................. 286 
Figure 6.17. NMR (DMSO-d6) comparison of desotamide (6.01) and desotamide B (6.02) .......... 286 
Figure 6.18. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of standard amino acids 
reacting with D-FDAA ............................................................................................................. 290 
Figure 6.19. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of desotamide C (6.03). ... 290 
Figure 6.20. HMBC (DMSO d6) spectrum (Trp) of desotamide C (6.03) ...................................... 291 
Figure 6.21. HMBC (DMSO d6) spectrum of desotamide C (6.03) ................................................ 292 
Figure 6.22. HMBC (DMSO-d6) spectrum (Val) of desotamide C (6.03) ...................................... 292 
Figure 6.23. HMBC (DMSO-d6) spectrum (Ile) of desotamide C (6.03) ........................................ 293 
Figure 6.24. HMBC (DMSO-d6) spectrum of desotamide C (6.03) ................................................ 293 
Figure 6.25. HMBC (DMSO-d6) spectrum (Gly) of desotamide C (6.03) ...................................... 294 
Figure 6.26. NMR (DMSO-d6) and UV-vis spectra of desotamide C (6.03) .................................. 294 
Figure 6.27. NMR (DMSO-d6) comparison of desotamide (6.01) and desotamide C (6.03) .......... 295 
Figure 6.28. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of derivatized standard amino 
acids reacting with D-FDAA ................................................................................................... 299 
Figure 6.29. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of desotamide D (6.04). ... 299 
Figure 6.30. HMBC (DMSO-d6) spectrum (Trp) of desotamide D (6.04) ...................................... 300 
Figure 6.31. HMBC (DMSO-d6) spectrum of desotamide D (6.04) ............................................... 301 
  
 
xxxiii 
Figure 6.32. HMBC (DMSO-d6) spectrum (Val) of desotamide D (6.04) ...................................... 301 
Figure 6.33. HMBC (DMSO-d6) spectrum (Asn) of desotamide D (6.04) ..................................... 302 
Figure 6.34. HMBC (DMSO-d6) spectrum (Gly) of desotamide D (6.04) ...................................... 302 
Figure 6.35. NMR (DMSO-d6) of desotamide D (6.04) .................................................................. 303 
Figure 6.36. NMR (DMSO-d6) comparison of desotamide (6.01) and desotamide D (6.04) ......... 303 
Figure 6.37. HPLC trace from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids 
reacting with D-FDAA ............................................................................................................. 307 
Figure 6.38. HPLC trace from HPLC-DAD-MS Marfey’s analysis of desotamide E (6.05). ......... 308 
Figure 6.39. HMBC (DMSO-d6) spectrum (Trp) of desotamide E (6.05) ...................................... 308 
Figure 6.40. HMBC (DMSO-d6) spectrum of desotamide E (6.05) ................................................ 309 
Figure 6.41. HMBC (DMSO-d6) spectrum (allo-Ile) of desotamide E (6.05) ................................ 309 
Figure 6.42. HMBC (DMSO-d6) spectrum (Asn) of desotamide E (6.05) ...................................... 310 
Figure 6.43. HMBC (DMSO-d6) spectrum (Orn) of desotamide E (6.05) ...................................... 310 
Figure 6.44. NMR (DMSO-d6) of desotamide E (6.05) .................................................................. 311 
Figure 6.45. NMR (DMSO-d6) comparison of desotamide E (6.05) and deostamide (6.01) .......... 311 
Figure 6.46. Key 2D NMR correlations of desotamide F (6.06) ..................................................... 314 
Figure 6.47. NMR (DMSO-d6) of desotamide F (6.06) .................................................................. 315 
Figure 6.48. NMR (DMSO-d6) comparison of 6.05  and 6.06 ........................................................ 315 
Figure 6.49. HMBC (DMSO-d6) of amide/carbonyl of the amino acid residues of six desotamides 
(6.01 – 6.06) ............................................................................................................................. 318 
Figure 6.50. ROESY (DMSO-d6) correlations of amino acid of desotmaides (6.01 – 6.06) .......... 319 
Figure 6.51. Proposed sequence homology based on biosynthetic grounds ................................... 319 
Figure 6.52. Antimicrobial assay screening graphs of desotamides (6.01 – 6.06) .......................... 321 
Figure 6.53. Cytotoxicity assay of the desotamides (6.01 – 6.06) against SW620 and NCIH460 .. 322 
Figure 6.54. Antibacterial assay of desotamides 6.05 and 6.06 aganist of M. bovis ....................... 323 
Figure 6.55. Antibacterial assay of desotamides 6.05 aganist of M. bovis ...................................... 323 
Figure 7.1. Solid phase culture of Streptomyces sp. (CMB-M448) ................................................ 327 
Figure 7.2. HPLC-DAD chromatogram of crude extract from Streptomyces sp. (CMB-M448) .... 328 
Figure 7.3. UV-vis (DAD) at 254 nm of aranciamycin A (7.01) .................................................... 329 
Figure 7.4. Key 2D NMR (DMSO-d6) correlations of aranciamycin A (7.01) ............................... 330 
Figure 7.5. NMR (DMSO d6) of aranciamycin A (7.01) ................................................................. 331 
Figure 7.6. UV-vis (DAD) at 254 nm of aranciamycin A (7.01) .................................................... 331 
Figure 7.7. Key 2D NMR (DMSO-d6) correlations of aranciamycin (7.02) ................................... 334 
Figure 7.8. NMR (CDCl3) spectrum of aranciamycin (7.02) .......................................................... 335 
  
 
xxxiv 
Figure 7.9. UV-vis (DAD) at 254 nm of aranciamycin (7.02) ........................................................ 335 
Figure 7.10. Key 2D NMR (DMSO-d6) correlations of aranciamycin I (7.03) ............................... 339 
Figure 7.11. NMR (DMSO-d6) of aranciamycin I (7.03) ................................................................ 340 
Figure 7.12. UV-vis (DAD) at 254 nm of aranciamycin I (7.03) .................................................... 340 
Figure 7.13. NMR (DMSO-d6) spectra of aranciamycins (7.01 – 7.03) ......................................... 341 
Figure 7.14. Key 2D NMR (DMSO-d6) correlations of aranciamycin J (7.04) .............................. 343 
Figure 7.15. NMR (DMSO-d6) of aranciamycin J (7.04) ................................................................ 344 
Figure 7.16. UV-vis (DAD) at 254 nm of aranciamycin J (7.04) .................................................... 344 
Figure 7.17. NMR (DMSO d6) comparison of aranciamycian J (7.04) and aranciamycin (7.02) ... 345 
Figure 7.18. Antimicrobial assay of aranciamycins (7.01 – 7.04) ................................................... 347 
Figure 7.19. Aranciamycins structures ............................................................................................ 349 
Figure 8.1. Structures of pyrrolomycin analogues .......................................................................... 353 
Figure 8.2. Structures of aureothin derivatives ................................................................................ 354 
Figure 8.3. Structures of the paraherquamides derivatives .............................................................. 354 
Figure 8.4. Structures of marcfortine A, brevianamide B, stephacidin A and avrainvillamide ...... 355 
Figure 8.5. Pencillium sp. (CMB-TF438) ....................................................................................... 356 
Figure 8.6. HPLC chromatogram of the crude extract from Penicillium sp. ................................... 357 
Figure 8.7. Key correlations of citrinaline X (8.30) showing the assigned fragments .................... 359 
Figure 8.8. HMBC (MeOH-d4) spectrum with key correlation for citrinaline X (8.30) ................. 359 
Figure 8.9. ROESY (MeOH-d4) spectrum of citrinaline X ............................................................. 360 
Figure 8.10. ROESY (MeOH-d4) spectrum of citrinaline X (8.28) ................................................. 360 
Figure 8.11. Energy minimized molecular model (Chem, 3D, MM2) of citrinaline X (8.30) ........ 361 
Figure 8.12. The chromatogram of citrinaline X (8.30) and citrinaline A (8.28) ............................ 361 
Figure 8.13. CD spectrum of citrinaline X (8.30) and citrinaline A (8.28) ..................................... 362 
Figure 8.14. NMR (MeOH-d4) and UV-vis spectra of citrinaline X (8.30) .................................... 363 
Figure 8.15. NMR (MeOH-d4) spectra of citrinaline X (8.28) and citrinaline A (8.30) ................. 366 
Figure 8.16. 1H -13C HSQC (MeOH-d4) of citrinaline X (8.28) and citrinaline A (8.30) ............... 366 
Figure 8.17. 1H-13C HSQC (MeOH-d4) of citrinaline X (8.28) and citrinaline A (8.30) ................ 367 
Figure 8.18 A plausible biosynthetic route to the citrinaline X (8.30) ............................................ 367 
Figure 8.19. NMR (CDCl3) and UV-vis spectra of citrinin (8.31) .................................................. 368 
Figure 8.20. Chromatogram of Penicillium sp. (CMB-TF438) with cyclo-(L-Trp-L-Phe) (5.28). .. 371 
Figure 8.21.NMR (CDCl3) and UV-vis  spectra of janthinona (8.32) ............................................. 372 
Figure 8.22. NMR (DMSO-d6) and UV-vis  spectra of citrinolactone B (8.33) ............................. 374 
Figure 8.23. Cytotoxicity assay of citrinaline X (8.30) and citrinaline A (8.28) ............................. 376 
  
 
xxxv 
Figure 8.24. Antibacterial and antifungal assay of 8.30, 8.32 and 8.33 .......................................... 377 
Figure 9.1. NMR (CDCl3) and UV-vis  spectra of streptonigrin (9.01) .......................................... 383 
Figure 9.2. NMR (DMSO-d6) and UV-vis  spectra of 1-N-methylalbonourisin (9.02) .................. 385 
Figure 9.3. NMR (DMSO-d6) and UV-vis  spectra of undecyl prodigiosin (9.04) ......................... 387 
Figure 9.4. NMR (DMSO-d6) of 6,8-dihydroxy-3-methylisocoumarin (9.05) ............................... 390 
Figure 9.5. NMR (DMSO-d6) of trindoline (9.06) .......................................................................... 391 
Figure 9.6. NMR (CDCl3) of actinomycin Z1 (9.07) ....................................................................... 392 
Figure 10.1. Schematic demonstration of stamping technique ........................................................ 397 
Figure 10.2. Example for antimicrobial screening for the microbial crude extracts ....................... 400 
  
 
xxxvi 
List of Tables 
Table 1.1. Examples of marketed antibiotics originated from microbial origin .................................. 1 
Table 3.1. NMR (CDCl3) data of resistoflavin (3.01) ....................................................................... 48 
Table 3.2. NMR (DMSO-d6) of experimental and literature data of resistoflavine (3.01) ................ 48 
Table 3.3. NMR (MeOH-d4) data of resistomycin (3.02) .................................................................. 50 
Table 3.4. NMR (DMSO-d6) of experimental and literature data of resistomycin (3.02) ................. 50 
Table 3.5. NMR (DMSO-d6) data of rugulosin (3.03) ...................................................................... 55 
Table 3.6. NMR (DMSO-d6) of experimental and literature data of rugulosin (3.03) ...................... 55 
Table 3.7. NMR (MeOH-d4) data of skyrin (3.04) ............................................................................ 57 
Table 3.8. 13C (DMSO-d6) data of experimental and literature data of skyrin (3.04) ....................... 57 
Table 3.9. NMR (CDCl3) data of neoasterriquinone (3.05) .............................................................. 61 
Table 3.10. NMR (CDCl3) of experimental and literature data of neoasterriquinone (3.05) ............ 61 
Table 3.11. NMR (CDCl3) data of julichrome Q3.5 (3.07) ................................................................ 66 
Table 3.12. NMR data (CDCl3) of experimental and literature data of julichrome Q3.5 (3.07) ......... 67 
Table 3.13. NMR (CDCl3) data of ACM-4008-1-2-1 (3.06) ............................................................. 69 
Table 3.14. NMR (CDCl3) similarity between 3.06 and 3.07 ........................................................... 70 
Table 4.1. Major differences between mammalian and bacterial NOSs ........................................... 81 
Table 4.2. NMR (CDCl3) data of pseurotin A2 (4.30) ....................................................................... 91 
Table 4.3. NMR (DMSO-d6) of experimental and literature data of pseurotin A2 (4.30) ................. 92 
Table 4.4. NMR (CDCl3) data of gliotoxin (4.31) ............................................................................. 94 
Table 4.5. NMR (CDCl3) of experimental and literature data of gliotoxin (4.31) ............................. 95 
Table 4.6. NMR (CDCl3) data of bisdethiobis(methylthio)gliotoxin (4.32) ..................................... 97 
Table 4.7. NMR (CDCl3) of experimental and literature data of bisdethiobis(methylthio)gliotoxin 
(4.32) .......................................................................................................................................... 98 
Table 4.8. NMR (CDCl3) data of fumitremorgin C (4.33) .............................................................. 100 
Table 4.9. NMR (CDCl3) of experimental and literature data of fumitremorgin C (4.33) .............. 101 
Table 4.10. NMR (CDCl3) data of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) ........................... 103 
Table 4.11. NMR (CDCl3) of experimental and literature  data of cyclo-(L-Phe-trans-4-hydroxy-L-
Pro) (4.34) ................................................................................................................................ 104 
Table 4.12. NMR (CDCl3) data of cyclo-(L-Phe-L-Pro) (4.35) ....................................................... 108 
Table 4.13. NMR (CDCl3) of experimental and published  data of cyclo-(L-Phe-L-Pro) ............... 109 
Table 4.14. Diketopiperazine derivatives 4.39a – l ......................................................................... 122 
Table 4.15. NMR (CDCl3) data of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.39a) ......................... 125 
Table 4.16. NMR (CDCl3) data of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39b) ............................. 129 
  
 
xxxvii 
Table 4.17. NMR (CDCl3) data of cyclo-(L-Phe-cis-4-hydroxy-L-Pro) (4.39c) ............................. 133 
Table 4.18. NMR (CDCl3) data of cyclo-(L-Phe-trans-4-hydroxy-D-Pro) (4.39d) ......................... 137 
Table 4.19. NMR (MeOH-d4) data of cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) ..................... 145 
Table 4.20. NMR (MeOH-d4) data of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) ........................ 149 
Table 4.21. NMR (DMSO-d6) of cyclo-(L-Tyr-L-Tyr) (4.39h) ....................................................... 153 
Table 4.22 NMR (DMSO-d6) of cyclo-(L-Tyr-D-Tyr) (4.39i) ......................................................... 156 
Table 4.23. NMR (MeOH-d4) of cyclo-(L-Tyr-D-Pro) (4.39j) ........................................................ 162 
Table 4.24. NMR (MeOH-d4) of cyclo-(L-Tyr-L-Pro) (4.39k) ........................................................ 166 
Table 4.25. NMR (MeOH-d4) of cyclo-(L-Pro-L-Pro) (4.39l) ......................................................... 170 
Table 4.26. NMR (CDCl3) of experimental and published data of 2-nitropyrrole (4.40) ............... 180 
Table 4.27. NMR (CDCl3) of experimental and published data of 3-nitropyrrole (4.41) ............... 181 
Table 4.28. NMR (CDCl3) data of debromomarinone (4.53) .......................................................... 194 
Table 4.29. 13C (CDCl3) of experimental and published data of debromomarinone  (4.53) ........... 195 
Table 4.30. NMR (DMSO d6) data of debromomarinone (4.53) ..................................................... 196 
Table 4.31. Average production of heronapyrrole B in the presence of of 2,4-DNP ...................... 208 
Table 5.1. NMR (DMSO-d6) data of seco-shornephine (5.15) ........................................................ 219 
Table 5.2. NMR (CDCl3) data of shornephine A (5.16) .................................................................. 223 
Table 5.3. NMR (CDCl3) of 15b-β-hydroxy-5-N-acetylardeemin (5.17) ....................................... 228 
Table 5.4. NMR (DMSO-d6) of experimental and literature  data of 15b-β-hydroxy-5-N-
acetylardeemin (5.17) .............................................................................................................. 228 
Table 5.5. NMR (CDCl3) of 5-N-acetylardeemin (5.18) ................................................................. 231 
Table 5.6. NMR (CDCl3) data of experimental and literature data of 5-N-acetylardeemin (5.18) . 231 
Table 5.7. NMR (CDCl3) data of 15b-β-methoxy-5-N-acetylardeemin (5.19) ............................... 233 
Table 5.8. NMR (CDCl3) data of 15b-β-hydroxy-5-N-acetylardeemin (5.17) and 15b-β-methoxy-5-
N-acetylardeemin (5.19) .......................................................................................................... 234 
Table 5.9. Methyl ester of the dipeptides 5.4a – h .......................................................................... 237 
Table 5.10. DKM derivatives 5.5a – h ............................................................................................ 237 
Table 5.11. NMR (CDCl3) data of 5.5a ........................................................................................... 248 
Table 5.12. NMR (CDCl3) data of 5.5b .......................................................................................... 249 
Table 5.13. NMR (CDCl3) data of 5.5c ........................................................................................... 250 
Table 5.14. NMR (CDCl3) data of 5.5d .......................................................................................... 251 
Table 5.15. NMR (CDCl3) data of 5.5e ........................................................................................... 252 
Table 5.16. NMR (CDCl3) data of 5.5f ........................................................................................... 253 
Table 5.17. NMR (CDCl3) data of 5.5g ........................................................................................... 254 
  
 
xxxviii 
Table 5.18. NMR (CDCl3) data of 5.5h .......................................................................................... 255 
Table 5.19. Diketomorpholine interaction with P-glycoprotein ...................................................... 261 
Table 6.1. NMR (DMSO-d6) data of desotamide (6.01) ................................................................. 283 
Table 6.2. NMR (DMSO-d6) of experimental and literature data of desotamide (6.01) ................. 284 
Table 6.3. NMR (DMSO-d6) data of desotamide B (6.02) .............................................................. 287 
Table 6.4. NMR (DMSO-d6) comparison of desotamide (6.01) and desotamide B (6.02) ............. 288 
Table 6.5. NMR (DMSO-d6) data of desotamide C (6.03) .............................................................. 296 
Table 6.6. NMR (DMSO-d6) comparison of desotamide (6.01) and desotamide C (6.03) ............. 297 
Table 6.7. NMR (DMSO-d6) data of desotamide D (6.04) ............................................................. 304 
Table 6.8. NMR (DMSO-d6) comparison of desotamide (6.01) and desotamide D (6.04) ............. 305 
Table 6.9. NMR (DMSO-d6) data of desotamide E (6.05) .............................................................. 312 
Table 6.10. NMR (DMSO-d6) comparison of desotamide E (6.05) and desotamide (6.01) ........... 313 
Table 6.11. NMR (DMSO-d6) data of desotamide F (6.06) ............................................................ 316 
Table 6.12. NMR (DMSO-d6) comparison of desotamide E (6.05) and desotamide F (6.06) ........ 317 
Table 6.13. Antibacterial and antifungal screening results .............................................................. 320 
Table 7.1. NMR (DMSO-d6) data of aranciamycin A (7.01) .......................................................... 332 
Table 7.2. NMR and 13C (DMSO-d6) of experimental and literature data of aranciamycin A (6.08)
 ................................................................................................................................................. 333 
Table 7.3. NMR (CDCl3) data of aranciamycin (7.02) .................................................................... 336 
Table 7.4. NMR (DMSO-d6) data of aranciamycin (7.02) .............................................................. 337 
Table 7.5. NMR (CDCl3) of experimental and literature data of aranciamycin (7.02) ................... 338 
Table 7.6. NMR (DMSO-d6) data of aranciamycin I (7.03) ............................................................ 341 
Table 7.7. NMR (DMSO-d6) data of aranciamycins I (7.01 – 7.03) ............................................... 342 
Table 7.8. NMR (DMSO-d6) data of aranciamycin J (7.04) ........................................................... 345 
Table 7.9. NMR (DMSO-d6) data comparison of aranciamycin J (7.04) and aranciamycin (7.02) 346 
Table 7.10. Antibacterial and antifungal screening results of aranciamycins (7.01 – 7.04) ........... 348 
Table 8.1. NMR data (MeOH-d4) of citrinaline X (8.30) ................................................................ 364 
Table 8.2. NMR and 13C (MeOH-d4) comparison of citrinaline X (8.30) and citrinaline A (8.28) 365 
Table 8.3. NMR data (CDCl3) of citrinin (8.31) ............................................................................. 369 
Table 8.4. NMR (CDCl3) of experimental and published data of citrinin (8.31) ............................ 369 
Table 8.5. NMR (CDCl3) data of janthinona (8.32) ........................................................................ 373 
Table 8.6. NMR (CDCl3) of experimental and literature data of janthinona (8.32) ........................ 373 
Table 8.7. NMR (DMSO-d6) data of citrinolactone B (8.33) .......................................................... 375 
Table 8.8. NMR (CDCl3) of experimental and published data of citrinolactone B (8.33) .............. 375 
  
 
xxxix 
Table 9.1. NMR (CDCl3) data of streptonigrin (9.01) ..................................................................... 384 
Table 9.2. NMR (CDCl3) of experimental and literature data of streptonigrin (9.01) .................... 384 
Table 9.3. NMR (DMSO-d6) data of 1-N-methylalbonourisin (9.02) and lansai D (9.03) ............. 386 
Table 9.4. NMR (DMSO-d6) data of undecyl prodigiosin (9.04) .................................................... 388 
Table 9.5. NMR (CDCl3) of experimental and literature data of undecyl prodigiosin (9.04) ......... 388 
Table 9.6. NMR (DMSO-d6) data of 6,8-dihydroxy-3-methylisocoumarin 9.05 ............................ 390 
Table 9.7. NMR (DMSO-d6) comparison of experimental and literature data of 9.05 ................... 390 
Table 9.8. NMR (DMSO-d6) data of trindoline (9.06) .................................................................... 391 
Table 9.9. NMR (MeOH-d4) of experimental and literature data of trindoline (9.06) .................... 391 
Table 9.10. NMR (CDCl3) data of actinomycin Z1 (9.07) .............................................................. 393 
Table 9.11. NMR (CDCl3) of experimental and literature data of actinomycin Z1 (9.07) .............. 394 
Table 10.1. Summary for the description of the different isolation media ...................................... 399 
  
 
xl 
List of Schemes 
Scheme 3.1. Flow chart for the construction of microbial library and crude extract ........................ 38 
Scheme 3.2. Scheme for the high-throughput activation of microbial secondary metabolites ......... 39 
Scheme 3.3.  Activation of microbial secondary metabolites by LPS ............................................... 42 
Scheme 3.4. Isolation scheme for the metabolites from crude extract of ACM-2573 ...................... 46 
Scheme 3.5. Isolation scheme for the metabolites from crude extract of CMB-TF411 .................... 53 
Scheme 3.6. Isolation scheme for the metabolites from crude extract of CMB-M81F ..................... 59 
Scheme 3.7. Isolation scheme of the metabolites from crude extract of ACM4008 ......................... 63 
Scheme 4.1. Isolation scheme of Streptomyces sp. (CMB-M0423) cultured in the presence of AG 89 
Scheme 4.2. Synthesis of DKPs derivatives .................................................................................... 121 
Scheme 4.3. Fractionation scheme of the reaction of methyl ester of L-Phe (4.38a) with methyl ester 
of trans-4-hydroxy-L-Pro (4.38c) ............................................................................................ 123 
Scheme 4.4. Synthesis of different stereoisomers of cyclo-(Phe-4-hydroxy-Pro) ........................... 141 
Scheme 4.5. Fractionation scheme for the reaction of methyl ester of L-Tyr (4.38b) with methyl 
ester of trans-4-hydroxy-L-Pro (4.38c) ................................................................................... 142 
Scheme 4.6. Synthesis of different stereoisomers of cyclo-(Tyr-4-hydroxy-Pro) ........................... 158 
Scheme 4.7. Fractionation scheme of the reaction of methyl ester of L-Tyr (4.38b) with methyl ester 
of L-Pro (4.38d) ....................................................................................................................... 159 
Scheme 4.8. Synthesis of different stereoisomers of cyclo-(Tyr-Pro) ............................................. 171 
Scheme 4.9. Scheme showing the biosynthetic pathway for heronapyrrole B production ............. 189 
Scheme 5.1. Isolation scheme of crude extract from CMB-M081F ................................................ 216 
Scheme 5.2. Synthesis of amino acids methyl esters (5.2a – d) ...................................................... 236 
Scheme 5.3. Synthesis of morpholine derivatives (5.5a – h) .......................................................... 237 
Scheme 6.1. Isolation scheme for desotamide (6.01 – 6.06) ........................................................... 274 
Scheme 7.1. Isolation scheme of the microbial metabolites, 7.01 - 7.04 ........................................ 329 
Scheme 8.1. Isolation scheme of crude extract Penicillium sp. (CMB-TF438) .............................. 357 
Scheme 9.1. Isolation scheme of crude extract from CMB-M0137 ................................................ 382 
Scheme 9.2. Isolation scheme of crude extract from CMB-TB376 ................................................ 387 
Scheme 9.3. Isolation scheme of crude extract from CMB-TB385 ................................................ 389 
Scheme 9.4. Isolation scheme of crude extract from CMB-TB350 ................................................ 392 
Scheme 10.1. Schematic demonstration of heat shock and dilution technique. .............................. 398 
Scheme 10.2. Schematic demonstration for the microbial isolation from sediment samples ......... 398 
Scheme 10.3. Scheme for the purification, chemical and biological profiling of microbes ............ 401 
 
  
 
xli 
List of Abbreviations used in the thesis 
Companies/Organizations 
 
IMB   Institute for Molecular Bioscience 
MST   Microbial Screening Technologies Pty Ltd 
 
Biology 
 
ATCC    American Type Culture Collection 
ED50    Effective Dose affecting 50% of the test subject 
IC50   Inhibitory Concentration 50 (concentration at which 50% of organisms are 
inhibited) 
MIC    Minimum Inhibitory Concentration 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MRSA   methicillin resistant Staphylococcus aureus 
VREF    vancomycin resistant Enterococcus faecium 
P-gp    permeability glycoprotein 
SW620  colorectal adenocarcinoma ATCC CCL-227 
SW620 Ad300 P-gp–overexpressing human colon adenocarcinoma cell line resistant to 
Adriamycin 300 ng/mL 
KB-3-1  P-gp overexpressing human cervical carcinoma cell line 
KV-3-1  human cervical cell line 
E. coli   Escherichia coli 
S. aureus  Staphylococcus aureus 
B. subtilis  Bacillus subtilis 
Ps. aeruginosa Pseudomonaus aeruginosa 
 
 
Chemical and Reagents 
 
Ala    alanine 
ABA    aminobutyric acid 
  
 
xlii 
DMSO   dimethyl sulfoxide 
CDCl3    deuterated chloroform 
Acetone-d6   deuterated acetone 
MeOH-d4  deuterated methanol 
MeOH   MeOH 
MeCN   acetonitrile 
CH2Cl2  dichloromethane 
DEANO  diethylamino nitric oxide 
SIN   3-morpholinosydnonimine 
SNAP   S-nitroso-N-acetylpenicillamine 
CPTIO   2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide 
FDAA   Nα-(2,4-dinitro-5-fluorophenyl)-D-alaninamide 
Leu    leucine 
Ile   isoleucine 
allo-Ile  allo-isoleucine 
Asn   aspartic acid 
Gly   glycine 
Orn   ornithine 
Arg   arginine 
Lys   lysine 
MTPA   α-methoxy-α-trifluoromethylphenylacetic acid 
Pro    proline 
4-hydroxy-Pro  4-hydroxy-proline 
Tyr   tyrosine 
Phe   phenylalanine 
TFA    trifluoroacetic acid 
Trp    tryptophan 
AcOH   acetic acid 
EtOH   ethanol 
AG   aminoguanidine 
NAME  nitro-L-arginine-methyl ester 
NMMA  NG-methyl-L-arginine 
R-Mosher  (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid 
S-Mosher  (S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid 
  
 
xliii 
Phe lactic acid  Phenyl lactic acid 
DCC   N,N'-dicyclohexylcarbodiimide 
DMAP   4-dimethylaminopyridine 
LPS   lipopolysaccharide 
2,4-DNP  2,4-dinitrophenol 
 
Chromatography and Spectroscopy 
 
[α]D    optical rotation (room temperature) 
DAD    Diode Array Detector 
ESIMS   Electrospray Ionization Mass Spectrometry 
HRESIMS   High Resolution Electrospray Ionization Mass Spectrometry 
HPLC    High Performance Liquid Chromatography 
MS    Mass Spectrometry 
NMR    Nuclear Magnetic Resonance 
UV-vis   Ultraviolet-visible 
CD   Circular dichroism 
 
Nuclear Magnetic Resonance 
 
COSY   Correlation Spectroscopy 
HSQC   Heteronuclear Single Quantum Coherence 
HMBC   Heteronuclear Multiple Bond Correlation 
J    coupling constant (in Hz) 
NOESY   Nuclear Overhauser Effect Spectroscopy 
ROESY   Rotational nuclear Overhauser Effect Spectroscopy 
br    broad 
s    singlet 
d    doublet 
t    triplet 
q    quartet 
m    multiplet 
 
 
  
 
xliv 
 
Other 
 
Kd    dissociation constant 
ACM   Australian Collection of Microbes 
rt    room temperature 
tR   retention time 
aq    aqueous 
ATP    adenosine triphosphate 
bNOS   bacterial nitric oxide synthase 
iNOS   inducible nitric oxide synthase 
eNOS   endothelial nitric oxide synthase 
nNOS   neuronal nitric oxide synthase 
NADPH  nicotinamide-adenine-dinucleotide phosphate 
NO   nitric oxide 
H4B   tetrahydrobiopterin 
BSA    bovine serum albumin 
Calcein   AM calcein acetomethoxy derivative 
GS   gain in sensitivity 
FAR   fluorescence arbitrary ratio 
CFU    colony-forming unit 
CO2    carbon dioxide 
DMEM  Dulbecco/Vogt modified Eagle's minimal essential medium 
RPMI   Roswell Park Memorial Institute (RPMI) 1640 medium 
EDTA   ethylenediaminetetraacetic acid 
ELSD   evaporative light scattering detector 
ESI   electrospray ionisation 
ESIMS  electrospray ionisation mass spectrum 
FBS   foetal bovine serum 
HPLC   high performance liquid chromatography 
HR   high resolution 
HTS   high-throughput screening 
LR   low resolution 
MDR   multidrug resistance 
  
 
xlv 
MS   mass spectrometry 
NEAA   non-essential amino acids 
NMR   nuclear magnetic resonance 
PBS   phosphate buffer serum 
PTFE   polytetrafluoroethylene 
SAR   Structure-Activities Relationships 
RFU   relative fluorescent unit 
RPMI   1640 Roswell Park Memorial Institute medium 
TLC   thin layer chromatography 
UV   ultraviolet 
DKP(s)  diketopiperazines(s) 
DKM(s)  diketomorpholine(s) 
Trp-mandelic  Tryptophan mandelic diketomorpholine 
Trp-Phenyl lactic Tryptophan phenyl lactic acid diketomorpholine 
mg   milligram 
g   gram 
min   minutes 
h   hour 
sp.   species 
approx.  Approximately 
HIV   human immunodeficiency 
MTP(s)  microtiter plate(s) 
MBR(s)  micro-bioreactor plate(s) 
CDW   cell density weight 
KDO   3-deoxy-D-manno-2-octulosonate 
ROS   reactive oxygen species 
QS   quorum sensing 
d   day 
 
Chapter 1. Introduction to Microbial Biodiscovery 
 
 
1 
1 Chapter 1. Introduction to Microbial Biodiscovery 
1.1 Historical impact of microbial natural products 
Natural products continue to play a crucial role in the discovery of new drugs and drug leads.1 
Biodiscovery from microbial resources can be defined as the exploration of microbial metabolic 
products that provide important benefits to the fields of medicine, agriculture and biotechnology.2 It 
has been reported that approximately 50% of approved drugs in the market are derived from 
microbial origin (Table 1.1).3 Actinomycetes and fungi are very important groups of 
microorganisms that are known for their ability to produce secondary metabolites with therapeutic 
activities.4 Actinobacteria produce over half of the bioactive compounds that are present in the 
antibiotic literature.5 These compounds include well-known antibacterials such as aminoglycosides 
and tetracyclines, antifungals such as amphotericin B (1.01), anticancer agents such as adriamycin 
(1.02), immunosuppressants such as tacrolimus (1.03) and anthelmintics such as avermectin (1.04), 
plus numerous other valuable therapeutic drugs. Fungi also play a vital role in the microbial 
discovery, with the genus Penicillium providing several well-known drugs (e.g. penicillins) (Table 
1.1).6 Therefore, the drug discovery process is considered as a very critical issue in the industrial 
field as it is a very expensive process and it requires multiple steps to produce new drug potentials 
to target specific disease.2,7,8  
 
Table 1.1. Examples of marketed antibiotics originated from microbial origin3 
Original metabolite Commercial products Producing organism 
Penicillins Penicillin G, V, Ampicillin, Methicillin Penicillium spp., Aspergillus spp. 
Cephalosporins Mefoxin, Ceclor Acremonuim spp. 
Thienamycin Primaxin, Invanz Streptomyces cattleya 
Erythromycin Erythrocin, Zithromax Saccharopolyspora erythraea 
Vancomycin Vancocin Streptomyces orientalis 
Fosfomycin Monuril Streptomyces fradiae 
Daptomycin Cubicin Streptomyces roseosporus 
 
Despite this great success in the discovery of valuable antibiotics and other pharmaceutical active 
agents, there has been a dramatic decline in the discovery of new antibiotics in the 21st century. 
Despite a 2007 review9 revealing that 70% of hospital-acquired infections in the US are resistant to 
one or more antibiotics, with the exception of the narrow spectrum antibiotic daptomycin (1.05), 
and linezolid (1.06), very few new classes of clinically relevant antibiotics have been approved over 
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the last 40 years. Tigecycline (1.07) is one of a new class of antibiotics derived from the 
tetracycline nucleus. This broad-spectrum antibiotic was approved for the treatment of complicated 
skin infections and is also active against MRSA, vancomycin-resistant Enterococcus faecium and 
beta-lactamase-producing bacteria as Escherichia coli and Klebsiella pneumonia.10,11 
 
 
 
 
1.2 Therapeutic fields responsive to natural products 
Microbial secondary metabolites are highly potent and selective for the treatment of many diseases. 
Many of these metabolites can be interpreted to be a signal molecule or defense mechanism against 
competitors or pathogens, an aid to the survival of the microorganism.  
1.2.1 Bacterial pathogens 
Natural products are still the main source of promising new antibiotics for the treatment of bacterial 
diseases. Platensimycin (1.08), was first reported in 2006 from Streptomyces platensis by Merck 
researchers,12 followed by the isolation of platencin (1.09).13-15 In 2008, another platensimycin 
analogues B1-B3 (1.10 - 1.12)16 and platensimycin B4 (1.13)17. This class of antibiotics 
demonstrated a novel mode of action against Gram-positive bacteria through inhibition of cellular 
lipid biosynthesis. Because of this unique role, it shows no cross resistance to MRSA, VRE or other 
antibiotic resistant microbes.  
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1.2.2 Fungal pathogens 
The need for the discovery of new antifungal agents continues, as we seek to treat the opportunistic 
infections in immune-compromised patients and the emerging resistance to existing antifungal 
agents. Jacob et al.18 recently discussed the whole cell screening techniques targeting natural 
products and their mode of action including the use of genetically modified fungal strains in which 
the antifungal drug is targeting the cell wall and cell membrane. Caspofungin (1.14), is a promising 
new antifungal agents derived from pneumocandin, a natural product produced by Glarea 
lozoyensis.19 
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1.2.3 Viral pathogens 
New anti-HIV (human immunodeficiency) drugs are targeting the point of entrance of the virus into 
the cell such as interferon signaling and cell surface receptors as CCR5-human cytokine receptor 
and CD4.20 Many antiviral lectins are from algal origin and they are mainly small proteins that bind 
to carbohydrates found on the viral envelopes and prevent the transmission of HIV.21 In addition, 
viral polymerases are the key for viral replication and are considered as promising targets for anti-
viral drugs, with inhibitors for viral polymerase and proteases in clinical use for the treatment of 
AIDS and chronic hepatitis. All drugs that are in the market for the treatment of HIV are synthetic 
in origin, although the activities of many natural products have been explored in the recent years.22 
Yu et al.23 discovered a plant-derived modified betulinic acid derivative, DSB (1.15) as a first in 
class HIV maturation inhibitor. This natural product is currently in Phase II clinical trials.23 
 
 
1.3 Resistance to microbial natural products 
1.3.1 Antibiotics and the resistance in nature 
The discovery of antibiotics more than 70 years ago initiated an era of drug innovation in human 
and animal health. These discoveries were interrupted by the emergence of antibiotic resistance, 
largely due to the widespread overuse of antibiotics in both medicine and agriculture.24 
Notwithstanding the outstanding list of antibiotics that were discovered from microbial sources, 
especially soil microbes, resistance to these antibiotics evolved in the environment long before they 
were developed as commercial antibiotics.25 The resistance we see in the clinic today is to a great 
extent similar to the environmental one. Although the resistance in both contexts are similar, 
clinical resistance tends to increase substantially with time. Therefore there should be a certain 
mechanism that keeps control of resistance in the environment.26-28 
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1.3.2 Anticancer resistance 
Cancer cells become resistant to anticancer drugs by several mechanisms. One way is to pump 
drugs out of cells by increasing the activity of efflux pumps, such as ATP-dependent transporters. 
Alternatively, resistance can occur as a result of reduced drug influx - a mechanism reported for 
agents that interact with intracellular carriers or enter the cell by means of endocytosis. In cases 
where drug accumulation is unchanged, activation of detoxifying proteins, such as cytochrome 
P450 mixed-function oxidases, can promote drug resistance. Cells can also activate mechanisms 
that repair drug-induced DNA damage. Finally, disruptions in apoptotic signalling pathways (e.g. 
p53 or ceramide) allow cells to become resistant to drug-induced cell death.29 
 
In order to overcome these problems, we need to better understand the microbial genomics. In the 
last 10 years, advances in genomics have revealed new knowledge of a silent microbial secondary 
metabolism, offering a glimpse of a new source of potentially valuable biomedical agents and tools. 
To access this genetic resource requires molecular tools capable of activating latent secondary 
metabolism gene clusters, to build knowledge of microbial systems biology, and facilitate access to 
new microbial natural products.  
 
1.4 Silent resources 
After 100 years of discovering microbes, there is great evidence that microbes are capable of 
producing different classes of bioactive secondary metabolites. However, strong evidence revealed 
that we are only scratching the surface of microbial genomes. Microbes share and accumulate 
multiple secondary metabolite gene clusters, which are capable of producing different bioactive 
metabolites, with a wide range of biological activities.30 Some challenges limit our ability to access 
the microbial genome; for example both the bacteria and fungi harbour massive number of genes in 
which these genes usually remain dormant and do not produce any metabolites under normal 
laboratory conditions until they become activated. It is very probable that these genes are activated 
by chemical stimuli produced by other competing microbes. Such chemical stimuli represent 
valuable molecular tools that could be used to unlock the silent secondary metabolism, improving 
prospective for next generation antibiotics.31 
1.4.1 Detection of silent secondary gene cluster 
A 2001 study by Omura et al., on the genome of Streptomyces avermitilis, the microbial source of 
anthelmintic drug avermectins, revealed an 8.7 Mbp linear chromosome with 25 recognizable 
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secondary metabolite gene clusters accounting for 6.4% of the genome. This study concluded that 
there are many uncharacterized genes involved in the secondary metabolism. Twenty-five 
secondary metabolite gene clusters were found in the genome of S. avermitilis. Four of them are 
responsible for the production of melanin pigment on solid medium, two are derived from tyrosine 
and one is an aromatic polyketide. Another melanin is an ochronotic pigment, which is derived 
from homogentiginic acid and produced, in both solid and liquid media.32 S. avermitilis has the 
highest number of secondary metabolite gene clusters of all bacterial genomes sequenced. The 
production of different metabolites can be attributed to the presence of many gene clusters, which 
can encode for enzymes for the activation of different secondary metabolic pathway. The report 
concluded that there are “many other uncharacterized genes involved in secondary metabolism”. 
In 2002, Bentley et al.33 reported that the genome of Streptomyces coelicolor contained 20 
secondary metabolite gene clusters and metabolic enzymes of known or predicated secondary 
metabolites. Furthermore, the genome contained an unprecedented proportion of regulatory genes 
that are involved in response to external stimuli and stresses. S. coelicolor contains duplicated genes 
that operate in different phases during colonial development, which if stimulated could lead to new 
pharmaceutical compounds. The report concluded by noting “The abundance of previously 
uncharacterized metabolic enzymes, particularly those likely to be involved in the production of 
natural products, is a resource of enormous potential values”. In 2005, McAlpine et al.34 reported 
the genome analysis of Streptomyces aizunensis to detect the presence of hitherto unexpressed 
natural product in which different media where used to express microbial secondary metabolites. 
Udwary et al.35 analysed the genome of Salinospora tropica to show a large percentage of its 
genome is dedicated to natural product assembly. In addition, this study identified secondary 
metabolic biosynthetic gene clusters from the complete genome sequence of S. tropica revealing an 
unrealised secondary metabolism potential and the importance of the understanding and the control 
for the secondary metabolite pathway. 
 
Therefore, modern genomics has redefined our understanding of microbial secondary metabolism. 
The computational analysis of microbial metabolism provides the sequencing of thousands of 
microbial genomes. This knowledge will provide a new pathway to access the microbial molecular 
diversity and also will help to develop more tools and methodologies to take advantage of this 
potential. In addition, the previous articles noted a growing appreciation of a global microbial 
genome that encompasses molecular discovery value than previously appreciated. On the other 
hand, while learning that microbes possess a secondary metabolism, the challenge is how to activate 
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and benefit from that the activation of silent secondary gene clusters and produce new 
pharmaceutical compounds. 
1.5 Activating of silent genes 
1.5.1 Effect of culturing conditions on secondary metabolite production 
The choice of the cultivation parameters is crucial for the production of secondary metabolites by 
microorganisms. It is well known fact that a change in culture conditions (temperature, pH, oxygen 
etc.) can affect secondary metabolites production. Any small change in the culture medium may 
impact not only the level of production of certain compounds, but also the diversity.36 Paranagama 
et al.37 studied the effect of tap water and distilled water on the metabolite profiling of two plant 
associated fungus, the first fungus, Paraphaeosphaeria quadriseptata, by the changing the water 
used in fermentation from tap to distilled resulted in the production of six new compounds, 
cytosporones F – I (1.16 – 1.19), 5′-hydroxymonocillin (1.20) and quadriseptin A (1.21).  
 
 
The second fungus, Chaetomium chiversii, produced radicicol (1.22) on solid phase media, but 
shifted to chaetochromin (1.23) in liquid phase.37 
 
In addition to various culture conditions, Ayer et al., have studied the impression of the diverse 
stress conditions on secondary metabolite production. They were able to isolate jadomycin B (1.24), 
a glycosylated nezoxazolophenanthridine antibiotic from Streptomyces venezuelae. The aglycone 
jadomycin was produced in a galactose-isoleucine medium at 37 °C.38 Increasing the temperature to 
42 °C increased the level of production of jadomycin B (1.24). Other parameters were found to 
increase the production of jadomycin B such as addition of ethanol as well as bacteriophage 
infection.39 Also, Overy et al. cultivated different strains of necrotrophic Penicillium strains in 
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different macerated host tissue media. This led to the stimulation of production of corymbiferone 
(1.25) and corymbiferan lactones I – IV (1.26 – 1.28).40 
 
1.5.2 Novel metabolites in co-cultures 
The functional role of natural products in microbes has long been a topic of discussion. It was found 
that some natural products result from the interaction of the organism with its own environment. 
Cueto et al., cultured a marine Pestalotia sp. with an unidentified antibiotic resistant marine 
bacterium, resulting in the biosynthesis of pestalone (1.30), a new benzophenone. This compound 
could not be detected when each strain was cultivated independently. Pestalone was found to be 
active against MRSA and vancomycin-resistant Enterococcus faecium.41 The marine derived fungus 
Emericella sp. was challenged with the actinomycete Salinispora arenicola. This co-culture 
activated the production of two new cyclic depsipeptides, emericellamide A (1.31) and 
emericellamide B (1.32).42 Latifi et al. reported another interesting example of the synergistic 
function of co-culturing in 2006. A co-culture between Pseudomonas aeruginosa and Enterobacter 
sp. stimulated P. aeruginosa to produce the blue pigment pyocyanin, (1.33).43 To establish whether 
any other microorganism can induce the production of pyocyanin, P. aeruginosa was cultivated 
with different microorganisms. These results showed that P. aeruginosa lost its ability to produce 
pyocyanin when co-cultured with other microbes.44 These related examples highlight the role that 
co-culture can play in the regulation of secondary metabolite production. 
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Although these strategies have been studied and can lead to promising results, it is nevertheless a 
time consuming and unpredictable process that while it can express silent metabolites, is not up to 
the challenge of activating the broad array of silent metabolites hidden within the global microbial 
genome. In order to access the microbial genome, new approaches informed by the microbial 
evolution need to be acquired.45 
1.5.3 Autoregulators 
Autoregulators are compounds that act as triggers to improve cellular development and activate 
silent secondary metabolite genes, leading to the production of secondary metabolites. Knowing 
that a microbe is genetically far more capable than previously suspected, reveals a potential, but 
activating that potential is another challenge entirely. Even without detailed knowledge of the 
microbial genome, early researchers enjoyed some success in stimulating microbial secondary 
metabolites. For example, it had been recognized that morphological differentiation during the 
growth of Streptomyces sp. was closely associated with the secondary metabolites production. More 
specifically, the transition from primary to secondary metabolism occurred simultaneously with the 
formation of the aerial hyphae. In exploring these phenomena a selection of low molecular weight 
metabolites were found to act as regulators of secondary metabolism.  
1.5.3.1 γ-Butyrolactones of actinomycetes 
The potential value of autoregulators as tools to regulate antibiotic production was quickly 
recognized, such that γ-butyrolactones came under intense investigation. An early example, of such 
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a regulator (called an autoregulator) discovered in 1979 was A-factor (1.34), a γ-butyrolactone 
produced by Streptomyces griseus. A-factor induced both aerial mycelium formation in S. griseus 
and production of the antibiotic streptomycin, with A-factor appearing prior to streptomycin 
production and disappearing before streptomycin reached its maximum level.46 
 
In addition to its effect on streptomycin (1.35) production,47 other achievements of A-factor 
included inducing the production of pristinamycins in a mutant strain of S. pristinaespiralis, in 
which pristinamycins biosynthesis was otherwise blocked, and initiating the production in S. 
griseus (under phosphate depletion) of the parasiticidal metabolites grixazones A and B (1.36 and 
1.37). Other closely related naturally occurring microbial γ-butyrolactone autoregulators included 
the virginiae butenolides (1.38) (eg. VB-A), which activated the production of virginoamycin that 
consists of 75% virginamycin M1 (1.39) and 25% virginamycin S1 (1.40), IM-2 (1.41), which 
activated the production of showdomycin (1.42) and minimycin (1.43), and SCB1 (1.44), which 
activated the production of actinorhodine (1.45) and undecylprodigiosin (1.46). IM-2 is noteworthy 
in that it both activates and suppress secondary metabolism. For instance, biosynthesis of the 
antituberculosis antibiotic D-cycloserine by S. lavendulae was completely suppressed in the 
presence of IM-2. Further investigations into the autoregulation of microbial secondary metabolism 
revealed that this capability was not limited to γ-butyrolactones. 
 
A limited selection of Streptomyces metabolites have been described as promoters of 
morphogenesis and secondary metabolism, and include the thiazole/oxazole peptide, the polyether 
pamamycin-607 (1.47) and the siderophore desferrioxamine E (1.48). Pamamycin-607 (1.47) plays 
an important role in the regulation of aerial mycelium production in 67% of Streptomyces.48 
Desferrioxamine E (1.48) simulates secondary metabolites production in different strains of 
actinomycetes such as Streptomyces coelicolor.49 However there are some non-butyrolactone 
Streptomyces metabolites that have been discovered as promoters of secondary metabolites, 
including thiazole/oxazole peptide goadsporin. Goadsporin (1.49) is an oligopeptide consisting of 
19 amino acids, which acts on the sporulation pathway and regulates secondary metabolites 
production for Streptomyces.50  
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1.5.3.2 Homoserine lactones of Gram-negative bacteria 
Acyl homoserine lactones (acyl-HSLs) are important intercellular signalling molecules used by 
many bacteria to monitor their population density in quorum-sensing control of gene expression.51 
These signals are synthesized by members of the LuxI family of proteins.51 Homoserine lactones 
(HSLs) function by “quorum sensing” in which they reach a particular extracellular concentration 
due to high cell density. They act in bioluminescence, antibiotic biosynthesis, animal pathogenicity, 
plant pathogenicity and extracellular enzyme synthesis.52 HSLs are similar in structure to A-factor. 
They can also induce exoenzymes, which are plant and animal virulence defense against E. 
carotovora and P. aeruginosa respectively.53 
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1.6 Genomics-inspired screening for novel natural products 
The idea of screening extract libraries on different types of microorganisms has emerged as an 
important aspect to determine new metabolites. Microbial metabolites (gene activators) may be 
capable of eliciting the expression of silent secondary metabolism on other microbes. The activation 
of silent gene clusters will advance the discovery of next generation antibiotics. Zazopoulos et al.54  
analysed the genome of different actinomycetes looking for the genes that were responsible for the 
production “enydiyne” class of antitumor agents. These loci remain inactive until certain chemical 
or physical signals activate them. After optimizing the growth conditions, Zazopoulos et al.54 were 
able to induce the expression of the gene cluster and leading to production of “enydiyne”. In 
addition, McAlpine et al. scanned the genome of Streptomyces aizunensis. The genome scanning 
identified 11 gene clusters coding for the biosynthesis of wide range of bioactive metabolites. One 
of these gene clusters was responsible for the production of type I polyketide synthase generating a 
novel polyketide with characteristic UV absorbance at 300 nm. Varying the culture conditions 
helped trigger the biosynthesis of compound ECO-02301 (1.50).34 Scanning the genome sequence 
of Aspergillus nidulans revealed the presence of three copies of genes that codes for proteins with 
high similarity to anthranylate synthases (ASs). These enzymes are responsible for the conversion 
of chorismate to anthranilic acid, which is important for the synthesis of tryptophan. By altering the 
cultivation conditions, four new prenylated quinoline alkaloids aspoquinolones I, II and III (1.51 - 
1.54) were produced.55 
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The strategy of epigenetic modifiers (gene activators) was further studied by many researchers. 
Some of these studies reported that Aspergillus sp. contains nuclear transcriptional regulator LaeA, 
that controls secondary metabolite production, suggesting the existence of different regulatory 
mechanisms that ensure secondary metabolites production at certain developmental stages or under 
specific environmental conditions.56-58 Cichewicz et al. treated twelve fungi with several DNA 
methyltransferase and histone deacetylase inhibitors. Eleven strains were found to respond, with the 
production of new or enhancement of known natural products. One of these strains, Cladosporium 
cladosporioides, was treated with 5-azacytidine, and led to the production of oxylipins I, II and III 
(1.55 - 1.57).59  
 
All these observations listed above highlight that the microbial genome offers for greater molecular 
potential that previously imagined, and that molecular tools are required to access this resource. 
 
1.7 Focus of this thesis 
This thesis focuses on the discovery of microbial secondary metabolites and the activation of 
microbial secondary metabolites. Putting this aspect as the main target, we started collecting 
different soil samples from regions in Australia to construct a terrestrial microbial library. We were 
able to screen this library together with some microbes from marine microbial library as well as the 
Australian collection of microbes (ACM) library that contains more than 5,000 different species of 
Streptomyces sp. In the same time, the microbioreactor technique had been used for screening the 
microbial libraries and constructing the microbial extract library which was subjected for both 
chemical profiling analysis using our HPLC-DAD-MS and biological profiling using our different 
biological assays (in house) as antimicrobial, cytotoxic, P-glycoprotein (P-gp), kinase, 
Mycobacterium bovis (BCG) assay (Figure 1.1). The second chapter reports the optimization 
conditions that have been performed in the microbioreactor to optimize the culture conditions. The 
third, fourth and fifth illustrates the activation of microbial secondary metabolites and the isolation 
of novel metabolites that possess biological activity. Chapter 4 illustartes the co-evolution between 
fungus and bacteria, Chapter 5 illustartes the isolation of new diketomorpholine metabolites and 
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explains its P-glycoprotein inhibiotor activity. The last chapters (Chapter 6,7 and 8) explain the 
isolation, structural elucidation and biological activity of the novel metabolites, desotamides, 
aranciamycins and citrinaline X.  
 
Figure 1.1. General figure for the PhD projects includes isolation of microbes, microbial secondary metabolites and 
activation of silent secondary metabolites
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2 Chapter 2. Developing a Micro-bioreactor technique for 
Microbial cultivation 
2.1 Introduction 
Microbial (bacterial and fungal) secondary metabolites remain an important source for molecular 
diversity that can improve drug discovery. Traditional microbial biodiscovery employs to liquid and 
solid phase culture approaches. Small-scale cultivation in either liquid or solid phase is considered 
the preferred means for initial discovery “lead identification” for natural products. Small-scale 
liquid cultivations are typically performed in shake flasks (10 – 80 mL), which can be time 
consuming and costly exercise when dealing with hundreds to thousands of isolates. 
Notwithstanding these limitations, shake flasks have been used for cultivating microbes since 1940, 
and are still the method of choice for many laboratories.60 Major limitations of shake flasks are their 
reliance on surface aeration, which may lead to reduction in the oxygen transfer.61 Some researchers 
have experimented the use of flaks with baffles which can increase the oxygen transfer rate at lower 
shaking frequencies, however, at high speeds this can lead to splashing that can lead to oxygen 
starvation which in turn slows the cell growth and likely alters secondary metabolite production.62  
There is a clear need for an innovate new approach to facilitate high-throughput small-scale culture 
of microbes, for the purpose of biodiscovery. 
 
2.1.1 Progression from shake flasks to micro-bioreactors 
Microscale culture technology has attracted great interest in recent years. Among some 
microbiologists, microtiter plates (MTP) have become an alternative technique for optimizing 
cultivation conditions. The use of small-scale liquid cultivation volumes is viewed as fast and 
effective. The number of wells contained in MTPs range from 6, 12, 24, 96 to 384, and allow for 
high-throughput cultivation and screening.63 Duetz et al. developed a cultivation system to make 
use of 24 or 96-well square-shape micro-bioreactor plates (MBR).64 Oxygen transfer rate in this 
system was 38 mmol O2/L/h in 0.5 mL culture, while 18 mmol O2/L/h in 1 mL culture volume. For 
example, this cultivation system allowed Pseudomonas putida to grow on glucose minimal medium 
(18 h) and reach a cell density of 9 g (dry weight)/L. To prevent cross contamination between the 
cultures during shaking, the MTP was covered with a spongy silicone layer (8 mm thick) perforated 
with holes (1.5 mm diameter) positioned directly above the centers of the wells. This spongy 
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silicone layer was covered with a rigid polypropylene layer with 96 holes 6 mm in diameter and the 
whole system was capped with stainless steel sandwich cover.65  
  
2.1.2 Different types of micro-bioreactors 
In 2000, Wolfgang et al.64 used the 96-well MTP from Duetz et al. to study the growth and 
production of secondary metabolites on different Streptomyces strains in micro-cultures, assessing 
the growth of mycelium-forming Streptomyces strains cultivated in one mL liquid micro-cultures 
versus large Erlenmeyer flasks. The flasks were filled with the appropriate media required for the 
growth of Streptomyces to 1/5 of the total volume and incubated at 30 °C for 15 days with 300 rpm 
in an incubator shaker. In the same time, liquid micro-cultures containing one mL broth media were 
incubated at the same conditions. This study reported that the evaporation rate of the culture volume 
was minimal (4 to 7.5%) and proved that the cell density weight (CDW) was much better in the 
micro-cultures than the flask. These authors also performed a time-course study on secondary 
metabolite production for 5 Streptomyces strains, confirming that secondary metabolites production 
was the same between micro-cultures and flasks, with very small culture to culture deviation.64 In 
2005, Harms et al.66 demonstrated two high quality bioprocessing micro-bioreactors for commercial 
use, both consist of the 24-well format. The difference between these reactors was that the first 
lacks a plate seal and requires the use of a laminar flow hood. By comparison, the second system 
employed a sterilized plate cap, and a motor for agitation control. Both contained optical sensors for 
monitoring pH and dissolved oxygen. In 2005, Kensy et al.67 developed a new method to measure 
the dissolved oxygen and pH in standard 24-well MTP using fluorophores at the bottom of the 24-
well MTPs. This new technology consists of sensor dish reader for 24-well MTP. The reader 
consists of controller and 24 optical read out units placed in the center below each well.  This new 
method provided continuous measurements for different parameters in 24-well MTPs during 
shaking. The drawbacks for this method were fluctuations in the light intensity, scattering of light 
and auto fluorescence within same culture. All these systems contributed to the evolution of a more 
robust model system. 
 
2.1.3 Applikon system 
Applikon Biotechnology® developed a micro-bioreactor cultivation system (Figure 2.1), which 
turns microtiter plates into reliable and easy operating cultivation systems for microbes, which 
reliable, easy to operate, and offers reproducible cultivation results. Applikon micro-bioreactor is 
available in both 24 and 96 well microtiter plate formats. Both formats provide benefits compared 
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to shake flasks that include, (1) lower cost, (2) stackable design - lower footprint, (3) comparable 
performance - cell density, (4) no well-to-well contamination and (5) well-to-well reproducibility. 
 
Figure 2.1. Applikon bioreactor system; (A) 24-well microbioreactor plate, (B) stainless steel cover plus sandwich 
covers  
2.1.4 Chapter outlines 
While the Applikon micro-bioreactor has been used by a number of microbiology laboratories, to 
the best of our knowledge this technology has not been employed in a microbial biodiscovery 
format. To develop high-throughput (HTP) microbial biodiscovery methodology based on this 
system, we needed to independently test and validate a number of critical hypotheses – that go to 
the issues of efficacy, reproducibility, HTP practicality and HTP versatility. 
Efficacy: Micro-bioreactor technology will generate secondary metabolite yields and diversity 
comparable to shake flasks. 
Reproducibility: Micro-bioreactor technology will return high levels of reproducibility, particularly 
in secondary metabolites yields and diversity. 
HTP practicality: Micro-bioreactor technology produces a practical HTP format that does not suffer 
from well-well cross contamination. 
HTP versatility: Micro-bioreactor technology provides a HTP format suited to multiple culture 
media. 
To test these hypotheses, the bacterial isolates CMB-TB365 and CMB-TB385, obtained during a 
program of environmental sampling (see Chapter 10) were chosen for these studies. These studies 
were carried out in duplicate/triplicate in a 24 well micro-bioreactor format, with each well 
extracted in situ with EtOAc (2 mL), decanted, concentrated under N2, re-constituted to 
approximately 1 mg/mL in MeOH, and analyzed by HPLC-DAD-MS. 
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2.2 Results and discussion 
2.2.1 Efficacy 
To test the efficacy hypothesis, twenty microbes were chosen from the microbial library (Chapter 
10) and cultivated in the micro-bioreactor and shake flask. After the cultivation period, the cell 
biomass and crude extracts weight were determined. 
2.2.1.1 Biomass and crude extract determination in the microbioreactor and flask 
From the microbial library, the effect of microbioreactor on the microbial cultivation was tested and 
the results were compared to the culture conditions in the shake flasks. Therefore, 20 different 
microbes (15 actinomycetes and 5 fungi) were chosen from the terrestrial library. The microbes 
were cultivated in both microbioreactor and Erlenmeyer flask (250 mL). In the microbioreactor, 
broth (1.5 mL) was added to the wells in the presence of microbe, while in the shake flask, broth 
(80 mL) was added in the presence of the microbe. Both the micro-biorecator and the flasks were 
incubated at 26 °C, 190 rpm. After the incubation period, the broth in the microbioreactor was 
extracted by the addition of 2 mL EtOAc and the plate was shaken for another 30 min. In the shake 
flask, the broth was extracted with EtOAc (80 mL × 3). The crude extract from the microbioreactor 
was dried under N2 while the crude extract from shake flask was dried in vacuo. At the same time, 
the colonies from both experiments were centrifuged and dried down in the biological hood for 24 
h. This study showed that there is almost no difference between the microbioreactor and the flask, 
the microbes (actinomycetes or fungi) were cultivated and grew to an optimum concentration in 
which they were capable to express their secondary metabolites as shown in Figure 2.2 and Figure 
2.3. 
 
From the micro-bioreactor, the cell dry weight (CDW) was determined by collecting the broth and 
biomass attached to the walls. The entire cells were filtered through pre-weighed filter paper and 
the filter was washed twice with water and left to dry at room temperature. CDW in the shake flask 
cultivations was determined by withdrawing 5 mL samples from the broth, followed by filtration, 
washing and drying steps.  
Chapter 2. Developing a Micro-bioreactor technique for Microbial cultivation 
20 
 
 
 
Figure 2.2. Study showing a comparison between the microbioreactor and shake flask, colonies from micro-bioreactor 
( ), crude extract from micro-bioreactor ( ), colonies from shake flask ( ) and crude extract from shake flask 
( ) for different microbes. CMB-TF = terrestrial fungi, CMB-TB = terrestrial bacteria 
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Continued Figure 2.2 
 
 
Figure 2.2. Study showing a comparison between the microbioreactor and shake flask, colonies from micro-bioreactor 
( ), crude extract from micro-bioreactor ( ), colonies from shake flask ( ) and crude extract from shake flask 
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Continued Figure 2.2 
 
Figure 2.2. Study showing a comparison between the microbioreactor and shake flask, colonies from micro-bioreactor 
( ), crude extract from micro-bioreactor ( ), colonies from shake flask ( ) and crude extract from shake flask 
( ) for different microbes. CMB-TF = terrestrial fungi, CMB-TB = terrestrial bacteria 
 
Figure 2.3. Picture for the micro-bioreactor showing the growth of different microbes 
 
All the above experiments were performed in triplicate and therefore we can conclude that the 
amount of cell mass and crude extracts was efficient compared to the shake flask. In fact in some 
cases the growth of microbes in the micro-bioreactor was far much better than the shake flask. 
 
 
CMB-TF32
0
10
20
30
40
A
m
o
u
n
t 
in
 m
g
/m
L
CMB-TF40
0
5
10
15
20
A
m
o
u
n
t 
in
 m
g
/m
L
CMB-TF35
0
5
10
15
20
A
m
o
u
n
t 
in
 m
g
/m
L
CMB-TF45
0
5
10
15
20
A
m
o
u
n
t 
in
 m
g
/m
L
colonies-microbioreactor crude extract-microbioreactor colonies-flask
crude extract-flask
Chapter 2. Developing a Micro-bioreactor technique for Microbial cultivation 
23 
 
2.2.2 Reproducibility 
After proving that the microbioreactor is capable of allowing the microbes to grow without 
affecting the microbial growth and the microbial secondary metabolites expression. We mainly 
focused on two actinomycetes strains CMB-TB365 and CMB-TB385 due to their capability of 
producing different metabolites. 
2.2.2.1 Case study #1 for CMB-TB365 
2.2.2.1.1 Growth phase-dependent production of secondary metabolites for CMB-TB0365  
Growth of CMB-TB365 in the micro-bioreactor (1.5 mL) was compared to the growth in the shake 
flask (80 mL). Twenty wells of 24 wells of micro-bioreactor were each filled with M1 broth (1.5 
mL) and spore taken by the loop. The growth stages of actinomycetes CMB-TB0365 in liquid 
culture in both the micro-bioreactor and the flask were determined by extracting the broth with 
EtOAc (2 mL) from every well. The crude extracts were dried down under N2, re-dissolved in 
MeOH and analysed using HPLC-DAD-MS and measured spectrophotometrically at 400 nm. 
Samples (50 µL) were withdrawn from each well aseptically and transferred into a flat bottom 
microtiter plate for spectrophotometric analysis (Figure 2.4). Since the cultivation of CMB-TB365 
was conducted over extended period of time, it was important to observe that after 7 days of 
cultivation the loss of culture volume due to evaporation was minimal. There was almost no 
difference between the cultivation process on the micro-bioreactor and shake flask (Figure 2.5). 
 
Figure 2.4. HPLC-DAD chromatogram of analytical gradient H2O/MeCN plus 0.05% HCO2H, using Zorbax C8 for the 
crude extract from strain CMB-TB365 over incubation period from 1 to 7 d in (a) the micro-bioreactor and (b) shake 
flask 
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Figure 2.5. Time course of secondary metabolite production for strain CMB-TB365 during 7 d of cultivation in micro-
bioreactor (1.5 mL) and shake flask. Filled circles represent the crude from micro-bioreactor while filled squares 
represent the crude extract from shake flask. 
2.2.2.2 Case study #2 for CMB-TB385 
2.2.2.2.1 Growth phase-dependent production of secondary metabolites for CMB-TB0385  
The same procedure described above was repeated with strain CMB-TB385 (Figure 2.6 and Figure 
2.7).  
 
Figure 2.6. HPLC-DAD chromatogram of analytical gradient H2O/MeCN plus 0.05% HCO2H, using Zorbax C8 for the 
crude extract from strain CMB-TB385 over incubation period from 1 to 7 d in (a) micro-bioreactor and (b) shake flask 
 
Figure 2.7. Time course of secondary metabolite production of strain CMB-TB385 during 7 d of cultivation in micro-
bioreactor (1.5 mL) and shake flask (80 mL). Filled circles represent the crude from micro-bioreactor while filled 
squares represent the crude extract from shake flask. 
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The progress of microbial cultivation in the micro-bioreactor was compared with parallel 
cultivations carried out by the same organism in both micro-bioreactor and shake flask. Both OD 
and HPLC-DAD-MS monitored growth of microbes and secondary metabolites production in the 
micro-bioreactor and shake flask. In the micro-bioreactor, the growth of the two strains CMB-
TB365 and CMB-TB385 was slightly higher than the shake flask which could be attributed to the 
small cross sectional dimensions in the micro-bioreactor that gives rapid heat and mass transfer. 
The crude extract production was monitored and it was observed that the amount of crude extract 
was not affected by cultivation the microbes in the micro-bioreactor, in fact we proved that the 
micro-bioreactor can allow the microbe to grow and produce crude extract that is enough to be 
analysed using HPLC-DAD-MS. 
 
2.2.3 Practicality 
To further evaluate the performance of micro-bioreactor, the hypothesis of practicality was tested in 
order to determine that there is no risk of cultivating both actinomycetes and fungi in the same 
plate, different microbes were cultivated from the microbial library in the presence of media (1.5 
mL). The media in the micro-bioreactor was inoculated with a single colony from a seed culture 
cultivated on ISP-2 agar plate. After inoculation, the plates were incubated at 26 °C, 190 rpm for 7 
days (Figure 2.8). 
 
 
Figure 2.8. Micro-bioreactor showing the growth of different fungi and actinomyetes 
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2.2.4 Versatility 
To test the hypothesis of versatility, two microbes (CMB-TB365 and CMB-TB385) were cultivated 
in different media. 
2.2.4.1 Case study #1 CMB-TB365 
The study on the production of secondary metabolites on CMB-TB365 was evaluated on 12 
different media. The media was inoculated from the plate containing the spores. An aliquot of each 
media (1.5 mL) was dispensed into 24 wells of the micro-bioreactor and incubated at 26.5 °C for 7 
d, 190 rpm. After the incubation period, the broth was extracted with EtOAc (2 mL) and the organic 
layer was dried under N2, re-dissolved in MeOH and analysed using HPLC-DAD-MS. The results 
show that the maximum growth rates and secondary metabolite production were different for the 
same strain on different media. However, CMB-TB365 showed the best production on M8 and M1 
media. These results were not surprising as we expected that the microbes could behave differently 
when cultivated on different media but it emphasis the capability of the microbe to grow in the 
micro-bioreactor (Figure 2.9). 
 
5 10 15
0
50
100
Retention time (min)
A
b
s
o
rb
a
n
c
e
 a
t 
2
5
4
 n
m
 (
m
A
U
) 
Crude extract
M8 media only
5 10 15
0
50
100
Retention time (min)
A
b
s
o
rb
a
n
c
e
 a
t 
2
5
4
 n
m
  
(m
A
U
)
Crude extract
Terrific broth media
5 10 15
0
50
100
Retention time (min)
A
b
s
o
rb
a
n
c
e
 a
t 
2
5
4
 n
m
  
(m
A
U
)
Crude extract
TSB media only
5 10 15
0
50
100
Retention time (min)
A
b
s
o
rb
a
n
c
e
 a
t 
2
5
4
 n
m
  
(m
A
U
)
Crude extract
M12 media only
Chapter 2. Developing a Micro-bioreactor technique for Microbial cultivation 
27 
 
 
 
Figure 2.9. HPLC-DAD chromatograms of analytical gradient, H2O/MeCN plus 0.05% HCO2H using Zorbax C8 for 
the crude extracts from CMB-TB365 cultivated in different media in the micro-bioreactor  
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2.2.4.2 Case study #2 for CMB-TB385 
As discussed earlier with strain CMB-TB365, the same procedure had been repeated with strain 
CMB-TB385 using the same twelve media (Figure 2.10). 
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Figure 2.10. HPLC-DAD chromatograms of analytical gradient, H2O/MeCN plus 0.05% HCO2H using Zorbax C8 for 
the crude extracts from CMB-TB385 cultivated in different media in the micro-bioreactor 
 
These results were similar to the one from CMB-TB365, in which CMB-TB385 was capable to 
grow and produce its secondary metabolites when cultivated on ISP2, M5, M1 and M6.  
2.3 Conclusion 
We have demonstrated that the simple and low cost micro-bioreactor can speed up the 
bioprocessing techniques by using small amount of reagents and very few seed cultures. The results 
obtained from the micro-bioreactor were parallel to the ones obtained from the shake flask, in fact 
in some cases the growth of the microbes in the micro-bioreactor was superior to the shake flask. 
The microbioreactor has the potential of replacing the normal conventional scale process and offers 
a high-throughput efficient and analytical technique in addressing some of the challenges 
encountered in bioprocessing starting that includes bacterial growth and secondary metabolites 
production. In our case studies, we proved that microbes were capable of growing in the micro-
bioreactor and the production of microbial secondary metabolites was reproducible and detectable 
in HPLC-DAD-MS. 
In this respect, it was notable to start use this new micro-bioreactor cultivation system and to carry 
out further studies in the chemical profiling for microbes. In order to perform these tasks, the 
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system had been optimized in respect of the culture volume, method of extraction, colonies dry 
weight and secondary metabolites profiling. Around 20 different microbes have been chosen for the 
study, in which the biomass yields were similar or better than in the shake flask. Secondary 
metabolites production were further studied on two Streptomyces sp. strains with codes (CMB-
TB365 and CMB-TB385). Secondary metabolites levels were within the range compared to those 
determined in the shake flask. Comparison between different media showed the almost the same 
metabolites production in the shake flask and micro-bioreactor. In the case of fungi the higher 
surface to volume ratio in the square wells of micro-bioreactor compared to shake flask provided a 
good substrate for the attachment, growth and morphological differentiation in which the aerial 
hyphae formulation and sporulation were observed. Also, there was no signs of cross contamination 
when cultivating both the fungi and actinomycetes in the same plate, which make it a good tool for 
screening different microbes in the same place. This new technique allows the cultivation of large 
number of microbes and generation of the microbial crude extract library (220) in which their 
biological activity were screened against our in house biological assay and continue working on the 
hits (chapter 3). 
 
In conclusion, this new micro-bioreactor technique facilitates cost- and labour-efficient, massive 
reproducible cultivations of different microbes including actinomycetes and fungi suitable for 
screening purposes or activation of microbial secondary metabolites studies. 
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2.4 Experimental section 
2.4.1 Cultivation of strains for chemical profiling 
2.4.1.1 Actinomycetes 
Strains were chosen from the terrestrial library for chemical investigation depending on their 
chemical profiling as well as their morphological appearance.  A primary culture of the strain was 
started using the total volume of the preserved frozen stock as a seed culture in 100 mL of media in 
a shake flask at 190 rpm for 7 − 10 d. After the cultivation period, the whole culture was extracted 
with EtOAc (100 mL × 3), and the decanted EtOAc extract was concentrated in vacuo. Chemical 
profiling was achieved by HPLC-DAD (Zorbax C8 analytical column, 150 × 4.6 mm, 5 µm, eluting 
with 1.0 mL/min 90 − 0% H2O/MeCN (0.05% HCO2H modifier) over 15 min, then held for 5 min) 
and detecting at 210 and 254 nm (DAD). Archived crude extracts were stored at −32 °C in 96 well 
microtiter plate. 
2.4.1.2 Fungi 
Fungi colonies were inoculated onto agar petri dish from cryo-preserved stock. After 5 − 10 d, agar 
subculture samples (approx. 1.5 cm3) were excised from the plate and used to inoculate broth media 
(80 mL) in a shake flask. Cultivation conditions and media used were identical to those used for 
actinomycetes. Archived crude extracts were stored at −32 °C in 96-well microtiter plate for further 
investigation. 
 
2.4.2 Growth phase studies 
2.4.2.1 Growth phase-dependent production of secondary metabolites for both strains CMB-
TB0365 and CMB-TB0385 
Two strains CMB-TB0365 and CMB-TB0385 were chosen to be cultivated with the crude extract 
library for the activation of secondary metabolites production. These strains were cultivated for 7 d 
in M1 and ISP-2 broth media respectively at 190 rpm. Liquid micro-cultures were cultivated in 
polypropylene deep well plates with 40 mm deep wells and cross section of 17 × 17 mm. The plates 
were covered by the sandwich covers. The sandwich covers were designed to provide headspace 
refreshment. They consist of stainless steel lid for rigid support, micro fibre layer, extruded or 
ePTFE (0.2 µm pores) for sterility and soft silicone layer to seal the mini-reactors. These sandwich 
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covers also act to secure the oxygen concentration and to limit the evaporation of water. These 
micro-cultures enclosed 1.5 mL broth and inoculated with spores from the seed culture.  Plates were 
put on cover clamp and then mounted on orbital platform shaker and incubated at 26.5 °C with 
shaking at 150 rpm. For the micro-bioreactor and the flask, metabolites productions in liquid 
cultures were determined by withdrawing 50 µL everyday to measure the OD at 400 nm. At the 
same time, for the micro-bioreactor, 1.5 mL ethyl acetate was added to one well daily. The plate 
was incubated for 2 h and then the ethyl acetate layer was transferred to 8 mL vial and concentrated 
to dryness under N2. For the flasks, 1 mL of the culture broth was withdrawn into 8 mL vial and 
then 1 mL of EtOAc was added, then the EtOAc layer was concentrated to dryness under N2. The 
crude extracts were solubilised in 100 µL MeOH. The extracts were analysed using Zorbax C8 
analytical column, 150 × 4.6 mm, 5 µm, eluting with 1.0 mL/min 90 − 0% H2O/MeCN (0.05% 
HCO2H modifier) over 15 min, then held for 5 min and detecting at 210 and 254 nm (DAD). 
2.4.2.2 Effect of different media on the secondary metabolites produced by Strain CMB-
TB0365 and CMB-TB0385 
The expression of secondary metabolites might depend on the culture conditions especially the 
media components. Therefore, 12 different media were selected from the literature (Appendix 1) for 
the cultivation of CMB-TE0385. These twelve media were prepared in duplicate as water and ocean 
seawater based media.  
In this experiment, 1.35 mL from each medium was transferred to a 24 well microtiter plate. Then 
15 µL of the seed culture of strain CMB-TB0365 and CMB-TB0385 was transferred to all the 
wells. The plates were incubated on linear shaker 190 rpm at 26.5 °C for 7 d. After the incubation 
time, 2 mL of EtOAc was added to all the wells and the plates were further shaken for another 2 h. 
The organic layer was then transferred to 8 mL vial and dried under N2. The crude extract was 
subjected to chemical profiling using the CMB standard gradient, Zorbax C8 analytical column, 150 
× 4.6 mm, 5 µm, eluting with 1.0 mL/min 90 − 0% H2O/MeCN (0.05% HCO2H modifier) over 15 
min, then held for 5 min and detecting at 210 and 254 nm (DAD). 
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3 Chapter 3. Activation of Microbial Secondary Metabolites 
3.1 General outlines 
Chapter 1 raised the importance of activating microbial secondary metabolites noting the need for 
new tools to access the full microbial genome, while Chapter 2 commented on the construction and 
operation of a micro-bioreactor, and its validation against multiple strains, plus reproducibility of 
yields and productivity. Chapter 3 looks more closely as the challenge of activating microbial 
secondary metabolite production. It is well known that altering culture conditions (i.e media 
composition, temperature, pH, etc.) can lead to significant changes in the expression of microbial 
secondary metabolites. Although this technique has been successfully used for over a century, it is 
nevertheless a somewhat unpredictable process that to date has still failed to activate the full suite 
of “silent” metabolites. This chapter seeks to address the questions of how to activate silent 
secondary metabolites by looking for nature chemical cues that stimulate metabolism. This study 
explored two different sources of chemical cues; (1) microbial crude extracts, (2) 
lipopolysaccharide (LPS) from the Gram-negative bacterium (Escherichia coli).  
3.1.1 Microbial crude extracts 
It is quite evident that microbial (bacteria or fungi) crude extracts contain several important 
bioactive compounds and some have already shown their therapeutic activity. Unfortunately, most 
of the compounds have not properly been evaluated for the exploration of new lead molecule. 
Moreover, some of the mechanisms of actions of few bioactive compounds have not been identified 
so far. Hence, extensive research is required to find out the activity of compounds in the microbial 
crude extracts and to exploit their therapeutic potential to unlock silent secondary metabolites. 
Therefore, this study aimed to develop a new program through extensive investigation of the 
bioactivity of crude extracts isolated from different microbes including actinomycetes and fungi. 
This chapter will explain the construction of microbial crude extracts library using the micro-
bioreactor technique and the usage of this library to activate microbial secondary metabolites in 
microbes. 
3.1.2 Lipoplysaccharide 
The lipolysaccharide (LPS) is the main component of the cell wall of all the Gram-negative 
bacteria. The composition of the cell wall of the Gram-negative bacteria is made up of an outer 
membrane, inner plasma membrane and a peptidoglycan layer in the periplasm. The inner cell wall 
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is mainly considered of phospholipids while the outer surface of the outer membrane is composed 
of 90% LPS, plus the addition of some phospholipids and proteins. LPS consists of phospholipids 
in which the hydrophilic portion contains different polysaccharide made of core and outer 
portion.68,69  
 
LPS is a tripartite molecule comprising a membrane-anchored lipid A moiety, a core 
oligosaccharide and an O-antigen polysaccharide made up of repeating units. 3-deoxy-D-manno-2-
octulosonate (KDO) residues link lipid A to the core oligosaccharide, which can also be decorated 
with other (often nonstoichiometric) substituents, such as phosphate and phosphoethanolamine. 
LPS is only found in Gram-negative bacteria.70  
 
LPS contributes to the structural integrity of the cell wall, as a barrier that prevents the penetration 
of toxic substances such as antimicrobial agents. The outer polysaccharide component of LPS is 
composed of up to 40 repeating units that extend into the extracellular environment. The outer 
polysaccharide – also referred to as the O-antigen of the bacteria – varies among different Gram-
negative bacteria and is the major antigenic determinant involved in interactions with antibodies, 
porins, LPS-binding protein. The presence or absence of O-antigen determines whether the LPS is 
rough or smooth. Full-length O-chains would render the LPS smooth, whereas the absence or 
reduction of O-chains would make the LPS rough.69 
 
Figure 3.1. A Gram-negative bacterium. Electron micrograph of Escherichia coli (a) together with a schematic 
representation of the location of lipopolysaccharide (LPS; endotoxin) in the bacterial cell wall (b) and the architecture 
of LPS. (c). Also shown is the primary structure of the toxic center of LPS, the lipid A component (d). GlcN, D-
glucosamine; Hep, L-glycero-D-manno-heptose; Kdo, 2-keto-3-deoxy-octulosonic acid; P, phosphate. Figure from 
Giuliani et al.69  
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Bacteria with rough LPS usually have more penetrable cell membranes to hydrophobic antibiotics, 
since a rough LPS is more hydrophobic. O-antigen is exposed on the very outer surface of the 
bacterial cell, and, as a consequence, is a target for recognition by host antibodies. The Core domain 
always contains an oligosaccharide component that attaches directly to lipid A and commonly 
contains sugars such as heptose and 3-deoxy-D-mannooctulosonic acid (also known as KDO, keto-
deoxyoctulosonate). The LPS Cores of many bacteria also contain non-carbohydrate components, 
such as phosphate, amino acids, and ethanolamine substituents.68 The hydrophobic, membrane-
anchoring region of LPS is called lipid A. This part of the LPS is well conserved among bacterial 
species, and is considered as the most active moiety of LPS, responsible for many of the 
pathophysiological effects associated with infection. Lipid A is composed of phosphorylated 
glucosamine disaccharide decorated with saturated acyl chains linked through amide and ester 
bonds. When bacterial cells are lysed by the immune system, fragments of membrane containing 
lipid A are released into the circulation, causing fever, diarrhoea, and even fatal endotoxic shock 
(also called septic shock)70 as shown in Figure 3.1. LPS plays a vital role in mediating interaction 
between Gram-negative bacteria and environment, influencing colonization and immunological 
responses. Investigators provided different evidences the LPS can play a crucial role beyond our 
understanding. For example, consider the case study for Helicobacter pylori responsible for chronic 
gastritis, which may develop into ulcers or cancers.71,72 This kind of microbial invasion is 
recognized by the host and promotes an inflammatory response, leading to the release of 
macrophages and neutrophils. For the immunity response to be activated requires the recognition of 
the microbial chemistry associated with structural units as flagella, lipoproteins, peptidoglycan and 
LPS.73 
 
LPS is considered to be a potentially potent signal driving inflammation.74 In order to overcome this 
problem, the H. pylori acquired an important adaptation, a modified lipid A region with a much 
lower endotoxic effect and a low ability to stimulate immune response.75,76 In addition, H.pylori 
also expresses an O-antigen that decrease Lewis blood group antigens present in the human cells 
and therefore avoids an immune response77 and inhibits phagocytosis. The antiphagocytic 
mechanism is regulated by the bacterial surface structure in which the LPS mediate direct 
bacteria/phagocyte interaction and inhibits the ingestion by human blood granulocytes.78 In 2008, 
Hui et al. proved that LPS was capable of inducing a proliferation of B-cells and that this effect was 
dose dependent manner. They examined the accessory roles of LPS-activated murine splenic B cells 
in initiating/modulating T-cell in the immune system.79 There is a great demand on the use of 
microbes for the environmental remediation purposes. It has been proved that LPS in Pseudomonas 
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aeruginosa is the key factor in the process that controls the ability on reducing metals in the 
respiratory cycle and uptake of solvated metal ions from the surrounding environment as well as 
absorb metal ions. There are some experimental evidence that prove that P. aeruginosa has the 
ability to bind to ions such as Cu2+, Fe3+, La3+, Eu3+ and UO22+ in the cell wall which suggests that 
the binding site for the metal ions is located in the LPS unit.80-82  
 
In the environment, which is rich with both pathogenic microbes and eukaryotic organisms, the 
crucial defence mechanism, which is the innate immunity, becomes the only and the first defence 
mechanism in plants and eukaryotic organisms.83-85 Bacterial LPSs from the outer membrane of the 
Gram-negative bacteria is considered as main elicitors of associated plant innate immunity. LPS has 
been reported to induce the immune response in plants that includes oxidative brust, NO 
production, calcium influx mechanism, the induction of pathogenesis related (PR) gene expression 
and alterations in the cell wall that includes the deposition of callose and phenolics, in which LPS 
has been added from different sources of bacteria to the cell suspension of leaves.86-90 All these 
common effects from different LPS sources suggest that LPS has a common shared molecule 
determinant which is lipid A and indeed isolated lipid A was also active.91 The concentrations of 
LPS that is required to induce of the effects described above are in the range of 5 - 100 mg/mL, 
which may suggests that plants possess low affinity system/less sensitive to LPSs compared to 
mammalian cells, which can respond at concentrations in the range of pg/mL to ng/mL.91 
 
In mammals, it was observed that LPS is a potent activator of the hypothalamo-pituitary-adrenal 
axis (HPA)92 by stimulating CRH secretion and there is strong evidence for CRH-independent 
effects93,94 which in turn plays an important role in the stress response and acute infection to 
maintain homeostasis. It appears that LPS may act on each tissue comprising the HPA axis, because 
there is evidence for a pituitary-independent effect of LPS on the adrenal gland, which in turn 
causing the LPS to increase corticosterone secretion in both intact and hypophysectomized rats.95 
More recently, it has been shown that LPS inhibits ACTH-stimulated corticosterone secretion by 
cultured rat zona glomerulosa cells, although the effect on basal secretion was not determined.96 It 
has been shown that LPS from Gram negative bacteria (Escherichia coli LPS) has the affinity to 
bind/act though Toll-like receptors (TLRs), specifically exerting a direct stimulatory effect on the 
induction of cortisol but not aldosterone secretion by human adrenocortical cells.97 Based on all 
these information, LPS from Escherichia coli was tested on different microbes including 
actinomycetes (Streptomyces sp.) and fungi. This chapter seeks to test the hypothesis that microbes 
have many silent gene clusters that remain dormant under normal laboratory conditions, but can be 
activated in response to the chemical signal. 
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3.2 Results and discussion 
3.2.1 Assembly of an integrated set of microbial diversity libraries 
During my PhD, the library of microbes was assembled in which it consists of around 440 microbes 
including actinomycetes, fungi and unicellular bacteria with the codes CMB-TB (terrestrial 
bacteria) and CMB-TF (terrestrial fungi). In addition, Capon group has access to the pre-existing 
library of Australian marine bacteria (CMB-M) and fungi (CMB-MF) plus around 5000 different 
species including 500 different species of Streptomyces from Australian Collection of Microbes 
(ACM). Having access to this vast number of strains, the micro-bioreactor was used to construct a 
selected library of microbial crude extracts by subjection a subset of isolates (~ 500) to liquid 
cultivation using the micro-bioreactor. Solvent extraction and high throughput HPLC-DAD-HRMS 
and HPLC-DAD-MS analysis provided qualitative and quantitative data defining a structurally 
diverse set of metabolites (Scheme 3.1).  
 
Scheme 3.1. Flow chart for the construction of microbial library and crude extract 
 
3.2.2 Activation of silent microbial secondary metabolites 
In an innovative combinatorial assay, the microbial biodiversity library was incubated in the 
presence of the metabolite rich extract library and pure compound library to generate a library of 
activated microbial crude extract (Scheme 3.2). 
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Scheme 3.2. Scheme of the high-throughput activation of microbial secondary metabolites using crude extracts/pure 
compounds 
 
3.2.3 Activation of silent metabolites using microbial crude extracts 
A terrestrial actinomycete (CMB-TB365) was chosen for this study to be cultivated in the presence 
of the microbial extract library. Strain CMB-TB0365 was cultivated on M1 media in the 
microbioreactor (1.45 mL) in the presence of 0.1 mg of the microbial crude extract (1% DMSO). 
CMB-TB365 was challenged with around 200 crude extracts. The plates were incubated at 26.5 °C 
for 7 – 10 days at 190 rpm. The cultures were treated in situ with EtOAc (2 mL), shaken for 1 h and 
the decanted organic layer was dried under N2, re-dissolved in MeOH (100 µL) prior to analysis by 
HPLC-DAD-MS. Therefore, 200 experiments revealed two hits, in which the crude extracts from 
microbial isolates CMB-TB225 and CMB-TB464 were able to activate silent microbial metabolites 
in strain CMB-TB365 (Figure 3.2 and Figure 3.3). This study supported our original hypothesis that 
the organic extracts from microbial cultures possess chemical cues capable of activating otherwise 
silent secondary metabolites. Future studies should employ a larger combination of extracts and 
microbial cultures and should concentrate on isolating both the “activated” metabolites, and the 
chemical cues responsible for “activation”. 
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Figure 3.2. HPLC-DAD chromatogram, analytical gradient H2O/MeCN, 0.05% HCO2H using Zorbax C8 of the 
activation of microbial secondary metabolites for strain CM-TB365 in the presence of (a) crude extract from CMB-
TE225 and (b) absence of crude extract CMB0TE225 
 
 
Figure 3.3. HPLC-DAD chromatogram, analytical gradient H2O/MeCN, 0.05% HCO2H using Zorbax C8 of the 
activation of microbial secondary metabolites of strain CMB-TB365 in the presence of (a) crude extract from CMB-
TE464 and (b) absence of crude extract CMB-TE464 
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3.2.4 Activation of silent metabolites using LPS 
In this section, we will describe the activation of microbial secondary metabolites upon the addition 
of lipopolysaccharide (LPS) isolated from Escherichia coli purchased from Sigma-Aldrich and the 
effect on different actinomycetes and fungi. Extracts from different actinomycetes and fungi that 
showed secondary metabolites activation with LPS were screened against antibacterial assay. All 
the hits were tested against antimicrobial assay and they showed Gram-negative inhibition. The hits 
that showed antimicrobial effect where further more subjected to large-scale cultivation and the 
isolation of the microbial metabolites. Antibacterial extracts conformed to the criteria of the project 
and were considered ‘lead’ extracts for further investigation. ‘Leads’ were found in three 
actinomycetes and two fungi. Bioassay-guided fractionation of the microbial extract led to the 
identification of 5 known compounds and one new metabolite. This chapter will show the isolation, 
purification and structural elucidation of ten different microbial compounds including 1 new 
compound.  
LPS was added to different culture media of 40 different actinomycetes and 30 different fungi. The 
LPS is soluble in water and was added at a final concentration 1 ng/mL to all the culture media of 
the microbes. The microbes were incubated for a period of 7 – 10 days at 27 °C. After the 
incubation period the whole broth/agar was extracted with EtOAc and the organic layer of 
concentrated in vacuo. The organic was re-dissolved in MeOH (100 µL) and analyzed by HPLC-
DAD-MS. The crude extracts that showed activation/enhancement of microbial secondary 
metabolites were subjected to further analysis by scaling up the cultivation process and isolation of 
the activated/enhancement secondary metabolites. 
  
Therefore, a study has been done by testing around 40 different actinomycetes/fungi from the 
Australian collection of microbes (ACM); with and without the presence of LPS. This study 
confirmed that LPS added at low concentration could activate secondary metabolites in both 
bacteria and fungi. The activated crude extracts have been tested against their antibacterial activity 
against different Gram-negative and Gram-positive bacteria. This chapter will outline the chemical 
analysis of the promising activating events (Scheme 3.3, Figure 3.5, Figure 3.6 and Figure 3.7). 
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Scheme 3.3.  Activation of microbial secondary metabolites by LPS 
 
3.2.4.1 Hits from the activation of microbial metabolites by LPS 
According to the scheme described above (Scheme 3.3), different strains including actinomycetes 
and fungi were tested with LPS in which media broth ISP-2 (1.485 mL) was transferred to all the 
wells plus LPS (15 µL) to give a final concentration 1 ng/mL plus spores from seed culture 
cultivated on ISP-2 agar plate. The plates were incubated at 26 °C, 190 rpm for 7 − 10 days. After 
the incubation period, the broth was extracted by the addition of EtOAc (2 mL) and the organic 
layer was decanted and dried under N2. The crude extract was dissolved in MeOH (100 µL) and 
analysed by the HPLC-DAD-MS (Figure 3.4, Figure 3.5 and Figure 3.6). The control wells contain 
only water. The hits where tested for their antibacterial activity against Gram negative and Gram 
positive bacteria (Figure 3.7) and they were cultivated on large scale for isolation of the activated 
metabolites. Figure 3.4, Figure 3.5 and Figure 3.6 are examples for the activation process with LPS. 
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Figure 3.4. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 of the 
crude extract from ACM-165F in the (a) presence and (b) absence of LPS. The highlighted peak represent the 
enhancement of fungal metabolites while the blue peak represent the activation of fungal metabolites 
 
Figure 3.5. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 of the 
crude extract from ACM-194F in the (a) presence and (b) absence of LPS. The highlighted peak (blue) represents the 
activation of fungal metabolites 
 
Figure 3.6. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 of the 
crude extract from ACM-4993F in the (a) presence and (b) absence of LPS.  The highlighted peak (blue) represents the 
activation of fungal metabolites 
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The above figures showed the enhancement of secondary metabolites (Figure 3.4) and activation of 
metabolites (Figure 3.5 and Figure 3.6). Most of the activated metabolites belong to the class of 
metabolites as indicated from the UV spectrum. 
The antibacterial activity of the activated crude extracts was investigated against Gram-positive 
bacteria where they showed potent inhibition against Bacillus subtilis ATCC 6051 and 6633 (Figure 
3.7) 
 
Figure 3.7. Antibacterial assay results showing the effect of the crude extract with LPS compared to the control. The 
activated crude extract showed activity against Bacillus subtilis ATCC 6051/6633 
 
All these promising results prompted us to start looking into the activated crude extracts and 
investigate the activated secondary metabolites. In the next section, we will focus on four crude 
extracts that showed good antibacterial activity. 
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3.2.5  Streptomyces pseudoechinosporeus (ACM-2573) 
 
Figure 3.8. Streptomyces pseudoechinosporeus (ACM-2573) 
3.2.5.1 Analytical cultivation and chemical analysis 
A single colony of ACM-2573 was used to inoculate ISP-2 agar media, which was cultivated for a 
period of 10 days. After cultivation, spores from seed culture were used to inoculate ISP-2 broth 
(1.48 mL) in the microbioreactor to which LPS (15 µL) was added to give final concentration 0.6 
ng/mL. The micro-bioreactor was incubated at 26 °C, 190 rpm for 7 days. After the incubation 
period, the broth was extracted with EtOAc (2 mL), and the organic extract was dried in vacuo. The 
resulting crude extract was resuspended in MeOH (100 µL) and analysed by HPLC-DAD-MS. The 
control wells were only inoculated with the bacterial spores. HPLC chromatogram was dominated 
by a single peak attributed to 3.02. After the addition of LPS, 3.02 was enhanced and another new 
metabolite was produced 3.01. Peaks with the following retention times tR = 13.1 and 14.8 min 
exhibited the following m/z [M+H]+ 393 (3.01) and 377 (3.02) as shown in Figure 3.9. 
 
Figure 3.9. HPLC-DAD (254 nm) chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 
for the crude extract from ACM2573F in the (a) presence and (b) absence of LPS. The highlighted peak (blue) 
represents the activated metabolite and represents the enhanced metabolite in the presence of LPS 
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3.2.5.2 Preparative cultivation 
A seed culture was prepared by inoculating a 250 mL flask containing liquid medium (80 mL 
deionized water containing 0.4% starch, 0.2% yeast extract, 1% malt extract) with a single colony 
of ACM-2573 followed by shaking at 190 rpm for 7 d at 26.5 °C. Aliquots of the seed culture (5 
mL) were transferred to two 2 L Fernbach flasks, each containing the same liquid medium (500 
mL) and LPS (1 ng/mL), and the flasks were shaken at 190 rpm for 7 d at 26.5 °C. The resulting 
cultures were each extracted with EtOAc (400 mL) and the combined organic phases concentrated 
in vacuo to yield an extract (60.2 mg). The extract was sequentially triturated with hexane (15 mL) 
and CH2Cl2 (15 mL) to afford, after concentration in vacuo, 3.0 and 60.2 mg, respectively. The 
CH2Cl2 fraction was subjected to semi-preparative reversed-phase HPLC (Zorbax C8 column, 250 × 
9.4 mm, 5 µm, 4 mL/min gradient elution 90% H2O/MeCN to 100% MeCN over 30 min to yield 
resistoflavin (3.01) (tR = 23.9 min, 1.1 mg, 1.8%) and resistomycin (3.02) (tR = 25.5 min, 0.9 mg, 
1.5%) (Scheme 3.4).  
 
 
 
Scheme 3.4. Isolation scheme of ACM-2573 leading to the 2 metabolites. Compounds shaded in blue were isolated and 
tested against antimicrobial assay. (a) Trituration [hexane (-1-1) and CH2Cl2 (-1-2)], (b) Semi-preparative HPLC: 
Zorbax-C8, 90-10% H2O/MeCN, 3 mL/min, 30 min 
crude extract
83.2 mg
-1-1
3 mg
-1-2
60.2 mg
-1-2-2
1.1 mg
3.01
-1-2-4
0.9 mg
3.02
(a)
(b)
(a)- Trituration [Hexane (-1-1), DCM (-1-2)
(b)- Semi-preparative HPLC: Zorbax-C8, 90-10% H2O/MeCN, 3 mL/min, 30 min
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3.2.5.2.1 Resistoflavin (3.01) 
 
HRESI(+)MS data for 3.01 revealed a quasi-molecular ion (M+H)+ indicative of a molecular 
formula C22H16O7 (Δmmu –0.1). The 1H NMR and 2D NMR (CDCl3) data (Figure 3.11 and Table 
3.1) for 3.01 showed the presence of three chelated hydroxyl groups (δH 13.52, 12.69 and 12.53), 
three singlets isolated aromatic resonances at (δH 6.94, 6.56 and 6.52), an aromatic methyl (δH 2.76) 
and two aliphatic methyls (δH 1.73 and 1.62). The structure elucidation was further supported by 2D 
NMR data, including HSQC, COSY and HMBC, as outlined in Figure 3.10. On searching the 
literature with the molecular formula, molecular weight and structure fragment, 3.01 was identified 
as resistoflavin, an actinomycete metabolite first reported by Eckardt et al. in 197099 and it was re-
isolated with its O-methyl derivative from different terrestrial and marine derived Streptomyces sp. 
(Streptomyces griseoflavus and Streptomyces resistomycificus).100-102 Comparison of full 
experimental and literature data (Table 3.2), including experimental [α]22D +537 (c 0.02, pyridine) 
and literature [α]23D –96 (c 0.5, pyridine) suggested that we may have the enantiomer of the 
unknown resistoflavin. The variation in the optical rotation between our candidate and the literature 
data is due to the high concentration of resistoflavin that has been reported. Resistoflavin was 
considered as potent cytotoxic against gastric adenocarcinoma and exhibited weak antibacterial 
activity against Gram-negative and Gram-positive bacteria.103  
 
 
Figure 3.10. Key 2D NMR correlations of resistoflavin (3.01) 
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Figure 3.11. 1H NMR (600 MHz, CDCl3) spectrum of resistoflavin (3.01) 
 Table 3.1. NMR (600 MHz, CDCl3) data of resistoflavin (3.01) 
Pos.  δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1  47.5   
2  203.1   
2a  109.1   
2b  b   
3-OH 13.52, s  13, 14 2a, 4, 5 
4 6.56, s 105.5  3 
5  169.6   
5-OH 12.69, s    
5a  b   
6  165.7   
6a  b   
6b  b   
7-OH 12.53, s   6, 8 
8 6.52, s 128.3 12 9a 
9  151.6   
9a  120.2   
10  b   
11 6.94, s 123.3  9a 
11a  156.3   
11b  b   
12-Me 2.76, s 32.6 8 8, 9 
13-Me 1.73, s 24.0 3, 14 1, 2, 11a, 14 
14-Me 1.62, s 24.8 3, 13 1, 2, 11a,13 
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) signals not detected 
 
Table 3.2. 1H NMR (DMSO-d6) comparison of experimental and literature103 data of resistoflavine (3.01)  
Pos δH, mult, (J in Hz)a experimental δH, mult, (J in Hz)b literature 
4 6.52, s 6.55, s 
7-OH 12.35, s 12.37, s 
8 6.97, s 7.00, s 
11 6.45, s 6.49, s 
12-Me 2.65, s 2.69, s 
13-Me 1.59, s 1.61, s 
14-Me 1.50, s 1.54, s 
measured in (a) (600 MHz, DMSO-d6), (b) (200 MHz, DMSO-d6) 
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3.2.5.2.2 Resistomycin (3.02) 
 
HRESI(+)MS data for 3.02 revealed a quasi-molecular ion (M+H)+ indicative of molecular formula 
C22H16O6 (Δmmu –0.6). The 1H NMR and 2D NMR (MeOH-d4) data (Figure 3.12, Figure 3.13 and 
Table 3.3) showed that 3.02 was very similar to 3.01, but lacking the 11b-OH. The structure 
elucidation was supported by 2D NMR data, including HSQC, COSY and HMBC, as outlined in 
Figure 3.12. Literature searching led the known bacterial metabolite resistomycin. Resistomycin 
(3.02) was first reported from Streptomyces griseoflavus by Hofle et al. in 1983.101 Analysis of all 
the NMR data with comparison to literature data (Table 3.3), strongly suggested that 3.02 was the 
known metabolite resistomycin. Resistomycin is a quinone-related antibiotic with unique structure 
and exhibited bactericidal and vasoconstrictive activity. In addition, it inhibits RNA and protein 
synthesis, but have no effect on the DNA synthesis.104 
 
 
Figure 3.12. Key 2D NMR correlations of resistomycin (3.02)  
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Figure 3.13. 1H NMR (600 MHz, MeOH-d4) spectrum of resistomycin (5.02). (x)- signals for impurities 
 
Table 3.3. NMR (600 MHz, MeOH-d4) data of resistomycin (3.02) 
Pos.  δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1  45.1   
2  205.9   
3  b   
4 6.28, s 100.0   
5  b   
6b  106.8   
7  b   
8 6.97, s 118.3   
9  152.1   
10  b   
11 7.09, s 111.7  6b 
11a  152.7   
12-Me 3.01, s 24.4 8 8,9 
13,14-Me 1.63, s 28.3  1, 2, 11 
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Signals not observed 
 
Table 3.4. 1H NMR (DMSO-d6) comparison of experimental and literature105 data of resistomycin (3.02)  
Pos δH, multa experimental δH, multb literature 
3-OH 14.13, s 14.42 
4 6.30, s 6.29, s 
5-OH 14.39, s 14.30, s 
7,10-OH 12.21, s 12.27, s 
8 6.97, s 6.93, s 
11 7.17, s 7.21, s 
12-Me 2.89, s 2.87, s 
13,14-Me 1.50, s 1.56, s 
measured in (a) (600 MHz, DMSO-d6), (b) (500 MHz, DMSO-d6) 
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3.2.5.2.3 Conclusion 
We were able to report that trace levels of LPS added to a culture of Streptomyces 
pseudoechinosporeus (ACM-2573) stimulated the production of resistoflavin (3.01) and enhanced 
the produced of the oxidized analogue of the co-metabolite resistomycin (3.02). Recent literature 
report notes106 that oxidation of 3.02 into 3.01 is catalyzed by RemO, flavin adenine dinucleotide 
(FAD) dependent monooxygenase, which uniquely oxidizes the Re face of 3.02 to deliver 3.01 as a 
single (−) entianmer. By contrast, the sample of resistoflavin produced by LPS activation (during 
our study) was the (+) enantiomer, a new metabolite. This observation requires further analysis of 
3.02 to authetntic resistomycin. Also, this observation suggests that LPS activation stimulates the 
transcription and/or functionality of RemO106 or an equivalent monooxygenase, with the opposite 
enantio selectivity to that reported earlier. 
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3.2.6 CMB-TF411 
3.2.6.1 Analytical cultivation and chemical analysis 
 
Figure 3.14. Picture of CMB-TF411 
 
Fungal strain (CMB-TF411) was isolated from a terrestrial sample collected from North Stradbroke 
Island, Brisbane (see Chapter 10). A single colony of CMB-TF411 was used to inoculate a seed 
culture on ISP-2 agar media, which was cultivated for a period of 10 d. A single colony was used to 
inoculate ISP-2 broth (1.48 mL) in micro-bioreactor in the presence of LPS (15 µL) to give final 
concentration (0.6 ng/mL). The micro-bioreactor was incubated at 26 °C, 190 rpm for 7 days. After 
the incubation period, the broth was extracted with EtOAc (2 mL), and the organic extract was 
dried under N2. The resulting crude extract was resuspended in MeOH (100 µL) and analysed by 
HPLC-DAD-MS. The control wells were only inoculated with the fungal spores. HPLC 
chromatogram was dominated by a single peak attributed to 3.03. The addition of LPS, 3.04 was 
activated. Peaks with the following retention times tR = 12.2 and 13.9 min exhibited the following 
m/z [M+H]+ 543 (3.03) and 539 (3.04) as shown in Figure 3.15. 
 
Figure 3.15. HPLC-DAD (254 nm) chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax 
C8 of the crude extract from CMB-TF411 in the (a) presence and (b) absence of LPS cultivated on ISP-2 medium. The 
highlighted peak represents the activated metabolite in the presence of LPS 
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3.2.6.2 Preparative cultivation 
A seed culture was prepared by inoculating a 250 mL flask containing liquid medium (80 mL 
deionized water containing 0.4% starch, 0.2% yeast extract, 1% malt extract) with a single colony 
of CMB-TF411 followed by shaking at 190 rpm for 7 d at 26.5 °C. Aliquots of the seed culture (5 
mL) were transferred to two 2 L Fernbach flasks, each containing the same liquid medium (500 
mL) and LPS (0.6 ng/mL), and the flasks were shaken at 190 rpm for 7 d at 26.5 °C. The resulting 
cultures were each extracted with EtOAc (400 mL) and the combined organic phases concentrated 
in vacuo to yield an extract (83.2 mg). The extract was sequentially triturated with hexane (15 mL), 
CH2Cl2 (15 mL) and MeOH (15 mL) to afford, after concentration in vacuo, 8, 10 and 45.2 mg 
fractions, respectively. The MeOH fraction was subsequently subjected to semi-preparative 
reversed-phase HPLC (Zorbax C8 column, 250 × 9.4 mm, 5 µm, 3 mL/min gradient elution 90 − 
10% H2O/MeOH over 30 min to yield rugluosin (3.03) (tR = 21.6 min, 0.8 mg, 1.7%) and skyrin 
(3.04) (tR = 24.5 min, 1.4 mg, 3.1%) (Scheme 3.5).  
 
Scheme 3.5. Isolation scheme for CMB-TF411 leading to the 2 metabolites. Compounds shaded in blue were isolated 
and tested against antimicrobial assay. (a) Trituration [hexane (-1-1), CH2Cl2 (-1-2) and MeOH (-1-3)], (b) Semi-
preparative HPLC: Zorbax-C8, 90 −  10% H2O/MeOH, 3 mL/min, 30 min 
crude extract
83.2 mg
-1-1
8 mg
-1-3
45.2 mg
-1-2
10 mg
-1-3-1
0.8 mg
3.03
-1-3-2
1.4 mg
3.04
(a) Trituration [hexane (-1-1), DCM (-1-2) and MeOH (-1-3)]
(b) Semi-preparative HPLC: Zorbax-C8, 90-10% H2O/MeOH, 3 mL/min, 30 min
(a)
(b)
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3.2.6.2.1 Rugulosin (3.03) 
 
 
HRESI(+)MS data of 3.03 revealed a quasi-molecular ion (M+H)+ indicative of molecular formula 
C30H22O10 (Δmmu +0.5).  The 1H NMR and 2D NMR (DMSO-d6) data (Figure 3.16, Figure 3.17 
and Table 3.5) was suggestive of anthraquinone. The structure assignment was supported by 2D 
NMR data, including HSQC, COSY and HMBC, as outlined in Figure 3.16 and comparison which 
determined that 3.03 was very likely rugulosin107. Comparison of NMR data with literature data 
(Table 3.6) suggested this assignment, while a comparison of the experimental [α]22D +68.6 (c 0.05, 
MeOH) and literature [α]30D +276 (c 0.35, MeOH)108. The difference in the optical rotation was 
attributed to the presence of impurities in 3.03. (+) rugulosin (3.03) was first reported from 
Penicillium rugulosum.107 Rugulosin (3.03) has been reported before to possess toxic, mutagenic 
and insecticidal activities.109-111  
 
 
Figure 3.16. Key 2D NMR correlations of rugulosin (3.03) 
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Figure 3.17. 1H NMR (600 MHz, DMSO-d6) spectrum of rugulosin (3.03) 
Table 3.5. NMR (600 MHz, DMSO-d6) data of rugulosin (3.03) 
Pos.  δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1,1′-OH b    
2 2.46, d (4.7) 58.2 3  
3 4.43, m 58.3 2  
3,3′-OH 6.01, s    
4,4′ 3.49, d (2.6) 52.2 3,3′  
5,5′ b    
6,6′ 7.45, d (8.8) 122.2 15,15′ 8/8′, 13/13′ 
7,7′  119.2   
8,8′ 7.20, d (4.9) 124.2 15,15′ 6/6′ 
9,9′  150.3   
9,9′-OH 11.4   11/11′ 
10,10′  115.2   
11,11′  160.4   
12,12′  b   
13,13′  195.1   
14,14′  135.6   
15,15′ 2.39, s 135.6 6, 8  
1′-OH b    
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) signals not detected 
 
Table 3.6. 1H NMR (DMSO-d6) comparison for experimental and literature112 data of rugulosin (3.03)  
Pos. δH, mult, (J in Hz)a experimental δH, mult, (J in Hz)a literature 
1,1′-OH b 14.54, s 
2,2′ 2.76, d (4.7) 2.78, d (5.5) 
3,3′ 4.43, m 4.38, br d (5.5) 
4,4′ 3.48, d (2.6) 3.38, brs 
6,6′ 7.45, d (1.4) 7.43, d (1.2) 
8,8′ 7.20, d (4.9) 7.16, d (1.2) 
9,9′ 11.4, s 11.37, s 
15,15′ 2.39, s 2.42, s 
measured in (a) (600 MHz, DMSO-d6), (b) signals not detected 
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3.2.6.2.2 Skyrin (3.04)  
 
HRESI(+)MS data for 3.04 revealed a quasi-molecular ion [M+H]+ indicative of molecular formula 
C30H18O10 (Δmmu +0.3). The 1H NMR and 2D NMR (DMSO-d6) data (Figure 3.19 and Table 3.7) 
was suggestive of anthraquinone. The structure assignment was supported by 2D NMR data, 
including HSQC, COSY and HMBC, as outlined in Figure 3.18, and comparison with literature 
data, which determined that 3.04 was very likely skyrin. Analysis of all the NMR data with 
comparison to literature data (Table 3.8), strongly suggested that 3.04 was the known metabolite 
fungal metabolites skyrin.107 In 1975, Toma et al. reported NMR (DMSO-d6) for the skyrin (3.04) 
isolated from Penicillium rugulosum.  
Since skyrin has an [α]D but no chiral centre, it must exist as atropisomers, comparison of the 
experimental [α]22D −16 (c 0.05, dioxane) and literature [α]13D +105 (c 0.4, dioxane), it may suggest 
that we have isolated the first reported enantiomer of skyrin. Skyrin (3.04) has been reported before 
to possess toxic, mutagenic activity and skyrin analogues have been claimed for the treatment of 
Diabetes mellitus.109,113 
 
Figure 3.18. Key 2D NMR correlation of skyrin (3.04) 
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Figure 3.19. 1H NMR (600 MHz, MeOH-d4) spectrum of skyrin (3.04) 
 
Table 3.7. NMR (600 MHz, MeOH-d4) data of skyrin (3.04) 
Pos.  δH, mult (J in Hz)a δCa 
1H-13C HMBC 
1,1′  b  
2, 2′ 7.02, s 122.3 11/11′ 
3, 3′  148.5  
4, 4′ 7.30, s 120.1 5/5′, 9/9′, 10/10′, 11/11′ 
5, 5′  124.3  
6, 6′  164.2  
7, 7′ 6.56, s 108.4 8/8′ 
8, 8′  168.2  
9, 9′  b  
9a, 9′a  128.4  
10, 10′  182.3  
Me-11, 11′ 2.34, s 20.1 3/3′ 
measured in (a) (600 MHz, MeOH-d4), (b) signals not detected 
 
Table 3.8. 13C (DMSO-d6) data comparison of experimental and literature114 data of skyrin (3.04)  
Pos δc, mult, (J in Hz) experimental δc, mult, (J in Hz) literature 
2,2′ 122.2 123.5 
3,3′ 148.0 148.1 
4,4′ 119.1 120.4 
7,7′ 106.5 107.2 
Me-11,11′ 20.9 21.5 
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3.2.7  (CMB-M81F) 
(CMB-M81F) was isolated from a marine sediment sample collected from Shonecliff, Australia. 
CMB-M81F was very interested fungus as it showed many metabolites (see chapter 5). In this 
section, we will discuss only the metabolites that have been activated in the presence of LPS, while 
the rest of the active metabolites will be discussed in chapter 5. 
 
Figure 3.20. Picture of fungus CMB-M81F 
 
3.2.7.1 Analytical cultivation and chemical analysis 
Fungal strain (CMB-M81F) was isolated from a marine sample collected from Shorncliffe, 
Australia by previous PhD student in Capon group. A single colony of CMB-M81F was used to 
inoculate a seed culture on M1 agar media (0.4% starch, 0.2% yeast extract, 1% peptone and 0.8% 
agar) prepared in 3.3% artificial ocean sea salt, which was cultivated for a period of 4 weeks. A 
single colony was used to inoculate M1 broth (0.4% starch, 0.2% yeast extract and 1% peptone) 
3.3% artificial ocean sea salt (1.48 mL) in micro-bioreactor in the presence of LPS (15 µL) to give 
final concentration (0.6 ng/mL). The micro-bioreactor was incubated at 26 °C, 190 rpm for 4 
weeks. After the incubation period, the broth was extracted with EtOAc (2 mL), and the organic 
extract was dried under N2. The resulting crude extract was resuspended in MeCN (100 µL) and 
analysed by HPLC-DAD-MS. The control wells were only inoculated with the fungal spores. Peaks 
with the following retention times tR = 13.2 min exhibited the following m/z [M+H]+ 507 (3.05) as 
shown in Figure 3.21. 
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Figure 3.21. HPLC-DAD (254 nm) chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax 
C8 for the crude extract from CMB-M81F in the (a) presence and (b) absence of LPS cultivated on M1 agar medium. 
The highlighted blue peak represents the activated metabolite 3.05, while the highlighted green peaks will be discussed 
in details in chapter 5   
3.2.7.2 Preparative cultivation 
A seed culture was prepared by inoculating a 250 mL flask containing liquid medium (80 mL 
deionized water containing 0.4% starch, 0.2% yeast extract, 1% peptone) in the presence of 3.3% 
artificial ocean sea salt with a single colony of CMB-M81F followed by shaking at 190 rpm for 4 
weeks at 26.5 °C. Aliquots of the seed culture (5 mL) were transferred to two 2 L Fernbach flasks, 
each containing the same liquid medium (400 mL) and LPS (1 ng/mL), and the flasks were shaken 
at 190 rpm for 4 weeks at 26.5 °C. The resulting cultures were each extracted with EtOAc (400 mL) 
and the combined organic phases concentrated in vacuo to yield an extract (100.5 mg). The extract 
was sequentially triturated with hexane (15 mL) and DCM (15 mL) to afford, after concentration in 
vacuo, 6.3 and 85.6 mg, respectively. The DCM fraction was subsequently subjected to semi-
preparative reversed-phase HPLC (Zorbax C8 column, 250 × 9.4 mm, 5 µm, 3 mL/min gradient 
elution 90 − 10% H2O/MeCN over 30 min to yield neoasterquinone (3.05) (tR = 23.9 min, 1.1 mg, 
1.8%) (Scheme 3.6). 
 
Scheme 3.6. Isolation scheme of CMB-M81F leading to the enhancement of the metabolites listed in below in green 
and the activation of 1 metabolite in blue (3.05). (a) Trituration [hexane (-1-1) and CH2Cl2 (-1-2)] and (b) semi-
preparative HPLC: Zorbax-C8, 90 – 10% H2O/MeCN, 3 mL/min, 30 min 
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3.2.7.2.1 Neoasterriquinone (3.05) 
 
 
HRESI(+)MS data for 3.05 revealed a quasi-molecular ion [M+H]+ indicative of molecular formula 
C32H30N2O4 (Δmmu +0.4). The 1H NMR and 2D NMR (CDCl3) data (Figure 3.23 and Table 3.9) 
showed the presence of quinone moiety. It worth noting that only 13 resonances were observed 
from the 13C and not 16 resonances which may suggest that 3.05 is symmetrical dimer in which the 
quinone and the phenolics carbons are missing due to the rapid inter-conversion of two equivalent 
tautomeric forms of the 2,5-dihydroxyquinone ring system. The structure elucidation was further 
supported by 2D NMR data, including HSQC, COSY and HMBC, as outlined in Figure 3.22, 
literature comparisons (Table 3.10), which determined that 3.05 was very likely neoasterriquinone. 
115,116 Neoasterriquinone has been isolated before from the mycelia of Aspergillus terreus and they 
were potent antitumor compounds.117  
 
 
Figure 3.22. Key 2D NMR correlations of neoasterriquinone (3.05) 
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Figure 3.23. 1H NMR (600 MHz, CDCl3) spectrum of neoasterriquinone (3.05) 
Table 3.9. NMR (600 MHz, CDCl3) data of neoasterriquinone (3.05) 
Pos.  δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1  b   
2  b   
3-OH  b   
4  b   
5  b   
6-OH  b   
1′,1′′ 8.17, s   2′, 3′, 8′, 9′ 
2′,2′′  135.4   
3′,3′′  100.8   
4′,4′′ 7.14b 121.2  2′/2′′,6′/6′′ 
5′,5′′ 7.10b 120.5  7′/7′′, 8′/8′′ 
6′,6′′ 7.31c 120.1  7′/7′′,8′/8′′ 
7′,7′′ 7.33c 111.1  5′/5′′ 
8′,8′′  128.0   
9′,9′′  138.6   
10′,10′′ 3.45, dd (12.7, 7.2) 27.1 11′/11′′,13′/13′′,14′/14′′ 2′/2′′,9′/9′′,12′/12′′ 
11′,11′′ 5.39, br s 120.2 13′/13′′,14′/14′′ 10′/10′′, 13′/13′′ 
12′,12′′  135.6   
13′,13′′ 1.74, s 19.6 10′/10′′,11′/11′′ 11′/11′′,12′/2′′,14′/14′′ 
14′,14′′ 1.80, s 28.5 10′/10′′,11′/11′′ 11′/11′′,12′/12′′,13′/13′′ 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b and c) Overlapping resonances. 
Table 3.10. 1H NMR data (CDCl3) comparison of experimental and literature117 data of neoasterriquinone (3.05) 
Pos δH, mult, (J in Hz) experimental δH, mult, (J in Hz) literature 
1′,1′′ 8.17, s 8.20, br s 
4′,4′′ 7.14b 7.12 – 7.36 
5′,5′′ 7.10b 7.12 – 7.36 
6′,6′′ 7.31c 7.12 – 7.36 
7′,7′′ 7.33c 7.12 – 7.36 
10′,10′′ 3.45, dd (12.7, 7.2) 3.47, d (7.3) 
11′,11′′ 5.39, br s 5.42, t (7.3) 
13′,13′′ 1.74, s 1.77, s 
14′,14′′ 1.80, s 1.83, s 
3,6-OH a 8.07, s 
*(a) signals not observed, (b) Overlapping resonances. (c) Overlapping resonances 
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3.2.8 Streptomyces afghaniensis (ACM-4008) 
 
Figure 3.24. Streptomyces afghaniensis (ACM-4008) 
 
3.2.8.1 Analytical cultivation and chemical analysis 
A single colony of ACM-4008 was used to inoculate a seed culture on ISP-2 agar media (0.4% 
starch, 0.2% yeast extract, 1% peptone and 0.8% agar), which was cultivated for a period of 10 
days. A single colony was used to inoculate ISP-2 broth (0.4% starch, 0.2% yeast extract and 1% 
peptone) (1.48 mL) in micro-bioreactor in the presence of LPS (15 µL) to give final concentration 
(0.6 ng/mL). The micro-bioreactor was incubated at 26 °C, 190 rpm for 10 days. After the 
incubation period, the broth was extracted with EtOAc (2 mL), and the organic extract was dried 
under N2. The crude extract was then resuspended in MeOH and analysed by HPLC-DAD-MS. 
Peaks with the following retention times tR = 8.9 and 9.8 min exhibited the following m/z [M+Na]+ 
739 (3.06) and 693 (3.07) as shown in Figure 3.25 
 
Figure 3.25. HPLC-DAD (254 nm) chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax 
C8 for the crude extract from ACM4008 in the (a) presence and (b) absence of LPS cultivated on ISP-2 broth medium. 
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3.2.8.2 Preparative cultivation 
A seed culture was prepared by inoculating a 250 mL flask containing liquid medium (80 mL 
deionized water containing 0.4% starch, 0.2% yeast extract, 1% malt extract) with a single colony 
of ACM-4008 followed by shaking at 190 rpm for 10 d at 26.5 °C. Aliquots of the seed culture (5 
mL) were transferred to one 2 L flasks, each containing the same liquid medium (400 mL) and LPS 
(0.6 ng/mL), and the flasks were shaken at 190 rpm for 10 d at 26.5 °C. The resulting cultures were 
each extracted with EtOAc (400 mL) and the combined organic phases concentrated in vacuo to 
yield an extract (100 mg). The extract was sequentially triturated with hexane (15 mL) and DCM 
(15 mL) to afford, after concentration in vacuo, 23.2 and 85.6 mg, respectively. The DCM fraction, 
which was found to be rich in the target metabolites 3.06 and 3.07 was subsequently subjected to 
semi-preparative reversed-phase HPLC (Zorbax C8 250 × 9.4 mm, 5 µm column, 3 mL/min 
gradient elution from 90 − 10% H2O/MeCN over 40 min with a hold at 100% MeCN for 5 min), to 
yield julichrome analogue (3.06) (tR = 19.1 min, 1.5 mg, 1.7%) and julichrome Q3.4 (3.07) (tR = 22.4 
min, 1.2 mg, 1.4%) (Scheme 3.7). 
 
 
 
Scheme 3.7. Isolation scheme of the metabolites from crude extract of ACM4008. (a) Trituration [hexane (-1-1) and 
CH2Cl2 (-1-2)] and (b) Semi-preparative HPLC: Zorbax-C8, 90 – 10% H2O/MeCN, 3 mL/min, 30 min  
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(a)
(b)
Chapter 3. Activation of Microbial Secondary metabolites Production 
64 
 
3.2.8.2.1 Julichrome Q3.5 (3.07) 
 
 
HRESI(+)MS data of 3.07 revealed an adduct ion [M+Na]+ corresponding to a molecular formula 
C36H30O13 (Δmmu +2.0). The NMR (CDCl3) data of 3.07 showed the presence of five aromatic 
protons [δ 7.77, d, 7.7 Hz, H-6′; δ 7.89, d, 7.7 Hz, H-5′; δ 7.85, d, 8.0 Hz, H-5; δ 7.48, d, 8.0 Hz, H-
6 and δ 7.19, s, H-2′], and two carbonyl at δ 204.7, C-1 and δ 170.8, C-12. All these observations 
accounted for 20 DBE, while two were not observed; therefore we assume the presence of two 
another carbonyl groups, which may suggest that 3.07 at least incorporated four rings. Analysis of 
the HMBC NMR (CDCl3) for 3.07 revealed structure subunits as indicated in Figure 3.26, 
comprising (i) a correlation from methyl group H-11′ to the carbonyl C-11′; the deshielded methyl 
H-3′ to H-4′a through H-2′, (ii) 9-OH to C-9a, (iii) the deshielded methylene H-2 to H-13 through 
H-2 to C1; H-2 to H-4; H-4 to H-11 and H-13 to C-12. The structure elucidation was further 
supported by 2D NMR data, including HSQC, COSY and HMBC, as outlined in Figure 3.26, 
Figure 3.27 and Table 3.11. On searching the literature and our database based on the molecular 
formula, molecular weight and structure fragment, 3.07 was consistent with julichrome Q3.5. 
Analysis of all the NMR data with comparison to literature data (Table 3.12) strongly suggested 
that 3.07 was the known metabolites julichrome Q3.5.118 
 
Figure 3.26. Key 2D NMR correlations of julichrome Q3.5 (3.07) 
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Figure 3.27. 1H NMR (600 MHz, CDCl3) spectrum of julichrome Q3.5 (3.07) 
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Table 3.11. NMR (600 MHz, CDCl3) data of julichrome Q3.5 (3.07) 
Pos.  δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1  204.7   
2 a 2.77, d (18.9)  50.8 3-Me 1, 4 
 b 2.73 d (18.9)    
3  69.5   
3-Me 1.66, s 34.3 2 2, 3, 4 
4 3.31b 45.4 11 2, 3, 11, 11-Me 
4a  c   
5 7.85, d (8.0) 120.7 6 7, 8a 
6 7.48, d (8.0) 132.1 5 8, 10a 
7  131.1   
8  153.0   
8a  126.3   
9 6.01, br s 60.8 9-OH 9a 
9a  64.5   
10  c   
10a  128.8   
11 5.60, m 68.5 4, 11-Me  
11-Me 1.38, d (6.5) 22.1 11 4 
12  170.8   
13-Me 1.80, s 21.5  12 
1′  162.8   
2′ 7.19, s 126.5 3′-Me 3′-Me, 4′, 9′a 
3′  144.9 2′  
3′-Me 2.34, s 19.9  2′, 3′, 4′ 
4′  137.5   
5′ 7.89, d (7.7) 120.7 6′ 7′,8′a 
6′ 7.77, d (7.7) 139.5 5′ 8′ 
7′  133.6   
8a′  115.9   
9′  c   
9a′  113.3   
11′  204.7   
12′-Me 2.53, s 31.4 11 11′ 
8-OH c    
1′-OH 12.04, s  1′  
8′-OH 13.02, s    
9-OH 4.15, br s  9  
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) signals not observed 
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Table 3.12. 1H NMR data (CDCl3) comparison of experimental and literature118 data of julichrome Q3.5 (3.07) 
Pos δH, mult, (J in Hz) experimental δH, mult, (J in Hz) literature  
2 2.77, d (18.9) and 2.73 d (18.9) 2.78, d (18.5) and 2.74, d (18.9) 
4 3.31a 3.30, d (3.8) 
5 7.85, d (8.0) 7.83, d (8.1) 
6 7.48, d (8.0) 7.46, d (8.1) 
9 6.01, br s 6.01, s 
11 5.60, m 5.60, m 
2′ 7.19, s 7.17, s 
5′ 7.89, d (7.7) 7.86, d (7.8) 
6′ 7.77, d (7.7) 7.75, d (7.8) 
3-Me 1.66, s 1.65, s 
11-Me 1.38, d (6.5) 1.38, d (6.5) 
13-Me 1.80, s 1.80, s 
3′-Me 2.34, s 2.33, s 
12′-Me 2.53, s 2.52, s 
1′-OH 12.04, s 12.08, s 
8′-OH 13.02, s 12.88, br s 
8-OH b b 
3-OH 4.15, br s 4.15, br s 
 *(a) overlapping resonances, (b) signals not observed 
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3.2.8.2.2 ACM4008-1-2-1 (3.06) 
 
ESI(+)MS data of 3.06 revealed a molecular ion [M+H]+ corresponding to a m/z 717 [M+H]. The 
UV spectrum was consistent with julichrome like compounds. The 1H NMR (CDCl3) data for 3.06 
was very similar to julichrome Q3.5 (3.07) with exception for the presence of acetyl group. This 
compound still under investigation. 
 
Figure 3.28. Key 2D NMR correlations of ACM-4008-1-2-1 (3.06) 
 
Figure 3.29. 1H NMR (600 MHz, CDCl3) spectrum of ACM-4008-1-2-1 (3.06) 
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Table 3.13. NMR (600 MHz, CDCl3) data of ACM-4008-1-2-1 (3.06) 
Pos.  δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1  204.5   
2 2.64c, m 53.6 3-Me 1, 4 
3  d   
3-Me 1.77, s 23.9 2  
4 3.16, d (4.0) 49.7 11 2, 3, 11, 11-Me 
4a  d   
5 7.75b 123.3 6  
6 7.68, d (7.2) 135.2 5  
7  
d   
8  
d   
8a  
d   
9 6.01, s 61.7  9a 
9a  64.4   
10  
d   
10a  
d   
11 5.65, q (6.2) 72.3 4, 11-Me  
11-Me 1.45, d (6.2) 25.1 11 4 
12  174.6   
13-Me 1.78, s 20.3  12 
1′  d   
2′ 7.06 121.2   
3′  d   
3′-Me 2.51c 22.1   
4′  
d   
4a′  
d   
5′ 7.75b 123.3 6′  
6′ 7.41, d (7.2) 142.1 5′  
7′  
d   
8′  
d   
8a′  
d   
9′  
d   
9a′  
d   
10′  
d   
10a′  
d   
11′ 5.79, br s 72.3   
12′  171.3   
11′-Me 1.25, d (6.2) 25.1 11  
13′-Me 1.90, s 24.4  12′ 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Overlapping resonances.  (d) signals not observed 
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By 1H NMR analysis, it was observed that fragment A in 3.06 and 3.07 are approximately similar in 
the chemical shifts which may suggests that they can have the same stereochemistry (Table 3.14). 
Fragment B in 3.06 was quite different than fragment B in 3.07, in which the COMe has been 
replace with OAc group (Figure 3.30 and Figure 3.31).  
 
Figure 3.30. Comparison between ACM4008-1-2-1 (3.06) and julichrome Q3.5 (3.07) 
 
Table 3.14. NMR (600 MHz, CDCl3) similarity between 3.06 and 3.07 
Pos.  δH, mult (J in Hz) (3.07) δCa  δH, mult (J in Hz) (3.06) δCa 
1  204.7  204.5 
2 2.77, d (18.9) and 2.73 d (18.9) 50.8 2.64, m 53.6 
3  69.5  c 
3-Me 1.66, s 34.3 1.77, s 23.9 
4 3.31b 45.4 3.16, d (4.0) 49.7 
4a  c  c 
5 7.85, d (8.0) 120.7 7.75, d (8.0) 123.3 
6 7.48, d (8.0) 132.1 7.68, d (7.2) 135.2 
7  131.1  
c 
8  153.0  
c 
8a  126.3  
c 
9 6.01, br s 60.8 6.01, s 61.7 
9a  64.5  64.4 
10  c  
c 
10a  128.8  
c 
11 5.60, m 68.5 5.65, q (6.2) 72.3 
11-Me 1.38, d (6.5) 22.1 1.45, d (6.2) 25.1 
12  170.8  174.6 
13-Me 1.80, s 21.5 1.78, s 20.3 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonces. (c) signals not observed 
 
O
O
O OH
OH OH
O
O
O
OH
julichrome Q3.5 (3.07)
O
OH
H
O
O
O
O OH
OH OH
O
O
O
OH
O
HO
OH
O
1
4
12
9
8
5
5'
8'
9'4'
1'
11'
O
1
4
12
9
8
5
5'
8'
9'4'
1'
11'
ACM4008-1-2-1 (3.06)
10
11
13
11
13
12'
13'
Fragment A
Fragment B
Fragment B
Fragment A
Chapter 3. Activation of Microbial Secondary metabolites Production 
71 
 
 
Figure 3.31. 1H NMR (600 MHz, CDCl3) spectrum of both julichrome Q3.5 (3.07) (red) and (3.06) (blue) highlighting 
the difference between the two structures 
 
3.3 Conclusion 
This chapter illustartes a new paradigm for drug discovery to help to overcome the limited 
laboratory conditions and to establish a new technique to target the production of antibiotics. In 
order to perform such paradigm, combinatorial chemical libraries were established in order to cover 
much chemical space to increase the probability of wakening up the silent genes and turning on new 
secondary metabolites. Therefore, the micro-bioreactor was used to screen large number of 
microbes against the microbial crude extracts library and pure compounds as well as the LPS from 
Escherichia coli. Activation of silent metabolites was perfomed by the addition of another 
microbial crude extract and this section is still under investigation. Unfortunately, this approach was 
not practical as we got only 2 hits from around 300 experiments; therefore we decided to start 
looking into using LPS. 
  
Lipopolysaccharide (LPS) from Gram-negative bacteria (Escherichia coli) was purchased from 
Sigma and tested for the induction of microbial secondary metabolites that may have antibacterial 
activity. Different microbes (actinomycetes and fungi) were chosen from the constructed terrestrial 
microbial library as well as from the ACM and marine collection. All the microbes were screened 
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extracts using our HPLC/DAD/MS, the hits were screened against antimicrobial assay using both 
Gram negative and Gram positive bacteria, Escherichia coli (ATCC 11775), Pseudomonaus 
aeruginosa (ATCC 10145), Staphylococcus aureus (ATCC 25293/9144), Bacillus subtilis (ATCC 
6051/6633). The hits that showed antibacterial effect against Gram-positive bacteria were further 
investigated through large-scale cultivation and structural elucidation. Three hits were chosen, 
which are ACM 2573, CMB-TF411, CMB-M81F and ACM 4008. The first hit was ACM 2573 in 
which two metabolites were isolated, resistomycin (3.01) and activated metabolite resistoflavine 
(3.02). The second hit, CMB-TF411 the known metabolites, rugulosin (3.03) and activated 
metabolite skyrin (3.04) were isolated. The third hit was CMb-M81F in which the activated 
metabolite neoasterriquinone (3.05) was isolated. The fourth hit was from ACM 4008, in which the 
known metabolite julichrome Q3.5 (3.06) was isolated and another unknown metabolite (3.07) in 
which it is related to the julichrome family because of the similarity of its UV spectrum and 1H 
NMR of 3.06. We can conclude that LPS can be considered as a new tool for the access of 
microbial genome and the activation of microbial secondary metabolites that may have a role as 
pharmaceutically active agents especially in the antibiotic field. 
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3.4 Experimental section 
resistoflavine (3.01): deep purple powder; NMR (600 MHz, CDCl3) see Table 3.1; HRESI(+)MS 
m/z 393.0970 [M+H]+ (calcd for C22H17O7 393.0969). 
 
resistomycin (3.02): deep purple powder; NMR (600 MHz, MeOD d4) see Table 3.3; HRESI(+)MS 
m/z 377.1026 [M+H]+ (calcd for C22H17O6 377.1020). 
 
rugulosin (3.03): deep yellow oil; [α]23D +68.4 (c 0.05, MeOH); NMR (600 MHz, CDCl3) see Table 
3.5; see HRESI(+)MS m/z 565.1105 [M+H]+ (calcd for C30H22O10Na 565.1110). 
 
skyrin (3.04): deep violet powder; [α]23D −20.7 (c 0.05, CDCl3); NMR (600 MHz, MeOH-d4) see 
Table 3.7; HRESI(+)MS m/z 539.0970 [M+H]+ (calcd for C30H19O10 539.0973). 
 
neoasterriquinine (3.05): deep violet oil; NMR (600 MHz, CDCl3) see Table 3.9; HRESI(+)MS m/z 
507.2274 [M+H]+ (calcd for C32H31N2O4 507.2278). 
 
julichrome analogue (3.06): reddish brown powder; [α]23D −29.8 (c 0.05, CDCl3); NMR (600 MHz, 
CDCl3) seeTable 3.13; ESI(+)MS m/z 717 [M+H]+  
 
julichrome Q3.5 (3.07): reddish brown powder; [α]23D −30.4 (c 0.05, CDCl3); NMR (600 MHz, 
CDCl3) see Table 3.11; HRESI(+)MS m/z 693.1548 [M+Na]+ (calcd for C36H30O13Na 693.1570.
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4 Chapter 4: Beach warfare: An Aspergillus stimulates 
antifungal defenses in a Streptomyces sp. 
4.1 Heronapyrroles 
The heronapyrroles A – C (4.01 – 4.03) as shown in Figure 4.1 and Figure 4.2 belong to a rare 
mixed pyrroloterpene structure class bearing the nitro functionality α to the pyrrole nitrogen. These 
compounds have been isolated from an Australian marine derived-microbe Streptomyces sp. (CMB-
M0423) obtained from a shallow water (− 1 m) sand sample collected near Heron Island, 
Queensland, Australia. HPLC-DAD-MS analysis of a small-scale liquid cultivation (100 mL) 
revealed biosynthetically related yellow pigments [m/z 421 (4.01), 405 (4.02), and 407 (4.03)] 
sharing an unusual polyene-like chromophore [λmax 348] as shown in Figure 4.1. These compounds 
(Figure 4.2) isolated by a previous PhD student in our group, exhibited promising antibacterial 
activity against Staphylococcus aureus (ATCC 2593 and 9144) and Bacillus subtilis (ATCC 6051 
and 6633). 
 
Figure 4.1. HPLC-DAD chromatogram (360 nm) of crude EtOAc extract from Streptomyces sp. (CMB-M0423)119 
 
 
Figure 4.2. Structures of the heronapyrroles 
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It is also a noteworthy that heronapyrroles belong to the rare family of nitropyrrole natural products, 
known examples of which are limited to the 3-nitropyrrole pyrrolomycin class of Streptomyces 
antibiotics, pyrrolomycin A (4.04) and B (4.05).120 Furthermore, the heronapyrroles are considered 
as the first documented examples of natural products bearing a 2-nitropyrrole functionality.  
 
 
 
 
Although natural products of mixed biosynthesis featuring terpenoid residues attached to various 
aromatic/heterocyclic systems are well known across the field of natural products chemistry, 
pyrroloterpenes are especially rare. The few known examples are limited to the lipid peroxidation 
inhibitor pyrrolostatin (4.06) from a Brazilian soil Streptomyces chestomyceticus,121 and the 
antimicrobial and anticancer glaciapyrroles A – C (3.07 – 3.09) from an Alaskan marine-derived 
Streptomyces sp.122 Following publication of the heronapyrroles, closely related analogues, 
nitropyrrolins A – E (4.10 - 4.14) were reported by Fenical et al. from a marine-derived 
actinomycete.123 
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4.2 Future of heronapyrroles 
A plausible biosynthesis for the heronapyrroles is outlined in Figure 4.3. In this pathway, aromatic 
substitution of the pyrrole moiety by farnesyl pyrophosphate provided access to the pyrroloterpene 
carbon framework, further elaborated by nitration, oxidation and nucleophilic ring opening of the 
epoxide intermediates in which a cascade cyclization provides the full suite of heronapyrroles.119  
 
Figure 4.3. Plausible biosynthesis of heronapyrroles 
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to oxidative conversion to a bis-THF sub-structure as shown as in Figure 4.4. This hypothesis 
requires an alternative (left to right) intramolecular cyclization proposed for 4.03, with H2O attack 
at the first epoxide (Figure 4.4).124 
 
Figure 4.4. New possible biosynthesis of heronapyrrole C (4.03)124 
 
While our research group had published the heronapyrroles, we were nevertheless interested in 
pursing their antibacterial properties further. To achieve this goal we needed a secure supply of the 
three known heronapyrroles (4.01 - 4.03) and if possible a selection of biosynthetically related 
analogues. Taking note of the role that bacterial nitric oxide synthase (bNOS) can play in the 
nitration of secondary metabolites.125 We speculated on the involvement of bNOS in heronapyrroles 
biosynthesis. To test our hypothesis, a series of experiments were designed in which Streptomyces 
sp. (CMB-M0423) was cultivated in the presence of the commercially available NOS inhibitors 
aminoguanidine (AG) (4.16), NG-methyl-L-arginine (NMMA) (4.17) and nitro-L-arginine-methyl 
ester (NAME) (4.18). These studies were designed to inhibit a hypothetical bNOS, with a possible 
consequence being the production of non-nitrated heronapyrroles analogues. Such unnatural 
heronapyrroles would be very valuable in the structure activity relationship studies designed to 
probe the antibacterial properties of this unique structure class. Before proceeding to the results and 
discussion, it is necessary to pause and reflect on the history and the role of NOS in both 
mammalian and bacterial systems. 
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process in acquiring energy as well as balancing the redox state during anaerobic respiration.127 In 
1980, NO was discovered as an essential regulator in many biological mechanisms, including 
cellular signalling and immune responses such as the regulation of blood pressure, control of 
vascular tone, protection against other pathogens as a defence mechanism and cancer, hormone 
regulation, nerve cell transmission and angiogenesis.128-130 
4.3.1 Mammlian NOS 
Nitric oxide is a crucial messenger molecule, which has numerous molecular targets such as 
neurotransmission131,132, control of vascular tone133,134 and regulation of gene transcription135 and 
mRNA translation136. In mammals, NO can be generated by three different isoforms of the enzyme 
NO synthase (NOS). This important discovery led to the identification of three isoenzymes 
responsible for the regulation of NO, endothelial nitric oxide synthase (eNOS), inducible NOS 
(iNOS) and neuronal NOS (nNOS).137,138 All isoforms utilize L-arginine as the substrate, and 
molecular oxygen and reduced nicotinamide-adenine-dinucleotide phosphate (NADPH) as co-
substrates.134,139 
 
Mammalian NO synthases (mNOSs) are complex enzymes that consist of dimeric proteins which 
contain an amino-terminal haem oxygenase domain (NOSoxy) and a carboxy-terminal flavoprotein 
reducatse domain (NOSred). The oxygenase domain binds to L-arginine (L-Arg), haem and the redox 
active cofactor tetrahydrobiopterin, while the reductase domain binds to flavin adenine dinucleotide 
(FAD), flavin mononucleotide (FMN) and nicotinamide adenine dinucleotide phosphate (NADPH) 
which later catalyzes the oxidation of L-Arg to NO and citrulline and the molecular signal NO as 
well as a reductase domain that shuttles electrons to the heme of the oxygenase domain as shown in 
Figure 4.5.140 
 
Figure 4.5. Two-step oxidation of L-arginine to L-citrulline and NO. Abbreviation: NOHA, NG-hydroxy-L-arginine 
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induced by the presence of bacterial lipopolysaccharide, cytokines and other agents. Once 
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expressed, iNOS is constantly active and not regulated by intracellular Ca2+ concentrations.142 
When iNOS is induced in the macrophages, the resulting NO binds to protein-bound iron and 
inhibits key enzymes that contain iron in their catalytic centres. These effects are considered the 
basis of the cytostatic and cytotoxic effects of NO on parasitic microorganisms and tumour cells.143 
Endothelial NOS is a homostatic regulator of numerous essential cardiovascular functions in which 
it dilates all types of blood vessels leading to increase in the blood pressure.133 NO released towards 
the vascular lumen helps to inhibit platelet aggregation and therefore aid in the protection from 
thrombosis.144 
4.3.2 Bacterial NOS (bNOS) 
The genome sequencing for bacterial NOSs has revealed that some bacteria contain genes coding 
for NOS proteins. This outcome is consistent with studies of NOS-like activities in bacterial 
extracts. By 2004, bacterial NOS (bNOS) had been found in more than 20 bacterial genera, such as 
Bacillus, Staphylococcus and Deinococcus.145 Other studies provided in vivo evidence for bNOS 
dependent NO production in B. subtilis, Rhodococcus sp. and other Streptomyces species.146,147 
Differences between mammalian and bNOSs include the absence of a C-terminal reductase domain 
in the latter.148 The first discovery of bNOS activity in 1994 was reported from a Nocardia 
species149, while the first discovery of biological function came in 2004 from the discovery that 
bNOS was responsible for the potato scab disease caused by a Streptomyces toxin thaxtomin A 
(4.15), which interfered with plant cell wall synthesis. Thaxtomin A (4.15) is a dipeptide produced 
by non-ribosomal peptide synthase, in which a tryptophanyl moiety is nitrated at C-4. The location 
of a bNOS gene cluster close to the non-ribosomal peptide synthase genes suggested that bNOS 
may be involved in the nitration process. Kers et al.125 proved that NOS inhibitors such as 
aminoguandine (AG), nitro-L-arginine methyl ester (NAME) and NG-methyl-L-arginine (NMMA) 
suppress bNOS and the production of thaxtomin A (4.15) without affecting the bacterial growth.  
Thaxotamin A (4.15) plays a vital role in the cellulose biosynthesis inhibition which is crucial for 
plant pathogenicity in most pathogenic streptomycetes150 and it would appear that a functioning 
bNOS is essential for its biosynthesis. 
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In subsequent studies in 2008, Evan et al. proved that bNOS in plant pathogenic Streptomyces 
provides the NO necessary for the production of thaxtomin A (4.15). These workers also 
demonstrated that bNOS is capable of releasing NO in vivo and that NO has significant implications 
for bacterial signalling in which a plant pathogenic Streptomyces sp. produce NO at the host-
pathogen interface and they proved that NO synthesis is induced by plant cell wall component, 
cellobiose.148 
4.3.3 Structural differences between nitric oxide synthases 
Key residues in the cofactor and the substrate binding sites are well conserved among different 
NOS. Still there are notable differences within the oxygenase domain as shown in Table 4.1, Figure 
4.6 and Figure 4.7. 
 
Table 4.1. Major differences between mammalian and bacterial NOSs151 
 Mammlian NOS Bacterial NOS 
Oxygenase/reductase domain 
moiety 
N-terminal oxygenase, C-terminal 
reductase domains 
Oxygenase domain only, multiple 
reductase partners 
Oxygenase domain dimer Stabilized by Zn2+ bound at the dimer 
interface 
Lacks Zn2+ binding site but forms 
stable dimers 
Pterin binding site Closed; can only fit H4B Exposed, can carry H4B and other 
molecules 
Targeting Isotype specific N-terminal domains Lack the domains 
Regulation Ca2+/CaM (nNOS, eNOS) 
Transcriptionally (iNOS) 
Unknown mechanism 
Roles of NO Neurotransmission (nNOS), 
vasodilation (eNOS), host defence 
(iNOS) and others functions. 
antioxidative stress, and UV damage, 
plays a role in the biosynthesis of 
different nitrated compounds as well 
as transcriptional regulation. 
*nNOS = neuronal NOS, eNOS = epithelial NOS, iNOS = inducible NOS, H4B = tetrahydrobiopterin 
 
Figure 4.6. Structures of the N-terminal heme oxygenase domains of (a) B. subtilis bNOS and (b) human iNOS. The 
structures are highly similar with the exception of the missing N-terminal hook and zinc-binding regions in bNOS. 
Figure from Crane et al.152 
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Figure 4.7. Domain structure of NO synthases from different sources. Figure from Filippovich et al.153 
 
4.3.4 Nitric oxide synthase inhibitors 
The understanding of the involvement of NO in physiological processes makes it an important 
target for the development of many therapeutic agents. The depletion of NO can result in 
hypertension, angina and impotence, while in other cases the overproduction of NO can lead to 
shock, sepsis, stroke, inflammatory responses and some neurodegenerative diseases such as 
Parkinson’s Alzheimer’s and Huntington’s disease.154 The inhibition of nNOS (neuronal NOS) or 
iNOS (inducible NOS) could provide effective treatment for many diseases and the selective 
inhibitors could be a useful tool for investigating the biological functions of NO and the treatment 
of the involved disease. The last 6 years has been > 60 new patents focusing on NOS inhibitors, as 
evidence of considerable interest by the pharmaceutical industry. The NOS inhibitors, AG (4.16), L-
NAME (4.17) and L-NMME (4.18) are believed to exhibit isoform-selective NOS inhibition, 
decreasing NO concentration in specific tissues.155 These three NOS inhibitors will be discussed 
later in this thesis. Compounds reported as selective nNOS inhibitor are shown in Figure 4.9.155 
 
 
Figure 4.8. Structures of some bNOS inhibitors 
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Figure 4.9. Selective nNOS inhibitors 
 
4.3.5 Bacterial nitric oxide synthase and their importance 
4.3.5.1 Plant toxin production 
Based on the above findings, attempts have been made to find and characterize sources of NOS 
activity from microbial strains.  As discussed earlier, the first indication of bNOS function came 
from the discovery of a nos-like open reading frame in Streptomyces sp. that causes potato scab 
through the production of thaxtomin A (4.15).125 The position of nos on the pathogenicity island 
responsible for thaxtomin A biosynthesis, near the genes encoding non-ribosomal peptide synthase, 
strongly suggested that bNOS was involved in the nitration of thaxtomin A. Upon the addition of 
NOS inhibitor, non-nitrated thaxtomin A was not detected. The addition of NOS inhibitors did 
however lead to a decrease in the production of thaxtomin A without affecting the cell growth, and 
thereby decreasing the toxic effect.156 
Wach et al.156 used the NOS inhibitors to provide evidence for the involvement of bNOS in the 
biosynthesis of thaxtomin A (4.15), a toxin produced by the plant pathogen Streptomyces 
turgidiscabies that is responsible for causing potato scab disease. The addition of four NOS 
inhibitors; AG (4.16), NAME (4.17), NMMA (4.18) and 7-NI (4.19), and the NO scavenger 2-(4-
carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (CPTIO) (4.26), reduced production 
of 4.15 without affecting bacterial growth.125 Likewise addition of the NO donors, diethylamino 
nitric oxide (DEANO) (4.27); 3-morpholinosydnonimine (SIN) (4.28); and S-nitroso-N-
acetylpenicillamine (SNAP) (4.29) to S. turgidiscabies with a deleted nos gene restored the 
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production of 4.15. All these studies provide strong evidence that NO plays a crucial role in the 
biosynthesis of thaxtomin A (4.15) with bNOS being the source of NO. In these studies NOS 
inhibitors were used at different concentrations, AG (2.7, 27, 270 µM); NAME (32, 320 nM, 3.2, 
32, 350 µM); NMME (17, 170, 510 µM), and all NO donors, DEANO, SIN, and SNAP and the NO 
scavenger CPTIO were all tested at 1 mM.  
 
 
 
4.3.5.2 NO production and the defence mechanism against oxidative stress 
Energy demands of many aerobic organisms require the efficient synthesis of ATP by 
mitochondrial oxidative phosphorylation. Together with ATP synthesis, the organism is exposed to 
reactive oxygen species (ROS) that are considered as mitochondrial electron transport chain 
product. Under the conditions of continuous oxidative production, antioxidant enzymes that are 
responsible for removing ROS can be overwhelmed, leading to oxidative stress. Oxidative stress 
has been implicated in different degenerative diseases including carcinogenesis, hemochromatosis, 
Parkinson’s disease, Alzheimer disease and aging. Diseases associated with tissue iron 
accumulation are of great interest as iron catalyzes the generation of the highly reactive hydroxyl 
radical, in a process known as the Fenton reaction.157 
 
In bacteria, H2O2 reacts with free cellular Fe2+ to generate OH radical through a Fenton reaction, 
leading to DNA damage and depletion of Fe2+. Thus to drive the Fenton reaction, Fe3+ must be 
continuously reduced to Fe2+ by cellular reductants (Figure 4.10).158 
 
Figure 4.10. Fenton’s reaction 
 
In 2005, Gusarov et al.146 showed that NO plays a critical role in the adaptation mechanism to the 
oxidative stress associated with metabolic stress and defending the pathogen against immune 
oxidative attack.  These authors showed that NO protects bacterial cells against reactive oxygen 
species through suppressing the enzymatic reaction of free cysteine that catalyses the damaging 
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Fenton reaction. At the same time, NO also reactivates catalase, a major component of antioxidant 
enzyme that is inhibited by endogenous cysteine. 
4.3.5.3 NO production and the defence mechanism against antibiotics 
Anon et al.159 showed that NO generated by bNOS increases the resistance of bacteria to a broad 
spectrum of antibiotics which enable the bacteria to survive and share their environment with 
antibiotic-producing microorganisms. They proved that B. subtilis with nos is capable of defending 
itself against pyocyanin which is considered as one of many natural toxins with broad antimicrobial 
activity produced by P. aeruginosa. 
 
Bacteria use small molecules to communicate with nearby organisms in the surrounding 
environment. This process called quorum sensing (QS), commonly regulates bioluminescence, 
biofilm production and virulence. In 2012, Henares et al.160 investigated the effect of NO on the 
bioluminescence in Vibrio harveyi. They showed that NO is involved in QS through LuxU gene 
cluster in Vibrio harveyi, by detecting an NO concentration-dependent increase in bioluminescence. 
 
Figure 4.11. Summary of physiological functions of nitric oxide (NO) 
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4.4 Results and discussion 
4.4.1 Cultivation of Streptomyces sp. (CMB-M0423) in the micro-bioreactor 
Chapter 2 outlined the details of the methodology for cultivation in the micro-bioreactor. Micro-
bioreactor cultivation methodology was used to study the secondary metabolites chemical profiling 
of Streptomyces sp. (CMB-M0423). In order to ensure that the Streptomyces sp. (CMB-M0423) was 
not adversely affected by this technology, it was cultivated and analysed in the micro-bioreactor 
(1.5 mL broth), and a standard shake flask (80 mL broth), in the same M1 3.3% artificial ocean sea 
salt-based media (Figure 4.12). The results from this experiment suggested that the micro-
bioreactor do not affect the secondary metabolites produced by Streptomyces sp. (CMB-M0423). 
 
Figure 4.12. Production of heronapyrrole B (4.02) in the micro-bioreactor and shake flask (three replicates) 
 
4.4.2 Cultivation of Streptomyces sp. (CMB-M0423) 
Streptomyces sp. (CMB-M0423) was cultivated in the micro-bioreactor containing M1 broth (1.5 
mL) in 3.3% artificial ocean sea salt.  The micro-bioreactor was incubated for 7 days at 26.5 °C, 
190 rpm. After the incubation period, individual cultures were extracted by the addition of EtOAc 
(1.5 mL) to each well. The organic layer was decanted, dried in vacuo, re-weighed, re-dissolved in 
MeOH to give final concentration of 1 mg/mL, then analysed using HPLC-DAD-MS. The chemical 
profiling confirmed that the cryo-recovered strain of Streptomyces sp. (CMB-M0423) has ceased 
production of heronapyrroles A (4.01) and C (4.03), but had retained the capacity to produce 
heronapyrrole B (4.02) (Figure 4.13). 
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Figure 4.13. HPLC-DAD chromatogram analytical gradient H2O/MeCN plus HCO2H on a Zorbax C8 column of (a) 
heronapyrrole B standard, (b) crude extract from Streptomyces sp. (CMB-M0423) at 360 nm showing the production of 
heronapyrrole B (4.02) 
4.4.3 Quantification of heronapyrrole B production 
A calibration curve was generated in order to determine the concentration of heronapyrrole B in the 
crude extract of Streptomyces sp. (CMB-M0423). Known concentrations (4 to 0.06 nmol/10 µL) of 
heronapyrrole B (4.02) in MeOH were prepared in two-fold dilutions. The standard solutions were 
analysed by HPLC-DAD-MS, Zorbax C8 analytical HPLC column, 5.8 µm, 150 × 4.6 mm, 1 
mL/min gradient elution from 90% H2O/MeCN to 100% MeCN (with a constant 0.05% formic 
acid/MeCN modifier) over 15 min, monitoring at 210, 254 and 360 nm. The standard calibration 
curve was plotted using the area under the peak at 360 nm. From the standard calibration curve 
(Figure 4.14) the concentration of heronapyrrole B in the crude extract from the micro-bioreactor 
was determined to be 9.2 ± 0.8 µg/mL compared to 6.5 ± 0.7 µg/mL for the shake flask  
 
Figure 4.14. Calibration curve (360 nm) of 4.02 with values of 10 µL injection into the HPLC-DAD-MS of both micro-
bioreactor (black) and shake flask (red) 
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Using a calibrated analytical method, the production levels of heronapyrrole B (4.02) were 
confirmed and the concentration of 4.02 in the crude extract from the micro-bioreactor was proved 
to be 9.2 ± 0.8 µg/mL compares very favourably with the values obtained during shake flask culture 
6.7 ± 0.7 µg/mL. 
4.4.4 Cultivation of Streptomyces sp. (CMB-M0423) in the presence of NOS inhibitors 
 
Figure 4.15. Streptomyces sp. (CMB-M0423) 
 
We speculated that the addition of NOS inhibitors to the culture medium of Streptomyces sp. 
(CMB-M0423) may provide evidence for the involvement of bNOS in the biosynthesis of 
heronapyrroles, and may lead to the production of non-nitrated analogues. To test this hypothesis, 
the effect of three NOS inhibitors on Streptomyces sp. (CMB-M0423), AG (4.16), L-NAME (4.17) 
and L-NMME (4.18) were examined. Taking note of the tested concentrations previously reported 
for the NOS inhibitors, we chose 4 different concentrations 30, 15, 7.5 and 3.7 µM. From these 
studies, it was determined that 7.5 µM was optimum concentration to induce secondary metabolites 
production, and was used in all our future studies.  
 
Streptomyces sp. (CMB-M0423) was cultivated on M1 broth prepared using 3.3% artificial ocean 
sea salt in the presence of 7.5 µM (1% DMSO) of the NOS inhibitors, AG (4.16) or L-NAME 
(4.17) or L-NMME (4.18). The resulting EtOAc crude extracts were analysed by HPLC-DAD-MS, 
to reveal suppression of heronapyrrole B (4.02) biosynthesis, and the production of new metabolites 
with the following retention times tR = 7.8, 8.1, 8.5, 8.2, 5.2 and 4.8 min exhibited the following m/z 
(M+H)+ 432 (4.30), 327 (4.31), 357 (4.32), 380 (4.33), 261 (4.34) and 345 (4.35) respectively, as 
shown in the case of AG in Figure 4.16. 
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Figure 4.16. HPLC-DAD chromatogram from an analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 
column at 210 nm of the crude EtOAc extract from Streptomyces sp. (CMB-M0423) in the presence of AG (7.5 µM). * 
no production of 4.02 
 
Large-scale cultivation followed by fractionation yielded pseurotin A (tR= 21.3 min; 5.1 mg, 7.3%) 
(4.30), gliotoxin (tR= 22.0 min; 4.5 mg, 6.4%) (4.31), bisdethiobisgliotoxin (tR= 22.7 min; 3 mg, 
4.3%) (4.32) and fumitremorgin C (tR= 25 min; 2.4 mg, 3.4%) (4.33) and two diketopiperazines, 
cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (tR= 15.7 min; 3 mg, 3.6%) (4.34) and cyclo-(L-Phe-L-Pro) 
(tR= 17.2 min; 1.5 mg, 2.3%) (4.35). [Note - % yields were determined on a mass-to-mass basis 
against the EtOAc crude extract] (Scheme 4.1). 
 
Scheme 4.1. Isolation scheme of Streptomyces sp. (CMB-M0423) cultured in the presence of AG (7.5 µM). (a) 
trituration [hexane (-1-1) and CH2Cl2 (-1-2)], (b) semi-preparative HPLC: Zorbax C8, 90 – 10% H2O/MeOH, 3 mL/min, 
30 min  
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4.4.5 Pseurotin A2 (4.30) 
 
HRESI(+)MS analysis of 4.30 revealed an adduct ion ([M+Na]+) indicative of the molecular 
formula C22H25NO8 (Δmmu –0.4). The NMR (CDCl3) data for 4.30 (Figure 4.18 and Table 4.2) 
showed the presence of a mono-substituted aromatic ring and aliphatic chain with two hydroxyl 
groups. The structure elucidation was further supported by 2D NMR data, including HSQC, COSY 
and HMBC, as outlined in Table 4.2. On searching the literature, it was determined that 4.30 was 
identical to the known fungal metabolite pseurotin A. Analysis of all the NMR data with 
comparison to literature data, confirmed that 4.30 was identical to the known fungal metabolite 
pseurotin A2 (Table 4.3).  This assignment was further confirmed by a comparison of the [α]22D − 
11.5 (c 0.1, MeOH) for 4.30 compared to [α]23D −4.2 (c 0.1, MeOH) for pseurotin A2.161-163 (4.30) 
as outlined in Figure 4.17 and Table 4.3. 
 
Figure 4.17. HMBC (600 MHz, CDCl3) spectrum and 2D NMR correlations of pseurotin A2 (4.30) 
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Figure 4.18. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of pseurotin A2 
(4.30)  
Table 4.2. NMR (600 MHz, CDCl3) data of pseurotin A2 (4.30) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
2  186.2   
3  115.1   
4  197.2   
5  92.6   
6  b   
7-NH 8.01, br s    
8  93.2   
9 4.68, d (9.9) 15.1 9-OH 5, 8 
10 4.56, d (4.4) 73.5  11, 16 
11 4.73, br s 74.4 10, 11 2, 10, 12, 13 
12 5.26, dd (10.5, 9.5) 130.2 11, 13 11, 13 
13 5.59, ddd (10.5, 7.6, 7.6) 139.5 12, 14a,b 11, 14a/b, 15 
14 a 2.14, ddt (14.8, 7.6, 7.6) 24.8 13, 15 12, 13, 15 
 b 2.09, ddt (14.8, 7.6, 7.6)  13, 15 12, 13, 15 
15 0.96, t (7.6) 16.7 14a,b 13, 14 
16 1.65, s 7.4  2, 3, 4 
17  194.8   
18  134.4   
19/23 8.31, d (8.0) 133.7 20/22 18, 20/21, 22 
20/22 7.47, dd (8.0, 7.5) 131.8 19/23, 21 19/23, 20/22 
21 7.62, t (7.5) 137.6 20, 22 19/23, 20/22 
8-OMe 3.41, s 55.1   
9-OH 4.48, br s    
10-OH b    
11-OH b    
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) signals not observed. 
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Table 4.3.  1H NMR (DMSO-d6) data comparison for experimental and literature162 data of pseurotin A2 (4.30) 
Pos. δH, mult, (J in Hz) (experimental) δH, mult, (J in Hz) literature 
9 4.13, m 4.18, d (9.9) 
10 4.39, m 4.51, t (5.5) 
11 4.44, m 4.57, ddd (11.0, 8.4, 5.5) 
12 5.35, m 5.42, dd (11.0, 8.5) 
13 5.42, m 5.47, dd (11.0, 7.0) 
14a 2.05, m 2.08, m 
14b 2.05, m 2.08, m 
15 0.88, dd (7.6, 7.6) 0.93, dd (7.7, 7.3) 
16 1.62, s 1.66, s 
19/23 8.24, d (7.7) 8.28, d (7.3) 
20/22 7.52, dd (7.3, 7.3) 7.55, dd (8.0, 7.7) 
21 7.66, t (7.7) 7.69, t (7.3) 
7-NH 9.92, s 9.99, s 
8-OMe 3.20, s 3.20, s 
9-OH a 6.35, d (9.9) 
10-OH a 5.87, d (5.5) 
11-OH a 5.09, d (5.5) 
*(a) signals not observed  
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4.4.6 Gliotoxin (4.31) 
 
HRESI(+)MS analysis of 4.31 revealed an adduct ion ([M+Na]+) indicative of the molecular 
formula C13H14N2O4S2 (Δmmu +0.9). The NMR (CDCl3) data of 4.31 (Figure 4.19, Figure 4.20 and 
Table 4.4) showed the presence of a hydroxyl cyclohexadiene and a possible N-methyl serine 
residue. The structure elucidation was further supported by 2D NMR data, including HSQC, COSY 
and HMBC, as outlined in Table 4.4. On searching the literature, it was determined that 4.31 was 
consistent with gliotoxin. Analysis of all the NMR data with comparison to literature data, 
confirmed that 4.31 was the known fungal metabolite gliotoxin (Table 4.5). This assignment was 
further confirmed by a comparison of the [α]22D –167 (c 0.1, MeOH) of 4.31 compared to [α]25D –  
440 (c 0.1, MeOH) of the reported gliotoxin.164-166  
 
Figure 4.19. HMBC (600 MHz, CDCl3) spectrum and key 2D NMR correlations of gilotoxin (4.31) 
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Figure 4.20. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of gliotoxin 
(4.31) 
 
Table 4.4. NMR (600 MHz, CDCl3) data of gliotoxin (4.31) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1  166.1   
2-Me 3.17, s 26.7  1, 3, 11 
3  74.8   
4  164.1   
5a 4.81c, s 67.8  6, 8 
6 4.81c, s 71.3   
7 5.76, d (9.7) 123.2 8 5a, 8 
8 5.92, dd (9.7, 5.0) 128.1 7, 9 5a, 6, 9 
9 5.97, br  118.9 8  
10a  b   
10 α 3.72, d (20.1) 35.1 10β 4, 5a, 8, 9 
 β 2.93, d (20.1)  10α 4, 5a, 8, 9 
11 α 4.39, d (13.2) 59.1 11β, 11-OH 4 
 β 4.23, dd (13.2, 9.2)  11α, 11-OH 4 
6-OH 5.65, s   5a, 7, 8 
11-OH 3.61, br d   11 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) not observed. (c) overlapping resonances 
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Table 4.5. 1H NMR (CDCl3) data comparison of experimental and literature166 data of gliotoxin (3.31)  
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (literature) 
2-Me 3.17, s 3.20, s 
5a 4.81c, s 4.81c, s 
6 4.81c, s 4.81c, s 
7 5.76, d (9.7) 5.77, d (9.5) 
8 5.92, dd (9.7, 5.0) 5.93, dd (9.5, 4.6) 
9 5.97, br 5.98, br 
10 α 3.72, d (20.1) 3.74, dd (17.7, 1.5) 
 β 2.93, d (20.1) 2.94, d (17.7) 
11 α 4.39, d (13.2) 4.42, dd (12.5, 6.1) 
 β 4.23, dd (13.2, 9.2) 4.24, dd (12.5, 9.5) 
6-OH 5.65, s 5.69, s 
11-OH 3.61, br 3.76, dd (9.5, 6.1) 
*measured in (a) (600 MHz, CDCl3), (b) (400 MHz, CDCl3), (c) overlapping resonances 
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4.4.7 Bisdethiobis(methylthio)gliotoxin (4.32) 
 
HRESI(+)MS analysis of 4.32 revealed an adduct ion ([M+Na]+) indicative of the molecular 
formula C15H20N2O4S2 (Δmmu +0.3), consistent with a C2H6 homologue of the co-metabolite 4.31. 
The NMR (CDCl3) data of 4.32 (Figure 4.21, Figure 4.22 and Table 4.6) were similar to 4.31 except 
for opening of the disulphide bridge and the addition of two S-Me reasonces. The structure 
elucidation was further supported by 2D NMR data, including HSQC, COSY and HMBC, as 
outlined in Table 4.6. On searching the literature, it was determined that 4.32 was consistent with 
bisdethiobis(methylthio)gliotoxin. Analysis of all the NMR data with comparison to literature data, 
confirmed that 4.31 was the known fungal metabolite gliotoxin (Table 4.7). This assignment was 
further confirmed by comparison of the [α]22D –67.2 (c 0.1, MeOH) for 4.32 compared to [α]20D –  
51 (c 1.0, MeOH) for the reported bisdethiobis(methylthio)gliotoxin strongly suggested the known 
fungal metabolite bisdethiobis(methylthio)gliotoxin.164-166  
 
Figure 4.21. HMBC (600 MHz, CDCl3) spectrum and key 2D NMR correlations of bisdethiobis(methylthio)gliotoxin 
(4.32) 
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Figure 4.22. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of 
bisdethiobis(methylthio)gliotoxin (4.32) 
Table 4.6. NMR (600 MHz, CDCl3) data of bisdethiobis(methylthio)gliotoxin (4.32) 
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1  164.3   
2 3.13, s 29.1  11 
3  67.2   
3-Me 2.23, s 14.3   
4  167.4   
5a 4.91c 69.4   
6 4.91c 74.4 7 5a, 8, 9 
7 5.73, d (9.7) 130.7  5, 8 
8 5.87, m 122.9 7, 9 5a, 6, 7 
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Table 4.7. 1H NMR (CDCl3) comparison for experimental and literature167 data of bisdethiobis(methylthio)gliotoxin 
(4.32) 
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (literature) 
2-Me 3.13, s 3.15, s 
3-Me 2.23, s 2.27, s 
5a 4.91c 4.88, m 
6 4.91c 4.92, m 
7 5.73, d (9.7) 5.73, m 
8 5.87, m 5.88, m  
9 5.93, br s 5.93, m 
10 α 3.07, d (15.7) α 3.05, d (16.0) 
 β 2.92, d (15.7) β 2.90, d (16.0) 
11-Me 2.24, s 2.24, s 
11 α 4.38, d (12.4) α 4.37, d (12.0) 
 β 3.90, d (12.4) β 3.92, d (12.0) 
6-OH d d 
*measured in (a) (600 MHz, CDCl3). (b) (300 MHz, CDCl3). (c) overlapping resonances. (d) signals not observed 
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4.4.8 Fumitremorgin C (4.33) 
 
HRESI(+)MS analysis of 4.33 revealed a quasi molecular ion ([M+H]+) indicative of the molecular 
formula C22H25N3O3 (Δmmu −1.3). The NMR (CDCl3) data of 4.33, (Figure 4.23, Figure 4.24 and 
Table 4.8) showed the presence of 1,2,4 trisubstituted benzene ring, a diketopiperazine ring, plus 
prolinyl and isoprenyl units. The structure elucidation was further supported by 2D NMR data, 
including HSQC, COSY and HMBC, as outlined in Table 4.8, Figure 4.23 and Figure 4.24. On 
searching the literature, it was determined that 4.33 was consistent with fumitremorgin C. Analysis 
of all the NMR data with comparison to literature data, confirmed that 4.33 was the known fungal 
metabolite fumitremorgin C (Table 4.9). This assignment was further confirmed by comparison of 
the [α]22D –26.2 (c 0.04, MeOH) for 4.33 compared to [α]28D –13 (c 0.53, MeOH) for the reported 
fumitremorgin C.168-170 
 
Figure 4.23. HMBC (600 MHz, CDCl3) spectrum and key 2D NMR correlations of fumitremorgin C (4.33) 
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Figure 4.24. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of 
fumitremorgin C (4.33) 
Table 4.8. NMR (600 MHz, CDCl3) data of fumitremorgin C (4.33) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1-NH 7.64, s   15 
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4     
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13 a 3.51, dd (16.0, 5.2) 21.7 12, 13b 2, 14 
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24 1.99, s 19.2 21 3, 21 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) signals not observed 
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0
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2 0 0
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* D A D 1 ,  7 .9 2 0  :  8 .0 0 8  ( 5 2 7  m A U ,% F s ,  S ig = )  R e f = 0 .7 5 5  &  1 3 .2 3 5  o f  0 0 1 - 0 1 0 1 .D
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2 5 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
* D A D 1 , 8 .0 4 6  :  8 . 1 5 3  (3 2 3  m A U ,% F s ,  S i g = )  R e f = 0 . 7 5 5  &  1 3 .2 3 5  o f  0 0 1 - 0 1 0 1 . D
thio 
2 5 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0
fumitreo 
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Table 4.9. 1H NMR (CDCl3) data comparison of experimental and literature168 data of fumitremorgin C (4.33)  
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (literature) 
1-NH 7.64, s 7.89, br s 
3 5.96, d (9.6) 5.98, br d (9.5) 
6 4.09, dd (9.4, 7.5) 4.10, br dd (9.5, 7.5) 
7a 2.39, m 2.40, m 
7b 2.21, m 2.23, m 
8 a 2.05, m 2.06, m 
 b 1.93, m 1.94, m 
9 3.62, m 3.65, m 
12 4.17, dd (16.0, 5.2) 4.18, br dd (11.5, 5.0) 
13 a 3.51, dd (16.0, 5.2) 3.51, dd (16.0, 5.0) 
 b 3.08, dd (16.0, 5.2) 3.10, ddd (16.0, 11.5, 1.0) 
16 7.42, d (8.6) 7.43, d (9.0) 
17 6.80, d (8.6) 6.81, dd (9.0, 2.2) 
18-OMe 3.82, s 3.83, s 
19 6.84, br s 6.85, d (2.2) 
21 4.88, d (9.6) 4.91, dm (9.5) 
23 1.63, s 1.64, s 
24 1.99, s 1.99, s 
*measured in (a) (600 MHz, CDCl3), (b) (500 MHz, CDCl3) 
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4.4.9 cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) 
 
HRESI(+)MS analysis of 4.34 revealed a quasi-molecular ion ([M+H]+) indicative of the molecular 
formula C14H16N2O3 (Δmmu +0.8). The NMR (CDCl3) data of 4.34 (Figure 4.26) revealed the 
presence of phenylalanine and hydroxyl proline residues, with the molecular formula suggestive of 
a diketopiperazine. The structure elucidation was further supported by 2D NMR data, including 
HSQC, COSY and HMBC, as outlined in Table 4.10. On searching the literature, 4.34 was 
determined to be consistent with cyclo-(L-Phe-trans-4-hydroxy-L-Pro). Analysis of all the NMR 
data with comparison to literature data, confirmed 4.34 was the known fungal metabolite cyclo-(L-
Phe-trans-4-hydroxy-L-Pro) (Table 4.11). This assignment was further confirmed by comparison of 
the [α]22D – 20.9 (c 0.05, MeOH) for 4.34 with the [α]20D –6.7 (c 0.01, MeOH) reported for cyclo-
(L-Phe-trans-4-hydroxy-L-Pro)168,171,172 and C3 Marfey’s analysis  (Figure 4.28 and Figure 4.29). 
 
Figure 4.25. HMBC (600 MHz, CDCl3) spectrum and key 2D NMR correlations of cyclo-(L-Phe-trans-4-hydroxy-L-
Pro) (4.34) 
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Figure 4.26. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of cyclo-(L-Phe-
trans-4-hydroxy-L-Pro) (4.34) 
 
Table 4.10. NMR (600 MHz, CDCl3) data of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
hydroxyproline      
1  169.8    
2 4.46, dd (13.3, 3.8) 57.7 3a,b 3, 4 2′ 
3 a 2.34, dd (13.3, 3.8) 37.9 2, 4 2  
 b 2.06, dd (13.3, 3.8)   2  
4 4.31, d (13.3, 3.8) 56.6 5a,b   
5 a 3.58, dd (13.2, 10.3) 36.9 4 4  
 b 2.77, dd (13.2, 10.3)   4  
4-OH  b    
phenylalanine      
1′ -- 165.8    
2′-NH 5.57, br s --  2, 2′  
2′ 4.57, br s 68.7 3′a,b  2 
3′ a 3.79, dd (13.3, 4.1) 54.7 2′ 4′  
 b 3.62, d (13.3)  2′ 2′, 4′, 5′/9′  
4′ -- 135.7    
5′, 9′ 7.22, d (7.3) 129.5 6′, 8′ 3′, 7′  
6′, 8′ 7.35, t (7.3) 129.8 7′ 4′, 5′, 9′  
7′ 7.29, t (7.3) 127.9 6′, 8′ 5′, 6′, 10′  
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) signals not observed 
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Table 4.11. 1H NMR (CDCl3) data comparison for experimental and literature172 data of cyclo-(L-Phe-trans-4-hydroxy-
L-Pro) (4.34) 
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (literature) 
hydroxyproline   
2 4.46, dd (13.3, 3.8) 4.47, dd (11.1, 6.3) 
3 a 2.34, dd (13.3, 3.8) 2.36, dd (13.2, 6.2) 
 b 2.06, dd (13.3, 3.8) 2.06, ddd (13.5, 11.4, 4.2) 
4 4.31, d (13.3, 3.8) 4.31, dd (10.7, 2.6) 
5 a 3.58, dd (13.3, 10.3) 3.63, dd (15.9, 3.9) 
 b 2.77, dd (13.3, 10.3) 2.77, dd (14.6, 10.9) 
4-OH c c 
phenylalanine   
2′-NH 5.57, br s 5.89, s 
2′ 4.57, br s 4.60, t (4.1) 
3′ a 3.79, dd (13.3, 4.1) 3.80, dd (13.2, 4.5) 
 b 3.62, d (13.3) 3.58, d (13.8) 
5′, 9′ 7.22, d (7.3) 7.29, br m 
6′, 8′ 7.35, t (7.3) 7.29, br m 
7′ 7.29, t (6.9) 7.29, br m 
*measured in (a) (600 MHz, CDCl3), (b) (300 MHz, CDCl3), (c) signals not observed 
4.4.9.1 Assigning absolute configurations: C3 Marfey’s method 
The Marfey’s method173 is a popular method for the assignments of absolute configuration of amino 
acids residues in natural products. The method relies on acid hydrolysis followed by derivatisation 
of amino acid residues with N-α-(2,4-dinitro-5-fluorophenyl)-D/L-alaninamide (FDAA), and 
resolution of the resulting diastereomers by HPLC-DAD as shown in Figure 4.27. The Marfey’s 
method consists of the following steps: 
• Hydrolysis: The natural product to be analysed is subjected to acid hydrolysis (6 M HCl) in order to release the 
amino acid residue(s), and the resulting analyte is concentrated to dryness under nitrogen. 
• Derivatisation: The hydrolysed amino acid(s) is derivatised with Marfey’s reagent (D or L  
FDAA) under alkaline conditions (1 M NaHCO3). 
•  Neutralisation: The acidic reaction products are neutralized (1 M HCl) and diluted with MeCN (1 mL). 
• Analysis: The diluted solution is subjected to HPLC-DAD/MS analysis.  
The FDAA derivatives of pure amino acids standards are also prepared and analyzed using steps 
outlined above. 
 
F
O2N NO2
O
NH2
F
O2N NO2
O
NH2
N-!-(2,4-dinitro-5-fluorophenyl)-D-alaninamide
(D-FDAA)
N-!-(2,4-dinitro-5-fluorophenyl)-L-alaninamide
(L-FDAA)
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Figure 4.27. Reaction scheme between D/L amino acid with D/L-FDAA to give the diastereomeric derivatised amino 
acids *- chiral centre 
 
However, some drawbacks have appeared from using C18 Marfey’s method174 in that it cannot 
resolve L-Ile from L-allo-Ile, and D-Ile from D-allo-Ile, and also it does not transition seamlessly 
between HPLC-DAD and HPLC-MS detection methodology. The Capon group has refined and 
optimized the C18 Marfey’s method to address these limitations, and the refined method is referred 
to as the C3 Marfey’s method.45  
 
The absolute configuration of the 4.34 was confirmed using the C3 Marfey’s method. 45 Standard 
amino acids, D-Phe, L-Phe, trans-4-hydroxy-L-Pro and trans-4-hydroxy-D-Pro were derivatised 
with D-FDAA and analyzed by the HPLC as shown as in Figure 4.28. Absolute configuration of 
4.34 was determined by comparing the retention times of standard amino acids with the hydrolysate 
of 4.34. The amino acid residues in 4.34 were confirmed to be L-Phe and trans-4-hydroxy-L-Pro as 
shown in Figure 4.28 and Figure 4.29. 
 
Figure 4.28. C3 Marfey’s analysis of the selected amino acids derivatized with D-FDAA with the retention times. (a) 
trans-4-hydroxy-D-Pro + D-FDAA. (b) trans-4-hydroxy-L-Pro + D-FDAA. (c) D-Phe + D-FDAA and (d) L-Phe + D-
FDAA.  
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Figure 4.29. HPLC-DAD (340 nm) C3 Marfey’s analysis of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34). Identity of 
amino acids was confirmed by retention time and molecular weight. (a) coinjection of hydrolyzed 4.34 + D-FDAA with 
the standard L-Phe + D-FDAA and trans-4-hydroxy-L-Pro + D-FDAA. (b) trans-4-hydroxy-L-Pro + D-FDAA. (c) L-Phe 
+ D-FDAA. (d) D-FDAA derivatized hydrolysate of 4.34 showing the presence of L-Phe (tR = 32.5 min) and trans-4-
hydroxy-L-Pro (tR = 8.2 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 
15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min. 
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4.4.10 cyclo-(L-Phe-L-Pro) (4.35) 
 
HRESI(+)MS analysis of 4.35 revealed a quasi-molecular ion ([M+H]+) indicative of a molecular 
formula C14H16N2O2 (Δmmu +2.8). The NMR (CDCl3) data of 4.35 (Figure 4.31) were very similar 
to 4.34 with exception of the replacement of methine H-4 in 4.34 with methylene (δH 2.02 and 2.32) 
in 4.35 suggesting the absence of the hydroxyl moiety. The structure elucidation of 4.35 was further 
supported by 2D NMR data, including HSQC, COSY and HMBC, as outlined in Table 4.12. 
Analysis of all the NMR data with comparison to literature data, confirmed that 4.35 was the known 
fungal metabolite cyclo-(L-Phe-L-Pro) (4.35) (Table 4.13).168,171 This assignment was confirmed by 
C3 Marfey’s analysis  (Figure 4.32 and Figure 4.33). 
 
 
Figure 4.30. COSY (600 MHz, CDCl3) spectrum and key 2D NMR correlations of cyclo-(L-Phe-L-Pro) (4.35) 
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Figure 4.31. 1H NMR (600 MHz, CDCl3) and UV-vis spectrum (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of 
cyclo-(L-Phe-L-Pro) (4.35) 
 
Table 4.12. NMR (600 MHz, CDCl3) data of cyclo-(L-Phe-L-Pro) (4.35) 
Pos.  δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROSEY 
proline      
1  165.2    
2 4.06, dd (7.9, 7.3) 59.2 5a/b 1, 4 2′ 
3 a 2.32, m 28.3 3b, 4a/b 5  
 b 2.01b  3a, 4a/b 5  
4 a 2.02b  22.5 3a/b, 5a/b   
 b 1.89, m  3a/b, 5a/b   
5 a 3.65c, m 45.5 5b   
 b 3.63 c, m  5a   
phenylalanine      
1′ --  166.2    
2′-NH 5.54, br s --    
2′ 4.25, dd (14.7, 10.7) 56.3 3′a/b 1′, 3′ 2 
3′ a 3.64 c, m 36.9 2′, 3′b 1′, 2′, 4′, 5′/9′  
 b 2.75, dd (14.7, 10.7)  2′, 3′a 2′, 4′, 5′/9′  
4′ -- 136.1    
5′, 9′ 7.20, d (7.6) 129.5 6′, 8′ 3′, 4′  
6′, 8′ 7.33, t (7.6) 129.6 5′, 9′ 7′  
7′ 7.27, t (7.6) 128.0 6′, 8′ 6′/8′  
*(a)13C assignments obtained from gHSQC and gHMBC data. (b and c) Overlapping resonances.  
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Table 4.13. 1H NMR (CDCl3) data comparison of experimental and published 175 data of cyclo-(L-Phe-L-Pro)  
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (literature) 
proline   
2 4.06, t (7.9) 4.08, m 
3 a 2.32, m 1.90 – 2.10, m 
 b 2.02b 2.30 – 2.40, m 
4 a 2.02b  1.90 – 2.10, m 
 b 1.89, m  
5 a 3.63c, m 3.60 – 3.70, m 
 b 3.55, m  
phenylalanine   
2′-NH 5.54, br s 5.57, bs 
2′ 4.25, dd (10.4, 10.7) 4.28, dd (9.2, 2.8) 
3′ a 3.60c, m 3.60 – 3.70, m 
 b 2.75, dd (14.7, 10.7) 2.77, dd (14.4, 9.2) 
5′, 9′ 7.20, d (7.6) 7.2 – 7.39, m 
6′, 8′ 7.33, t (7.6)  
7′ 7.27, t (7.6)  
*measured in (a) (600 MHz, CDCl3). (b) (300 MHz, CDCl3). (c) Overlapping resonances 
4.4.10.1 C3 Marfey’s analysis of cyclo-(L-Phe-L-Pro) (4.35) 
Employing the C3 Marfey’s method as previously described, 4.35 was subjected to acid hydrolysis 
using 6M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the Phe and Pro amino acids residues. The absolute configuration of 4.35 
was determined by comparing the retention times of standard amino acids with the hydrolysate of 
4.35, to be L-Phe and L-Pro (Figure 4.32 and Figure 4.33). 
 
Figure 4.32. C3 Marfey’s analysis of the selected amino acids derivatized with D-FDAA with the retention times.  
(a) D-Pro + D-FDAA, (b) L-Pro + D-FDAA, (c) D-Phe + D-FDAA and (d) L-Phe + D-FDAA. * residual Marfey’s reagent !
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Figure 4.33. HPLC-DAD (340 nm) C3 Marfey’s analysis of cyclo-(L-Phe-L-Pro) (4.35). Identity of amino acids was 
confirmed by retention time and molecular weight. (a) coinjection of hydrolyzed 4.35 + D-FDAA with the standard L-
Phe + D-FDAA and L-Pro + D-FDAA. (b) L-Pro + D-FDAA. (c) L-Phe + D-FDAA. (d) hydrolyzed of 4.35 showing the 
presence of L-Phe (tR = 32.5 min) and L-Pro (tR = 8.2 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 
µm), 1 mL/min, gradient of 15 - 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min. 
 
4.4.11 Summary for impact of NOS inhibitors 
Surprisingly all three NOS inhibitors 4.16 − 4.18 shut down heronapyrrole B (4.02) production and 
resulted in the production of 4.30 − 4.35, a suite of known fungal metabolites. While our initial 
hypothesis that heronapyrrole B (4.02) biosynthesis was dependent on a functional bNOS has been 
vindicated, the unexpected appearance of fungal metabolites needs to be addressed. 
4.4.12 Detection of an Aspergillus in the Streptomyces (CMB-M0423) 
4.4.12.1 Fungal contamination 
In a busy research laboratory, fungal contamination of cultures is always a risk and a concern. 
While great care is taken to employ sterile technique, it is difficult to completely exclude the 
possibility of contamination from airborne spores. To test the hypothesis that Streptomyces sp. 
(CMB-M0423) was accidentally contaminated by a fungus, we cultured Streptomyces sp. (CMB-
M0423) multiple times on separate days in the presence and absence of NOS inhibitors. In the 
absence of NOS inhibitors, Streptomyces sp. (CMB-M0423) always produced heronapyrrole B 
(4.02), while in the presence of NOS inhibitors; Streptomyces sp. (CMB-M0423) always produced 
the fungal metabolites. To further challenge the contamination hypothesis, we recovered cryo-
preserved samples of Streptomyces sp. (CMB-M0423) and repeated the sequence of cultures with 
and without the addition of NOS inhibitors. On all occasions the results were the same as the first 
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study. From these results, we can unambiguously exclude accidental laboratory fungal 
contamination after accessing the cryopreserved sample.  
4.4.12.2 Associated fungus 
Having established that the original isolate of Streptomyces sp. (CMB-M0423) was not 
inadvertently contaminated with a fungus during laboratory handling, we hypothesized that the 
original culture was “naturally” co-inoculated with an “associated” fungus, but that this fungus was 
suppressed under standard culture conditions, and only appearing on addition of NOS inhibitors. To 
try to detect and even obtain pure isolates of this “silent” fungus, Streptomyces sp. (CMB-M0423) 
was cultured in the presence of the antibacterial rifampicin (4.36), to suppress the growth of the 
Streptomyces sp. (CMB-M0423), and in the presence of the antifungal cycloheximide (4.37), to 
suppress fungal growth. The intent of both studies was to recover pure strains of both the 
Streptomyces and its associated Aspergillus.  
 
The results of these culturing trials are shown in Figure 4.34. When cultured on oatmeal-based 
media in the presence of rifampicin for 45 days, the original culture of Streptomyces sp. (CMB-
M0423) displayed a multitude of individual black fungal colonies. These colonies were sub-
cultured to deliver a pure fungal isolate, which was subjected to DNA extraction using 
cetyltrimethylammonium bromide (CTAB) protocol176 (Appendix). A BLAST search on the 
resulting 18S rRNA sequence showed 98% homology with a species of the genus Aspergillus 
(Appendix). HPLC-DAD analysis of an extract derived from this pure Aspergillus sp. (CMB-
M0423) revealed all the fungal metabolites 4.30 − 4.35. We propose that this “associated fungus” 
be identified as Aspergillus sp. (CMB-M0423) (most likely Aspergillus fumigatus). By comparison, 
cultivation of the original Streptomyces sp. (CMB-M0423) isolate on M1 3.3% seawater media in 
the presence of the antifungal agent cycloheximide yielded a pure actinomycete strain that now can 
be assigned the correct description, Streptomyces sp. (CMB-M0423). To avoid confusion the 
original Streptomyces sp. (CMB-M0423) isolate is now renamed Aspergillus/Streptomyces sp. 
(CMB-M0423) 
OO
NH
OH OHMeO O
OHOH
OH
O
AcO
N
N
N
O
OH NH
O
O
H
rifampicin (3.36) cycloheximide (3.37)
Chapter 4. Beach warfare: An Aspergillus stimulates antifungal defenses in a Streptomyces sp. 
112 
 
 
Figure 4.34. Pictures showing the isolation of Aspergillus sp. (CMB-M0423) from Streptomyces sp. (CMB-M0423). (a) 
Original Aspergillus/Streptomyces sp. (CMB-M0423). The zoom picture of the presence of Aspergillus colonies. (b) 
Aspergillus sp. (CMB-M0423), (c) Streptomyces sp. (CMB-M0423). Note the difference in the colour between (a) and 
(c)  
4.4.13 Cultivation of Aspergillus sp. (CMB-M0423) 
Aspergillus sp. (CMB-M0423) was cultivated on M1 broth containing 3.3% artificial ocean sea salt 
and incubated at 190 rpm, 26.5 °C over 10 d. Over the incubation period Aspergillus sp. (CMB-
M0423) was capable of producing its fungal metabolites (4.30 – 4.35) (Figure 4.35). 
 
Figure 4.35. Graph showing production of Aspergillus sp. (CMB-M0423) secondary metabolites production over 10 d 
cultivation period. The crude extracts were analysed using HPLC-DAD-MS at 210 nm, analytical gradient H2O/MeCN 
plus 0.05% HCO2H using Zorbax C8 column at 210 nm. The graph was plotted using the peak height for every fungal 
metabolite versus days of cultivation. 
4.4.14 Cultivation of the pure Streptomyces sp. (CMB-M0423) 
Streptomyces sp. (CMB-M0423) was cultivated in the microbioreactor on M1 broth containing 
3.3% artificial ocean sea salt [composed of 0.5 g starch, 1 g yeast extract, 2 g peptone and 3.3% 
artificial ocean sea salt per 1 L of distilled water] (1.5 mL), at 26.5 °C for 7 days at 190 rpm. After 
the incubation period, the broth was extracted by the addition of EtOAc (1.5 mL) and the organic 
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layer dried under N2. The organic layer was re-dissolved in MeOH (100 µL) and analyzed by 
HPLC-DAD-MS. Streptomyces sp. (CMB-M0423), to reveal no heronapyrrole B (4.02), strongly 
suggestive that the presence of Aspergillus sp. (CMB-M0423) was critical to the induction of 
heronapyrrole B and related metabolites (Figure 4.36 and Figure 4.37). 
 
Figure 4.36. Picture showing micro-bioreactor culture of (a) Streptomyces sp. (CMB-M0423) and (b) 
Aspergillus/Streptomyces sp. (CMB-M0423) 
 
Figure 4.37. HPLC-DAD chromatogram at 360 nm, gradient elution H2O/MeCN, HCO2H using Zorbax C8.  (a) 
authentic heronapyrrole B, (b) crude extract from Streptomyces sp. (CMB-M0423) showing no production of 
heronapyrrole B (or indeed any secondary metabolites). 
 
4.4.15 Co-cultivation of Streptomyces sp. and Aspergillus sp. (CMB-M0423) 
Aspergillus sp. (CMB-M0423) was co-cultivated with Streptomyces sp. (CMB-M0423) in the 
micro-bioreactor (1.5 mL) using M1 broth containing 3.3% artificial ocean sea salt. After 7 days, 
the broth was extracted with EtOAc (1.5 mL) and re-dissolved in MeOH (100 µL) to give a final 
concentration of 1 mg/mL and analysed by HPLC-DAD-MS. The chemical profiling for the crude 
extract from Streptomyces sp. (CMB-M0423) showed no signs of heronapyrrole B production, 
while after co-culturing with Aspergillus sp. (CMB-M0423), heronapyrrole B production was 
observed (Figure 4.38) along with a large number of additional co-metabolites. 
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Figure 4.38. HPLC-DAD (360 nm) chromatogram, gradient elution H2O/MeCN, HCO2H using Zorbax C8 for the crude 
extract in MeOH from mixing the Aspergillus sp. (CMB-M0423) and the Streptomyces sp. (CMB-M0423). The 
heronapyrrole B is co-eluted with the standard compound of heronapyrrole B. (a) authentic heronapyrrole B, (b) crude 
extract for co-culture of Aspergillus sp. (CMB-M0423) plus Streptomyces sp. (CMB-M0423). 
These studies confirm that: 
• The original Streptomyces sp. (CMB-M0423) isolate was in fact a mixed culture of 
Streptomyces sp. (CMB-M0423) plus quiescent Aspergillus sp. (CMB-M0423). 
• The presence of the Aspergillus sp. (CMB-M0423) is essential for activating Streptomyces sp. 
(CMB-M0423) to produce heronapyrrole B. 
4.4.16 Effect of Aspergillus chemistry on Streptomyces sp. (CMB-M0423) 
4.4.16.1 Fungal metabolites as activators of Streptomyces sp. (CMB-M0423) 
All the fungal metabolites listed above (4.30 – 4.35) were individually tested at 10 µM on 
Streptomyces sp. (CMB-M0423) to determine if any induced heronapyrrole B production. Only 
cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) was capable on inducing heronapyrrole B production 
(Figure 4.39). Indeed, addition of 4.34 at 10 µM to a liquid micro-bioreactor culture of 
Streptomyces sp. (CMB-M0423) retrieved a 20.4 µg/mL yield of heronapyrrole B. 
 
Figure 4.39. HPLC-DAD chromatogram, analytical gradient H2O/MeCN, HCO2H at 360 nm using Zorbax, C8 showing 
metabolite profile of a micro-bioreactor culture of Streptomyces sp. (CMB-M0423) (a) in the presence of 4.34 (10 µM) 
and (b) in the absence of 4.34  
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To further explore the effect of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) on the pure 
Streptomyces sp. (CMB-M0423), a concentration profile had been carried out in which a stock 
solutions of 4.34 were prepared in 2-fold dilution, ranging from 138 mM to 15 nM in 30% DMSO. 
An aliquot (15 µL) from each stock solution was transferred to micro-bioreactor wells containing 
M1 broth in 3.3% artificial ocean sea salt (1.45 mL), to deliver final 4.34 concentrations ranging 
from 4.6 mM to 0.5 nM plus 1% DMSO per well. After 7 d of incubation period, the broth was 
extracted with EtOAc (2 mL) and the organic layer dried under N2. The crude extract was 
suspended in MeOH (100 µL) and analysed by HPLC-DAD-MS. The results showed that cyclo-(L-
Phe-trans-4-hydroxy-L-Pro) at concentrations ranging from 291 µM to 1.1 µM induced the 
production of heronapyrrole B in Streptomyces sp. (CMB-M0423), with the optimum production of 
heronapyrrole B occurring at 10 – 40 µM, returning 20 ± 2 µg/mL of heronapyrrole B. Curiously, 
concentrations of 4.34 above 583 µM and below 0.5 µM failed to induce the production of 
heronapyrrole B (Figure 4.40 and Figure 4.41). This experiment provided strong evidence that 4.34 
is an important regulator molecule for the induction of Streptomyces sp. (CMB-M0423) secondary 
metabolites, including but not limited to heronapyrrole B (4.02).  
 
 
Figure 4.40. Graph showing the effect of different concentrations of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) (µM) 
highlighting min and max concentrations and the production of heronapyrrole B (µg/mL) in Streptomyces sp. (CMB-
M0423) 
 
Figure 4.41. Picture of micro-bioreactor showing the effect of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) two fold 
dilution starting with (5.1 mM to 0.3 nM) on the production of heronapyrrole B by Streptomyces sp. (CMB-M0423). 
The brown colour in the wells coincides with the induction of the heronapyrrole B. 
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Having confirmed the induction of 4.02 by 4.34 in liquid culture, the effect of cyclo-(L-Phe-trans-4-
hydroxy-L-Pro) (4.34) was tested on solid phase (agar) culture of  Streptomyces sp. (CMB-M0423). 
Streptomyces sp. (CMB-M0423) exhibited morphological differences when cultivated on solid 
phase (agar plates) exposed to 4.34 (10 µM) (Figure 4.42). Figure 4.42 A/B demonstrate the effect 
of the absence (A) and presence (B) of 4.34 (10 µM) during micro-bioreactor liquid cultivation of 
Streptomyces p. (CMB-M0423). The brown colouration of the latter coincides with activation of 
heronapyrrole B (4.02) production. Figure 4.42C illustrates the growth of Streptomyces sp. (CMB-
M0423) (white boat shape), riding a brown colouration (sea) caused by addition of 4.34 (DKP) to 
the lower 20% quadrant of the agar plate. Figure 4.42D represents an alternative representation 
where 4.34 is applied to the lower quadrant of the agar plate by way of a paper disc (10 µM) with 
the resulting gradient of 4.34 activating the lower (beard) section of the face cartoon to produce 
brown colouration – coinciding with production of 4.02 and co-metabolites. Figure 4.42E is an 
alternate representative where a plate inoculated with Streptomyces sp. (CMB-M0423) has been 
stimulated in the east and west quadrant by addition of 4.34 (10 µM). 
 
Figure 4.42. Picture shows the effect of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) (DKP) on Streptomyces sp. (CMB-
M0423). (A) Streptomyces sp. (CMB-M0423) cultivated in the 24 well microbioreactor in the absence of cyclo-(L-Phe-
trans-4-hydroxy-L-Pro) in M1 broth 3.3% artificial ocean sea salt. (B) Streptomyces sp. (CMB-M0423) cultivated in the 
presence of 0.01 mM cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) in M1 broth 3.3% ocean sea salt. (D) Cultivation of 
Streptomyces sp. (CMB-M0423) on the M1 3.3% agar in the presence of disc containing 0.01 mM cyclo-(L-Phe-trans-
4-hydroxy-L-Pro) (4.34). The inductions of heronapyrroles start to appear towards the disc while the rest of the 
Streptomyces is white in colour. (E) Streptomyces sp. (CMB-M0423) cultivated in the whole M1 agar plate containing 
3.3% artificial ocean sea salt. The arrows point to the addition of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) and the 
induction of the heronapyrrole B. 
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4.4.17 Detecting the presence of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) in the crude extract of 
Aspergillus/ Streptomyces. sp (CMB-M0423) 
Our emerging theory suggests that cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) is the regulator 
molecule produced by Aspergillus sp. (CMB-M0423) that activates Streptomyces sp. (CMB-
M0423) to produce heronapyrrole B (4.02). This theory has been supported by the observation that 
Aspergillus metabolites, in particular cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34), do indeed 
activate Streptomyces sp. (CMB-M0423) to produce heronapyrrole B (4.02). To further confirm this 
theory required detection and quantification of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) in the 
crude extract of an Aspergillus/Streptomyces sp. (CMB-M0423) culture. To achieve this, HPLC-
DAD-ESI(+)MS data on the crude extracts, were examined by single ion extraction methodology, 
using the m/z 261 [M+H]+ for 4.34. This approach detected cyclo-(L-Phe-trans-4-hydroxy-L-Pro) 
(4.34) in the crude extract of an Aspergillus/Streptomyces sp. (CMB-M0423) culture (Figure 4.43). 
 
Figure 4.43. Chromatograms showing Aspergillus/Streptomyces sp. (CMB-M0423) crude extract, (a) HPLC-DAD-MS, 
gradient elution H2O/MeCN, HCO2H using Zorbax C8 for the crude extract from Streptomyces sp. (CMB-M0423) at 
360 nm showing the presence of heronapyrrole B (4.02). (b) Single ion extraction at 261 [M+H] showing the presence 
of cyclo-(L-Phe-trans-4-hydroxy-L-proline) (4.34) in the crude extract of Aspergillus/Streptomyces sp. (CMB-M0423). 
(c) Authentic cyclo-(L-Phe-trans-4-hydroxy-L-proline) (4.34) 
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4.4.18 Quantify cyclo-(L-Phe-trans-4-hydroxy-L-proline) (4.34)  
Having demonstrated above that cyclo-(L-Phe-trans-4-hydroxy-L-proline) (4.34) is present in the 
crude extract of Aspergillus/Streptomyces sp. (CMB-M0423), we moved on to quantify these levels 
to establish if they were high enough to initiate heronapyrrole B (4.02) biosynthesis. A standard 
calibration curve was prepared using cyclo-(L-Phe-trans-4-hydroxy-L-proline) in 2-fold dilution 
ranging from 7.8 to 0.4 µg/mL in MeOH, in which 10 µL was injected into the HPLC-DAD-MS. 
The graph was plotted using the area under the peak for the extracted ion 261 [M+H]+ consistent 
with the molecular weight for cyclo-(L-Phe-trans-4-hydroxy-L-proline) (Figure 4.44). 
 
Figure 4.44. Graph showing the standard calibration curve using ion extraction at 261[M+H]+ for standard 
concentrations of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34). Red dashed line represents the area under the peak for 
the extracted ion for 4.34 in the crude extract of Aspergillus/Streptomyces sp. (CMB-M0423). 
 
Figure 4.44 demonstrated that cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) has a crucial effect on 
the induction of heronapyrrole B by Streptomyces sp. (CMB-M0423), with the levels of 4.34 in 
Aspergillus/Streptomyces sp. (CMB-M0423) crude extract being 0.47 ± 0.07 µg/mL (1.8 ± 0.3 µM) 
which induces the production of 9.2 ± 0.8 µg/mL of heronapyrrole B in the crude extract. 
  
4.4.19 Effect of Streptomyces chemistry on Aspergillus sp. (CMB-M0423) 
Pure samples of heronapyrrole A (4.01), B (4.02) and C (4.03) were individually added to micro-
bioreactor culture wells to give final concentration of 10 µM in 1% DMSO per well, and wells were 
inoculated with Aspergillus sp. (CMB-M0423) in M1 3.3% artificial ocean sea salt. Micro-
bioreactor cultures were monitored every day of 12 days, by removing an aliquot (100 µL) from 
each well and measuring the OD (600 nm). All cultures remained in the stationary phase until day 
5. It was also observed that heronapyrrole C (4.03) did not affect the growth as OD values 
continued to increase until day 10. On the other hand, both heronapyrrole A (4.01) and B (4.02) 
inhibited the growth at day 7 (Figure 4.47). Simultaneous chemical profiling (HPLC-DAD) 
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revealed a suppression/loss of secondary metabolite production for all secondary metabolites except 
4.34 – the only metabolite critical to activating heronapyrrole biosynthesis in Streptomyces sp. 
(CMB-M0423) (Figure 4.48). 
These experiments demonstrated that Aspergillus sp. (CMB-M0423) exposed to heronapyrroles 
experiences retarded cell growth, and an altered secondary metabolite production. These 
observations suggest that heronapyrroles A (4.01) and B (4.02) and possibly heronapyrrole C (4.03) 
are fungistatic (Figure 4.45 and Figure 4.46). 
 
Figure 4.45. Pictures showing co-culture of both the Aspergillus sp. (CMB-M0423) and Streptomyces sp. (CMB-
M0423) on M1 agar plate containing 3.3% ocean sea salt.  
 
 
Figure 4.46. (A) Streaking of Aspergillus sp. (CMB-M0423) on M1 agar with 3.3% artificial ocean sea salt, and then 
re-streaking of Streptomyces sp. (CMB-M0423). The picture shows that on the edges of the plate the Aspergillus sp. 
(CMB-M0423) starts growing until it reaches Streptomyces sp. (CMB-M0423) where it induces heronapyrrole 
production, which inhibits Aspergillus sp. (CMB-M0423). In the middle of the plate Streptomyces sp. (CMB-M0423) is 
completely white in colour. (B) Expanded image illustrating inhibition of Aspergillus sp. (CMB-M0423). 
 
Figure 4.47. Graph showing the effect of (a) heronapyrrole A (4.01), (b) heronapyrrole B (4.02) and (c) heronapyrrole 
C (4.03) in red at 10 µM on the growth of Aspergillus sp. (CMB-M0423) versus control (blue) 
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Figure 4.48. Graph showing peak height of 4.34 using HPLC-DAD (254 nm) chromatogram, gradient elution, 
H2O/MeCN, HCO2H using Zorbax C8 of the crude extract from Aspergillus sp. (CMB-M0423) in the presence of 
heronapyrrole B (10 µM) 
 
4.4.20 The effect of heronapyrrole B on Aspergillus sp. (CMB-M0423) 
As demonstrated above, 10 µM of heronapyrrole B (4.02) is fungistatic towards Aspergillus sp. 
(CMB-M0423). As the levels of heronapyrrole B (4.02) in Aspergillus/Streptomyces sp. (CMB-
M0423) cultures was quantified at 9.2 ± 0.8 µg/mL (see Figure 4.14), and as a 10 µM concentration 
equates to 3.8 µg/mL, we elected to undertake a study into the fungistatic properties of 4.02 on 
Aspergillus sp. (CMB-M0423) across a range of concentrations. Therefore, two-fold dilutions from 
stock solution of heronapyrrole B were prepared starting from 1800 to 54 µM in 30% DMSO. An 
aliquot (50 µL) from the stock solutions was transferred to the wells of the microbioreactor plate 
containing seed culture of Aspergillus sp. in M1 broth 3.3% artificial ocean sea salt (1.45 mL) to 
give a final concentration of 60 – 1.8 µM/1% DMSO per well. The experiment was performed in 
triplicate. The plate was incubated at 26.5 °C, 190 rpm for 10 days. After the incubation period, an 
aliquot (200 µL) from the broth was transferred into microtiter plate and the absorbance was 
measured spectrophotometrically at 600 nm in which IC50 of heronapyrrole B against Aspergillus 
sp. (CMB-M0423) was 12.1 µM, while the MIC was between 60 – 30 µM (Figure 4.49). 
 
Figure 4.49. Graph showing the fungistatic effect of heronapyrrole B (4.02) on Aspergillus sp. (CMB-M0423) 
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4.4.21 Synthesis of diketopiperazine analogue library 
The studies discussed above illustrated that cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34) is crucial 
for the production of heronapyrroles. In order to test if other diketopiperazines (DKPs) have an 
effect on the production of heronapyrroles, different DKP analogues were synthesized and tested 
using a fast, simple and convenient microwave approach. To arrive at a large array of synthetic 
DKPs, we employed a microwave assisted chemical synthesis, which nowadays is becoming 
increasingly popular and offers a number of significant advantages, by increasing rates and yields. 
 
4.4.22 Synthesis of methyl esters (4.38a – e) and diketopiperazines (4.39a – l) 
A series of DKPs 4.39a – l (Table 4.14) were prepared in a 2 steps. Esterification of the amino acids 
4.37a – d using standard procedures, followed by microwave irradiation of mixtures of 
hydrochloride salts of the corresponding methyl esters 4.38a – e in the presence of triethylamine, 
afforded the diketopiperazines 4.39a – l (Scheme 4.2). 
 
Scheme 4.2. Synthesis of DKPs derivatives. (a) addition of SOCl2 in the presence of MeOH under reflux for 18 h. (b) 
The reaction mixture was dissolved in H2O (5 mL), triethylamine (2.5 eq) and heated in the microwave at 140 °C, 300 
W for 3 min 
 
 
 
Figure 4.50. Structures of amino acids (4.37a – d) and their methyl esters (4.38a – b) 
 
 
 
 
(a)
R1 NH2
O OMe
4.38a-d
(b)
4.39a-l
.HCl
4.37a-d
NH
HN
O
O
R1
R2R1 NH2
O OH
CO2Me
NH2
4.38a
CO2Me
NH2
CO2Me
NH
HO
4.38c
CO2Me
NH
4.38d
HO
4.38b
CO2H
NH2
4.37a
CO2H
NH2
CO2H
NH
HO
4.37c
CO2H
NH
4.37d
HO
4.37b
Chapter 4. Beach warfare: An Aspergillus stimulates antifungal defenses in a Streptomyces sp. 
122 
 
Table 4.14. Diketopiperazine derivatives 4.39a – l  
Molecular Structure of synthetic DKPs 
  
  
  
  
  
  
4.4.22.1 Stereochemical Equilibrium 
Prior literature studies have demonstrated that proline and 4-hydroxy-proline undergo racemization 
during conversion into DKPs, leading to a mixture of stereoisomers.177,178 We set out to explore this 
equilibration, to achieve a larger array of DKP stereoisomers. 
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4.4.23 Synthesis of cyclo-(Phe-4-hydroxy-Pro) stereoisomers 
The reaction was performed by irradiating a 1:1 mixture of L-Phe methyl ester (4.37a) with trans-4-
hydroxy-L-Pro methyl ester (4.37b) in H2O (3 mL) in the presence of triethylamine (2.5 
equivalent). The reaction was performed in a microwave reactor at 140 ˚C, 300 WATT for 3 min, 
the crude product was washed with H2O, and the H2O insoluble residue was dried in vacuo to 
recover a product that was analysed by HPLC-DAD-MS as containing multiple diketopiperazines 
(Figure 4.51 and Scheme 4.3). 
  
 
Figure 4.51. HPLC-DAD-MS reaction product of cyclo-(L-Phe-4-hydroxy-Pro). Reacting the methyl ester of L-Phe 
(4.38a) with methyl ester of trans-4-hydroxy-L-Pro (4.38c). The highlighted peaks represent DKPs 
 
 
Scheme 4.3. Fractionation scheme of the reaction of methyl ester of L-Phe (4.38a) with methyl ester of trans-4-
hydroxy-L-Pro (4.38c). (a) Semi-preparative gradient HPLC: Zorbax-C8, 90 – 30% H2O/MeOH, 3 mL/min, 30 min 
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4.4.23.1 cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.39a) 
 
Compound 4.39a was synthesized as an optically active amorphous white powder ([α]22D −5.5, c 
0.15, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ (Δmmu +0.8) consistent with the 
molecular formula C14H16N2O3. Optimizing the isolation method, we were able to isolate 4.39a 
from 4.39c (Figure 4.53). The 1H NMR (CDCl3) data, of 4.39a compared very well with data for 
the natural product 4.34, confirming the assigned structure.  
 
Figure 4.52. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture highlighting 4.39a 
 
Figure 4.53. Semi-preparative HPLC-DAD chromatogram using H2O/MeOH at 210 nm using Zorbax C8 column 
optimized for resolution of 4.39a – d  
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Table 4.15. NMR (600 MHz, CDCl3) data of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.39a) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
hydroxyproline      
1  169.8    
2 4.46, dd (14.1, 3.2) 57.7 3a,b 3, 4 2′ 
3 a 2.34, dd (14.1, 3.2) 37.9 2 2  
 b 2.06, dd (14.1, 3.2)   2  
4 4.31, d (13.3) 56.6 5a,b   
5 a 3.58, d (13.3) 36.9 4 4  
 b 2.77, dd (13.3, 10.3)   4  
4-OH  b    
phenylalanine      
1′ -- 165.8    
2′-NH 5.57, br  --  2, 2′  
2′ 4.57, br  68.7 3′a,b  2 
3′ a 3.79, dd (13.3, 4.1) 54.7 2′ 4′  
 b 3.62, d (13.3)  2′ 2′, 4′, 5′/9′  
4′ -- 135.7    
5′, 9′ 7.22, d (7.3) 129.5 6′, 8′ 3′, 7′  
6′, 8′ 7.35, t (7.3) 129.8 7′ 4′, 5′, 9′  
7′ 7.29, t (7.3) 127.9 6′, 8′ 5′, 6′, 10′  
(a)13C assignments obtained from gHSQC and gHMBC data. (b) signals not observed 
 
The NMR data of both 4.34 and 4.39a were identical. Further analysis using ROESY data 
confirmed a cis relationship between H-2 and H-2′ (Figure 4.54). 
 
Figure 4.54. ROESY (600 MHz, CDCl3) spectrum showing the correlations of cyclo-(L-Phe-trans-4-hydroxy-L-Pro) 
(4.39a)  
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Figure 4.55. Comparison of 1H NMR (600 MHz, CDCl3) of (a) natural metabolite cyclo-(L-Phe-trans-4-hydroxy-L-Pro) 
(4.34) and (b) synthetic cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.39a) 
[ppm] 8  6  4  2 
[re
l]
 0
 
 5
 
 1
0 
 1
5 
 2
0 
 2
5 
 3
0 
5’,9’
6’,8’ 7’
2’-NH
2’
2 4 3’a
3’b 5a 5b 3a 3b
5’,9’
6’,8’
7’
2’-NH 2’
2 4 3’a
3’b
5a
5b 3a 3b
4-OH
(a)
(b)
HN
O
N
O
OH
H
2'
2
1
5
5'
9'
H
7'
1'
Chapter 4. Beach warfare: An Aspergillus stimulates antifungal defenses in a Streptomyces sp. 
127 
 
4.4.23.2 cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39b) 
 
Compound 4.39b was synthesized as an optically active amorphous white powder ([α]22D −33, c 
0.06, MeOH). HRESI(+)MS showed a adduct ion (M+Na)+ consistent with the molecular formula 
C14H16N2O3 (Δmmu +0.5). The 1H NMR (CDCl3) data of 4.39b are presented in Figure 4.58 and 
Table 4.16 and supported the assigned structure. ROESY correlations confirmed a cis configuration 
between H-2 and H-4 as shown as in Figure 4.57 and the absolute configuration of 4.39b was 
confirmed by C3 Marfey’s analysis (Figure 4.59 and Figure 4.60). 
 
Figure 4.56. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture, highlighting 4.39b 
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Figure 4.57. ROESY (600 MHz, CDCl3) spectrum showing the correlations of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) 
(4.39b)  
 
Figure 4.58. 1H NMR (600 MHz, CDCl3) of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39b) 
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Table 4.16. NMR (600 MHz, CDCl3) data of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39b) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
hydroxyproline      
1  169.6    
2 4.17, br s 59.7 3 1, 1′, 5 2′-NH 
3 a 2.21, dd (13.1, 5.8) 38.8 2, 4 1  
 b 1.90, ddd (13.1, 12.5, 5.8)  2, 4 1  
4 2.54, dd (13.1, 5.8) 56.2 5a/b 1 2 
5 a 3.09, br  40.7 4 1′, 2 5′a,b 
 b 3.08, br   4 5  
4-OH c     
phenylalanine      
1′  165.4    
2′-NH 5.87, brd  2′   
2′ 4,48, brd 68.2 3′b  3 
3′ a 3.81, dd (13.1, 4.6) 56.2 3′b   
 b 3.39, d (13.1)  2′, 3′a 3′  
4′  135.4    
5′, 9′ 7.19, d (7.1) 130.4 6′, 8′ 6′,7′,8′  
6′, 8′ 7.30b 129.6    
7′ 7.30b 128.3    
(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Signals are not observed 
 
4.4.23.2.1 C3 Marfey’s analysis of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39b) 
Employing the C3 Marfey’s method as previously described, 4.39b was subjected to acid hydrolysis 
using 6M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the associated amino acids residues. The absolute configuration of 4.39b 
was determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39b, as L-Phe and cis-4-hydroxy-D-Pro (Figure 4.59 and Figure 4.60). 
 
Figure 4.59. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) cis-4-hydroxy-L-Pro 
+ D-FDAA (tR = 12.8 min), (b) cis-4-hydroxy-D-Pro + D-FDAA (tR = 12.5 min), (c) L-Phe + D-FDAA (tR = 32.5 min) 
and (d) D-Phe + D-FDAA (tR = 33.2 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, 
gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
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Figure 4.60. HPLC trace (340 nm) from HPLC-MS C3 Marfey’s analysis of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (3.39b). 
Identity of amino acids was confirmed by retention time and molecular weight. (a) Co-injection of D-FDAA derivatized 
hydrolysate of 3.39b with L-Phe and cis-4-hydroxy-D-Pro + D-FDAA, (b) cis-4-hydroxy-D-Pro + D-FDAA, (c) L-Phe + 
D-FDAA, (d) D-FDAA derivatized hydrolyzed of 4.39b (200 µg) showing the presence of L-Phe (tR = 32.5 min) and cis-
4-hydroxy-D-Pro (tR = 12.6 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient 
of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
 
 
!
0 20 40
Retention time  (min)
Ab
so
rb
an
ce
 a
t 3
40
 n
m
32.5
12.6
(a)
(b)
(c)
(d)
Chapter 4. Beach warfare: An Aspergillus stimulates antifungal defenses in a Streptomyces sp. 
131 
 
4.4.23.3 cyclo-(L-Phe-cis-4-hydroxy-L-Pro) (4.39c) 
 
Compound 4.39c was synthesized as an optically active amorphous white powder ([α]21D −7.6, c 
0.05, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula 
C14H16N2O3 (Δmmu +1.5). The 1H NMR (CDCl3) spectrum and tabulated data of 4.39c are 
presented in Figure 4.63 and Table 4.17 respectively. ROESY correlations confirmed the cis 
relationship between H-2′, H-2 and H-4 as shown in Figure 4.62. Marfey analysis was used to 
confirm the absolute configuration (Figure 4.64 and Figure 4.65). 
 
Figure 4.61. Semi-preparative HPLC-DAD chromatogram using H2O/MeOH at 210 nm using Zorbax C8 column 
optimized for resolution of 4.39c 
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Figure 4.62. ROESY (600 MHz, CDCl3) spectrum showing the correlations of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) 
(4.39c)  
 
Figure 4.63. 1H NMR (600 MHz, CDCl3) spectrum of cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39c) 
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Table 4.17. NMR (600 MHz, CDCl3) data of cyclo-(L-Phe-cis-4-hydroxy-L-Pro) (4.39c) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
hydroxyproline      
1  165.9    
2 4.21, br s 59.7 3a,b 1′, 1  4 
3 a 2.32, m 37.8 2, 4 1′  
 b 2.18, m  2, 4 1′  
4 3.08b,m 56.5  1, 3 2 
5 a 3.08b,m 40.8  1′, 2  
 b 3.07b,m   1′, 2  
4-OH c     
phenylalanine      
1′  169.1    
2′-NH 6.04, br s  2′   
2′ 4.36, m 68.8 2′-NH   
3′ a 3.82, d (12.6) 54.1 2′, 3′b 2′ 3′b 
 b 3.29, dd (12.6, 4.9)  2′, 3′a 2′ 3′a 
4′  127.9    
5′, 9′ 7.18, d (7.1) 130.5 6′, 8′   
6′, 8′ 7,28b,m 129.7 4′, 5′, 9′   
7′ 7.28b,m 128.5 6′,8′   
(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Signals are not observed 
4.4.23.3.1 C3 Marfey’s analysis of cyclo-(L-Phe-cis-4-hydroxy-L-Pro) (4.39c) 
Employing the C3 Marfey’s method as previously described, 4.39c was subjected to acid hydrolysis 
using 6 M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the amino acid residues. The absolute configuration of 4.39c was 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39c to be L-Phe and cis-4-hydroxy-L-Pro (Figure 4.64 and Figure 
4.65). 
 
Figure 4.64. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) cis-4-hydroxy-D-Pro 
+ D-FDAA (tR = 12.5 min), (b) cis-4-hydroxy-L-Pro + D-FDAA (tR = 12.8 min), (c) L-Phe + D-FDAA (tR = 32.5 min) 
and (d) D-Phe + D-FDAA (tR = 33.2 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, 
gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
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Figure 4.65. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Phe-cis-4-hydroxy-L-Pro) 
(4.39c). Identity of amino acids was confirmed by retention time and molecular weight. (a) Co-injection of D-FDAA 
derivatized hydrolysate of 4.39c with L-Phe and cis-4-hydroxy-L-Pro + D-FDAA, (b) cis-4-hydroxy-L-Pro + D-FDAA, 
(c) L-Phe + D-FDAA and (d) D-FDAA derivatized hydrolyzed of 4.39c (200 µg) showing the presence of L-Phe (tR = 
32.5 min) and cis-4-hydroxy-L-Pro (tR = 12.6 min) as well as co-injection of the hydrolysate 4.39c with the standards. 
HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% MeOH/H2O 
(isocratic 5% MeCN containing 1% formic acid) over 55 min 
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4.4.23.4 cyclo-(L-Phe-trans-4-hydroxy-D-Pro) (4.39d) 
 
Compound 4.39d was synthesized as an optically active amorphous white powder ([α]22D −5.4, c 
0.1, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula 
C14H16N2O3 (Δmmu +0.5). The 1H NMR (CDCl3) spectrum and tabulated data of 4.39d are 
presented in Figure 4.67, Figure 4.68 and Table 4.18 respectively. The absence of ROESY 
correlations (Figure 4.67) was consistent with the assigned configuration, which was subsequently 
confirmed by C3 Marfey’s analysis (Figure 4.69 and Figure 4.70). 
 
Figure 4.66. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture highlighting 4.39d 
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Figure 4.67. ROESY (600 MHz, CDCl3) spectrum showing the absence of key correlations of cyclo-(L-Phe-trans-4-
hydroxy-D-Pro) (4.39d)  
 
Figure 4.68. 1H NMR (600 MHz, CDCl3) of cyclo-(L-Phe-trans-4-hydroxy-D-Pro) (4.39d) 
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Table 4.18. NMR (600 MHz, CDCl3) data of cyclo-(L-Phe-trans-4-hydroxy-D-Pro) (4.39d) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
hydroxyproline      
1  166.7    
2 4.15, t (7.1) 57.4 3 1′, 5  
3 2.43, br 36.0 2 2  
4 4.26, d (11.3, 3.1) 56.2 5a,b  3′a/b, 5a 
5 a 3.61, d (11.3) 36.1 4, 5b 2 4 
 b 2.78, dd (11.3, 10.1)  4, 5a 1, 2, 3  
4-OH c     
phenylalanine      
1′  169.8    
2′-NH 5.59, br s     
2′ 4.50, br s 68.6 3′b  3′a,b 
3′ a 3.87, d (12.4) 53.5 3′b  2′ 
 b 3.45, dd (12.4, 4.6)  2′, 3′a  2′, 4 
4′  136.1    
5′, 9′ 7.22b 129.5 6′, 8′ 7′  
6′, 8′ 7.33b,m 129.7 5′, 9′ 4′, 5′, 9′  
7′ 7.27,t (7.1) 128.0 6′, 8′   
(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Signals are not observed 
 
4.4.23.4.1 C3 Marfey’s analysis for cyclo-(L-Phe-trans-4-hydroxy-D-Pro) (4.39d) 
Employing the C3 Marfey’s method as previously described, 4.39d was subjected to acid hydrolysis 
using 6 M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the amino acid residues. The absolute configuration of 4.39d was 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39d, to be L-Phe and trans-4-hydroxy-D-Pro (Figure 4.69 and Figure 
4.70). 
 
Figure 4.69. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) trans-4-hydroxy-D-
Pro + D-FDAA (tR = 9.2 min), (b) trans-4-hydroxy-L-Pro + D-FDAA (tR = 8.2 min), (c) L-Phe + D-FDAA (tR = 32.5 
min) and (d) D-Phe + D-FDAA (tR = 33.2 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 
mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
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Figure 4.70. HPLC trace (340 nm) from HPLC-MS C3 Marfey’s analysis of cyclo-(L-Phe-trans-4-hydroxy-D-Pro) 
(4.39d). Identity of amino acids was confirmed by retention time and molecular weight. (a) Co-injection of the D-
FDAA derivatized hydrolysate 4.39d with the standards L-Phe and trans-4-hydroxy-D-Pro + D-FDAA, (b) trans-4-
hydroxy-D-Pro + D-FDAA, (c) L-Phe + D-FDAA and (d) D-FDAA derivatized hydrolyzed of 4.39d (200 µg) showing 
the presence of L-Phe (tR = 32.5 min) and trans-4-hydroxy-D-Pro (tR = 9.3 min). HPLC conditions, Zorbax, SB-C3 
column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic 
acid) over 55 min 
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4.4.24 cyclo-(Phe-Phe) (4.39e) 
 
Compound 4.39e was isolated as a white powder with NMR (CDCl3), ES(+)MS data (m/z, 295, 
M+H+) and ([α]21D 0, c 0.05, MeOH) suggestive of a mixture of cyclo-(L-Phe-L-Phe), cyclo-(D-Phe-
D-Phe) and cyclo-(L-Phe-D-Phe). The relatively high yield (19%) of symmetric dimers depletes the 
availability of L-Phe in the reaction mixture and may (at least in part) explain the low yield of 
unsymmetric (Phe + Pro) diketopiperazines products. This observation suggests that a change in the 
ratio of Pro to Phe starting material from 1:1 to 1:10 may improve the yields of Phe-Pro products.  
 
Figure 4.71. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture highlighting 4.39e 
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4.4.24.1 Summary for all the cyclo-(Phe-4-hydroxy-Pro) stereoisomers 
Following a microwave assisted synthetic approach, four stereoisomers of cyclo-(Phe-4-hydroxy-
Pro) were synthesized (Figure 4.72 and Scheme 4.4). Curiously, the configuration about the L-Phe 
residue in these diketopiperazines was preserved; where as the configurations about both chiral 
centres in the trans-4-hydroxy-L-Pro residue were racemized. While this synthetic approach may 
seem inelegant from a synthetic methodology standpoint, in practice it proved to be effective at 
delivering a suite of stereoisomers for SAR investigations. 
 
Figure 4.72. 1H NMR (600 MHz, CDCl3) comparison of cyclo-(Phe-4-hydroxy-Pro) stereoisomers 
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Scheme 4.4. Synthesis of different stereoisomers of cyclo-(Phe-4-hydroxy-Pro) 
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4.4.25 Synthesis of cyclo-(Tyr-4-hydroxy-Pro) stereoisomers 
The reaction was performed by microwave irradiation of a 1:1 mixture of L-Tyr methyl ester 
(4.38b) and trans-4-hydroxy-L-Pro methyl ester (4.38c) in H2O (3 mL) in the presence of 
triethylamine (2.5 eq) in a microwave reactor at 140 °C, 300 W for 3 min. The dried reaction 
product was washed with H2O and the H2O insoluble residue was dried in vacuo to recover a 
product that analysed by HPLC-DAD-MS as containing multiple diketopiperazines (Figure 4.73). 
 
 
Figure 4.73. HPLC-DAD-MS reaction product of cyclo-(Tyr-4-hydroxy-Pro). Reacting the methyl ester of L-Tyr 
(4.38b) with methyl ester of trans-4-hydroxy-L-Pro (4.38c). The highlighted peaks represent DKPs  
 
Scheme 4.5. Fractionation scheme for the reaction of methyl ester of L-Tyr (4.38b) with methyl ester of trans-4-
hydroxy-L-Pro (4.38c). (a) Semi-preparative gradient HPLC: Zorbax C8, 90 – 50% H2O/MeOH, 3 mL/min 
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4.4.25.1 cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) 
 
Compound 4.39f was synthesized as an optically active amorphous white powder ([α]22D −33.9, c 
0.06, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula 
C14H16N2O3 (Δmmu −0.1). The 1H NMR (MeOH-d4) spectum and tabulated data of 4.39f are 
presented in Figure 4.76 and Table 4.19. The absence of ROESY correlations between H-2′, H-2 and 
H-4 (Figure 4.75), was consistent with the proposed configuration, however this assignment was 
subsequently confirmed by C3 Marfey’s analysis (Figure 4.77 and Figure 4.78). 
 
Figure 4.74. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture, highlighting 4.39f 
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Figure 4.75. ROESY (600 MHz, MeOH-d4) spectrum of cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) revealing the 
absence of key correlations  
 
Figure 4.76. 1H NMR (600 MHz, MeOH-d4) spectrum of cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) 
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Table 4.19. NMR (600 MHz, MeOH-d4) data of cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
hydroxyproline      
1  167.5    
2 4.14, t (4.6) 59.5 3, 5a,b 1, 1′ 5a 
3 a 2.03, dd (13.1, 6.0) 39.0 3b, 4 2′ 3b 
 b 1.77, ddd (13.1, 12.1, 6.0)  3a, 4 1′, 4 3a 
4 3.06, dd (13.1, 6.0) 57.2 3a,b 1′ 3b 
5 a 3.11, dd (13.1, 4.4) 40.2 2, 5b 1, 2  2, 5b 
 b 2.89, dd (13.1, 4.4)  2, 5a 1, 2 5a 
4-OH b     
tyrosine      
1′  171.8    
2′-NH      
2′ 4.32, t (4.6) 68.4 3′a 3′ 3′a 
3′ a 3.72, dd (13.1, 4.6) 55.2 2′,3′b 1 2′,3′b 
 b 3.21, d (13.1)  3′a 2′ 3′a 
4′  126.8    
5′, 9′ 6.97, d (8.4) 132.1 6′, 8′ 7′  
6′, 8′ 6.72, d (8.4) 116.3 5′, 9′ 4′,7′  
7′  158.1    
(a)13C assignments obtained from gHSQC and gHMBC data. (b) Signals not observed 
4.4.25.1.1 C3 Marfey’s analysis for cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f) 
Employing the C3 Marfey’s method as previously described, 4.39d was subjected to acid hydrolysis 
using 6M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the amino acid residues. The absolute configuration of 4.39f was 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39f to be L-Tyr and trans-4-hydroxy-D-Pro (Figure 4.77 and Figure 
4.78). 
 
Figure 4.77. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) trans-4-hydroxy-D-
Pro + D-FDAA (tR = 9.4 min), (b) trans-4-hydroxy-L-Pro + D-FDAA (tR = 8.6 min), (c) D-Tyr + D-FDAA (tR = 26.5 
min) and (d) L-Tyr + D-FDAA (tR = 31.5 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 
mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
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Figure 4.78. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-trans-4-hydroxy-D-
Pro) (4.39f). Identity of amino acids was confirmed by retention time and molecular weight. (a) Co-injection of the D-
FDAA derivatized hydrolysate 4.39f with the standards, (b) trans-4-hydroxy-D-Pro + D-FDAA, (c) L-Tyr + D-FDAA 
and (d) D-FDAA derivatized hydrolyzed of 4.39f (300 µg) showing the presence of L-Tyr (tR = 31.5 min) and trans-4-
hydroxy-D-Pro (tR = 9.4 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 
15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min.* residual of Marfey’s reagent  
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4.4.25.2 cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) 
 
Compound 4.39g was synthesized as an optically active amorphous white powder ([α]22D −34, c 
0.06, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula 
C14H16N2O3 (Δmmu −0.4). The 1H NMR (MeOH-d4) spectrum and tabulated data for 4.39g are 
presented in Figure 4.80 and Table 4.20. ROESY correlations confirmed the cis configuration 
between H-2′, H-2 and H-4 (Figure 4.80), with absolute configurations confirmed by C3 Marfey’s 
analysis (Figure 4.82 and Figure 4.83). 
 
Figure 4.79. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture, highlighting (4.39g) 
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Figure 4.80. ROESY (600 MHz, MeOH-d4) spectrum showing key correlations of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) 
(4.39g)  
 
Figure 4.81. 1H NMR (600 MHz, MeOH-d4) spectrum of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) 
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Table 4.20. NMR (600 MHz, MeOH-d4) data of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
hydroxyproline      
1  167.3    
2 4.16, t (4.4) 59.3 5a, b 1, 1′, 4′, 5 4 
3 a 2.25, m 37.6 3b, 4 2  
 b 1.89, m  3a, 4 1′, 2′, 2  
4 2.75, t (4.5) 57.0 3a, b 1′, 3 2 
5 a 3.10, dd (14.0, 4.5) 40.3 2, 5b 2, 4  
 b 2.88, dd (14.0, 4.5)  2, 5a 1, 2, 4  
4-OH b     
tyrosine      
1′  171.4    
2′-NH      
2′ 4.32, m 68.6 3′a, b   
3′ a 3.59, dd (12.4, 3.4) 54.3 2′, 3′b 2′  
 b 3.26, dd (12.4, 3.4)  2′, 3′a   
4′  127.3    
5′, 9′ 6.97, d (8.3) 132.2 6′/8′ 7′  
6′, 8′ 6.71, d (8.3) 116.3 5′/9′ 7′  
7′  158.3    
(a)13C assignments obtained from gHSQC and gHMBC data. (b) Signals not observed 
4.4.25.2.1 C3 Marfey’s analysis for cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) 
Employing the C3 Marfey’s method as previously described, 4.39g was subjected to acid hydrolysis 
using 6 M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the amino acid residues. The absolute configuration of 4.39g was 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39g to be L-Tyr and cis-4-hydroxy-D-Pro (Figure 4.82 and Figure 
4.83). 
 
Figure 4.82. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis for the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) cis-4-hydroxy-L-Pro 
+ D-FDAA (tR = 12.9 min), (b) cis-4-hydroxy-D-Pro + D-FDAA (tR = 12.3 min), (c) D-Tyr + D-FDAA (tR = 26.5 min) 
and (d) L-Tyr + D-FDAA (tR = 31.9 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, 
gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
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Figure 4.83. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) 
(4.39g). Identity of amino acids was confirmed by retention time and molecular weight. (a) Co-injection of the D-FDAA 
derivatized hydrolysate 4.39g with the standards, (b) cis-4-hydroxy-D-Pro + D-FDAA, (c) L-Tyr + D-FDAA and (d) D-
FDAA derivatized hydrolysate of 4.39g (300 µg) showing the presence of L-Tyr (tR = 31.9 min) and cis-4-hydroxy-D-
Pro (tR = 12.6 min).  HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% 
MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min.* residual of Marfey’s reagent 
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4.4.25.3 cyclo-(L-Tyr-L-Tyr) (4.39h) 
 
Compound 4.39h was synthesized as an optically active amorphous white powder ([α]21D −8, c 
0.08, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula 
C18H18N2O4 (Δmmu +1.6). The 1H NMR (DMSO-d6) spectra and tabulated data of 4.39h are 
presented in Figure 4.86 and Table 4.21. ROESY correlations were not very helpful in the 
assignment of configuration between H-2 and H-2′, due to symmetry. Absolute configurations were 
determined by C3 Marfey’s analysis (Figure 4.87). 
 
 
Figure 4.84. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture, highlighting 4.39h 
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Figure 4.85. COSY (600 MHz, DMSO-d6) spectrum showing the key correlations of cyclo-(L-Tyr-L-Tyr)  (4.39h) 
 
 
Figure 4.86. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of cyclo-(L-
Tyr-L-Tyr) (4.39h)  
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Table 4.21. NMR (600 MHz, DMSO-d6) of cyclo-(L-Tyr-L-Tyr) (4.39h)  
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
tyrosine      
1, 1′  166.7    
2, 2′-NH 7.76, s  2/2′ 1/1′, 2/2′ 2/2′, 5/5′, 9/9′ 
2, 2′ 3.83, br s 55.9 2/2′NH, 3 /3′ 1/1′ 5/5′, 9/9′ 
3, 3′ a 2.51b 39.1 2/2′, 3b/3′b   
3, 3′ b 2.09, dd (13.6, 6.2)  2/2′, 3a/3′a 1/1′, 2/2′, 4/4′, 5/5′ 2/2′ 
4, 4′  127.6    
5, 5′, 9, 9′ 6.82, d (8.2) 131.1 6/6′, 8/8′ 3/3′, 7/7′ 2/2′,3/3′ 
6, 6′, 8, 8′ 6.66, d (8.2) 115.7 5/5′, 9/9′ 4/4′  
7, 7′  156.2    
7, 7′-OH 9.21, s    6/6′, 8/8′ 
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Obscured by the solvent 
 
4.4.25.3.1 C3 Marfey’s analysis for cyclo-(L-Tyr-L-Tyr) (4.39h) 
Employing the C3 Marfey’s method as previously described, 4.39h was subjected to acid hydrolysis 
using 6 M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the amino acid residues. The absolute configuration of 4.39h was 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39h to be L-Tyr (Figure 4.87). 
 
Figure 4.87. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-L-Tyr) (4.39h). Identity 
of amino acids was confirmed by retention time and molecular weight. (a) Co-injection of the D-FDAA derivatized 
hydrolysate 4.39h with the standards. (b) D-Tyr + D-FDAA, (c) L-Tyr + D-FDAA and (d) D-FDAA derivatized 
hydrolyzed of 4.39h (300 µg) showing the presence of L-Tyr (tR = 31.5 min). HPLC conditions, Zorbax, SB-C3 column 
(150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) 
over 55 min. * residual of Marfey’s reagent 
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4.4.25.4 cyclo-(L-Tyr-D-Tyr) (4.39i) 
 
Compound 4.39i was synthesized as meso amorphous white powder ([α]21D −0, c 0.05, MeOH). 
HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula C18H18N2O4 
(Δmmu +2.6). The 1H NMR (CDCl3) spectrum and tabulated data of 4.39i are presented in Figure 
4.90 and Table 4.22. ROESY correlations could not be used to solve the configuration about the 
two stereocenters, due to symmetry. Absolute configurations were determined by C3 Marfey’s 
analysis (Figure 4.91). 
 
Figure 4.88. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture, highlighting 4.39i 
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Figure 4.89. HMBC (600 MHz, DMSO-d6) spectrum showing key correlations of cyclo-(L-Tyr-D-Tyr) (4.39i) 
 
Figure 4.90. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of cyclo-(L-
Tyr-D-Tyr) (4.39i) 
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Table 4.22 NMR (600 MHz, DMSO-d6) of cyclo-(L-Tyr-D-Tyr) (4.39i) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
tyrosine      
1,1′  171.4    
2, 2′-NH 7.90, br   2/2′   
2, 2′ 3.29b 57.3 2/2′NH, 3/3′a,b 1/1′, 3/3′, 4/4′  
3, 3′ a 2.87, dd (13.8, 5.1) 39.9 2/2′, 3/3′b 2/2′, 4/4′, 5/5′, 9/9′ 5/5′, 9/9′ 
3, 3′ b 2.57, dd (13.8, 5.1)  2/2′, 3/3′a 1/1′, 2/2′, 4/4′, 5/5′, 9/9′ 5/5′, 9/9′ 
4, 4′  128.4    
5, 5′, 9, 9′ 6.88, d (8.4) 133.2 6/6′, 8/8′ 3/3′, 7/7′ 3/3′a,b 
6, 6′, 8, 8′ 6.60, d (8.4) 117.8 5/5′, 9/9′ 4/4′  
7, 7′  158.8    
*(a)13C assignments obtained from gHSQC and gHMBC data. (b) Obscured by the solvent 
 
4.4.25.4.1 C3 Marfey’s analysis for cyclo-(L-Tyr-D-Tyr) (4.39i) 
Employing the C3 Marfey method as previously described, 4.39i was subjected to acid hydrolysis 
using 6 M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the amino acid residues. The absolute configuration of 4.39i was 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39i to be L-Tyr and D-Tyr (Figure 4.91). 
 
 
Figure 4.91. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-D-Tyr) (4.39i). Identity 
of amino acids was confirmed by retention time and molecular weight. (a) Co-injection of the D-FDAA derivatized 
hydrolysate 4.39i with the standards. (b) D-Tyr + D-FDAA, (c) L-Tyr + D-FDAA and (d) D-FDAA derivatized 
hydrolyzed of 4.39i (300 µg) showing the presence of L-Tyr (tR = 31.6 min) and D-Tyr (tR = 26.4 min). HPLC 
conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% 
MeCN containing 1% formic acid) over 55 min. * residual of Marfey’s reagent 
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4.4.25.5 Summary for all the cyclo-(Tyr-4-hydroxy-Pro) stereoisomers 
In this part, we were able to synthesise different stereoisomers of cyclo-(Tyr-4-hydroxy-Pro) as 
shown in Figure 4.92 and Figure 4.93. 
 
Figure 4.92. Comparison of 1H NMR (600 MHz, MeOH-d4) spectrum of cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g) 
and cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39f)  
 
Figure 4.93. Comparison for 1H NMR (600 MHz, DMSO-d6) of cyclo-(L-Tyr-L-Tyr) (4.39i) and cyclo-(L-Tyr-D-Tyr) 
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As with the microwave-assisted synthesis of Phe and hydroxyl-Pro diketopiperazines, the product 
mixture from microwave assisted reaction of Tyr and hydroxyl-Pro features significant yields of 
Tyr/Tyr diketopiperazines (Scheme 4.6). These latter products deplete the pool of available Tyr 
thereby reducing product yields of Tyr and hydroxyl-Pro diketopiperazines. Future efforts to 
optimize yields would benefit from increasing the ratio of Tyr to hydroxyl-Pro from 1:1 to 10:1. 
 
 
Scheme 4.6. Synthesis of different stereoisomers of cyclo-(Tyr-4-hydroxy-Pro) 
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4.4.26  Synthesis of cyclo-(L-Tyr-Pro) stereoisomers 
The reaction was performed by irradiating L-Tyr and L-Pro methyl esters (4.38b and 4.38d) 
respectively in H2O (3 mL) in the presence of triethylamine (2.5 eq.), in a microwave reactor at 140 
˚C, 300 W for 3 min. The recovered dried reaction product was washed with H2O and dried in 
vacuo to yield a MeOH soluble product that was analysed by HPLC-DAD-MS (Figure 4.94 and 
Scheme 4.7). 
 
 
Figure 4.94. HPLC-DAD-MS reaction product for cyclo-(Tyr-Pro). Reacting the methyl ester of L-Tyr (4.38b) with 
methyl ester of L-Pro (4.38d). The highlighted peaks represent DKPs  
 
Scheme 4.7. Fractionation scheme of the reaction of methyl ester of L-Tyr (4.38b) with methyl ester of L-Pro (4.38d). 
(a) Semi-preparative gradient HPLC: Zorbax C8, 90 – 50% H2O/MeOH, 3 mL/min 
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4.4.26.1 cyclo-(L-Tyr-D-Pro) (4.39j) 
 
Compound 4.39j was synthesized as an optically active amorphous white powder ([α]22D −2.2, c 
0.1, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula 
C14H16N2O3 (Δmmu +0.3). The 1H NMR (MeOH-d4) spectrum and tabulated data of 4.39j are 
presented Figure 4.97 and Table 4.23. The ROESY data showed no correlations between H-2 and 
H-2′ (Figure 4.96), consistent with a trans relationship, however the absolute configuration of 4.39i 
was confirmed by C3 Marfey’s analysis (Figure 4.98 and Figure 4.99). 
 
 
Figure 4.95. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture, highlighting 4.39j 
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Figure 4.96. ROESY (600 MHz, CDCl3) spectrum showing the absence of key correlations of cyclo-(L-Tyr-D-Pro) 
(4.39j)  
 
Figure 4.97. 1H NMR (600 MHz, MeOH-d4) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of cyclo-(L-
Tyr-D-Pro) (4.39j) 
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Table 4.23. NMR (600 MHz, MeOH-d4) of cyclo-(L-Tyr-D-Pro) (4.39j) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
proline      
1  167.5    
2 2.60, dd (10.4, 6.2) 58.6 3a/b 1′  
3 a 2.05, m 29.4 2, 4a,3b 2, 4, 5  
 b 1.65b, m  3a   
4 a 1.91, m 22.1 3a/b, 4b   
 b 1.65b,m 22.1 5a/b   
5 a 3.53, m 45.6 4a/b, 5b 4  
 b 3.33c  4a/b, 5a 3, 4  
tyrosine      
1′  171.7    
2′-NH d     
2′ 4.14, t (4.4) 59.3 3′a/b 4′ 3′a/b 
3′ a 3.10, dd (14.0, 4.4) 39.8 2′,3′b 1,2′,4′ 5′/9′ 2′, 5/9′ 
 b 2.87, dd (14.0, 4.4) 39.8 2′,3′a 1,2′,4′ 5′/9′  
4′ -- 126.8    
5′, 9′ 6.97, d (8.4) 132.5 6′,8′ 3′, 6′/8′, 7′ 3′a/b 
6′, 8′ 6.71, d (8.4) 116.3 5′,9′ 4′,5′/9′, 7′  
7′  158.0    
*(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Obscured by the solvent. (d) Not observed 
4.4.26.1.1 C3 Marfey’s analysis for cyclo-(L-Tyr-D-Pro) (4.39j) 
Employing the C3 Marfey method as previously described, 4.39j was subjected to acid hydrolysis 
using 6 M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the amino acid residues. The absolute configuration of 4.39j was 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39j to be L-Tyr and D-Pro (Figure 4.98 and Figure 4.99). 
 
Figure 4.98. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) D-Pro + D-FDAA (tR 
= 19.7 min), (b) L-Pro + D-FDAA (tR = 21.9 min), (c) D-Tyr + D-FDAA (tR = 26.7 min and (d) L-Tyr + D-FDAA (tR = 
31.5 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% 
MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
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Figure 4.99. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-D-pro) (4.39j). Identify 
of amino acids was confirmed by retention time and molecular weight. (a) co-injection of the D-FDAA derivatized 
hydrolysate 4.39j with the standards, (b) D-Pro + D-FDAA, (c) L-Tyr + D-FDAA and (d) D-FDAA derivatized 
hydrolyzed of 4.39j (300 µg) showing the presence of L-Tyr (tR = 31.6 min) and L-Tyr (tR = 31.5 min) and D-Pro (tR = 
19.7 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% 
MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min. * residual of Marfey’s reagent 
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4.4.26.2  cyclo-(L-Tyr-L-Pro) (4.39k) 
 
Compound 4.39k was synthesized as an optically active amorphous white powder ([α]22D −6.8, c 
0.06, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula 
C14H16N2O3 (Δmmu +0.2). The 1H NMR (MeOH-d4) spectrum and tabulated data of 4.39k are 
presented in Figure 4.102 and Table 4.24. The ROESY data confirmed the cis relationship between 
H-2 and H-2′ as shown in Figure 4.101. The absolute configurations were assigned by C3 Marfey’s 
analysis (Figure 4.103 and Figure 4.104). 
 
 
Figure 4.100. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture, highlighing 4.39k 
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Figure 4.101. ROESY (600 MHz, MeOH-d4) spectrum showing key correlations of cyclo-(L-Tyr-L-Pro)  (4.39k)  
 
 
Figure 4.102. 1H NMR (600 MHz, MeOH-d4) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of cyclo-(L-
Tyr-L-Pro) (4.39k) 
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Table 4.24. NMR (600 MHz, MeOH-d4) of cyclo-(L-Tyr-L-Pro) (4.39k) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
proline      
1  166.3    
2 4.04, m 59.6 3a/b 1′, 3 2′ 
3 a 2.10, m 28.3 2, 3b, 4a/b 1′, 5  
 b 1.22, q (10.3)  2, 3a, 4a/b 1′, 5  
4 a 1.80b, m 22.1 3b, 5a/b  3  
 b 1.80b, m  3b, 5a/b  3  
5 a 3.55, ddd (16.7, 11.9, 7.8) 45.3 4a/b, 5b  3, 4  
 b 3.35, ddd (16.7, 11.9, 7.8)  4a/b, 5a  3, 4  
tyrosine      
1′  170.5    
2′-NH c     
2′ 4.36, br s 57.3 3′a/b 1, 3′,4′ 2 
3′ a 3.05, ddd (15.3, 13.6, 5.1) 37.6 2′, 3′b 1,2′, 4′, 5′/9′  
 b 3.01, ddd (15.3, 13.6, 5.1) 37.6 2′, 3′a 1, 2′, 4′, 5′/9′  
4′  127.5    
5′, 9′ 7.03, d (8.2) 132.1 6′, 8′ 3′, 7′  
6′, 8′ 6.70, d (8.2) 115.8 5′, 9′ 4′  
7′  156.8    
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Not observed 
4.4.26.2.1 C3 Marfey’s analysis for cyclo-(L-Tyr-L-Pro) (4.39k) 
Employing the C3 Marfey’s method as previously described, 4.39k was subjected to acid hydrolysis 
using 6 M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute configuration of the amino acids residues. Absolute configuration for 4.39k were 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39k, to be L-Tyr and L-Pro (Figure 4.103 and Figure 4.104). 
 
Figure 4.103. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) D-Pro + D-FDAA (tR 
= 19.7 min), (b) L-Pro + D-FDAA (tR = 21.9 min), (c) D-Tyr + D-FDAA (tR = 26.2 min) and (d) L-Tyr + D-FDAA (tR = 
31.5 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% 
MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
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Figure 4.104. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Tyr-L-Pro) (4.39k). 
Identity of amino acids was confirmed by retention time and molecular weight. (a) co-injection of the D-FDAA 
derivatized hydrolysate 4.39k with the standards, (b) L-Pro + D-FDAA, (c) L-Tyr + D-FDAA and (d) D-FDAA 
derivatized hydrolyzed of 4.39k (200 µg) showing the presence of L-Tyr (tR = 31.5 min) and L-Pro (tR = 21.9 min). 
HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% MeOH/H2O 
(isocratic 5% MeCN containing 1% formic acid) over 55 min. * residual of Marfey’s reagent 
   
Figure 4.105. Comparison for 1H NMR (600 MHz, MeOH-d4) of cyclo-(L-Tyr-D-Pro) (4.39j) and cyclo-(L-Tyr-L-Pro) 
(4.39k) 
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4.4.26.3  cyclo-(L-Pro-L-Pro) (4.39l) 
 
Compound 4.39l was synthesized as an optically active amorphous white powder ([α]22D −5.9, c 
0.1, MeOH). HRESI(+)MS showed an adduct ion (M+Na)+ consistent with the molecular formula 
C10H14N2O2 (Δmmu +2.0).  The 1H NMR (MeOH-d4) spectrum and tabulated data of 4.39l are 
presented in Figure 4.107, Figure 4.108 and Table 4.25. ROESY correlations could not be used to 
assign the stereochemistry of the two chiral centres H-2 and H-2′ due to symmetry. The absolute 
configuration of cyclo-(L-Pro-L-Pro) was determined by application of the C3 Marfey’s analysis 
(Figure 4.109). 
 
Figure 4.106. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus HCO2H at 210 nm using Zorbax C8 
column of the reaction mixture, highlighting 4.39l 
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Figure 4.107. HMBC (600 MHz, MeOH-d4) spectrum and key correlations of cyclo-(L-Pro-L-Pro) (4.39l) 
 
 
Figure 4.108. 1H NMR (600 MHz, MeOH-d4) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of cyclo-(L-
Pro-L-Pro) (4.39l) 
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Table 4.25. NMR (600 MHz, MeOH-d4) of cyclo-(L-Pro-L-Pro) (4.39l) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC ROESY 
proline      
1,1′  167.5    
2, 2′ 4.34,t (7.2) 60.6 3/3′ 1/1′, 3/3′ 5/5′ 
3, 3′ a 2.29, m 27.5 4/4′ 1/1′, 2/2′  
 b 2.06b, m 27.5    
4, 4′ a 2.04b, m 22.9  2/2′  
 b 1.96, m 22.9    
5, 5′ 3.50, m 45.1 3/3′ 1/1′, 2/2′ 2/2′ 
(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances.  
 
4.4.26.3.1 C3 Marfey analysis for cyclo-(L-Pro-L-Pro) (4.39l) 
Employing the C3 Marfey’s method as previously described, 4.39k was subjected to acid hydrolysis 
using 6 M HCl, derivatized with D-FDAA, and subjected to HPLC analysis to determine the 
absolute stereochemistry of the three chiral centres H-2 and H-2′. Absolute configuration of 4.39k 
was determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 4.39k, to be L-Tyr and L-Pro (Figure 4.109). 
 
Figure 4.109. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of cyclo-(L-Pro-L-Pro) (4.39l). 
Identity of amino acids was confirmed by retention time and molecular weight. (a) co-injection of the D-FDAA 
derivatized hydrolysate 4.39l with the standards, (b) D-Pro + D-FDAA, (c) L-Pro + D-FDAA and (d) D-FDAA 
derivatized hydrolyzed of 4.39l (100 µg) showing the presence of L-Pro (tR = 21.5 min).  HPLC conditions, Zorbax, SB-
C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% 
formic acid) over 55 min. * residual of Marfey’s reagent 
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4.4.26.4 Summary for the cyclo-(Tyr-Pro) reaction 
The microwave reaction leading to the cyclo-(Tyr-Pro) afforded 3 compounds (Scheme 4.8), 4.39j 
(yield 5%), 4.39k (yield 5%) and 4.39l (yield 11%). The high yield of 4.39l, 11% could possibly be 
avoided in the future by increasing the ratio of the Pro versus the Tyr from 1:1 to 10:1 
 
Scheme 4.8. Synthesis of different stereoisomers of cyclo-(Tyr-Pro) 
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4.4.27 Summary for the different synthetic diketopiperazines analogues 
# Name H-2′  H-2 H-4 Yield % 
4.39a cyclo-(L-Phe-trans-4-hydroxy-L-Pro) S S R 5 
4.39b cyclo-(L-Phe-cis-4-hydroxy-D-Pro) S R R 4.5 
4.39c cyclo-(L-Phe-cis-4-hydroxy-L-Pro) S S S 5 
4.39d cyclo-(L-Phe-trans-4-hydroxy-D-Pro) S R S 3 
3.39e cyclo-(Phe-Phe)    19 
 
# Name H-2′  H-2 H-4 Yield % 
4.39f cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) S R S 7 
4.39g cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) S R R 6 
4.39h cyclo-(L-Tyr-L-Tyr) S S -- 17 
4.39i cyclo-(L-Tyr-D-Tyr) S R -- 13 
 
# Name H-2′  H-2 H-4 Yield % 
4.39j cyclo-(L-Tyr-D-Pro) S R -- 5 
4.39k cyclo-(L-Tyr-L-Pro) S S -- 5 
4.39l cyclo-(L-Pro-L-Pro) S S -- 11 
 
All these diketopiperazines analogues were tested in the following sections on Streptomyces sp. 
(CMB-M0423) to determine if they were capable of activating the biosynthesis of heronapyrrole B 
(4.02). 
 
4.4.28 Effect of DKPs on Streptomyces sp. (CMB-M0423) secondary metabolism 
The observation that the Aspergillus sp. (CMB-M0423) diketopiperazine 4.34 stimulated 
Streptomyces sp. (CMB-M0423) to produce heronapyrrole B (4.02) (and other metabolites) raises 
the intriguing question as to how specific is this structure activity relationship (SAR), and could 
other DKPs also act as activators of Streptomyces sp. (CMB-M0423) secondary metabolism. With a 
library of synthetic DKPs in hand, we set out to test this hypthesis. 
 
DKPs stock solutions were prepared in 2-fold dilution ranging from 138 mM to 15 nM in 30% 
DMSO/H2O. An aliquot (15 µL) from each stock solution was transferred to micro-bioreactor wells 
containing 1.45 mL M1 broth in 3.3% artificial ocean sea salt to give a final DKP concentrations 
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ranging from 4.6 mM to 0.5 nM in 1% DMSO per well. The positive control micro-bioreactor wells 
were inoculated with Aspergillus/Streptomyces sp. (CMB-M0423) seed culture (15 µL), while the 
negative control micro-bioreactor wells were inoculated with Streptomyces sp. (CMB-M0423). 
Both positive and negative controls were treated with 1% DMSO/H2O per well. Micro-bioreactor 
wells containing DKPs were inoculated with Streptomyces sp. (CMB-M0423) seed culture (15 µL). 
All micro-bioreactor plates were incubated at 27 °C for 10 days at 190 rpm, after which the broth 
was extracted in situ with EtOAc (2 mL), and the decanted organic layer dried under N2. The 
resulting crude EtOAc extract was resuspended in MeOH (100 µL) and analysed using HPLC-
DAD-MS. All the diketopiperazines 4.39a – l were tested on Streptomyces sp. (CMB-M0423), but 
only 4.39a, which corresponds to 4.34, activated production of heronapyrrole B (4.02). This data 
provides compelling evidence of a very specific DKP SAR requirement, confirming that 
Aspergillus sp. (CMB-M0423) possesses a unique ability to activate Streptomyces sp. (CMB-
M0423) secondary metabolism. 
 
4.4.29 Effect of 4.34 on the activation of bNOS in Streptomyces sp. (CMB-M0423) 
Having established that 4.34 possessed a unique ability to activate heronapyrrole B (4.02) 
biosynthesis, and having established that heronapyrrole B (4.02) biosynthesis was dependent on a 
functioning bNOS, we hypothesized that 4.34 was a regulator/activator of bNOS. To test this 
hypothesis required experimental evidence of a link between the addition of 4.34 and activation of 
bNOS. To acquire this evidence, we employed two independent but complementary approaches. 
The first approach set out to determine if 4.34 activation of Streptomyces sp. (CMB-M0423) could 
be suppressed by co-incubation with a NOS inhibitor. The second approach set out to detect the 
levels of NO in Streptomyces sp. (CMB-M0423) cultures that had and had not been exposed to 
4.34. 
 
4.4.29.1 Approach #1: NOS inhibitor inactivation of 4.34 
Replicate micro-bioreactor cultures of Streptomyces sp. (CMB-M0423) were treated with 4.34 (10 
µM) in 1% DMSO on day 0, and on day 2 were treated with NOS inhibitor AG (4.16) (7.5 µM). 
After 7 days incubation the cultures were extracted in situ with EtOAc (2 mL) and the organic layer 
decanted, dried under N2, re-dissolved in MeOH (100 µL) and analysed by HPLC-DAD-MS. This 
study demonstrated that activation of heronapyrrole B (4.02) production could be successfully 
inhibited by addition of AG (4.16) to the culture media. This result strongly suggests that 4.34 
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activated bNOS, which in turn is essential for the production of heronapyrrole B (and other 
metabolites) (Figure 4.110). 
 
Figure 4.110. HPLC-DAD (360 nm) chromatogram of (a) standard heronapyrrole B (4.02). (b) Streptomyces sp. 
(CMB-M0423) exposed to 4.34 plus AG (7.5 µM), (c) Streptomyces sp. (CMB-M0423) exposed to 4.34 (d) 
Streptomyces sp. (CMB-M0423) only (control) 
 
4.4.29.2 Approach #2: Measuring NO levels 
As prior studies had demonstrated that Streptomyces sp. (CMB-M0423) exposed to 4.34 undergo 
bNOS mediated activation of heronapyrrole B biosynthesis, we set out to independently confirm 
this association by detecting and correlating NO production with heronapyrrole B production. To 
achieve this we employed a commercial fluorescent, nitric oxide quantification kit (total nitric oxide 
assay kit, assay designs, Enzo life Sciences, Ann Arbor, MI). This kit contained a proprietary dye(s) 
that fluoresced in the presence of NO. This commercial kit was developed to assist the 
revisualization and quantification of NO levels in mammalian cells, using fluorescence microscopy, 
so before applying the kit to Streptomyces sp. (CMB-M0423) it was necessary to first confirm that 
that the kit can work on mammalian cells. The kit was successfully trailed on mammalian cells KB-
3-1 (adherent epithelial like, human cervix carcinoma) and SW620 (adherent epithelial like, human 
colorectal carcinoma) stimulated by LPS, with NO levels clearly visible by fluorescence 
microscopy – employing an BD pathway 855 high content screening confocal microscope 
(Olympus IX81 OEM, plan Apo 40x/0.90 LWD) (see Appendix 2). 
 
With a functional, albeit mammalian NO fluorescence detection kit in hand, we turned our attention 
to Streptomyces sp. (CMB-M0423). Replicate micro-bioreactor cultures of Streptomyces sp. (CMB-
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M0423) were cultured (a) without 4.34 activation, (b) with 4.34 activation (10 µM) and (c) with 
addition of 4.34 (10 µM) and the NOS inhibitor AG (7.5 µM). After 10 days incubation, cells of 
these cultures were prepared for fluorescence microscopy by treatment with the NO dye kit. 
Simultaneous to these studies, EtOAc extracts were prepared and analysed by HPLC-DAD. The 
results from these studies as illustrated in Figure 4.111, clearly indicate that in the absence of 4.34 
Streptomyces sp. (CMB-M0423) does not produce either NO or heronapyrrole B (4.02) or any other 
co-metabolites, but that on addition of 4.34 secondary metabolism is activated as is NO production. 
Finally and fully consistent with our theory, addition of both 4.34 and AG (4.16) result in no NO 
and no heronapyrrole B production.  
 
Figure 4.111. (Top) HPLC-DAD-MS chromatograms and (bottom) fluorescence images. (A) Streptomyces sp. (CMB-
M0423), (B) Streptomyces sp., (CMB-M0423) with 4.34 (10 µM). (C) Streptomyces sp. (CMB0423) with 4.34 (10 µM) 
and AG (7.5 µM). Left hand images are visible light microscopy of cell cultures, while right hand images show 
commercial dye kit fluorescence activation of NO levels. Scale bar are 26 µm 
The results of both approach #1 and #2 clearly confirm that 4.34 activates the Streptomyces sp. 
(CMB-M0423) bNOS, which subsequently produces NO, and heronapyrrole B (and the other co-
metabolites). 
 
4.4.30 The relationship between NO and heronapyrrole B production 
As noted above, 4.34 activates Streptomyces sp. (CMB-M0423) to produce both NO and 
heronapyrrole B (4.02) (and other co-metabolites). Likewise, activation by 4.34 can be suppressed 
(quenched) by the addition of the NOS inhibitor AG (4.16). These observations support the 
hypothesis that, “Heronapyrrole biosynthesis is independent on a functioning bNOS delivering 
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NO”. While the data assembled to date is strongly supportive of this hypothesis, it is necessary to 
challenge the possibility that 4.34 activation of NOS and heronapyrrole B are parallel and mutual 
exclusive events. To test this we employed two complementary approaches. In the first approach, 
we challenged Streptomyces sp. (CMB-M0423) cultures with 4.34 and the NO scavenger, 2-(4-
carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (CPTIO) (4.26), and in the second 
approach we challenged Streptomyces sp. (CMB-M0423) with the NO donor dimethylamine nitric 
oxide (DEANO) (4.27). 
 
 
4.4.30.1 Approach #1: NO scavenger CPTIO (4.26) 
A stock solution (30 mM in 30% DMSO) of CPTIO (4.26) was prepared and an aliquot (50 µL) 
transferred to micro-bioreactor wells containing 1.45 mL of M1 broth (3.3% artificial ocean sea salt 
and seed culture from Streptomyces sp. (CMB-M0423)) and 4.34 (10 µM) to deliver a final CPTIO 
concentration of 1 mM in 1% DMSO per well. To establish the appropriate time to add CPTIO 
(4.26) to the culture, separate trials were undertaken with addition at days 1, 5 and 6, with the 
cultures being extracted in situ with EtOAc (2 mL) on day 10 and analysed by HPLC-DAD-MS. All 
studies were carried out in duplicate, and delivered the same result. Despite the addition of 4.34, 
addition of the NO scavenger CPTIO (4.26) had the effect of suppressing the production of 
heronapyrrole B (4.02). This results supports the theory that heronapyrrole B biosynthesis is 
dependent on NO. 
 
4.4.30.2 Approach #2: NO donor DEANO (4.27) 
 A stock solution of DEANO (4.27) was prepared as outlined above for CPTIO (4.26). Aliquots (50 
µL) of these stock solutions were added to three different cultures (I-III). 
(I) Streptomyces sp. (CMB-M0423) in the absence of activation by 4.34. 
(II) Streptomyces sp. (CMB-M0423) activated by 4.34 (10 µM) on day 0, with NO 
production quenched by addition of AG (4.16) (7.5 µM) on day 2. 
(III) Aspergillus/Streptomyces sp. (CMB-M0423) in the presence of AG (4.16) (7.5 µM). 
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In all cases (I-III), the 50 µL aliquot of the NO donor DEANO (4.27) was added on day 5, and the 
culture extracted with EtOAc (2 mL) on day 10, and the extract analysed by HPLC-DAD-MS. 
Despite failure to activate bNOS (I), or quenching of NO production (II-III), all these cultures 
produced detectable levels of heronapyrrole B (4.02). In the case of (III) this also coincided with 
suppression of Aspergillus sp. (CMB-M0423) secondary metabolism. This studies support the 
theory that heronapyrrole B biosynthesis is dependent on NO (Figure 4.114 and Figure 4.115). 
  
Figure 4.112. HPLC-DAD chromatograms at 360 nm for the microbial extract from Streptomyces sp. (CMB-M0423) in 
the absence/presence of 4.34, CPTIO (4.26) and DEANO (4.27). (a)- 4.34 (10 µM) plus CPTIO (4.26) (1 mM). (b)- 
4.34 (10 µM) plus AG (7.5 µM) plus DEANO (1 mM) showing the production of heronapyrrole B (5.7 ± 0.5 µg/mL) , 
(c)- Streptomyces sp. (CMB-M0423) plus DEANO (4.27) (1 mM) showing the production of heronapyrrole B (7.5 ± 0.7 
µg/mL), (d)- Streptomyces sp. (CMB-M0423) only 
 
 
Figure 4.113. (1) Aspergillus/Streptomyces sp. (CMB-M0423) in the presence of AG (4.16) (7.5 µM) with no 
heronapyrrole B production. (2) Streptomyces sp. (CMB-M0423) in the presence of DEANO (4.27) (1mM) with 
heronapyrrole production. (3) Streptomyces sp. (CMB-M0423) with no heronapyrrole production 
 
Figure 4.114. Visualization of NO production in Aspergillus/ Streptomyces sp. (CMB-M0423) 
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Figure 4.115. Electron microscope images. (A)- Aspergillus sp./Streptomyces sp. (CMB-M0423). (B)- Streptomyces sp. 
(CMB-M0423). (C and D)- Aspergillus sp. (CMB-M0423) 
5!
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4.4.31 Precursor directed biosynthesis 
Having established a relationship between heronapyrrole B (4.02), 4.34 and bNOS, the original 
objective of this investigation had been the manipulation of Streptomyces sp. (CMB-M0423) 
biosynthesis to deliver new (unnatural) heronapyrroles, that could be used in SAR studies to probe 
antibacterial properties and potentials. Unfortunately, the use of NOS inhibitors did not deliver such 
analogues. Nevertheless, with newfound knowledge of heronapyrrole biosynthesis we elected to 
expose Streptomyces sp. (CMB-M0423) micro-bioreactor cultures that had not been activated by 
addition of 4.34, with the plausible natural biosynthetic precursor 2-nitropyrrole. The rationale 
behind this study was that if 2-nitropyrrole (4.40) could initiate heronapyrrole biosynthesis, we 
could then challenge Streptomyces sp. (CMB-M0423) cultures with a range of unnatural precursors, 
such as 3-nitropyrrole (4.41) and other nitro aromatics. The hypothesis to be tested was: addition of 
nitro aromatics to cultures of Streptomyces sp. (CMB-M0423) will yield new unnatural 
heronapyrroles. Before this study could proceed we first had to acquire samples of the target nitro 
aromatics. 
 
4.4.32 Synthesis of 2 and 3- nitropyrrole 
Samples of 2 and 3-nitropyrrole were prepared according the method described by Iranpoor et al. to 
afford 2-nitropyrrole (tR= 10 min, 1.5 mg, 3%) (4.40) and 3-nitropyrrole (tR= 12 min, 1.1 mg, 2%) 
(4.41)179 as shown in Figure 4.116 
 
 
Figure 4.116. HPLC-DAD-MS chromatogram and UV-vis spectrum, analytical gradient H2O/MeCN plus 0.05% 
HCO2H using Zorbax C8 of the nitration of pyrrole to yield 2-nitropyrrole (4.40) and 3-nitropyrrole (4.41) 
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4.4.32.1 2-nitropyrrole (4.40) 
Compound 4.40 was synthesized as pale yellow oil, which was purified by semi-preparative 
gradient HPLC, 10-50% MeOH over 30 min, 3 mL/min. HRESI(+)MS showed an adduct ion 
(2M+Na)+ consistent with the molecular formula C4H4N2O2 (Δmmu +0.7). The 1H NMR (CDCl3) 
data, for 2-nitropyrrole (4.40) (Figure 4.117 and Table 4.26). 
 
Figure 4.117. 1H NMR (600 MHz, CDCl3) spectrum of 2-nitropyrrole (4.40) 
 
Table 4.26. Comparison of 1H NMR (600 MHz, CDCl3) of experimental and published180 data of 2-nitropyrrole (4.40)  
Pos. δH, mult (J in Hz) 4.40 (experimental) δH, mult (J in Hz) (published) 
1-NH 9.09, br s  
2 6.99, br s 7.05, s 
3-NO2 -- -- 
4 6.97, br s 7.13, s 
5 6.27, s 6.29, s 
 
4.4.32.2 3-nitropyrrole (4.41) 
Compound 4.41 was synthesized as pale yellow oil which was purified by semi-preparative gradient 
HPLC, 10-50% MeOH over 30 min, 3 mL/min. HRESI(+)MS showed an adduct ion (2M+Na)+ 
consistent with the molecular formula C4H4N2O2 (Δmmu +0.6). The 1H NMR (CDCl3) data for 3-
nitropyrrole (4.41) (Figure 4.118 and Table 4.27). 
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Figure 4.118. 1H NMR (600 MHz, CDCl3) spectrum of 3-nitropyrrole (4.41) 
 
Table 4.27. Comparison of 1H NMR (600 MHz, CDCl3) for experimental and published180 data of 3-nitropyrrole (4.41) 
Pos. δH, mult (J in Hz) (experimental) δH, mult (J in Hz) (published) 
1-NH 8.69, br   
2 7.65, br s 7.66, br s 
3-NO2   
4 6.80, br s 6.75, br s 
5 6.73, d (2.4) 6.75 d (2.1) 
 
4.4.33 Assembly of an analogue library for precursor directed biosynthesis 
Different nitro-aromatics and nitrogen heterocycles were chosen as substrates for precursor directed 
the heronapyrrole biosynthesis in Streptomyces sp. (CMB-M0423) as shown in Figure 4.119. All 
these nitro aromatics were commercially available. 
 
Figure 4.119. Structures of the different nitro aromatics substrates 
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4.4.34 Addition of 2-nitropyrrole to Streptomyces sp. (CMB-M0423) 
This study tested the hypothesis that addition of the putative heronapyrrole biosynthetic precursor 
2-nitropyrrole to a culture of Streptomyces sp. (CMB-M0423), which has not been activated for 
heronapyrrole biosynthesis, will nevertheless lead to the production of heronapyrroles with 2-
nitropyrrole being incorporated into the biosynthetic pathway. 
 
Micro-bioreactor cultures (1.45 mL) of Streptomyces sp. (CMB-M0423) were incubated for 10 days 
in the presence of 2-nitropyrrole (0.25 µM) (4.40). The absence of 4.34 from the culture media was 
designed to “ensure” that bNOS was not activated, that NO was not available, and that normal 
heronapyrrole biosynthesis was not activated. HPLC-DAD-MS analysis of the EtOAc extracts from 
these cultures confirmed the production of heronapyrrole B (4.02) albeit at low levels (1.1 µg/mL) 
(Figure 4.120). At the first glance this observation appeared to validate the hypothesis shown above, 
that the addition of 2-nitropyrrole provides a critical substrate essential to (re) activate 
heronapyrrole biosynthesis. 
 
Figure 4.120. HPLC-DAD (360 nm) chromatogram of the crude extract from Streptomyces sp. (CMB-M0423) showing 
the production of heronapyrrole B (4.02) in the presence of 2-nitropyrrole (4.40) (0.25 µM) 
 
4.4.35 Addition of 3-nitropyrrole to Streptomyces sp. (CMB-M0423) 
Following the approach outlined above for 2-nitropyrrole (4.40), a culture of Streptomyces sp. 
(CMB-M0423) was challenged with 3-nitropyrrole (4.41). Much to our surprise addition of 4.41 to 
the culture media did not lead to the production of unnatural heronapyrroles isomers, rather it 
(re)activated the production of heronapyrrole B (4.02) (1.1 µg/mL). This observation suggests that 
4.41 did not act as an “artificial” precursor, but rather, acted as an activator (Figure 4.121), and 
raises the possibility that the same was true for 4.40. 
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Figure 4.121. HPLC-DAD (360 nm) chromatogram of the crude extract from Streptomyces sp. (CMB-M0423) showing 
the production of heromapyrrole B (4.02) in the presence of 3-nitropyrrole (4.41) (0.25 µM) 
 
4.4.36 Addition of other nitroaromatics to pure Streptomyces sp. (CMB-M0423) culture 
Micro-bioreactor cultures (1.5 mL) of Streptomyces sp. (CMB-M0423) were incubated for 10 days 
in triplicate in the presence of five different concentrations (1 µM, 0.5 µM, 0.25 µM, 0.1 µM and 
0.05 µM) of six nitro aromatics (5-methyl-2-nitrophenol (4.42), 2-chloro-5-nitropyridine (4.43), m-
nitroaniline (4.44), p-nitroaniline (4.45), 4-nitrobenzaldehyde (4.46), 2-nitrophenol (4.47), as well 
as imidazole (4.48) and pyrrole (4.49). HPLC-DAD-MS analysis of the EtOAc extracts from these 
cultures determined that over the concentration range 0.1 to 0.5 µM, all six nitro aromatics activated 
production of heronapyrrole B (4.02) with yields ranging from 0.7 to 1.2 µg/mL. Heronapyrrole B 
production was not activated at either the highest (1 µM) or lowest (0.05 µM) concentration, nor 
was it activated by the unnitrated substrates pyrrole and imidazole. No incorporation of the 
nitroaromatics analogues 4.42 to 4.47 into heronapyrrole analogues was observed. These 
observations suggest that rather than acting as substrate for heronapyrrole biosynthesis, 
nitroaromatics are weak activators of bNOS, and deliver modest yields of heronapyrrole B (4.02).  
A second round of experiments validated this hypothesis where microbioreactor cultures (1.5 mL) 
of Streptomyces sp. (CMB-M0423) were cultured in the presence of each of the nitroaromatics 4.42 
to 4.47, with and without 7.5 µM of AG (4.16). HPLC-DAD-MS analysis of the resulting EtOAc 
extracts confirmed that NOS inhibitor AG (4.16) quenched the ability of 4.42 to 4.47 to stimulate 
heronapyrrole biosynthesis (Figure 4.122).  
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Figure 4.122. HPLC-DAD (360 nm) chromatograms of EtOAc extracts derived from Streptomyces sp. (CMB-M0423) 
culture treated with nitroaromatics (0.25 µM), yield heronapyrrole B (4.02) (µg/mL) (a) 1.1, (b) 0.9, (c) 0.6, (d) 1.2, (e) 
0.7, (f) 0.9 and (h) 0.6 µg/mL 
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4.4.37 Endogenous nitroaromatic activates bNOS 
The unexpected observation that nitroaromatics can act as activators of bNOS, much like 4.34, 
raises the possibility that Streptomyces sp. (CMB-M0423) may be stimulated by DKP 4.34 to 
produce an endogenous nitroaromatic as an internal bNOS activator. To test this hypothesis we 
analysed Streptomyces sp. (CMB-M0423) extracts activated by 4.34, and Aspergillus /Streptomyces 
sp. (CMB-M0423) extracts, using HPLC-DAD-MS single ion extraction methodology. This 
methodology operates by first acquiring a full HPLC-DAD-MS data set, and then selectively 
displaying only ions for a specific m/z value. As the identity of possible endogenous nitroaromatic 
bNOS activation was unknown, we speculated on a range of possible simple nitroaromatics, and 
extracted m/z ions accordingly. 
  
Using this approach we determine that both extracts contained low levels of 2,4-dinitrophenol (2,4-
DNP) (4.50). Although 4.50 is a well-known environmental pollutant associated with the 
manufacture of 2,4,6-trinitrotoluene (TNT) (4.51), to the best of our knowledge, this is the first 
occasion where it has been detected as a natural product (Figure 4.123). 
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Figure 4.123. (a) HPLC-DAD-MS of the crude extract from Aspergillus/Streptomyces sp. (CMB-M0423) at 360 nm 
showing the presence of heronapyrrole B (4.02). (b) Ion extract at m/z 183 [M-H] showing the presence of 2,4-DNP in 
the crude extract of Aspergillus/Streptomyces sp. (CMB-M0423). (c) Authentic sample 2,4-DNP co-eluted at the same 
retention time  
  
4.4.38 Quantify the amount of 2,4-DNP levels in the microbial culture 
Based on the HPLC-DAD-MS analysis, it was clear that the concentration of 2,4-DNP (4.50) in 
microbial extracts was well below the threshold of DAD detection. Consequently, in order to 
quantify the levels of 4.50 in these extracts we developed a calibration curve based on HPLC-MS 
analysis of a series of known concentrations of an authentic sample of 4.50. Stock solutions of 4.50 
were prepared in two-fold dilutions ranging from 0.8 µM to 0.05 µM. An aliquot (10 µL) from each 
was then analysed using HPLC-DAD-MS. In these analyses the target ion of m/z 183 was extracted 
from the total ion using the technique of single ion extraction, and the area under the peak 
quantified electronically. The measurements were plotted over the range 0.008, 0.004, 0.002, 0.001 
and 0.0005 nmoles (Figure 4.124) generating a linear response curve that permitted quantification 
of the levels of 2,4-DNP (4.50) in both the Aspergillus sp./Streptomyces sp. (CMB-M0423) (4.5 ± 
0.1 ng/mL or 2.4 ± 0.5 nM) and 4.34 (10 µM) activated Streptomyces sp. (CMB-M0423) at 470 ± 
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0.1 ng/mL or 2.6 ± 0.5 µM). Analysis of extracts derived from Streptomyces sp. (CMB-M0423) and 
Aspergillus sp. (CMB-M0423) failed to detect 4.50. These results confirm that activation of bNOS 
either in the co-culture Aspergillus/Streptomyces sp. (CMB-M0423), or in Streptomyces sp. (CMB-
M0423) activated by 4.34, leads to production of detectable levels of 2,4-DNP (4.50). Expectedly, 
where bNOS is not activated, 4.50 was not detected. This study does not however establish whether 
4.50 is itself an activator of Streptomyces sp. (CMB-M0423) bNOS, and as such heronapyrrole 
biosynthesis. The detection of 2,4-DNP (4.50) raises the possibility that 4.50 is an internal 
autoregulator of bNOS, produced by Streptomyces sp. (CMB-M0423) in response to 4.34 
activation, but capable of independent and sustained activation of bNOS and heronapyrrole 
biosynthesis. To test this hypothesis we exposed micro-bioreactor cultures of Streptomyces sp. 
(CMB-M0423) to a range of concentrations of 4.50, and analysed the resulting extracts by HPLC-
DAD-MS to detect heronapyrrole B (4.02). 
 
Figure 4.124. Calibration curve for 2,4-DNP (4.50) based on single ion extraction of m/z 183 [M-H] from the HPLC-
DAD-MS chromatograph. Red dashed line equals concentration of 4.50 in an Aspergillus/Streptomyces sp. (CMB-
M0423) extract 
 
4.4.39 Study on the effect of 2,4-DNP on Streptomyces sp. (CMB-M0423)  
Stock solutions of 2,4-DNP (4.50) were prepared ranging from 153 mM to 1.1 µM. An aliquot (50 
µL) of each was transferred to the wells of the micro-bioreactor containing M1 broth in 3.3% 
artificial ocean sea salt (1.45 mL) to give final concentrations 5100 µM to 0.03 µM. All 
experiments were performed in duplicate. Micro-bioreactor plates were incubated at 26.5 °C for 10 
days, after which the broth was extracted in situ with EtOAc (2 mL) and the crude extract dried 
under N2. The crude residue was dissolved in MeOH (100 µL). An aliquot (10 µL) analysed using 
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heronapyrrole biosynthesis was successfully activated, with maximum production at 0.03 µM. This 
observation indicates that even at extremely low concentrations, 2,4-DNP (4.50) is capable of 
activating production of heronapyrrole B (Figure 4.125). 
Heronapyrrole B levels in the crude extract were quantified according to the standard calibration 
curve reported in section 4.4.3. 
 
 
Figure 4.125. Graph showing the effect of different concentrations of 2,4-DNP (4.50) on the production of 
heronapyrrole B in Streptomyces sp. (CMB-M0423) 
 
From these studies, 2,4-DNP (4.50) when added to Streptomyces sp. (CMB-M0423) in the absence 
of 4.34, was able to activate the production of heronapyrrole B. Quantification of these studies 
confirm the 2,4-DNP (4.50) (3 nM) activates Streptomyces sp. (CMB-M0423) to produce 
heronapyrrole B (4.02) (8.1 µg/mL), a concentration 600 times lower than that required for 4.34 
(1.8 µM) to deliver heronapyrrole B (8.7 µg/mL). Importantly, 4.34 activation actually initiates 2,4-
DNP (4.50) activation. 
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heronapyrroles with which to probe antibacterial SAR’s, we uncovered an exquisite example of 
kingdom co-evolution. Along the way we discovered and quantified the potency of two new (first) 
classes of small molecule bNOS activators – one of which (2,4-DNP) appears to be an internal 
Streptomyces sp. (CMB-M0423) autoregulator of bNOS. We have proved and tested many 
hypotheses, and have assembled a remarkable picture of a biosynthetic regulatory system. Scheme 
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relationships reaching from Aspergillus sp. (CMB-M0423) to Streptomyces sp. (CMB-M0423), 
inclusive of activators, autoregulators, bNOS, NO and heronapyrrole biosynthesis. 
We have determined that Aspergillus sp. (CMB-M0423) releases the chemical cue 4.34, which 
triggers Streptomyces sp. (CMB-M0423) to activate its “silent” bNOS. The resulting flux of NO 
leads to the production of 2,4-DNP (4.50), which acts as an internal regulator (an amplifier) 
sustaining the activation event. The need for such an amplifier presumably is in the fact that 4.34 
also activate the biosynthesis of the heronapyrrole B (4.02) that is selectively fungistatic (12.1 µM) 
against Aspergillus sp. (CMB-M0423). As the Aspergillus sp. (CMB-M0423) cell density is 
suppressed by heronapyrrole B (4.02), the levels of 4.34 drop below their activation threshold. It is 
at this point that the amplifier properties of 2,4-DNP (4.50) emerge, sustain the activation event to 
ensure prolonged suppression of Aspergillus sp. (CMB-M0423) by Streptomyces sp. (CMB-
M0423). 
 
 
Scheme 4.9. Scheme showing the biosynthetic pathway for heronapyrrole B production 
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4.4.40  Heronapyrrole co-metabolites 
During this study, we noticed that the heronapyrrole B (4.02) was always co-activated with many 
other metabolites, and that while it was yellow in colour the activated extracts were consistently 
reddish brown in colour. Semi-preparative gradient HPLC permitted the isolation and identification 
of the red brown pigment 4.53, as a new member of the marinone class meroterpene (Figure 4.126 
and Figure 4.127), as well as new heronapyrrole, 4.52. 
 
 
Figure 4.126. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 at 360 
nm of the crude extract from Aspergillus/Streptomyces sp. (CMB-M0423) 
 
 
 
Figure 4.127. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 at 360 
nm of the crude extract from Aspergillus/Streptomyces sp. (CMB-M0423). (a) Highlighting the metabolites that had 
been isolated and identified. (b) Highlighting the metabolites that are still under investigation. 
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4.4.40.1 Heronapyrrole D (4.52) 
 
During the process of the isolating the co-metabolites produced with heronapyrrole B (4.02), we 
were able to isolate a new heronapyrrole metabolite “heronapyrrole D” (4.52). HRESI(+)MS 
analysis of 4.52 revealed a adduct molecular ion ([M+Na], m/z 389) that corresponds to a molecular 
formula (C20H26N6O1, Δmmu –0.2)  Unfortunately, the yield of 4.52 was insufficient to acquire 
clear and full NMR data. Fortunately, our collaborators Prof. Stark et al., have synthetized 4.52 
during their efforts at the synthesis of heronapyrrole C (4.03). Comparing both synthetic and natural 
samples of 4.52 by HPLC-DAD-MS (Figure 4.128) and optical rotation for synthetic heronapyrrole 
D [α]21D +82.4 (c 0.02, MeOH) compared to natural heronapyrrole D (4.52) [α]21D +172.4 (c 0.01, 
MeOH). The variation in the optical roataion measurement was attributed to due some impurities 
that were present in heronapyrrole D (4.52). All these data allowed us to unambiguously identify 
heronapyrrole D (4.52). 
 
 
Figure 4.128. HPLC-DAD chromatogram, analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 at 360 
nm. (a) Natural product heronapyrrole D (4.52). (b) Synthetic heronapyrrole D (4.52). (c) co-injection of natural and 
synthetic heronapyrrole D (4.52)  
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4.4.40.2  Debromomarinone (4.53) 
 
HRESI(−)MS analysis of 4.53 revealed a quasi-molecular ion ([M−H]-, m/z 408) that corresponds to 
a molecular formula (C25H28O5, Δmmu −0.25) requiring eleven double bond equivalents. Consistent 
with the red-brown colour and UV-vis spectrum (λmax 268, 312, 386 and 440) and 1D NMR 
(CDCl3) data for 4.53 revealed a highly conjugated aromatic system, rich in quaternary sp2 carbons 
(Table 4.28). Furthermore, although 4.53 possessed 25 carbons, only 22 of these could be detected 
from the HMBC data. Notwithstanding the incomplete characterization of the 1D NMR data, 
analysis of 2D NMR data (Figure 4.129, Figure 4.130, Figure 4.131 and Table 4.28) revealed a 
number of diagnostic correlations corresponding to: (a) an isoprenyl side chain spanning C-17 to C-
22, inclusive of C-23 and C-24; and (b) a methyl cyclohexenyl C-11 to C-16, inclusive of C-25, and 
pendant to the aromatic quaternary C-10. Further analysis for all the 2D data strongly suggested that 
4.53 was the known bacterial metabolite debromomarinone (Table 4.29). 
 
Figure 4.129. COSY, HMBC and ROESY (600 MHz, CDCl3) key correlations of debromomarinone (4.53) 
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Figure 4.130. ROESY (600 MHz, CDCl3) spectrum of debromomarinone (4.53) 
 
Figure 4.131. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of 
debromomarinone (4.53) 
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Table 4.28. NMR (600 MHz, CDCl3) data of debromomarinone (4.53) 
Pos. δH, mult (J in Hz)a δCa COSY ROESY 1H-13C HMBC 
1  c    
2  c    
3  108.9    
4  164.1    
5 6.49, s 107.4 7  3, 4, 7 
6  163.8    
7 7.04, s 109.7 5  3, 5, 9 
8  c    
9  184.0    
10  124.3    
11 3.43, br 31.3 12, 16 24 10 
12 6.03, br 120.6 11 11, 25 11, 14, 25 
13  136.0    
14 1.95b, m 30.1   12, 25 
15 1.89b, m 20.7    
16 1.86b, m 37.9    
17  83.1    
18 1.61b, m 37.1    
19 1.95 – 2.02b, m 22.7    
20 4.99, t (6.3) 124.1  24 22, 23 
21  132.9    
22 1.60, s 26.3 23  20, 21, 23 
23 1.53, s 17.8 22  20, 22 
24 1.51, s 22.9   17, 20 
25 1.65, s 24.2   12, 13, 14 
(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) signals not observed 
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Table 4.29. Comparison for 13C (150 MHz, CDCl3) of experimental and published181 data of debromomarinone  (4.53)  
Pos. δc for (experimental) δc (published) 
1 a 153.0 
2 a 182.5 
3 108.9 109.0 
4 164.1 165.1 
5 107.4 106.9 
6 163.8 164.4 
7 109.7 107.8 
8 a 134.5 
9 184.0 184.0 
10 124.3 123.8 
11 31.3 30.7 
12 120.6 119.9 
13 136.0 135.9 
14 30.1 29.6 
15 20.7 20.0 
16 37.9 37.2 
17 83.1 82.9 
18 37.1 36.5 
19 22.7 22.0 
20 124.1 123.0 
21 132.9 132.3 
22 18.0 25.4 
23 23.0 17.4 
24 25.8 22.4 
25 23.9 23.3 
(a) signals not observed 
 
Figure 4.132. 1H NMR (600 MHz, DMSO-d6) spectrum of debromomarinone (4.53) 
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Figure 4.133. HMBC (600 MHz, DMSO-d6) spectrum of debromomarinone (4.53) 
 
Table 4.30. 1H NMR (600 MHz, DMSO d6) data of debromomarinone (4.53) 
Pos. δH, mult (J in Hz)a δCa COSY ROESY 
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2  c    
3  c    
4  c    
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25 1.61, s 23.9  12 12, 13, 14 
4/6-OH 11.82, br s     
*(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Obstructed by solvent  
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Debromomarinone (4.53) belongs to the meroterpenoid class of natural product, defined as mixed 
polyketide-terpenoid scaffold (sesquiterpenoid naphthoquinone). Members of this group include 
naptherpine (4.54)182 and (−)-furaquinocin C (4.55)183. In 1992, Fenical et al.184 reported marinone 
(4.56) and the debrominated marinone analogues (4.57 and 4.58) from a marine actinomycete,  
noting that they exhibited antibacterial activity against Bacillus subtilis (MIC = 1 µg/mL) with 
debromomarione (4.53) exhibiting antibacterial activity against Staphylococcus aureus, 
Streptococcus epidermis and Streptococcus pyogenes (MIC = 1 − 2 µg/mL). In 2000, Fenical et al.  
185 reported neomarinone (4.57) and several other derivatives of the marionone class of the 
naphthoquinone (4.56 – 4.61) from another marine actinomycete, noting modest cytotoxicity 
towards human cancer cells. Although debromomarione has been reported, insufficient data exists 
to provide a definitive structure proof. Re-isolation of debromomarinone from 4.34 activation from 
Streptomyces sp. (CMB-M0423) offers an opportunity (for other research students in the Capon 
group) to revisit and confirm/revise the assigned structure. 
 
Figure 4.134. Different structures of marinone analogues 
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into the Australian marine derived Streptomyces sp. (CMB-M0423), five different fungal 
metabolites including two low molecular weight diketopiperazines molecules have been isolated.  
In revisiting Streptomyces sp. (CMB-M0423), it was observed the presence of Aspergillus sp. 
(CMB-M0423). Many attempts had been made to separate and isolate the Aspergillus sp. (CMB-
M0423) and Streptomyces sp. (CMB-M0423) in which the isolated Streptomyces sp. (CMB-
M0423) completely lost the ability to produce its secondary metabolites. From a pharmacological 
standpoint, the five known fungal metabolites were assessed for the ability to induce secondary 
metabolites production in Streptomyces sp. (CMB-M0423) and it was observed that only 
diketopiperazine cyclo-(L-Phe-trans-4-hydroxy-L-Pro) was capable of restoring the production of 
secondary metabolites. From an ecological standpoint, the observations made above draw our 
attention to the importance of synthesis of library of different diketopiperazines to understand and 
compare the effect of the synthetic DKPs and the natural product (4.34). Results suggested that the 
natural DKP (4.34) was, in particular, the only molecule that is capable on inducing secondary 
metabolites in Streptomyces sp. (CMB-M0423). To the best of our knowledge, this is the first 
instance for bacterial-fungal coevolution in which intimate fungal metabolite triggers the 
biosynthesis of bacterial secondary metabolites. 
 
Figure 4.135. General Scheme for the NOS project 
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4.6 Future Directions 
• Although we originally assessed heronapyrroles as not exhibiting any antifungal properties 
(against Candida), it appears that they may be selectively fungistatic towards Aspergillus. 
As Aspergillus sp. are important human pathogens, particularly in cystic fibrosis patients, 
this opens the possibility that heronapyrroles can be developed as an antifungal agents.  
• To the best of our knowledge Streptomyces sp. (CMB-M0423) is unique in its ability to 
"indicate" the activation of bNOS. This strain is currently being developed within our 
research group as a screening tool to search for other small molecule activators of bNOS. 
• The DKP (4.34) and 2,4-DNP (4.50) represent new tools to probe other microbes, and are 
currently being employed within our group to screen isolate libraries, to activate bNOS and 
related silent secondary metabolites. 
• The full array of activated secondary metabolites in Streptomyces sp. (CMB-M0423) (see 
Figure) need to be studied. These include but are not limited to heronapyrroles and 
marinones.  
• As both heronapyrroles and marinones depend on farnesyltransferases to farnesylate 
aromatic residues, its possible that the activation pathway (DKP - bNOS) triggers 
transcriptions/activation of prenyltransferases, which may be novel in their own right. 
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4.7 Experimental section 
4.7.1 Analytical and Preparative cultivation of CMB-M423 in presence of AG 
A single colony of strain CMB-M0423 was used to inoculate a seed culture composed of M1 media 
(100 mL in a 250 mL Schott flask) prepared using 3.3% artificial Ocean Nature Sea Salt. 
Aminoguanidine was added to the culture medium to give final concentration of 7.5 µM in 1% 
DMSO. The strains were shaken at 190 rpm for 7 days at 27 °C, extracted with EtOAc (2 × 50 mL 
per flask), and the organic phases concentrated in vacuo to yield a crude extract of 5.6 mg. The 
crude extracts were redissolved in MeOH generating a concentration of 1 mg/mL and analysed by 
HPLC-DAD-ESI(±) MS (Zorbax C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min gradient from 90% 
H2O to 10% MeCN (isocratic 0.05% formic acid) over 15 min, with a hold at 100% MeCN for 5 
min). Analysis of the small-scale saline liquid cultivation revealed biosynthetically related yellow 
pigments with the following retention times tR = 7.8, 8.1, 8.5, 8.2, 5.2 and 4.8 min exhibited the 
following m/z (M+H)+ 432 (4.30), 327 (4.31), 357 (4.32), 380 (4.33), 261 (4.34) and 245 (4.35) 
respectively.  
For large scale cultivation, six Erlenmeyer flasks (2 L) containing M1 marine broth (500 mL; 1% 
starch, 0.4 % yeast extract and 0.2% peptone) were inoculated with a starter culture (5 mL) of 
Streptomyces sp. (CMB-M0423) and incubated at 27 °C on a rotary shaker at 190 rpm for 7 days. 
The flasks were then extracted EtOAc (2 × 250 mL per flask) and the organic phases were 
combined and concentrated in vacuo to yield a combined EtOAc extract (95.6 mg). The EtOAc 
extract was sequentially triturated (25 mL aliquots) to recover hexane (5.3 mg), CH2Cl2 (60 mg) 
and MeOH (3 mg) soluble materials. The CH2Cl2 partition was further fractionated by HPLC 
(Zorbax C8 column, 250 × 9.4 mm, 5 µm, 3 mL/min, gradient elution from 90% H2O/MeOH to 
100% MeOH over 30 min) monitoring at 210, 254 and 360 nm to afford pure compounds pseurotin 
A (tR= 21.3 min; 5.1 mg, 7.3%) (4.30), gliotoxin (tR= 22.0 min; 4.5 mg, 6.4%) (4.31), bisdethiobis 
gliotoxin (tR= 22.7 min; 3 mg, 4.3%) (4.32) and fumitremorgin C (tR= 25 min; 2.4 mg, 3.4%) (4.33) 
and two diketopiperazines, cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (tR= 15.7 min; 3 mg, 3.6%) (4.34) 
and cyclo-(L-Phe-L-Pro) (tR= 17.2 min; 1.5 mg, 2.3%) (4.35).[Note - % yields are determined on a 
mass-to-mass basis against the EtOAc crude extract]. 
 
Pseurotin A (4.30): yellowish oil; [α]23D −178 (c 0.10, CDCl3); 1H NMR (600 MHz, CDCl3) see 
Table 4.2; HRESI(+)MS m/z 454.1476 [M+Na]+ (calcd for C22H25NO8Na 454.1472).  
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Gliotoxin (4.31): yellowish oil; [α]22D −167.2 (c 0.05, MeOH)  ;1H NMR (600 MHz, CDCl3) see 
Table 4.4; HRESI(+)MS m/z 349.0278 [M+Na]+ (calcd for C13H14N2O4Na 349.0287). 
Bisdethiobis(methylthio)gliotoxin (4.32): yellowish oil; [α]22D −67.2 (c 0.1, MeOH) ;1H NMR (600 
MHz, CDCl3) see Table 4.6; HRESI(+)MS m/z 379.0753 [M+Na]+ (calcd for C15H20N2O4S2Na 
379.0757). 
Fumitremorgin C (4.33): yellowish oil; [α]22D −26.2 (c 0.04, MeOH) ;1H NMR (600 MHz, CDCl3) 
see Table 4.8; HRESI(+)MS m/z 402.1801 [M+Na]+ (calcd for C22H25N3O3Na 402.1788). 
cyclo-(L-Phe-trans-4-hydroxy-L-Pro) (4.34): yellowish oil; [α]22D −20.9 (c 0.05, MeOH);1H NMR 
(600 MHz, CDCl3) see Table 4.10; HRESI(+)MS m/z 283.1045 [M+Na]+ (calcd for C14H16N2O3Na 
283.1053).  
cyclo-(L-Phe-L-Pro) (4.35): yellowish oil; [α]22D − 6.2 (c 0.07, MeOH);1H NMR (600 MHz, CDCl3) 
see Table 4.12; HRESI(+)MS m/z 267.1075 [M+Na]+ (calcd for C14H16N2O2Na 267.1104). 
debromomarinone (4.53): reddish brown; [α]22D − 98.8 (c 0.02, MeOH);1H NMR (600 MHz, 
CDCl3) see Table 4.28; HRESI(–)MS m/z 407.1866 [M-H]- (calcd for C25H27O5 407.1864).  
heronapyrrole D (4.52): yellow oil; [α]21D +172.4 (c 0.01, MeOH); HRESI(+)MS m/z 389.2063 
[M+Na]+ (calcd for C20H26N6O1Na 389.2060)  
4.7.2 Isolation of Aspergillus sp. (CMB-M0423) from Streptomyces sp. (CMB-M0423) 
Streptomyces sp. (CMB-M423) was streaked several times on agar containing M1 3.3% artificial 
ocean sea salt and 1 µg/mL rifampicin and the plate was incubated at 26.5 °C for 10 d. The plate 
was re-cultivated continuously for 45 d (around 10 d each). After the incubation period (45 d), 
small dark colonies start to appear on the plate. These colonies were sub-cultivated on oatmeal agar 
(72 g/L) plate and incubated at 27.5 °C for another 10 d. Fungal Genomic DNA extraction: DNA 
extraction was performed using cetyltrimethylammonium bromide (CTAB) protocol176(Appendix).  
 
4.7.3 The effect of heronapyrroles A - C on the growth of Aspergillus sp. (CMB-M0423) 
Heronapyrrole A (4.01), B (4.02) and C (4.03) were added to the wells of a microtiter plate to give 
final concentration of 0.1 µM, 1% DMSO per well. The plate was inoculated with the seed culture 
of Aspergillus sp. (CMB-M0423) (15 µL) in M1 3.3% artificial ocean sea salt (1.45 mL). The plate 
was shaken for 12 d at 190 rpm, 26.5 °C. An aliquot (300 µL) from each well was withdrawn each 
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day and the optical density was measured at 600 nm using microtiter plate reader. After the 
incubation period (7 d), the wells were extracted by the addition of EtOAc (2 mL) and concentrated 
to dryness under N2. The crude extracts were dissolved in MeOH (100 µL) and analysed by HPLC-
DAD-MS using Zorbax SB-C8 analytical HPLC column, 5.8 µM, 150 × 4.6 mm, 1 mL/min gradient 
elution from 90% H2O/MeCN to 100% MeCN (with a constant 0.05% formic acid/MeCN modifier) 
over 15 min monitoring at 210, 254 and 360 nm. 
4.7.4 Study on the production of Aspergillus metabolites 
Aspergillus sp. (CMB-M0423) was cultivated in M1 broth containing 3.3% artificial ocean sea salt 
in a 24˗well micro-bioreactor plate over 10 d at 190 rpm, 26.5 °C. Each day, one well was extracted 
with EtOAc (2 mL). The organic layer was dried down under N2, re-dissolved in MeOH (300 µL) 
and analysed using the HPLC-DAD-MS using Zorbax SB-C8 analytical HPLC column, 5.8 µM, 
150 × 4.6 mm, 1 mL/min gradient elution from 90% H2O/MeCN to 100% MeCN (with a constant 
0.05% formic acid/MeCN modifier) over 15 min monitoring at 210, 254 and 360 nm. The 
Aspergillus co-metabolites start to appear from day 4 and continue to day 6 in which it produces 
compound 4.30 – 4.35.  
4.7.5 The effect of the fungal metabolites on the heronapyrroles production of Streptomyces 
sp. 
All the fungal metabolites listed above 4.30 – 4.35 were tested on the culture broth of Streptomyces 
sp. Compounds 4.30 – 4.35 were prepared in 2˗fold dilutions starting from 5.1 mM to 0.1 nM in 
30% DMSO. An aliquot (15 µL) of each dilution was transferred to a well of the microbioreactor 
containing M1 broth with 3.3% artificial sea salt (1.45 mL) to give final concentration 0.05 mM to 
0.001 nM in 1% DMSO and seed culture from Streptomyces sp. (15 µL). The microbioreactor plate 
was incubated for 10 d, 190 rpm, 26.5 ˚C. After the incubation period, the wells were extracted by 
the addition of EtOAc (2 mL) and the whole microbioreactor was shaken for 1 h at 100 rpm. The 
organic layer was dried down under N2 and the crude extracts were dissolved in MeOH (100 µL) 
and analysed using the HPLC-DAD-MS using Zorbax SB-C8 analytical HPLC column, 5.8 µM, 
150 × 4.6 mm, 1 mL/min gradient elution from 90% H2O/MeCN to 100% MeCN (with a constant 
0.05% formic acid/MeCN modifier) over 15 min monitoring at 210, 254 and 360 nm. The optical 
density (400 nm) of each crude extract was also recorded using a microtiter plate reader. 
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4.7.6 Standard curve for heronapyrrole B (4.02) 
A solution of heronapyrrole B in MeOH was diluted from 0.4 mM to 0.006 µM in MeOH. An 
aliquot (10 µL) of each dilution was injected in HPLC-DAD-MS using Zorbax SB-C8 analytical 
HPLC column, 5.8 µM, 150 × 4.6 mm, 1 mL/min gradient elution from 90% H2O/MeCN to 100% 
MeCN (with a constant 0.05% formic acid/MeCN modifier) over 15 min monitoring at 210, 254 
and 360 nm. The area under the peak for each concentration of heronapyrrole B was determined 
from the extracted chromatogram as shown below 
The equation for the area under the peak: 𝑦 = 88.02𝑥 + 16.06 
 
Conc of Stock 
Heronapyrrole B 
(mM) 
10 µL of 
Stock (nmol) 
Area under the 
peak (reference 1) 
Area under the 
peak (reference 2) Average STDEV SEM 
0.4 4 366 362 364 3 2 
0.2 2 194 189 191 4 3 
0.1 1 114 111 112 2 1 
0.05 0.5 101 83 92 12 9 
0.02 0.25 23 24 24 1 0 
0.01 0.125 15 16 15 1 1 
0.006 0.06 12 13 13 1 0 
 
4.7.7 Standard curve for cyclo-(L-Phe-trans-4-OH-L-Pro) 
A solution of cyclo-(L-Phe-trans-4-OH-L-Pro) in MeOH was diluted from 5 mM to 0.6 µM in 
MeOH. An aliquot (10 µL) of each dilution was injected in HPLC-DAD-MS using Zorbax SB-C8 
analytical HPLC column, 5.8 µM, 150 × 4.6 mm, 1 mL/min gradient elution from 90% H2O/MeCN 
to 100% MeCN (with a constant 0.05% formic acid/MeCN modifier) over 15 min monitoring at 
210, 254 and 360 nm. The area under the peak for each concentration of cyclo-(L-Phe-trans-4-OH-
L-Pro) was determined from the extracted chromatogram as shown below 
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The equation for the area under the peak is: 𝑦 = 4.049×10!𝑥 − 49991 
 
Conc of Stock 
DKP (mM) 
10 µL of 
Stock (nmol) 
Area under the 
peak (reference 1) 
Area under the 
peak (reference 2) Average STDEV SEM 
0.03 0.3 1181662 1437600 1309631 180975 127969 
0.02 0.19 763678 641878 702778 86125 60900 
0.01 0.1 409338 391917 400627 12318 8710 
0.007 0.075 189694 187505 188600 1548 1095 
0.003 0.037 87973 92252 90112 3025 2139 
 
4.7.8 Standard curve for 2,4-dinitrophenol 
A solution of 2,4-DNP in MeOH was diluted from 0.008 nM to 0.0005 nM in MeOH. An aliquot 
(10 µL) of each dilution was injected in HPLC-DAD-MS using Zorbax SB-C8 analytical HPLC 
column, 5.8 µM, 150 × 4.6 mm, 1 mL/min gradient elution from 90% H2O/MeCN to 100% MeCN 
(with a constant 0.05% formic acid/MeCN modifier) over 15 min monitoring at 210, 254 and 360 
nm. The area under the peak for each concentration of 2,4-DNP was determined from the extracted 
chromatogram as shown below 𝑦 = 𝑚𝑥 + 𝑏 𝑦 = 3.65×10! 𝑥 + 2807 
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Conc of 
Stock 2,4-
DNP 
(µM) 
10 µL of 
Stock (nmol) 
Area under 
the peak 
(reference 1) 
Area under 
the peak 
(reference 2) 
Area under 
the peak 
(reference 2) 
Average STDEV SEM 
0.8 0.008 313059 281974 291988 295674 15867 9161 
0.4 0.004 148425 136600 154681 146569 9183 5302 
0.2 0.002 73414 78677 87152 79748 6932 4002 
0.1 0.001 34843 34720 35845 35136 618 357 
0.05 0.0005 25418 21682 22373 23158 1987 1147 
 
4.7.9  Synthesis of 2- and 3- nitropyrrole 
A solution of HNO3 (36%, 1 mL, 18 mmol) in acetic anhydride (6 mL) was cooled to  0 °C and 
added dropwise over 90 min to a solution of pyrrole (200 µL, 0.3 mmol) in acetic anhydride (6 mL) 
at − 50 ˚C. The mixture was stirred at −50 ˚C for a further 90 min and then allowed to return to 
room temperature over 1 h. The mixture was then poured over ice and the product was extracted 
into diethyl ether (4 × 100 mL). The organic layer was washed with H2O (4 × 100 mL) and 10% 
aqueous Na2CO3 (4 × 100 mL) and concentrated in vacuo. The resulting mixture was purified by 
HPLC Zorbax 5 µm C8, 250 × 9.4 mm column, 3 mL/min gradient elution from 90% H2O/MeOH to 
100% MeOH over 30 min) to afford 2-nitropyrrole (tR= 10 min, 1.5 mg, 3%) and 3-nitropyrrole 
(tR= 12 min, 1.1 mg, 2%) 179 
2-nitropyrrole (4.40): yellow oil; 1H NMR (600 MHz, CDCl3) see Table 4.26; HRESI(+)MS m/z 
247.0431 [2M+Na]+ (calcd for C8H8N4O4Na 247.0438).  
3-nitropyrrole (4.41): yellow oil; 1H NMR (600 MHz, CDCl3) see Table 4.27; HRESI(+)MS m/z 
247.0418 [2M+Na]+ (calcd for C8H8N4O4Na 247.0438). 
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4.7.10 General method for the preparation of the methyl ester of the amino acids 10a-e  
In a dry round bottom flask (100 mL), amino acids 10a-e (5 mmol) was dissolved in MeOH (15 
mL). Thionyl chloride (0.76 mL, 9.08 mmol) was added to the solution dropwise at 0 oC under 
argon atmosphere. The reaction mixture was refluxed for 3 h then evaporated under N2. Toluene (2 
× 5 mL) was added and evaporated in vacuo to afford the hydrochloride salt of methyl ester of 
amino acids 11a-e. 
4.7.11  General method for the preparation of the diketopiperazine compounds  
Two methylester of amino acids 4.38a-e (20 mg) were dissolved in water (3-5 mL) in the presence 
of triethylamine (2.5 eq.). The reaction mixture was heated in the microwave at 140 °C and 300 W 
for 3 min. The reaction mixture was filtered and the precipitate was washed 2 – 3 times with water 
and dried in vacuo. The crude extract was further purified using HPLC-DAD, Zorbax 5 µm C8, 250 
× 9.4 mm column, 3 mL/min gradient elution from 90% H2O/MeOH to 50% MeOH over 20 min) to 
afford different diketopiperazines 4.39a-l. 
4.7.12 General Marfey analysis for the synthetic diketopiperazine compounds 
Preparation of the standards: In the 2 mL vial, 50 µL of 50 mM amino acid was added to 20 µL 1N 
NaHCO3 followed by 50 µL 1% (w/v) D-FDAA in acetone. The two vials were heated for 60 min at 
40°C. This was followed by the addition of 20 µL 1N HCl and the whole solution was diluted to 1 
mL with MeCN. 
Preparation of Natural product: 200 µL 6M HCl was added to 100 - 200 µg of pure compound and 
heated overnight at 110 °C. In following day, the sample was dried under N2. 20 µL 1N NaHCO3 
and 50 µL 1% (w/v) D-FDAA in acetone were added and heated for 60 min at 40°C. This was 
followed by the addition of 20 µL 1N HCl. 
C3 Marfey’s method: A 5 µL aliquot of the 2 standards and the natural product were injected onto a 
Zorbax C3 HPLC column maintained at 50°C with flow rate 1 mL/min, consisting of mobile phase 
A: H2O; mobile phase B: MeOH 15%-60% over 55 min. Mobile phase C: 1% HCO2H in MeCN 
was maintained at 5% linear gradient. DAD was detected at 340 nm.45 
 
cyclo-(L-Phe-cis-4-hydroxy-D-Pro) (4.39b): white powder; [α]22D −34 (c 0.06, MeOH); 1H NMR 
(600 MHz, CDCl3) and 13C (150 MHz, CDCl3) see Table 4.16. HRESI(+)MS m/z 283.1048 [M+Na]+ 
(calcd for C14H16N2O3Na 283.1053). 
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cyclo-(L-Phe-cis-4-hydroxy-L-Pro) (4.39c): white powder; ; [α]21D −7.6 (c 0.05, MeOH), 1H NMR 
(600 MHz, CDCl3) and 13C (150 MHz, CDCl3) see Table 4.17.  HRESI(+)MS m/z 283.1038 
[M+Na]+ (calcd for C14H16N2O3Na 283.1053). 
cyclo-(L-Phe-trans-4-hydroxy-D-Pro) (4.39d): white powder; ;[α]22D −5.4 (c 0.1, MeOH); 1H NMR 
(600 MHz, CDCl3) and 13C (150 MHz, CDCl3) see Table 4.18. HRESI(+)MS m/z 283.1047 [M+Na]+ 
(calcd for C14H16N2O3Na 283.1053). 
cyclo-(L-Tyr-trans-4-hydroxy-D-Pro) (4.39e): white powder; ;[α]22D −33.9 (c 0.06, MeOH); 1H 
NMR (600 MHz, MeOH-d4) and 13C (150 MHz, MeOH-d4) see Table 4.19. HRESI(+)MS m/z 
299.1003 [M+Na]+ (calcd for C14H16N2O4Na 299.1002). 
cyclo-(L-Tyr-cis-4-hydroxy-D-Pro) (4.39g):white powder; [α]22D + 11.2 (c 0.05, MeOH); 1H NMR 
(600 MHz, MeOH-d4) and 13C (150 MHz, MeOH-d4) see Table 4.20. HRESI(+)MS m/z 299.1006 
[M+Na]+ (calcd for C14H16N2O4Na 299.1002). 
cyclo-(L-Tyr-L-Tyr) (4.39h): white powder; ;[α]21D −8.2 (c 0.08, MeOH); 1H NMR (600 MHz, 
DMSO-d6) and 13C (150 MHz, DMSO-d6) see Table 4.21. HRESI(+)MS m/z 349.1142 [M+Na]+ 
(calcd for C18H18N2O4Na 349.1159). 
cyclo-(L-Tyr-D-Tyr) (4.39i): white powder; ;[α]22D  0 (c 0.05, MeOH);1H NMR (600 MHz, DMSO-
d6) and 13C (150 MHz, MeOH-d4) see Table 4.22. HRESI(+)MS m/z 349.1133 [M+Na]+ (calcd for 
C18H18N2O4Na 349.1159). 
cyclo-(L-Tyr-D-Pro) (4.39j): white powder; [α]22D −2.2 (c 0.1, MeOH); 1H NMR (600 MHz, 
MeOH-d4) and 13C (150 MHz, MeOH-d4) see Table 4.23. HRESI(+)MS m/z 283.1050 [M+Na]+ 
(calcd for C14H16N2O3Na 283.1053). 
cyclo-(L-Tyr-L-Pro) (4.39k): white powder; [α]22D −6.8 (c 0.06, MeOH); 1H NMR (600 MHz, 
MeOH-d4) and 13C (150 MHz, MeOH-d4) see Table 4.24. HRESI(+)MS m/z 283.1051 [M+Na]+ 
(calcd for C14H16N2O3Na 283.1053). 
cyclo-(L-Pro-L-Pro) (4.39l): white powder;[α]21D −5.9 (c 0.1, MeOH); 1H NMR (600 MHz, MeOH-
d4) and 13C (150 MHz, MeOH-d4) see Table 4.25. HRESI(+)MS m/z 217.0927 [M+Na]+ (calcd for 
C10H14N2O2Na 217.0947). 
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4.7.13 The effect of nitro aromatic compounds on the secondary metabolites 
production of the pure Streptomyces sp. 
Seed culture from Streptomyces sp. (CMB-M423) was cultivated in M1 broth containing 3.3% 
artificial sea salt for 10 d, 190 rpm, 26.5 °C.  Seed culture (15 µL) was transferred to the wells of 
the microbioreactor plate containing 1.45 mL M1 broth containing 3.3% artificial sea salt and 
aminoguanidine (AG) (10 nM). The microbioreactor was incubated for 2 d at 190 rpm, 26.5 °C. In 
the third day, an aliquot (15 µL) of 10 nitro compounds 0.1 mg/mL (2-nitrophenol, 2-chloro-5-
nitropyridine, 4-nitrobenzaldehyde, 5-methyl-2-nitrophenol, 3-nitroaniline, 4-nitroaniline, 2- and 3-
nitropyrrole trans-2-nitrocinnamaldehyde), as well as pyrrole and imidazole were added to the 
wells. The plates were incubated for another 7 d, 190 rpm, 26.5 °C. After the incubation period, the 
wells were extracted by the addition of EtOAc (2 mL) and the plates were shaken for 1 h at 100 
rpm. The organic layer was dried down under N2, the crude extract was dissolved in MeOH (100 
µL) and analysed using HPLC-DAD-MS using Zorbax SB-C8 analytical HPLC column, 5 µM, 150 
× 4.6 mm, 1 mL/min gradient elution from 90% H2O/MeCN to 100% MeCN (with a constant 
0.05% formic acid/MeCN modifier) over 15 min monitoring at 210, 254 and 360 nm. 
4.7.14  Study on the effect of 2,4-DNP on the induction of heronapyrroles 
Table 4.31. Average production of heronapyrrole B in the presence of different concentrations of 2,4-DNP 
Concentration of 2,4-DNP (µM) Average amount of heronapyrrole B ± 0.7 (µg/mL)  
637 3.4 
159 3.3 
39.8 3.6 
9.9 7.3 
2.5 5.3 
0.6 7.4 
0.1 7.4 
0.03 8.7 
 
4.7.15  NO donor and scavenger assays 
Four plates were set for the NO donor and NO scavenger studies. At the onset of of heronapyrrole 
production, after approximately 4 – 5 days, NO donor or scavenger were added to the cultures, 
dissolved in 30% DMSO. The cultures were returned to the shaker and were futhur incubated for 
another 4 – 5 additional days. During this incubation period, a sample (200 µL) where withdrawn 
everyday for extraction with EtOAc (200 µL) and then dried down under N2 and the colorimetric 
absorbance was measured at 400 nm spectrophotometrically. Also, another sample (200 µL) was 
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withdrawn to measured at 600 nm spectrophotometrically as described above. Each experiment 
consisted of two to three replicates and each experiment was independently repeated twice. 
4.7.16 The effect of synthetic diketopiperazines on the induction of NO in cancer cells and 
pure Streptomyces sp. 
Nitric oxide detection kit consists of NO detection reagent (red), NO inducer (L-arginine) as 
positive control, NO scavenger (c-PTIO) and wash buffer. 
4.7.16.1 Reagents preparation according to manufacturer’s instructions: 
1. Dilution of NO detection reagent: An aliquot of the NO detection reagent (2.5 µL) was diluted 
1:400 with pre-warmed culture medium (1 mL) immediately prior to use. 
  
2. Positive control: The NO inducer (L-arginine) was supplied as a stock (100 mM) in deionized 
water. A final concentration per well is 1 mM. Therefore 2 µL of the stock was transferred to 198 
µL of the cell culture medium. 
 
3. Negative control: The NO Scavenger (c-PTIO) was supplied as lyophilized powder, which was 
dissolved in dry DMF (100 µL) to produce a stock solution of 4 mM.  
 
4. 1× Wash buffer: The wash buffer was supplied as a 10× solution, which was diluted 1/10 with 
deionized water to give a 1× working concentration. 
4.7.16.2 Cell Preparations 
Two cell lines were chosen for the assay, KB-3-1 (adherent epithelial like, human cervix 
carcinoma) and SW620 (adherent epithelial like, human colorectal carcinoma). Both cells, KB-3-1 
and SW620 were cultivated in 96 well plates 3 d prior to the experimental day to ensure 50-70% 
confluency in the day of the experiment. The cells were seeded in the plates in 2 different 
concentrations. KB-3-1 was seeded in plates to give final concentration 8000 cells/well, while 
SW620 was seeded in the plates to give final concentration 8000 cells/well. The plates were 
incubated at 37 °C for 3 d. On the day of the experiment, KB-3-1, 8000 cells/well gave confluency 
around 60% and for SW620, 8000 cells/well gave approx. confluency of 70% and the media used 
were DMEM for KB-3-1 and RPMI1640 for SW620 supplemented with L-glutamine and no phenol 
red. 
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4.7.17  BD microscope 
The KB-3-1 and SW620 cells were loaded with the pre-diluted NO detection reagent (50 µL) to 
ensure that the reagent covered the monolayers of the cells and the plates were incubated for 2 h. 
After 1 h and half, NO Scavenger (2 µL) was added to the negative control wells. After the 
incubation period, the NO reagent was removed carefully and the cells were washed with 50 µL of 
1× wash buffer. Fresh medium without phenol red (DMEM for KB-3-1 and RPMI1640 for SW620) 
supplemented with L-glutamine, was added to all wells (198 µL). KB-3-1 and SW620 cells were 
treated with experimental test agents (L-arginine, lipopolysaccharide (LPS) from Escherichia coli 
O111:B4 purchase from Sigma-aldrich, cyclo-(L-Phe-trans-4-hydroxy-L-Pro), 2,4-dinitrophenol. 
Stock solutions (100 mM) of each agent were prepared in DMF and serially diluted to give a final 
concentration (two fold dilution) per well 1 mM to 0.001 µM. An aliquot (2 µL) of each dilution 
was transferred to the wells of 96 well Nunc microtiter plate. LPS solution was prepared in two-fold 
dilution in water to give final concentration 2 µg to 2.5 ng per well. Other DKPs were tested at only 
one concentration (1 mM/1% DMF). After the addition of the compounds, the plates were 
incubated at 37 °C, 5% CO2 for another 20 min. After the incubation period, the cells were washed 
twice with 1X wash buffer (50 µL). The plates were observed using BD microscope using objective 
10X Olympus. Streptomyces sp. (CMB-M0423) was cultivated in MatTek plates (Coverglass 
bottom culture dishes, 12 mm well, ProSciTech Pty Ltd, Australia) in 200 µL M1 broth containing 
3.3% artificial ocean sea salt. An aliquot (2 µL) from cyclo-(L-Phe-trans-4-hydroxy-L-Pro) to give a 
final concentration 0.6 mM, 0.1 mM, 0.03 mM, 9.9 µM and 0.3 µM in 1% DMSO of each was 
added to the plates and the plates were incubated at 26.5 ˚C, 190 rpm for 10 d. 
4.7.18 Electron Microscope 
4.7.18.1 Sample processing and imaging 
Coverslips coated with poly-L-lysine (1 mg/mL) were inverted onto plates, then left for 5 min for 
samples to adhere. Coverslips were then immersed in 3% glutaraldehyde in 0.1 M sodium 
cacodylate buffer for 1 h before being washed twice in the same buffer for 5 min. Samples were 
then dehydrated in a series of ethanols before being dried in a critical point dryer (Autosamdri-815, 
Tousimis) according to manufacturer’s instructions. Coverslips were attached to stubs with double-
sided carbon tabs and coated with gold using an SPI-Module sputter coater (SPI) following 
manufacturer’s instructions. Samples were imaged in a Jeol Neoscope JCM 5000 at an accelerating 
voltage of 10kV. 
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5 Chapter 5: Rare marine-derived fungal alkaloids reveal 
diketomorpholines as inhibitors of P-glycoprotein-mediated 
multi-drug resistance in cancers, and a promising new 
scaffold for medicinal chemistry 
5.1 Introduction 
The diketopiperazine (DKP) motif is well represented among natural products, particularly fungal 
metabolites, with structural diversity inclusive of fused heterocycles, prenylation, polythio bridging, 
dimerization, nitration, halogenation, oxidation and far more. Commonly assumed to be produced 
by nonribosomal peptide synthases,186 the recent discovery of a DKP cyclase suggests a more 
complex biosynthetic landscape.187 The potent (and selective) biological properties displayed by 
many natural DKPs,175 combined with their ready availability from fungal cultivation, and the ease 
with which they can be synthesized and manipulated, has made the DKP scaffold an attractive and 
valuable resource for drug discovery.188 It is therefore surprising that, given the diverse and 
extensive literature surrounding DKPs, the sister diketomorpholine (DKM) scaffold has attracted so 
little attention.  Accounts of DKM natural products are rare, being largely limited to only a handful 
of fungal metabolites. To our knowledge, the first instance diketomorpholine natural product was 
reported in 1959, when Abe et al.189 isolated ergosecalinine (5.01) from the ergot Calviceps 
purpurea. In 1993, Hasumi et al.190 isolated lateritin (5.02) from the mycelia of Gibberella 
lateritium as a new inhibitor of acyl-CoA: cholesterol acetyl transferase (ACAT). In 2010, further 
studies were carried out on lateritin (5.02), documentating its cytotoxic activity against different 
human cancer cell lines (pancreas, breast, CNS, lung, colon and prostate), antimicrobial activity 
against Gram positive bacteria (Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 
29212 and Streptococcus pneumonia ATCC 6303) and antifungal activity against Candida albicans 
ATCC 90028 and Micrococcus luteus)191 In 1995, Kagamizono et al.192 isolated bassiatin (5.03) 
from Beauveria bassiana (K-717), and demonstrated its inhibitory effect against platelet 
aggregation. The structure of bassiatin was proved by chemical synthesis and X-ray 
crystallography. 
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In 1997, two new diketomorpholines, mollenine A (5.04) and B (5.05) were isolated from 
Eupenicillium molle in which mollenine A (5.04) exhibited moderate cytotoxicity and antibacterial 
activity.193 Another example of diketomorpholines are PF1233A (5.06) and B (5.07), which were 
isolated from Asperigllus niveus. These two substances are voltage-dependent sodium channel 
blockers, useful for the control of local anesthesia, arrhythmia, epilepsy, pain and psychiatric 
disorder.194 In 2005, Suntornchashwej et al. isolated another diketomorpholine (5.08) from the Thai 
sea hare Bursatella leachii.195 
 
 
 
In 2006, Nakadate et al.196 isolated two diketomorpholine derivatives, javanicunines A (5.09) and B 
(5.10) from the fungus Eupenicillium javanicum. These compounds possessed strong antifungal 
activity against Asperigllus fumigatus and were structural related to fructigenine B, also known as 
verrucofortine (5.11)197 which has previously been isolated from Penicillium verrucosum and 
Penicillium fructigenum.197 
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In 2011, the three diketomorpholines 5.12 – 5.14 were isolated from a pathogenic fungus, Fusarium 
sporotrichioides.198  
 
 
A previous PhD student in our group isolated the methyl ester 5.15 from marine derived fungus 
CMB-M081F isolated from marine sediment sample collected from Shorncliffe, Australia. After 
structure elucidation of 5.15, it was proposed that it is an artefact due to methanolysis process that 
occurred during handling. We speculated that diketomorpholine (DKM) ring structure (5.16) 
consisting of the hydroxy phenyl group and the prenylated tryptophan undergoing lactone 
solvolysis in MeOH generating 5.15 as an artefact. This was further reinforced by the fact that the 
crude extract was stored in MeOH for a long time and supported by HPLC-DAD-MS studies. 
(Figure 5.1) 
 
 
Figure 5.1. Proposed methanolysis of a putative natural product 5.16 to yield the artefact 5.15 
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5.2 Results and discussion 
5.2.1 Prior chemistry 
 
Figure 5.2. CMB-M081F 
CMB-M81F was isolated from a marine sediment sample collected from Shorncliffe, QLD, 
Australia. A previous student studying CMB-M081F isolated and identified 5.15. As the student 
made extensive use of MeOH during isolation and handling, this raised concern that the methyl 
ester 5.15 was an artefact caused by methanolysis. These concerns prompted a careful re-
investigation of the chemistry of CMB-M81F, avoiding the use of MeOH. 
5.2.2 Analytical cultivation and chemical analysis 
A single colony of CMB-M81F was used to inoculate a seed culture on M1 agar media in the 
presence of 3.3% artificial ocean sea salt, which was cultivated for a period of 30 days. After the 
initial cultivation the whole agar was extracted with EtOAc (25 mL), the EtOAc extract dried in 
vacuo to yield a crude extract (10 mg), and the crude extract was resuspended in MeCN and 
analysed by HPLC-DAD-MS. Noteworthy peaks were observed at 11.1 min (m/z 435, 5.16), 12.2 
min (m/z 485, 5.17), 12.4 min (m/z 469, 5.18) and 12.8 min (m/z 499, 5.19) (Figure 5.3). 
 
Figure 5.3. HPLC-DAD chromatogram from an analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8 
(254 nm) of the crude extract from CMB-M81F 
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5.2.3  Preparative cultivation and isolation 
A single colony of CMB-M81F was sub-sampled onto ten seawater M1 agar plates (300 mL of 
3.3% Ocean Nature seawater, 1% starch, 0.4% yeast extract and 0.2% peptone) and incubated at 27 
°C for 4 weeks. The resulting agar plates were extracted in EtOAc (500 mL) for 24 h and the 
organic phase concentrated in vacuo to yield an extract (60.2 mg). The extract was sequentially 
triturated with hexane (8 mL) and CH2Cl2 (8 mL) to afford, after concentration in vacuo, hexane (2 
mg) and CH2Cl2 (60 mg) soluble fractions. The CH2Cl2 fraction was subsequently subjected to 
semi-preparative reversed-phase HPLC (Zorbax C8 column, 250 × 9.4 mm, 5 µm, 4 mL/min 
gradient elution 90% H2O/MeCN to 100% MeCN over 30 min) to yield shornephine A (5.16) (tR = 
23.9 min, 2 mg, 1.8%), 15b-β-hydroxy-5-N-acetylardeemin (5.17) (tR = 25.5 min, 1.5 mg, 2.2%), 5-
N-acetylardeemin (5.18) (tR = 27.0 min, 1.9 mg, 2.5%) and 15b-β-methoxy-5-N-acetylardeemin 
(5.19) (tR = 28.0 min, 1.5 mg, 3.0%) (Scheme 5.1). 
 
  
Scheme 5.1. Isolation scheme of crude extract from CMB-M081F (a) Trituration [hexane (-1-1) and CH2Cl2 (-1-2)], (b) 
Semi-preparative HPLC: Zorbax-C8, 90 −  0% H2O/MeCN, 3 mL/min, 30 min. 
crude extract
60.2 mg
-1-1
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-1-2
60 mg
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5.2.4 Structure Elucidation of fungal metabolites  
5.2.4.1 seco-shornephine A (5.15) 
 
HRESI(+)MS analysis of seco-shornephine A (5.15) returned a molecular formula (C26H30N2O6) 
requiring thirteen DBE. The NMR (DMSO-d6) data (Figure 5.5 and Table 5.1) for 5.15 revealed 
three ester/amide carbonyls C-10, C-1 and C-1′ (δC 179.7, 172.5 and 173.5) and a further fourteen 
sp2 resonances (δC 115.6 to 143.5), accounting for ten DBE and requiring that 5.15 incorporate 3 
rings. The 1H and COSY NMR data indicated the presence of two isolated aromatic spin systems, 
the first with coupled protons H-5 (δH 6.56), H-6 (δH 6.78) and H-7 (δH 6.70) indicative of a 1,2,3-
trisubstituted benzene system. HMBC correlations were observed from H-4 to the quaternary 
carbon C-4 (δC 55.8) and C-8a (δC 131.0); H-6 to the quaternary carbon C-4a (δC 130.0) followed 
by the COSY spectrum indicating a –CH-CH2- sequence, H-2 (δH 3.79) and H2-3 (δH 2.32, 2.24), 
the methlyene from this sequence H2-3 showed HMBC correlations to the quaternary carbons C-4, 
C-4a, C-10 (δC 179.7), C-1 (δC 172.5) and C-11 (δC 42.3); and the methine H-2 to C-3 (δC 32.8), C-
1 and C-1′ (δC 173.5). 
 
This defined a C-1 to C-10 substituted tryptophan system. The carbonyl C-1 was confirmed to be a 
methyl ester based on HMBC correlations from the methoxy H3-1 (δH 3.38) to C-1. Furthermore a 
monosubstituted olefin system with coupled protons signals H-13a (δH 5.07) and H-13b (δH 4.99) 
on the carbon C-13 (δC 113.8) and the third proton H-12 (δH 6.04, δC 143.5) showed coupling to a 
quaternary carbon C-11 (δC 42.3). Also observed was the HMBC correlations for the two singlet 
methyls H3-14 (δH 1.01) and H3-15 (δH 0.93) to the same quaternary carbon C-11 defining an 
isoprene moiety C-11 – C-15. In addition, the methyl singlets H3-14 and H3-15 showed HMBC 
correlations to the quaternary carbon C-4 to which the methylene H2-3 and the aromatic proton H-5 
also showed coupling, allowing for the construction of fragment A. The second set of aromatic 
signals H-5′ (δH 7.22), H-6′ (δH 7.26), H-7′ (δH 7.18), H-8′ (δH 7.26) and H-9′ (δH 7.22) was 
suggestive of a monosubstituted benzene system, an extension of this system was confirmed from 
the second set of methylene signals H2-3′ (δH 2.79, 2.61) showing HMBC correlations to C-4′ (δC 
138.8), C-5′ (δC 129.7) and C-9′ (δC 129.7). The COSY correlation defined a second –CH-CH2- 
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system, H-2′ (δH 3.90) and H2-3′. The downfield characteristic of C-2′ (δH 72.5) indicated a 
hydroxy attachment, with reconfirmation of a COSY correlation of 2′-OH (δH 5.53) to H-2′. The 
following correlation was indicative of a hydroxy phenylalanine representing structural fragment B 
of 5.15 (Figure 5.4). This accounted for the molecular formula lacking in a hydroxy functionality 
that was positioned at C-8 of the first aromatic system. The complete planar structure of 5.15 was 
achieved by the key HMBC correlation of the amide (δH 7.35) to C-2 and C-1′ linking the two 
fragments together. 
 
 
Figure 5.4. Key 2D NMR (600 MHz, DMSO-d6) correlations of seco-shornephine A (5.15) 
 
 
 
 
Figure 5.5. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 
seco-shornenine A (5.15) 
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Table 5.1. NMR (600 MHz, DMSO-d6) data of seco-shornephine (5.15) 
Pos. δH, mult, (J in Hz) δCa COSY ROESY 
1H – 13C HMBC 
1  172.5    
2 3.79, ddd, (13.8, 9.6, 4.8) 49.8 3a/b, 2-NH 5, 2-NH 3, 1, 1′ 
3 a 2.32, dd, (13.8, 4.8) 32.8 3b, 2 5 10, 4a, 4, 2, 1, 11 
 b 2.24, dd, (13.8, 9.6)  3a, 2 2-NH 10, 4, 4a, 2, 1, 11 
4  55.8    
4a  130.0    
5 6.56, d, (7.8) 117.0 6 3a, 2, 12, 14, 15 4, 7, 8a 
6 6.78, t, (7.8) 121.4 5, 7  4a, 8 
7 6.70, d, (8.4) 115.6 6  5, 8, 8a 
8  141.5    
8a  131.0    
9 9.50, br s     
10  179.7    
11  42.3    
12 6.04, dd, (17.4, 10.8) 143.5 13a/b 5, 14, 15 11, 15 
13 a 5.07, dd, (10.8, 0.6) 113.8 12  11 
 b 4.99, dd, (17.4, 0.6)  12  11, 12 
14 1.01, s 22.1  5, 12 4, 11, 12, 15 
15 0.93, s 21.8  5, 12 4, 11, 12, 14 
1′  173.5    
2′ 3.90, dd, (9.6, 3.6) 72.5 3′a/b 2-NH 1′ 
3′ a 2.79, dd, (13.8, 3.6) 40.4 2′, 3′b  2′, 4′, 5′/9′ 
 b 2.61, dd, (13.8, 9.6)  2′, 3′a  2′, 4′, 5′/9′ 
4′  138.8    
5′ 7.22, db, (7.2) 129.7c 6′  7′, 5′/9′ 
6′ 7.26, dd, (7.2, 0.6) 128.2c 5′/9′, 7′  4′, 6′/8′ 
7′ 7.18, dd, (7.2, 0.6) 126.3 6′/8′  5′/9′ 
8′ 7.26, dd, (7.2, 0.6) 128.2c 7′, 5′/9′  4′, 6′/8′ 
9′ 7.22, d, (7.2) 129.7c 6′/8′  5′/9′, 7′ 
1-OMe 3.38, s 52.1   1 
2-NH 7.35, d, (7.8)  2 3b, 2, 2′ 2, 1′ 
8-OH 10.2, br s     
2′-OH 5.53, br s  2′   
*(a) assignments supported by HSQC and HMBC. (b) Overlapping resonances. (c) Interchangeable resonances 
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5.2.4.2 Shornephine A (5.16) 
 
HRESI(+)MS analysis of shornephine A (5.16) revealed a quasi-molecular ion [M+H]+ 
corresponding to a molecular formula (C25H26N2O5, Δmmu +0.3) requiring 14 double bond 
equivalents (DBE). The 1D and 2D NMR (CDCl3) data for 5.16 revealed a number of diagnostic 
resonances and correlations that could be assembled into significant structure fragments. For 
example, COSY correlation sequences from H-2′ to H-3′, and from H-7′ to H-8′ to H-9′ (inclusive 
of H-5′ and H-6′ due to symmetry), supported by HMBC correlations from H2-3′ to C-1′, C-4′ and 
C-5′/9′, together with deshielded 13C NMR resonances for C-2′ (δC 78.5) and carbonyl C-1′ (δC 
167.2) consistent with oxymethine, and suggestive of phenyl lactic acid residue (Fragment A) 
(Figure 5.6). Likewise, COSY correlation sequences from H-5 to H-6 to H-7, and diastereotopic 
methylene H2-3 to H1-2 supported by HMBC correlations from H-6 to C-8 (δC 141.4) and from H-5 
to C-4a (136.3) and H-2 to C-1 (δC 167.7) suggestive of tryptophane residue (Fragment B). In 
addition, COSY correlation sequences from H-12 to H-13 supported by HMBC correlation from 
H3-14/15 to C-12 (δC 144.1) suggesting isoprene residue (Fragment C) (Figure 5.6). All these data 
supported by the previous data from seco-shornephine A (5.15) strongly suggest the structure of 
shornephine A (5.16) (Figure 5.7 and Figure 5.8). 
 
 
 
Figure 5.6. Key 2D NMR (600 MHz, CDCl3) correlations of shornephine A (5.16) for fragment A, B and C 
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Figure 5.7. HMBC (600 MHz, CDCl3) spectrum of shornephine A (5.16) 
 
Figure 5.8. ROESY (600 MHz, CDCl3) spectrum of shornephine A (5.16) 
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Figure 5.9. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) spectra of shornephine A 
(5.16) 
 
 
 
Figure 5.10. Key 2D NMR (600 MHz, CDCl3) correlations of shornephine A (5.16) 
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Table 5.2. 1H NMR (600 MHz, CDCl3) data of shornephine A (5.16) 
Pos.  δH, mult (J in Hz)a δCa COSY ROESY 
1H-13C HMBC 
1  167.7    
2 4.32, d (13.7) 57.3 3a/b 2′, 14/15 1, 3, 4 
3 a 3.26, d (13.7) 36.9 2  1, 2, 4, 8a 
 b 2.89, dd (13.7,11.1)  2  1, 2, 4, 8a 
4  88.5    
4a  136.3    
5 6.67b, m 117.3d 6  4a, 7 
6 6.69b, m 121.2d 5, 7  8, 8a 
7 6.91, d (7.7) 117.1 6  4, 5/6 
8  141.4    
8a  130.9    
10  c    
11  44.9    
12 6.39, dd (17.3,10.6) 144.1 13a/b  11, 14, 15 
13 a 5.18, d (17.3) 113.1 12  11, 12 
 b 5.11, d (17.3)    11, 12 
1′  165.9     
2′ 4.76, dd (8.8, 1.6) 78.5 3′a/b 2 3′, 4′ 
3′ a 3.27, d (15.1) 34.4 2′, 3′b  4′, 5′/9′ 
 b 2.92, dd (15.1, 8.8)  2′, 3′a  1′, 2′, 4′, 5′/9′ 
4′  136.2    
5′ 7.20b 126.7d    
6′ 7.20b 129.3d    
7′ 7.20b 128.5d    
8′ 7.20b 126.7d    
9′ 7.20b 126.7d    
2-NH c     
9-NH c     
8-OH 6.34, s  7  4, 8a 
14-Me 1.38, s 22.6 12 2 11, 12, 13, 14/15 
15-Me 1.38, s 22.6 12 2 11, 12, 13, 14/15 
*(a)13C assignments obtained from gHSQC and gHMBC data. (b) overlapping resonances. (c) signals not observed. (d) interchangeable signals 
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5.2.4.2.1 Mosher ester derivation 
To assign an absolute configuration to shornephine A (5.16), mosher ester derivatives were 
prepared according to protocol published by Hoye et al.199 Shornephine A (5.16) was subjected to 
acid hydrolysis to release phenyllactic acid residue, which was derivatized with (R)-α-methoxy-α-
trifluoromethylphenylacetic acid (R-(+)-MTPA) to yield the corresponding R Mosher ester. 
Authentic samples of (S)-(–)-phenyllactic acid were also derivatized in this manner with R-(+)-
MTPA and  S-(+)-MTPA to yield the corresponding R and S Mosher esters respectively and the 
reactions were analysed using HPLC-DAD-MS using a 60 – 15% H2O/MeCN plus 0.05% HCO2H, 
gradient elution on a Zorbax Eclipse XDB-C8 column. 
 
Mosher ester derivatives were separated, R-(+)-MTPA + (S)-(−)-3-phenyl lactic acid showed tR= 
15.7 min and S-(+)-MTPA + (S)-L-(-)-phenyllactic acid showed tR= 16.2 min. Retention times of 
the two standards R-(+)-MTPA and S-(+)-MTPA reacted to (S)-L-(–)-phenyllactic acid compared to 
the reaction of R-(+)-MTPA  + hydrolyzed shornephine A (5.16) (15.7 min), confirming the 2S and 
2′S configuration of shornephine A (5.16) (Figure 5.11). 
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Figure 5.11. Chromatogram showing Mosher analysis for 5.16. LCMS condition: Zorbax Eclipse C8 analytical column, 
150 × 4.6 mm, eluting with 1.0 mL/min 60% H2O/MeCN to 15 H2O/MeCN (0.05% HCO2H modifier) over 40 min, 
then held for 5 min and detecting at extract ions 383 [M+H]/381 [M-H]. (a) coinjection of R-(+)-MTPA-OH + (S)-(−)-
3-phenyl lactic acid and S-(+)-MTPA-OH + (S)-(−)-3-phenyl lactic acid, (b) co-injection of R-(+)-MTPA-OH + (S)-(−)-
3-phenyl lactic acid and R-(+)-MTPA-OH + shornephine A (5.16) , (c) R-(+)-MTPA-OH + shornephine A (5.16), (d) S-
(+)-MTPA-OH + (S)-(−)-3-phenyl lactic acid and (e) R-(+)-MTPA-OH + (S)-(−)-3-phenyl lactic acid 
 
ROSEY correlations between H-2 and H-2′ (Figure 5.8) as well as Mosher analysis unambiguously 
confirmed the absolute configuration of H-2 and H-2′ as S configuration. Unfortunately, assignment 
of the absolute configuration of the remaining stereocentre C-4 of isoprene unit was undetermined. 
Chem 3D model studies could not give a definitive answer due to flexibility of the molecule. 
However, it can be tentatively inferred that the absolute configuration of C-4 in 5.16 can be based 
on the biosynthetic grounds of the other co-metabolites that will be discussed in the next sections.  
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5.2.4.3 15b-β-hydroxy-5-N-acetylardeemin (5.17) 
 
HRESI(+)MS data for 5.17 revealed an adduct ion (M+Na)+ corresponding to a molecular formula 
(C28H28N4O8, Δmmu –1.3). The 1H NMR (CDCl3) data of 5.17 (Figure 5.14 and Table 5.3) 
suggested the presence of indole, isoprene, piperazine and quinazoline residues, further supported 
by 2D NMR data, including HSQC, COSY and HMBC (Figure 5.12). On searching the literature, 
5.17 was determined to be consistent with the known fungal metabolite 15b-β-hydroxy-5-N-
acetylardeemin. Analysis of all the NMR data with comparison to literature data (Table 5.4), 
confirmed that 5.17 was 15b-β-hydroxy-5-N-acetylardeemin. This assignment was further 
supported by a comparison of the [α]23D −18 (c 0.09, MeOH) for 5.17 compared to [α]25D − 245 (c 
0.2, MeOH) for the reported 15b-β-hydroxy-5-N-acetylardeemin.200 The wide difference in the 
optical rotation of both compounds can be attributed to the possibility of other issues such as high 
concentration of the reported 15b-β-hydroxy-5-N-acetylardeemin. Karwowski et al., isolated 15b-β-
hydroxy-5-N-acetylardeemin from Aspergillus fischerai as a novel heterocyclic compound which 
reverses multidrug resistance in tumour cells.201  
  
 
Figure 5.12. Key 2D NMR correlations of 15b-β-hydroxy-5-N-acetylardeemin (5.17) 
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Figure 5.13. HMBC (600 MHz, CDCl3) spectrum of 15b-β-hydroxy-5-N-acetylardeemin (5.17) 
 
Figure 5.14. 1H NMR (600 MHz, CDCl3) and UV-vis spectrum (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) 
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Table 5.3. NMR (600 MHz, CDCl3) of 15b-β-hydroxy-5-N-acetylardeemin (5.17) 
Pos. δH, mult, (J in Hz)a  δCa COSY ROESY HMBC 
1 7.42, d (7.5) 124.4 2  3, 16α, 16β 
2 7.21, t (7.5) 124.9 1, 3  1, 3, 4, 4a, 16β 
3 7.45, t (7.5) 130.2 2, 4  1, 16b 
4 8.07, br d b 3   
4a  142.5    
5a 6.04, br  80.2  21, 22, 24  
7  168.4    
8 5.34, dd (14.1, 7.1) 53.5 17  7, 10, 15a, 17 
10  160.1    
10a  120.7    
11 8.27, d (7.5) 127.1 12, 13  10, 12, 14a 
12 7.77, t (7.5) 128.3 11, 12  10a, 11 
13 7.51, t (7.5) 134.9 11, 13, 14  11, 14a 
14 7.72, d (8.1) 127.8 13  10, 10a, 13 
15a  150.6    
15b  89.2    
16 α 3.15, d (14.8) 43.8  21, 22 15a, 15b, 16α, 16β, 18 
 β 3.06, d (14.8)   21, 22 5a, 15b, 16β 
16a  59.4    
16b  133.3    
17 1.64, d (7.1) 18.3 8  7, 8 
18  40.5    
19 5.78, dd (17.4, 10.8) 143.4 20α,β 16α, 21, 22 18, 22 
20 α 5.13, br d 115.9 19 21, 22 18, 19 
 β 5.11, d (17.4)   21, 22 18, 19 
21 0.98, s 22.6 22 5a, 19 16α, 18, 19, 22 
22 1.17, s 22.8 21 5a, 19 16α, 18, 19, 21 
23  170.8    
24 2.65, br s 23.6  21, 22 23 
15b-OH 2.21, br s    15a 
(a)13C assignments obtained from gHSQC and gHMBC data. (b) signals not observed 
 
Table 5.4. 1H NMR (600 MHz, DMSO-d6) data comparison of experimental and literature200 data of 15b-β-hydroxy-5-
N-acetylardeemin (5.17)  
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (literature) 
1 7.42, d (7.5) 7.41, dd, (7.8, 1.2) 
2 7.21, t (7.5) 7.13, td, (7.8, 0.8) 
3 7.45, t (7.5) 7.24, td, (7.8, 1.2) 
4 8.07, br  7.80, br s 
5a 6.04, br s 6.04, br s 
8 5.34, dd (14.1, 7.1) 5.03, q, (7.0) 
11 8.27, d (7.5) 8.18, dd, (8.2, 1.6) 
12 7.77, t (7.5) 7.58, br dd, (8.2, 7.1) 
13 7.51, t (7.5) 7.87, ddd, (8.1, 7.1, 1.6) 
14 7.72, d (8.1) 7.76, br d, (8.1) 
16 α 3.15, d (14.8) α 3.09, d, (13.7) 
 β 3.06, d (14.8) β 2.97, d, (13.7) 
17 1.64, d (7.1) 1.51, d, (7.0) 
19 5.78, dd (17.4, 10.8) 5.83, dd, (17.6, 11.0) 
20 α 5.13, br d α 5.08, br d, (11.0) 
 β 5.11, d (17.4) β 5.05, br d, (17.6) 
21 0.98, s 0.91, s 
22 1.17, s 1.08, s 
24 2.21, br s 2.55, br s 
*measured in (a) (600 MHz, DMSO-d6), (b) (500 MHz, DMSO-d6). 
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5.2.4.4 5-N-acetylardeemin (5.17) 
 
 
HRESI(+)MS data for 5.18 revealed an adduct ion (M+Na)+ corresponding to a molecular formula 
(C28H28N4O4, Δmmu +0.4). The 1H NMR (CDCl3) data for 5.18 were closely related to 5.17 with 
exception for the replacement of 15b-OH group in 5.17 with 15b-H in 5.18. The structure 
elucidation was further supported by 2D NMR data, including HSQC, COSY and HMBC (Figure 
5.15). On searching the literature 5.18 was determined to be consistent with 5-N-acetylardeemin. 
Analysis of all the NMR data with comparison to literature data (Table 5.6), confirmed that 5.17 was 
the known metabolite 5-N-acetylardeemin. This assignment was further confirmed by a comparison 
of the [α]23D –9.7 (c 0.05, MeOH) for 5.18 compared to [α]25D –33 (c 0.7, MeOH) for the reported 
5-N-acetylardeemin.200 Karwowski et al., isolated 5-N-acetylardeemin as a co-metabolite with 15b-
β-hydroxy-5-N-acetylardeemin from Aspergillus fischerai as a novel heterocyclic compound, which 
reverses multidrug resistance in tumour cells.201 An X-ray determination of 5-N-acetylardeemin 
assigned the relative configuration and confirmed the structure.200 
 
 
Figure 5.15. Key 2D NMR correlations of 5-N-acetylardeemin (5.18) 
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Figure 5.16. ROESY (600 MHz, CDCl3) spectrum of 5-N-acetylardeemin (5.18) 
 
 
Figure 5.17. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 5-
N-acetylardeemin (5.18) 
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Table 5.5. NMR (600 MHz, CDCl3) of 5-N-acetylardeemin (5.18) 
Pos. δH, mult, (J in Hz)a  δCa COSY ROESY HMBC 
1 7.39, d, (7.8) 124.7 2  4, 16 
2 7.18, t, (7.8) 124.5 1, 3  4 
3 7.36, dd, (7.8, 7.2) 130.1 2, 4  1, 4a 
4 8.03, br s 121.2 3  2 
4a  142.2    
5a 6.04, br s 81.2  16β, 21, 22 16, 18 
7  169.1    
8 5.41, q, (7.2) 53.6 17  7 
10  160.1    
10a  121.2    
11 8.27, d, (7.8) 127.8 12   
12 7.50, dd, (7.8, 7.2) 127.5 11, 13  10a 
13 7.72, ddd, (8.4, 7.2, 1.2) 135.2 12, 14  14a 
14 7.66, d, (8.4) 126.3 13   
14a  149.4    
15a  151.1    
15b 4.41, dd, (10.2, 5.4) 90.2 16a,b 16α,b, 17 15a 
16a  60.1    
16b  132.3    
16 α 3.02, dd, (12.6, 10.8) 59.2 15b, 16β  18 
 β 2.69, dd, (12.6, 10.8)  15b, 16α  18 
17 1.44, d, (7.2) 19.1 8 15b  
18  41.2    
19 5.85, dd, (17.4, 10.2) 145.3 20a, b 16β, 21, 22  
20 α 5.13, d, (16.8) 115.1 19, 20β 21, 22 21, 22 
 β 5.15, d, (16.8)  19, 20α  21, 22 
21 1.21, s 22.1 22  4a, 16α, 18, 20 
22 1.03, s 22.3 21  4a, 16α, 18, 20 
23  171.4    
24 2.67, s 23.6    
(a)13C assignments obtained from gHSQC and gHMBC data. 
 
Table 5.6. 1H NMR data comparison of experimental and literature200 data of 5-N-acetylardeemin (5.18)  
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (literature) 
1 7.39, d, (7.8) 7.38, br d, (7.6) 
2 7.18, t, (7.8) 7.17, br t, (7.6) 
3 7.36, dd, (7.8, 7.2) 7.34, dd, (8.1, 7.6) 
4 8.03, br s 8.00, br s 
5a 6.04, br s 6.08, br s 
8 5.41, q, (7.2) 5.37, q, (7.1) 
11 8.27, d, (7.8) 8.24, dd, (8.1, 1.5) 
12 7.50, dd, (7.8, 7.2) 7.47, dd, (8.1, 7.1) 
13 7.72, ddd, (8.4, 7.2, 1.2) 7.76, ddd, (8.1, 7.1, 1.5) 
14 7.66, d, (8.4) 7.65, d, (8.1) 
15b 4.41, dd, (10.2, 5.4) 4.41, dd, (10.7, 5.6) 
16 α 3.02, dd, (12.6, 10.8) 3.01, dd, (12.7, 5.6) 
 β 2.69, dd, (12.6, 10.8) 2.67, d, (12.7, 10.7) 
17 1.44, d, (7.2) 1.42, d, (7.1) 
19 5.85, dd, (17.4, 10.2) 5.84, dd, (17.3, 10.7) 
20 α 5.13, d, (16.8) 5.11, d, (10.7) 
 β 5.15, d, (16.8) 5.15, d, (17.3) 
21 1.21, s 1.20, s 
22 1.03, s 1.01, s 
24 2.67, s 2.63, s 
 *measured in (a) (600 MHz, CDCl3), (b) (500 MHz, CDCl3). 
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5.2.4.5 15b-β-methoxy-5-N-acetylardeemin (5.19) 
 
HRESI(+)MS data of 5.19 revealed an adduct ion (M+Na)+ corresponding to a molecular formula 
(C29H30N4O4, Δ mmu −0.4). The 1H NMR (CDCl3) data of 5.19 was very closely related to 5.17 
with exception for the replacement of 15b-OH in 5.17 with OMe in 5.19 (Figure 5.20, Figure 5.21, 
Table 5.7 and Table 5.8) Additional HSQC, COSY, HMBC and ROESY NMR data (Figure 5.18 and 
Table 5.7) provided further evidence to support the assigned structure (Figure 5.18). [α]22D –16 (c 
0.05, MeOH). On searching the literature 5.19 was determined to be new analogue to ardeemin 
family. 
 
Figure 5.18. Key 2D NMR correlations of 15b-β-methoxy-5-N-acetylardeemin (5.19) 
 
Figure 5.19. HMBC (600 MHz, CDCl3) spectrum of 15b-β-methoxy-5-N-acetylardeemin (5.19) 
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Figure 5.20. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 
15b-β-methoxy-5-N-acetylardeemin (5.19) 
Table 5.7. NMR (600 MHz, CDCl3) data of 15b-β-methoxy-5-N-acetylardeemin (5.19) 
Pos. δH, mult, (J in Hz) δC* COSY ROESY 
1H – 13C HMBC 
1 7.35, d, (7.8) 123.8 2 16β 3, 4a 
2 7.13, dd, (7.8, 0.6) 123.9 1, 3  4, 16β 
3 7.31, dd, (7.8, 0.6) 128.5 2, 4  1, 4a 
4 7.98, br d 119.5 3   
4a  143.0    
5a 6.10, br  80.5  24  
7  168.0    
8 5.29, q, (6.6) 54.9 17  7, 15a, 17 
10  160.0    
10a  120.8    
11 8.29, d, (7.8) 126.9 12  10, 13, 14a 
12 7.54, dd, (7.8, 1.8) 127.9 11, 13  10a, 14 
13 7.80, dd, (7.8, 1.8) 134.8 12, 14  11, 14a 
14 7.75, d, (7.8) 127.9 13  10a, 12 
14a  146.3    
15a  148.1    
15b  92.7    
16 α 3.15, d, (14.4) 37.4 16β 1, 21, 22 5a, 15b 
 β 2.79, d, (14.4)  16α 19 15a, 16α, 16β, 18 
16a  59.1    
16b  134.2    
17 1.64, d, (6.6) 18.9 8 15b-OMe 7, 8 
18  40.9    
19 5.85, dd, (16.8, 11.4) 143.3 20α, β 16b  
20 α 5.15, d, (16.8) 114.9 19  18 
 β 5.13, d, (16.8)  19  18 
21 1.20, s 22.6  16α 16α, 18, 19, 22 
22 1.01, s 23.3  16α 16α, 18, 19, 21 
23      
24 2.66, br s 23.9  5a  
15b-OMe 2.73, s 51.7  17 15b 
*(a)13C assignments obtained from gHSQC and gHMBC data 
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Figure 5.21. 1H NMR (600 MHz, CDCl3) spectra of 15b-β-hydroxy-5-N-acetylardeemin (5.17) (blue) and 15b-β-
methoxy-5-N-acetylardeemin (5.19) (red) 
 
Table 5.8. NMR (600 MHz, CDCl3) data comparison of 15b-β-hydroxy-5-N-acetylardeemin (5.17) and 15b-β-
methoxy-5-N-acetylardeemin (5.19)  
Pos. δH, mult, (J in Hz)a of 5.17 δCa Pos. δH, mult, (J in Hz)a of 5.19 δCa 
1 7.42, d (7.5) 124.4 1 7.35, d, (7.8) 123.8 
2 7.21, t (7.5) 124.9 2 7.13, dd, (7.8, 0.6) 123.9 
3 7.45, t (7.5) 130.2 3 7.31, dd, (7.8, 0.6) 128.5 
4 8.07, br b 4 7.98, br s 119.5 
4a  142.5 4a  143.0 
5a 6.04, br 80.2 5a 6.10, br s 80.5 
7  168.4 7  168.0 
8 5.34, dd (14.1, 7.1) 53.5 8 5.29, q, (6.6) 54.9 
10  160.1 10  160.0 
10a  120.7 10a  120.8 
11 8.27, d (7.5) 127.1 11 8.29, d, (7.8) 126.9 
12 7.77, t (7.5) 128.3 12 7.54, dd, (7.8, 1.8) 127.9 
13 7.51, t (7.5) 134.9 13 7.80, dd, (7.8, 1.8) 134.8 
14 7.72, d (8.1) 127.8 14 7.75, d, (7.8) 127.9 
14a   14a  146.3 
15a  150.6 15a  148.1 
15b  89.2 15b  92.7 
16 α 3.15, d (14.3) 43.8 16 α 3.15, d, (14.4) 37.4 
 β 3.06, d (14.3)   β 2.79, d, (14.4)  
16a  59.4 16a  59.1 
16b  133.3 16b  134.2 
17 1.64, d (7.1) 18.3 17 1.64, d, (6.6) 18.9 
18  40.5 18  40.9 
19 5.78, dd (17.1, 10.8) 143.4 19 5.85, dd, (16.8, 11.4) 143.3 
20 α 5.13, br 115.9 20 α 5.15, d, (16.8) 114.9 
 β 5.11, d (10.1)   β 5.13, d, (16.8)  
21 0.98, s 22.6 21 1.20, s 22.6 
22 1.17, s 22.8 22 1.01, s 23.3 
23  170.8 23  b 
24 2.65, br s 23.6 24 2.66, br s 23.9 
15b-OH 2.21, br s  15b-OMe 2.73, s 51.7 
*(a)13C assignments obtained from gHSQC and gHMBC data. (b) signals not observed 
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5.2.5 Plausible biosynthetic pathway linking shornephine A and ardeemins 
As shornephine A (5.16) and DKPs 5.17 – 5.19 are structurally related co-metabolites, it seems 
likely that they share common biosynthetic precursors and transformations. One such plausible 
biosynthetic relationship would have both sharing a common isoprenylated tryptophan precursor 
(Figure 5.22). Given that the α orientation of the isoprenyl moiety in 5.17 - 5.19 is conserved, and 
has been unambiguously assigned,200 on biosynthetic grounds we tentatively assign the same 
configuration to 5.16 – albeit acknowledging that this assignment would best be resolved by total 
synthesis. Give the above, the complete structures for shornephine A (5.16) and seco-shornephine A 
(5.15), inclusive of absolute configurations are assigned as S configuration. 
 
Figure 5.22. A plausible biosynthetic pathway linking shornephine A (DKM) and ardeemins (DKP) 
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5.2.6 Synthesis of diketomorpholines (DKMs) derviatives 
Shornephine A (5.16) and ardeemins (5.17 – 5.19) were tested in cytotoxic and antibacterial assay 
and were inactive. However, they showed good inhibitory effects against P-glycoprotein (discussed 
in Section 1.10). Therefore, a selection of DKMs analogues were synthesised (Figure 5.24) to test 
the hypothesis that DKM scaffold possesses P-gp inhibitory activity. The hydrochloride salts of 
methyl ester of amino acids 5.2a – d were prepared from refluxing 5.1a – d with SOCl2 in methanol 
in a quantitative yield (Scheme 5.2). 
 
Scheme 5.2. Synthesis of amino acids methyl esters (5.2a – d). Addition of SOCl2 in the presence of MeOH under 
reflux for 18 h.  
 
Figure 5.23. Structures of amino acids and their methyl esters 
The methyl ester of the dipeptides 5.4a – h were synthesized by coupling the α-hydroxycarboxylic 
acid, L-phenyllactic acid (5.3a) and L-mandelic acid (5.3b) with the methyl esters of the 
hydrochloride salts of 5.2a – d using HBTU and DIPEA in good yields (Table 5.9 and Scheme 5.3). 
Methyl ester of the dipeptides 5.4a – h were heated in the microwave at 140 oC for 3 min in 
presence of p-toluene sulphonic acid as a catalyst to afford DKMs derivatives 5.5a – h (Table 5.10, 
Scheme 5.3).  
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Scheme 5.3. Synthesis of morpholine derivatives (5.5a – h). (a)-addition of HBTU/DIPEA in the presence of dry DMF 
under argon for 3 h. (b)-The reaction mixture was dissolved in 5 mL dry toleune, pTSOH and heated in the microwave 
at 140 °C, 300 W for 3 min 
Table 5.9. Methyl ester of the dipeptides 5.4a – h 
Compound No. R1 R2 Yield % 
5.4a Bn Bn 85 
5.4b Bn Ph 82 
5.4c 
 
Bn 85 
5.4d 
 
Ph 85 
5.4e  
Bn 85 
5.4f  
Ph 84 
5.4g Me Bn 86 
5.4h Me Ph 85 
 
Table 5.10. DKM derivatives 5.5a – h 
Compound No. R1 R2 Yield % 
5.5a Bn Bn 75 
5.5b Bn Ph 72 
5.5c 
 
Bn 75 
5.5d 
 
Ph 75 
5.5e  
Bn 69 
5.5f  
Ph 65 
5.5g Me Bn 62 
5.5h Me Ph 69 
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Figure 5.24. Diagram that shows the synthesis of 8 different dioxomorpholine derivatives through the formation of 8 
different dipetides intermediates 
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5.2.6.1 (S)-Methyl 2-((S)-2-hydroxy-2-phenylacetamido)-3-phenylpropanoate (5.4a) 
 
The crude product was purified using flash column chromatography (10 – 60% EtOAc/hexane) to 
yield compound 5.4a as a white crystals (250 mg, 85%); [α]D22 +914.7 (c 0.05, CHCl3); Rf :0.29 (10 
–70% EtOAc/hexane and KMnO4 dip). ESIMS, m/z: 314 [M + H]+. HRESI(+)MS calculated for 
C18H19N1NaO4 336.1206, found 336.1252. 1H NMR (600 MHz, CDCl3) δH 7.24 (2H, m), 7.18 (5H, 
m), 6.99 (1H, d, 8.1), 6.93 (2H, m), 4.91 (1H, d, 2.3), 4.76 (1H, dd, 13.6, 6.6), 3.90 (1H, brd), 3.63 
(3H, s), 3.06 (1H, dd, 13.6, 6.6), 2.95 (1H, dd, 13.6, 6.6); 13C NMR (150 MHz, CDCl3) δC 172.1, 
171.9, 139.1, 135.7, 129.3, 128.7, 128.6, 128.5, 127.1, 126.7, 74.3, 52.9, 52.5, 37.7.  
 
 
Figure 5.25. 1H NMR (600 MHz, CDCl3) of (S)-Methyl-2-((S)-2-hydroxy-2-phenylacetamido)-3-phenylpropanoate 
(5.4a) 
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5.2.6.2  (S)-Methyl 2-((S)-2-hydroxy-3-phenylpropanamido)-3-phenylpropanoate (5.4b) 
 
The crude product was purified using flash column chromatography (10 – 60% EtOAc/hexane) to 
yield compound 5.4b as white crystals (200 mg, 82%); [α]D22 +60.7 (c 0.25, CHCl3); Rf :0.31 (10-
70% EtOAc/hexane and KMnO4 dip). ESIMS, m/z: 328 [M + H]+. HRESI(+)MS calculated for 
C19H22N1O4 328.1543, found 328.1550. 1H NMR (600 MHz, CDCl3) δH 7.28 (2H, t, 7.4), 7.21 (6H, 
m), 7.06 (1H, d, 8.0), 6.92 (2H, d, 8.0), 4.83 (1H, ddd, 14.8, 8.0, 6.8), 4.25 (1H, dd, 8.0, 6.8), 3.64 
(3H, s), 3.29 (1H, br d), 3.08 (1H, dd, 8.0, 6.8), 2.99 (2H, dd, 8.0, 6.8), 2.77 (1H, dd, 14.8, 6.8); 13C 
NMR (150 MHz, CDCl3) δC 174.2, 173.4, 138.5, 137.2, 131.3, 130.8, 130.1, 130.1, 128.6, 128.4, 
74.2, 54.1, 53.9, 42.1, 39.6. (Figure 5.26) 
 
 
 
Figure 5.26. 1H NMR (600 MHz, CDCl3) spectrum of (S)-Methyl-2-((S)-2-hydroxy-3-phenylpropanamido)-3-
phenylpropanoate (5.4b) 
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5.2.6.3  (S)-Methyl 2-((S)-2-hydroxy-2-phenylacetamido)-3-(1H-indol-3-yl)propanoate (5.4c) 
 
The crude product was purified using flash column chromatography (10-60% EtOAc/hexane) to 
yield compound 5.4c as white oil (210 mg, 83%); [α]D22 +20.5 (c 0.05, CHCl3);  Rf : 0.28 (10 – 70% 
EtOAc/hexane and KMnO4 dip). ESIMS, m/z: 367 [M + H]+. HRESI(+)MS calculated for 
C21H23N2O4 367.1652, found 367.1628.  1H NMR (600 MHz, CDCl3) δH 7.87 (1H, brd), 6.99 (1H, 
d, 8.0), 6.76 (4H, m), 6.69 (3H, m), 6.61 (2H, dd, 15.3, 7.8), 6.28 (1H, s), 4.43 (1H, s), 4.38 (1H, 
ddd, 13.5, 8.0, 5.8), 3.50 (1H, br d), 3.13 (3H, s), 2.78 (2H, d, 5.8); 13C NMR (150 MHz, CDCl3) δC 
172.3, 139.1, 136.2, 128.7, 128.4, 127.5, 126.7, 123.1, 122.2, 119.7, 118.5, 111.5, 109.4, 74.1, 52.8, 
52.5, 27.5. (Figure 5.27). 
 
 
 
Figure 5.27. 1H NMR (600 MHz, CDCl3) spectrum of (S)-Methyl-2-((S)-2-hydroxy-2-phenylacetamido)-3-(1H-indol-
3-yl)propanoate (5.4c). (x) impurities + EtOAc traces  
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5.2.6.4  (S)-Methyl 2-((S)2-hydroxy-3-phenylpropanamido)-3-(1H-indol-3-yl) propanoate 
(5.4d) 
 
The crude product was purified using flash column chromatography (10 – 60% EtOAc/hexane) to 
yield compound 5.4d as white oil (150 mg, 85%); [α]D22 +180.4 (c 0.05, CHCl3); Rf : 0.29 (10-70% 
EtOAc/hexane and KMnO4 dip). ESIMS, m/z: 367 [M + H]+. HRESI(+)MS calculated for 
C21H22N2NaO4 389.1472, found 389.1475.  1H NMR (600 MHz, CDCl3) δH 7.55 (1H, d, 8.0), 7.30 
(2H, t, 8.3), 7.27 (2H, t, 8.3), 7.17 (3H, m), 7.10 (2H, d, 7.6), 6.99 (1H, d, 8.2), 6.89 (1H, t, 7.6), 
6.53 (1H, s), 6.17 (1H, d, 7.6), 4.76 (1H, ddd, 12.4, 8.0, 5.2), 4.66 (1H, ddd, 13.1, 7.6, 5.8), 4.06 
(1H, dd, 7.6, 4.1), 3.61 (3H, s), 3.25 (1H, dd, 13.1, 5.8), 3.15 (1H, dd, 13.1, 5.8), 3.09 (1H, dd, 14.8, 
5.5), 3.02 (1H, dd, 13.9, 10.1), 2.98 (1H, dd, 12.4, 8.0), 2.75 (1H, dd, 12.4, 8.0); 13C NMR (150 
MHz, CDCl3) δC 172.8, 171.9, 170.7, 129.8, 128.8, 127.2, 123.7, 123.2, 120.0, 119.7, 119.2, 118.7, 
111.3, 111.2, 72.7, 53.3, 52.8, 52.5, 40.4, 27.9, 27.4 (Figure 5.28). 5.4d was not pure and was 
contaminated with the starting material(s). 
 
Figure 5.28. 1H NMR (600 MHz, CDCl3) spectrum of (S)-Methyl 2-((S)2-hydroxy-3-phenylpropanamido)-3-(1H-indol-
3-yl) propanoate (5.4d) 
CO2Me
H
N
O
N
H
(5.4d)
OH
+
N
H
NH2
CO2Me
L-tryptophan methyl ester (5.2b)
CO2H
OH
L-phenyllactic acid (5.3a)
HBTU/ DIPEA
DMF
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
12
95
.6
93
13
00
.7
93
16
35
.2
78
16
43
.0
79
16
49
.2
60
16
57
.0
01
17
59
.9
15
17
67
.5
36
17
74
.4
97
17
82
.1
18
18
10
.4
41
18
14
.2
22
18
24
.3
63
18
28
.2
64
18
45
.7
26
18
55
.2
67
18
60
.5
48
18
78
.0
10
18
83
.4
11
18
92
.7
72
18
98
.2
93
19
43
.1
79
19
48
.1
60
19
57
.8
21
19
62
.7
42
21
70
.2
49
24
35
.5
45
24
39
.2
65
24
43
.0
46
27
99
.6
13
28
04
.8
94
28
53
.3
81
28
60
.7
02
36
98
.5
93
37
06
.2
14
39
50
.8
67
40
95
.1
86
41
29
.7
51
41
37
.1
92
41
44
.6
93
41
91
.7
99
41
99
.7
20
42
54
.0
87
42
61
.4
68
42
68
.9
09
42
90
.2
72
42
97
.6
53
43
07
.6
75
43
12
.8
35
43
15
.4
16
43
19
.7
36
43
55
.6
81
43
63
.1
82
43
69
.9
63
43
77
.4
04
43
83
.4
05
43
91
.5
06
45
31
.8
04
45
39
.7
25
46
80
.9
24
47
24
.9
10
0.
84
0.
88
0.
88
2.
82
0.
91
3.
00
1.
01
1.
00
0.
97
0.
99
0.
90
0.
99
1.
01
2.
06
3.
27
3.
45
0.
98
1.
96
NAME     hydrolysis_morpholino_MeOH
EXPNO                 1
PROCNO                1
Date_          20110805
Time               9.53
INSTRUM           spect
PROBHD   5 mm PASEI 1H/
PULPROG              zg
TD                32768
SOLVENT           CDCl3
NS                    8
DS                    2
SWH            5434.783 Hz
FIDRES         0.165856 Hz
AQ            3.0147059 sec
RG                  512
DW               92.000 usec
DE                12.00 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 9.80 usec
PL1               -3.00 dB
PL1W        18.79452133 W
SFO1        600.0827526 MHz
SI                65536
SF          600.0800362 MHz
WDW                  EM
SSB                   0
LB                 1.00 Hz
GB                    0
PC                 1.00
1H NMR Spectrum (600 MHz, CDCl3) of hydrolysis_morpholino_MeO , 5/8/11
2 2’ OH
COOMe
3a 3b3’a
3’b
6-9 and 5’-9’
2-NH
CO2Me
H
N
O
HO
N
H
(5.4d)
2'1'2
1
3
9'
7'
12
3' 5'
5
7
9
Chapter 5. Rare marine-derived fungal alkaloids reveal diketomorpholines as inhibitors of P-glycoprotein 
 243 
5.2.6.5 (S)-Methyl-2-((S)-2-hydroxy-2-phenylacetamido)-3-(4-hydroxyphenyl)propanoate 
(5.4e) 
 
 The crude product was purified using flash column chromatography (10 – 70% EtOAc/hexane) to 
yield compound 5.4e as a white powder (150 mg, 85%); [α]D22 +167.5 (c 0.15, CHCl3);  Rf : 0.29 
(10-70% EtOAc/hexane and KMnO4 dip). ESIMS, m/z: 330 [M + H]+. HRESI(+)MS calculated for 
C18H20N1O5 330.1336, found 330.1320.  1H NMR (600 MHz, CDCl3) δ 7.22 (2H, m), 7.16 (2H, m), 
7.11 (1H, d 7.7), 6.93 (1H, brd), 6.76 (2H, d, 7.7), 6.52 (1H, d, 7.7), 4.92 (1H, brd), 4.75 (1H, dd, 
14.1, 6.9), 3.93 (2H, br s), 3.63 (3H, s), 3.01 (1H, dd, 14.1, 6.9), 2.89 (1H, dd, 14.1, 6.9); 13C NMR 
(150 MHz, CDCl3) δ 172.5, 172.3, 155.4, 138.8, 130.3, 128.8, 126.8, 115.7, 74.4, 53.1, 52.7, 37.0. 
(Figure 5.29). 
 
  
 
 
Figure 5.29. 1H NMR (600 MHz, CDCl3) spectrum of (S)-Methyl-2-((S)-2-hydroxy-2-phenylacetamido)-3-(4-
hydroxyphenyl) propanoate (5.4e) 
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5.2.6.6  (S)-Methyl-2-(S)-2-hydroxy-3-phenylpropanamido)-3-(4-hydroxyphenyl) propanoate 
(5.4f) 
 
The crude product was purified using flash column chromatography (10-70% EtOAc/hexane) to 
yield compound 5.4f as a white powder (150 mg, 85%); [α]D22 +167.5 (c 0.15, CHCl3);  Rf : 0.29 
(10-70% EtOAc/hexane and KMnO4 dip). ESIMS, m/z: 343 [M + H]+. HRESI(+)MS calculated for 
C19H22N1O5 344.1492, found 344.1481.  1H NMR (600 MHz, CDCl3) δH 7.28 - 7.19 (5H, m), 7.04 
(1H, d, 7.7) 6.76 (2H, d, 7.7), 6.65 (1H, d, 7.7), 4.82 (1H, dd, 13.8, 6.4), 4.27 (1H, dd, 13.9, 5.9), 
3.69 (3H, s), 3.10 (1H, dd, 13.8, 6.4), 2.95 (1H, dd, 13.9, 5.9), 2.90 (1H, dd, 13.9, 5.9), 2.78 (1H, 
dd, 13.8, 6.4); 13C NMR (150 MHz, CDCl3) δC 174.5, 173.8, 156.9, 138.2, 131.8, 131.2, 130.1, 
128.5, 117.1, 78.8, 78.6, 78.4, 74.2, 54.2, 54.0, 42.0, 38.7 (Figure 5.30). 
  
  
 
Figure 5.30. 1H NMR (600 MHz, CDCl3) spectrum of (S)-Methyl-2-(S)-2-hydroxy-3-phenylpropanamido)-3-(4-
hydroxyphenyl) propanoate (5.4f). (x) traces of EtOAc 
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5.2.6.7  (S)-Methyl 2-((S)-2-hydroxy-2-phenylacetamido)propanoate (5.4g) 
 
The crude product was purified using flash column chromatography (10-70% EtOAc/hexane) to 
yield compound 5.4g as colourless oil (200 mg, 86%); [α]D22 −161.7 (c 0.25, CHCl3);  Rf : 0.26 (10-
70% EtOAc/hexane in and KMnO4 dip). ESIMS, m/z: 238 [M + H]+. HRESI(+)MS calculated for 
C12H15N1NaO4 260.0893, found 260.0899.  1H NMR (600 MHz, CDCl3) δH 6.92 - 6.55 (5H, m), 
6.54 (1H, br d, 7.1), 4.55 (1H, s), 4.06 (1H, dd, 14.5, 7.1), 3.59 (1H, brd), 3.23, (3H, s), 0.90 (3H, d, 
7.1); 13C NMR (150 MHz, CDCl3) δC 173.3, 172.2, 139.2, 128.8, 128.6, 126.8, 74.1, 52.6, 48.1, 
18.2. (Figure 5.31). 
  
 
 
 
Figure 5.31. 1H NMR (600 MHz, CDCl3) spectrum of (S)-Methyl 2-((S)-2-hydroxy-2-phenylacetamido)propanoate 
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5.2.6.8  (S)-Methyl 2-((S)-2-hydroxy-3-phenylpropanamido)propanoate (5.4h) 
 
The crude product was purified using flash column chromatography (10-70% EtOAc/hexane) to 
yield compound 5.4h as colourless oil (200 mg, 85%); [α]D22 −160.7 (c 0.25, CHCl3);  Rf : 0.16 (10-
70% EtOAc/hexane and KMnO4 dip). ESI MS, m/z: 252 [M + H]+. HRESI(+)MS calculated for 
C13H18NO4 252.1230, found 252.1253.  1H NMR (600 MHz, CDCl3) δH 7.25 – 7.13 (6H, m), 4.47 
(1H, q, 7.3), 4.27 (1H, br), 3.97 (1H, d, 4.6), 3.63 (3H, s), 3.10 (1H, dd, 13.9, 4.6), 2.85 (1H, dd, 
13.9, 4.6), 1.24 (3H, d, 7.3); 13C NMR (150 MHz, CDCl3) δC 174.8, 174.7, 138.6, 131.2, 129.8, 
128.2, 74.1, 54.0, 49.1, 42.1, 19.5. (Figure 5.32).  
 
 
 
 
Figure 5.32. 1H NMR (600 MHz, CDCl3) spectrum of (S)-Methyl 2-((S)-2-hydroxy-3-phenylpropanamido)propanoate 
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5.2.7 General method for the preparation of the morpholine compounds 5.5a – h 
 
The dipeptides 5.4a – h (50 mg) were dissolved in anhydrous toluene (5 mL) in the presence of para 
toluene sulfonic acid (0.10 mg). The reaction was put in the microwave at 300 W, 140 °C for 10 
min. The reaction mixture was dried in vacuo. The crude extract was further purified using HPLC.  
 
5.2.7.1 (3S,6S)-3-benzyl-6-phenylmorpholine-2,5-dione (5.5a) 
 
HRESI(+)MS analysis of 5.5a returned a molecular formula (C17H15N1O3, Δ mmu +0.7). The crude 
product was purified using HPLC (10 − 70% MeCN/H2O) over 30 min, 3 mL/min using Zorbax C8 
to yield compound 5.5a as a colourless oil (3 mg, 75%); [α]D22 −73.9 (c 0.04, CHCl3);  Rf : 0.19 (10-
60% EtOAc/hexane and KMnO4 dip) (Figure 5.33 and Table 5.11). 
 
 
 
Figure 5.33. 1H NMR (600 MHz, CDCl3) spectrum of (3S,6S)-3-benzyl-6-phenylmorpholine-2,5-dione (5.5a) 
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Table 5.11. NMR (600 MHz, CDCl3) data of 5.5a 
Pos. δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1  162.3    
2 5.56, s 55.4 3a,b 1 2′ 
2-NH c     
3 a 3.30, dd (13.3, 2.7) 39.3 2, 3b   
 b 2.62, dd (13.3, 2.7)  2, 3a   
4  129.5    
5 7.35b, m 129.5d 8 7  
6 7.10b, m 128.0d 7, 9 5  
7 7.35b, m 129.5d    
8 7.10b, m 128.0d    
9 7.35b, m 129.5d    
1′  162.2    
2′ 4.48, d (13.3) 79.7  1′ 2 
3′  129.3    
4′ 7.40b, m 129.4d    
5′ 7.40b, m 126.5d    
6′ 7.40b, m 126.5d    
7′ 7.40b, m 126.5d    
8′ 7.40b, m 129.4d    
 *(a) assignments supported by HSQC. (b) Overlapping reasonces. (c) Signals not observed. (d) Interchangeable resonances 
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5.2.7.2 (3S,6S)-3,6-dibenzylmorpholine-2,5-dione (5.5b) 
 
HRESI(+)MS analysis of 5.5b returned a molecular formula (C18H17N1O3, Δmmu +0.4). The crude 
product was purified using HPLC (10 − 70% MeCN/H2O) over 30 min, 3 mL/min using Zorbax C8 
to yield compound 5.5b as white crystals (2.5 mg, 72%); [α]D22 −446.1 (c 0.05, CHCl3);  Rf : 0.16 
(10 − 60% EtOAc/hexane and KMnO4 dip) (Figure 5.34 and Table 5.12). 
 
 
Figure 5.34. 1H NMR (600 MHz, CDCl3) of (3S,6S)-3,6-dibenzylmorpholine-2,5-dione (5.5b) 
 
Table 5.12. NMR (600 MHz, CDCl3) data of 5.5b 
Pos. δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1  167.1    
2 4.11, d (10.5) 54.7 3a,b 1 2′ 
2-NH 5.67, br s   1′  
3a 3.02, dd (13.9, 3.8) 39.0 2 1, 4  
3b 1.58, dd (13.9, 3.8) 39.0 2 1, 4  
4  130.8    
5-9 7.31b, m 128.3d    
1′  166.9    
2′ 5.02, t (5.2) 78.1 3′a,b 1′ 2 
3′ a 3.20, dd (15.8, 5.2) 38.1 2′ 5′/9′  
 b 3.08, dd (15.8, 5.2) 38.1 2′ 5′/9′  
4′  132.1    
5′-9′ 6.93b, d (7.1) 128.8d  3′  
6′-8′ 7.23b, m 127.4d    
 *(a) assignments supported by HSQC. (b) Overlapping reasonaces. (c) Signals not observed. (d) Interchangeable resonances 
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5.2.7.3  (3S,6S)-3-((1H-Indol-3-yl)methyl)-6-phenylmorpholine-2,5-dione (5.5c) 
 
HRESI(+)MS analysis of 5.5c returned a molecular formula (C19H15N2O3, Δ mmu −0.2). The crude 
product was purified using HPLC (10 − 70% MeCN/H2O) over 30 min, 3 mL/min using Zorbax C8 
to yield compound 5.5c as a colourless oil (4 mg, 75%); [α]D22 −4.2 (c 0.14, CHCl3);  Rf : 0.15 (10 − 
60% EtOAc/hexane and KMnO4 dip.) (Figure 5.35 and Table 5.13). This compound was to an 
extent contaminated with the starting material. 
 
Figure 5.35. 1H NMR (600 MHz, CDCl3) spectrum of (3S,6S)-3-((1H-Indol-3-yl)methyl)-6-phenylmorpholine-2,5-
dione (5.5c) 
Table 5.13. NMR (600 MHz, CDCl3) data of 5.5c 
Pos. δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1  167.1    
2 4.41, t (8.7) 54.7 2-NH, 3a,b 1 2′ 
2-NH 3.24, br s  2   
3 a 3.47, dd (14.8, 8.4) 29.4 2 4, 11  
 b 2.87, dd (14.8, 8.4) 29.4 2 4, 11  
4  136.6    
4a  133.9    
5 7.37b, m 128.7c    
6 7.34b, m 128.8c    
7 7.34b, m 129.0c    
8 7.47b, d (8.4) 129.5c    
9  136.1    
10-NH 8.12, br s  11   
11 7.47b, d (8.4) 118.6c    
1′  166.5    
2′ 5.77, s 79.5  1′ 2 
3′  136.6    
4′ 7.20b, m 126.8c    
5′ 7.12b, m 128.7c    
6′ 7.12b, m 124.0c    
7′ 7.12b, m 123.3c    
8′ 7.12b, m 122.9c    
 *(a) assignments supported by HSQC. (b) Overlapping resonances. (c) Interchangeable resonances 
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5.2.7.4  (3S,6S)-3-((1H-Indol-3-yl)methyl)-6-benzylmorpholine-2,5-dione (5.5d) 
 
HRESI(+)MS analysis of 5.5d returned a molecular formula (C20H18N2O3, Δmmu +1.4). The crude 
product was purified using HPLC (10 − 70% MeCN/H2O) over 30 min, 3 mL/min using Zorbax C8 
to yield compound 5.5d as a colourless oil (4 mg, 75%); [α]D22 −75.6 (c 0.05, CHCl3);  Rf : 0.25 
(10-60% EtOAc/hexane and KMnO4 dip) (Figure 5.36 and Table 5.14). 
 
Figure 5.36. 1H NMR (600 MHz, CDCl3) spectrum of (3S,6S)-3-((1H-indol-3-yl)methyl)-6-benzylmorpholine-2,5-
dione (5.5d) 
Table 5.14. NMR (600 MHz, CDCl3) data of 5.5d 
Pos. δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1  167.1    
2 5.07, t (11.1) 53.9 2-NH, 3a,b 1 2′ 
2-NH c     
3 a 4.28, d (11.1) 38.1 2′ 4 3 
 b 3.31, m  2′ 4  
4  135.3   4 
5 7.29b, m 128.5c   5 
6 7.14, t (6.9) 121.2   6 
7 7.23, t (6.9) 123.8   7 
8 7.37b, t (7.3) 124.1c   8 
9  135.5   9 
10-NH 8.12, br    10-NH 
1′  165.9    
2′ 5.59, br 79.9 3′a,b 1′, 4′ 2 
3′ a 3.28, m 29.5 2′ 4′, 5′  
 b 3.15, dd (18.1, 6.0)  2′ 4′, 5′  
4′  131.3    
5′ 7.41, d (8.0) 119.3 6′   
6′ 7.37b, t (7.3) 112.5d 5′   
7′ 7.29b, m 129.6d    
8′ 7.37b, t (7.3) 128.6d    
9′ 7.29b, m 131.5d    
 *(a) assignments supported by HSQC. (b) Overlapping resonances. (c) signals not observed. (d) Interchangeable resonaces 
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5.2.7.5 (3S,6S)-3-(4-Hydroxybenzyl)-6-phenylmorpholine-2,5-dione (5.5e) 
 
HRESI(+)MS analysis of 5.5e returned a molecular formula (C17H15N1O4, Δ mmu +0.3). The crude 
product was purified using HPLC (10 – 70% MeCN/H2O) over 30 min, 3 mL/min using Zorbax C8 
to yield compound 5.5e as a colourless oil (2.5 mg, 69%); [α]D22 +0.5 (c 0.11, CHCl3); Rf : 0.28 (10-
60% EtOAc/hexane and KMnO4 dip) (Figure 5.37 and Table 5.15). 
 
 
Figure 5.37. 1H NMR (600 MHz, CDCl3) spectrum of (3S,6S)-3-(4-Hydroxybenzyl)-6-phenylmorpholine-2,5-dione 
(5.5e) 
Table 5.15. NMR (600 MHz, CDCl3) data of 5.5e 
Pos. δH, mult, (J in Hz) δCa COSY 
1  166.5  
2 4.36, dd (14.1, 10.4) 55.4 3a,b 
2-NH 4.72, br d   
3 a 3.21, dd (14.1, 10.4) 38.8 2 
 b 2.57, dd (14.1, 10.4) c 2 
4  c  
5, 9 6.76, d (8.1) 116.6  
6, 8 6.95, d (8.1) 131.1  
7  c  
1′  165.1  
2′ 5.82, s 79.5  
3′  c  
4′-8′ 7.38 - 7.41b, m 129.9  
 (a) assignments supported by HSQC. (b) Overlapping resonances. (c) Signals not observed 
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5.2.7.6 (3S,6S)-6-Benzyl-3-(4-hydroxybenzyl)morpholine-2,5-dione (5.5f) 
 
HRESI(+)MS analysis of 5.5f returned a molecular formula (C18H17N1O4, Δ mmu +0.5). The crude 
product was purified using HPLC (10 − 70% MeCN/H2O) over 30 min, 3 mL/min using Zorbax C8 
to yield compound 5.5f as a colourless oil (3.1 mg, 65%); [α]D22 −89.4 (c 0.1, CHCl3);  Rf : 0.25 (10 
− 70% EtOAc/hexane and KMnO4 dip) (Figure 5.38 and Table 5.16). 
 
Figure 5.38. 1H NMR (600 MHz, CDCl3) spectrum of (3S,6S)-6-Benzyl-3-(4-hydroxybenzyl)morpholine-2,5-dione 
(5.5f) 
Table 5.16. NMR (600 MHz, CDCl3) data of 5.5f 
Pos. δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1  178.3    
2 4.09, dd (13.3, 10.7) 58.9 3a,b 1 2′ 
2-NH 6.12, br     
3 a 2.99, dd (13.3, 10.7) 42.7  1  
 b 1.53, dd (13.3, 10.7)   1  
4  138.9    
5, 9 6.75, d (8.1) 120.4  6/8, 7  
6, 8 6.84, d (8.1) 134.8  5/9, 7  
7  159.9    
1′  170.0    
2′ 5.11, t (4.3) 82.6 3′a,b 1′, 4′ 2 
3′ a 3.29, dd (15.3, 4.3) 42.3 2′ 1′, 4′  
 b 3.18, dd (15.3, 4.3)  2′ 1′, 4′  
4′  138.8    
5′ 7.33b 132.1c    
7′ 7.30b 134.9c    
9′ 7.31b 132.7c    
6′, 8′ 7.40, t (7.1) 133.1    
 *(a) assignments supported by HSQC. (b) Overlapping resonances. (c) Interchangeable resonances 
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5.2.7.7 (3S,6S)-3-Methyl-6-phenylmorpholine-2,5-dione (5.5g) 
 
HRESI(+)MS analysis of 5.5g returned a molecular formula (C11H11NO3, Δmmu −0.7). The crude 
product was purified using HPLC (20 – 60% MeCN/H2O) over 30 min, 3 mL/min using Zorbax C3 
to yield compound 5g as a colourless oil (2.5 mg, 62%); [α]D22 +28.5 (c 0.05, CHCl3); Rf : 0.19 (10 
− 60% EtOAc/hexane and KMnO4 dip) (Figure 5.39 and Table 5.17). 
 
Figure 5.39. 1H NMR (600 MHz, CDCl3) spectrum of (3S,6S)-3-Methyl-6-phenylmorpholine-2,5-dione (5.5g) 
 
Table 5.17. NMR (600 MHz, CDCl3) data of 5.5g 
Pos. δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1  174.8    
2 4.50, m 49.7 3-Me, 2-NH 1 2′ 
3-Me 1.48, d (6.8) 19.1 2   
2-NH 3.42, br      
1′  174.8    
2′ 5.11, s 75.7  1′, 3′ 2 
3′  140.1    
4′ 7.43b, m 130.3    
5′ 7.42b, m 130.2    
6′ 7.33b, m 128.2    
7′ 7.32b, m 128.2    
8′ 7.32b, m 128.2    
 (a) assignments supported by HSQC and HMBC. (b) Overlapping resonances. 
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5.2.7.8 (3S,6S)-6-Benzyl-3-methylmorpholine-2,5-dione (5.5h) 
 
HRESI(+)MS analysis of 5.5h returned a molecular formula (C12H13NO3, Δ mmu −0.8). The crude 
product was purified using HPLC (20 – 60% MeCN/H2O) over 30 min, 3 mL/min using Zorbax C3 
to yield compound 5.5h as a colourless oil (3.1 mg, 69%); [α]D22 +85.4 (c 0.05, CHCl3);  Rf : 0.17 
(10 – 60% EtOAc/hexane and KMnO4 dip) (Figure 5.40 and Table 5.18). 
 
 
 
Figure 5.40. 1H NMR (600 MHz, CDCl3) spectrum of (3S,6S)-6-Benzyl-3-methylmorpholine-2,5-dione (5.5h) 
 
Table 5.18. NMR (600 MHz, CDCl3) data of 5.5h 
Pos. δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1  174.7    
2 4.45, br  72.8 3-Me  2′ 
3-Me 1.33, br  17.5 2 1  
2-NH 4.22, br      
1′  174.5    
2′ 4.29, br  50.2 3′a,b 1′ 2 
3′ a 3.14, d (13.3) 40.5 2′ 4′  
 b 2.85, dd (13.3, 7.6) 40.5 2′ 4′  
4′  136.9    
5′, 9′ 7.42b, m 129.7c 6′/8′ 4′  
6′, 8′ 7.33b, m 127.0c 5′/9′ 7′  
7′ 7.23b, m 128.6c 6′/8′   
 (a) assignments supported by HSQC. (b) Overlapping resonances. (c) Interchangeable resonances 
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5.2.8 Biological assays 
The natural product shornephine A (5.16) and DKPs (5.17 – 5.19), and synthetic DKMs 5.5a – 5.5f, 
displayed no antibiotic activity against the Gram negative bacteria Escherichia coli (ATCC 11775) 
and Pseudomonas aeruginosa (ATCC 10145), or the Gram positive bacteria Staphylococcus aureus 
(ATCC 9144 and ATCC 25923) and Bacillus subtilis (ATCC 6633 and ATCC 6051), or the fungus 
Candida albicans (ATCC 90028). Likewise, these same compounds failed to exhibit cytotoxicity 
(IC50 >30 µM) against the human colon cancer cell line SW620, or its doxorubicin selected P-gp 
over-expressing daughter cell line SW620 Ad300, or the human cervical carcinoma cell line KB-3-
1, or its vinblastine selected P-gp over-expressing daughter cell line KB-V1.  
 
Given the above it seems likely that if the natural products 5.16 – 5.19 were capable of providing 
CMB-M081F with a survival advantage, it must act via a mechanism other than direct cytotoxicity. 
Alternative strategies could include (a) inhibiting the ability of competing microbes to release 
defensive (antifungal) natural products into the environment, thereby rendering them ineffective, or 
(b) inhibiting the ability of competing microbes to defend against offensive (antibiotic) natural 
products produced by other organisms, thereby accentuating their potency. Both these objectives 
could be achieved by inhibiting ABC transporter mediated efflux system in competing microbes.  
5.2.8.1 Diketomorpholine Chemotype as a P-glycoprotein inhibitor 
Human cancers are often treated by systemic administration of chemotherapeutic agents (anticancer 
drugs), a process that relies on the ability of highly cytotoxic drugs to penetrate and selectively kill 
cancer cells. While this approach has proven to be clinically successful, many cancer cells exhibit 
either intrinsic or acquired resistance to multiple chemotherapeutic agents. A number of factors can 
contribute to multi-drug resistance (MDR), prominent among them being accelerated drug efflux 
by high levels of membrane spanning, adenosine triphosphate binding cassette175 transporter 
proteins. Discovered in 1976 by Ling et al.,202 the function, distribution and substrate specificity of 
the first MDR ABC transporter protein, P-glycoprotein (P-gp, ABCB1), has attracted much 
attention. P-gp plays an important role in many tissues and organs, including the blood brain 
barrier, regulating cellular exposure to xenotoxins and cytotoxins.203 While invaluable to natural 
cellular defences, over expression of P-gp can prove counter productive, leading to the premature 
efflux of many important drugs, including anticancer, antibiotic, antidepressant, antiepileptic, 
analgesic and antiviral agents.204 Inhibitors of P-gp have potential application as anticancer 
therapeutics that operate by modulation of MDR mediated by P-gp and ABC transporters.205,206 In 
1994, Zacherl et al. demonstrated that verapamil (5.20) inhibits P-gp mediated efflux of 
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doxorubicin (5.21), daunorubicin (5.22), vinblastine (5.23) and taxol (5.24) in the monolayer 
cultures of intestinal adenocarcinoma.204 With respect to P-gp inhibition and multidrug resistance, 
Golstein et al. demonstrated in 1999 that glibenclamide (5.25) and another two synthetic 
compounds (5.26 and 5.27) inhibits the P-gp mediated efflux in vinblastine-selected tumour cell 
line (VBL600) selected from a human T-cell line (CEM) derived from an acute leukaemia; and an 
epithelial cell line derived from colchicine-selected rat colonic adenocarcinoma (CC531mdr+).207 
While inhibition of P-gp mediated drug efflux represents an attractive strategy for dealing with 
MDR, no P-gp inhibitors have yet to advance to the clinic. 
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5.2.8.2 Investigation on the interaction of DKMs with P-glycoprotein 
High intrinsic or acquired expression of membrane spanning, adenosine triphosphate binding 
cassette175 transporter proteins, such as P-glycoprotein (P-gp), in cancers represents a major 
impediment to chemotherapy, with accelerated drug efflux leading to multi-drug resistance (MDR). 
Although P-gp inhibitors offer the prospect of reversing the MDR phenotype, no inhibitors have 
advanced to the clinic. Because very few marine natural products have been assessed/reported to 
inhibit P-gp mediated drug efflux associated with multi-drug resistance, we employed a range of 
cytotoxicity and MDR reversal assay, together with flow cytometry to discover the interaction of 
DKMs with P-gp. 
To better explore and understand the chemistry and biology of the CMB-M081F metabolites 5.16 - 
5.19, DKMs 5.5a – 5.5h (as shown above) and DKP cyclo-(L-Trp-L-Phe) (5.28) (Figure 5.41) were 
synthesised, employing standard synthetic methodology208. As predicted, whereas the cyclo-(L-Trp-
L-Phe) (5.28) was stable to methanolysis, the DKMs 5.5a – 5.5h underwent rapid and quantitative 
ring opening after even brief room temperature exposure to MeOH. 
 
Figure 5.41. cyclo-(L-Trp-L-Phe) 
 
5.2.8.3 Effect of DKMs on accumulation of calcein AM: identification of P-gp inhibitors 
 
In order to determine if DKMs inhibit P-gp mediated efflux of increase intracellular accumulation 
of P-gp substrate; flow cytometry was employed to examine their effect on the accumulation of 
acetomethyoxy derivative of calcein (calcein AM). This assay operates on the basis that the non-
fluorescent reagent calcein AM diffuses into the cellular cytoplasm of a doxorubicin selected P-gp 
over-expressing human colon cancer (SW620 Ad300) cell line, where it undergoes hydrolysis by 
esterases to yield the fluorescent dye calcein. Importantly, calcein AM is a P-gp substrate and the 
hydrolysed product calcein is not. In the presence of functioning P-gp calcein AM is (largely) 
effluxed prior to hydrolysis, resulting in low levels of intracellular fluorescence. In the presence of a 
P-gp inhibitor, calcein AM efflux is (partially or completely) blocked and calcein AM undergoes 
hydrolysis to calcein, leading to higher levels of intracellular fluorescence. Intracellular calcein 
fluorescence is quantified by cell flow cytometry to arrive at a fluorescence arbitrary ratio (FAR), 
N
H
HN
NH
O
O
5.28
Chapter 5. Rare marine‐derived fungal alkaloids reveal diketomorpholines as inhibitors of P‐glycoprotein 
259 
 
which measures intracellular calcein (hydrolysed from calcein AM) fluorescence in P-gp 
overexpressing cell line exposed to a P-gp inhibitor, with that from the same cell line not exposed to 
an inhibitor. The larger the FAR value then (in principle) the more effective the P-gp inhibitor. 
Verapamil, a calcium channel blocker, which inhibits P-gp and decreases the export of the 
substrates of P-gp, was employed to be a positive control. In this round of screening (Calcein AM), 
the P-gp inhibitory activities of 20 µM 5.16 – 5.19 and 5.5a – 5.5h, as well as 5.4d, 5.4h and 5.4g, 
were assessed by brief exposure (0.5 h) to SW620 Ad300 cells followed by immediate 
quantification of the intracellular (calcein) fluorescence by cell flow cytometry. After compensating 
for the baseline levels of the intracellular fluorescence and standardizing to the positive control 
verapamil (20 µM), three natural metabolites 5.16, 5.17, 5.19 (fluorescence arbitrary ratio FAR of 
35.5, 30.3 and 27.0 respectively, Table 5.19 and Figure 5.42a, b and c) and three synthetic 
compounds 5.5c, 5.5e and 5.5f (fluorescence arbitrary ratio FAR of 52.9, 41.5 and 40.5 
respectively, Table 5.19 and Figure 5.42d, e and f) showed a strong activity while 5.18 and the rest 
of the synthetic DKMs analogues only achieved very weak accumulation of calcein (~ 2.3-fold) 
(Figure 5.42, Figure 5.43 and Table 5.19). 
5.2.8.4 Effect of DKMs on the sensitivity of chemotherapeutic agents in the drug-selected 
cancer cells 
While a very useful discovery tool, the flow cytometry calcein AM assay is limited in that it 
measures inhibition of the P-gp mediated efflux of calcein AM, not an anticancer chemotherapeutic 
agent, and that the measurement (cell cultivation) window is only half an hour duration. As our 
objective was the discovery of new inhibitors capable of reversing P-gp mediated efflux of 
anticancer drugs and 5.5c, 5.5e, 5.5f, 5.16, 5.17 and 5.18 exerted promising inhibition on P-gp 
mediated efflux of calcein AM, we set out to establish if co-incubation (72-hour incubation) of 
MDR cells with active DKMs and clinical anticancer agents (eg vinblastine, doxorubicin, or 
paclitaxel) would lead to reversal of the MDR phenotype. Prior to undertaking these studies we 
determined (Table 5.19) that all DKMs exhibited very low cytotoxicity towards a P-gp–
overexpressing human colon adenocarcinoma cell line SW620 Ad300 and its parental cell line 
SW620, and another P-gp overexpressing human cervical carcinoma cell line KB-3-1 and the 
corresponding parental cell line KV-1 (IC50 > 30 µM).  
 
Due to the over-expressing of P-gp, SW620 Ad300 exhibits cross-resistance to a range of anti-
cancer agents such as vinblastine, doxorubicin or taxol in the absence of any modulator (14.2-, 
22.5- and 1410-fold, compared to parental SW620). Verapamil was employed to be a positive 
control. When co-administered with verapamil (10 µM), SW620 Ad300 resistance to vinblastine, 
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doxorubicin and paclitaxel was significantly reduced (17.3-, 11.8- and 638-fold respectively). 5.5c, 
which is the most potent inhibitor among DKMs and has similar effect as verapamil on the 
accumulation of calcein AM in flow cytometry, has the comparable ability to decrease the 
resistance of SW620 Ad300 to vinblastine (15.9-fold). However, the capacity of 5c to sensitize 
doxorubicin or paclitaxel to SW620 Ad300 (3.27- or 41.1-fold, respectively) was much inferior to 
that of verapamil. Another two potent P-gp inhibitors, 5.5e and 5.5f exhibited the similar weak 
ability to decrease the resistance of SW620 Ad300 to not only to doxorubicin and paclitaxel, but 
also to vinblastine (Table 5.19) The reduced ability of inhibiting P-gp mediated efflux of anticancer 
drug, which was not proportional to that in flow cytometry assay, was also discovered in another 
three P-gp inhibitors (5.16, 5.17 and 5.19). Overall, the finding confirmed the proposition that these 
six DKMs are partially capable of reversing P-gp mediated MDR associated with the clinical 
anticancer agents vinblastine, doxorubicin and paclitaxel. Although there were many factors such as 
different experiment methods or substrates that could be contributable to the inconsistency between 
the result from MDR reversal assay and calcein AM flow cytometry assay, the possible instability 
of any of these DKMs during long time incubation (72 h) raised our attention and led to further 
investigation. 
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Table 5.19. Diketomorpholine interaction with P-glycoprotein 
#(a) 
IC50 (µM) 
 
SW620b           SW620 Ad300b         KB-3-1c KB-V1c 
MDR reversal GS (d) 
 
Calcein 
FAR(e) 
Vinblastine Doxorubicin Taxol 
 (5.5c) >30 >30 >30 >30 15.9 3.27 41.1 52.9 
 (5.19) >30 >30 >30 >30 4.76 1.40 14.4 27.0 
 (5.5e) >30 >30 >30 >30 4.28 1.44 14.5 41.5 
 (5.5f) >30 >30 >30 >30 3.56 2.15 9.04 40.5 
(5.16) >30 >30 >30 >30 3.85 1.74 9.71 35.5 
(5.17) >30 >30 >30 >30 5.86 4.63 43.1 30.3 
(5.4h) >30 >30 >30 >30 -- -- -- 17.5 
5.28 >30 >30 >30 >30 -- -- -- 9.2 
(5.5b) >30 >30 >30 >30 -- -- -- 1.9 
(5.18) >30 >30 >30 >30 -- -- -- 2.3 
(5.4d) >30 >30 >30 >30 -- -- -- 2.0 
(5.5d) >30 >30 >30 >30 -- -- -- 1.1 
(5.5a) >30 >30 >30 >30 -- -- -- 1.2 
(5.5h) >30 >30 >30 >30 -- -- -- 1.1 
(5.4g) >30 >30 >30 >30 -- -- -- 0.8 
(5.5g) >30 >30 >30 >30 -- -- -- 0.9 
PBS -- -- -- -- -- -- -- 1.0 
Verapamil -- -- -- -- 17.3 11.8 638 72.7 
*(a) Tested compound number. (b) Cytotoxicity (MTT) assay against human colon carcinoma. (c) Cytotoxicity (MTT) assay against human cervix 
carcinoma (d) MDR reversal assay against SW620 Ad300 where GS (gain in sensitivity) = IC50 of anti-cancer drug (vinblastine, doxorubicin or taxol) 
without compound)/IC50 of (vinblastine, doxorubicin or taxol) with compound (10 µM). IC50 of vinblastine without compound was 0.38 µM, IC50 of 
doxorubicin without compound was 3.59 µM, IC50 of taxol without compound was 14.7 µM. (e) Cell flow cytometry analysis of intracellular calcein 
fluorescence: FAR (fluorescence arbitrary ratio) = calcein fluorescence intensity (Geo mean) in the presence of compound at 20 µM/calcein 
fluorescence intensity (Geo mean) in the presence of PBS, expressed as a ratio. Positive control is verapamil at 20 µM which FAR = 72.7. 
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Figure 5.42. Cell flow cytometry of DKMs at 30 µM through inhibiting P-gp in SW20 Ad300. PBS (black) and 
verapamil (red). (a) shornephine (5.16), (b) 15b-β-hydroxy-5-N-acetylardeemin (5.17), (c) 15b-β-methoxy-5-N-
acetylardeemin (5.19), (d) L-tryptophan-L-mandelic diketomorpholine (5.5c), (e) L-tyrosine-L-mandelic 
diketomorpholine (5.5d) and (f) L-tyrosine- L-phenyllactic acid diketomorpholine (5.5f) 
 
Figure 5.43. Cell flow cytometry of the other synthetic DKMs at 30 µM through inhibiting P-gp in SW20 Ad300. PBS 
(black) and verapamil (red) 
Calcein fluorescent intensity
C
el
l c
ou
nt
101 102 103 104 105
0
50
100
150
200
Calcein fluorescent intensity
C
el
l c
ou
nt
101 102 103 104 105
0
50
100
150
200
Calcein fluorescent intensity
C
el
l c
ou
nt
101 102 103 104 105
0
50
100
150
200
Calcein fluorescent intensity
C
el
l c
ou
nt
101 102 103 104 105
0
50
100
150
200
Calcein fluorescent intensity
C
el
l c
ou
nt
101 102 103 104 105
0
50
100
150
200
Calcein fluorescent intensity
C
el
l c
ou
nt
101 102 103 104 105
0
50
100
150
200
(a) (b)
(c) (d)
(e) (f )
PBS
verapamil
5.5b
5.18
5.4d
5.5d
5.5a
5.5h
5.4g
5.5g
Calcein fluorescent intensity
C
el
l c
ou
nt
101 102 103 104 105
0
50
100
150
200
Chapter 5. Rare marine‐derived fungal alkaloids reveal diketomorpholines as inhibitors of P‐glycoprotein 
263 
 
As we have demonstrated that natural product shornephine A (5.16), is prone to solvolysis, we 
speculated that the inability of DKM to reverse MDR was due to premature solvolysis/degradation 
during the assay. 
5.2.9 The stability of the diketomorpholines 
The six compounds, (3S,6S)-3-((1H-indol-3-yl)methyl)-6-phenylmorpholine-2,5-dione (5.5c), 
((3S,6S)-3-(4-hydroxybenzyl)-6-phenylmorpholine-2,5-dione (5.5e), ((3S,6S)-6-benzyl-3-(4-
hydroxybenzyl) morpholine-2,5-dione (5.5f), shornephine A (5.16) and 15b-β-hydroxy-5-N-
acetylardeemin (5.17) and 15b-β-methoxy-5-N-acetylardeemin (5.19) that exhibited P-gp inhibition 
were tested in the media to determine their stability. Each compound (10 µM) was added to the 
wells of the microtiter plate containing RPMI medium and the plate was incubated at 37 °C, 5% 
CO2 for 3 days. After the incubation period the wells were extracted with EtOAc (100 µL) and the 
organic layer was dried in vacuo. The crude extract was dissolved in MeCN (50 µL) and analysed 
using the HPLC-DAD-MS. The three synthetic compounds (5.5c, 5.5e and 5.5f) undergo hydrolysis 
to give the acid form of the diketomorpholine, which explains the fluctuation in the MDR reversal 
results. On the other hand the two natural products, shornephine A (5.16) and 15b-β-hydroxy-5-N-
acetylardeemin (5.17) were largely stable in the media (Figure 5.44 and Figure 5.45). 
 
Figure 5.44. HPLC-DAD chromatograms of the tested compounds in MeOH (a) (3S,6S)-3-((1H-Indol-3-yl)methyl)-6-
phenylmorpholine-2,5-dione (5.5c), (b) (3S,6S)-3-(4-hydroxybenzyl)-6-phenylmorpholine-2,5-dione (5.5e), (c) (3S,6S)-
6-benzyl-3-(4-hydroxybenzyl)morpholine-2,5-dione (5.5f), (d) shornephine A (5.16) and (e) 15b-β-hydroxy-5-N-
acetylardeemin (5.17) 
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The SAR data analysis proved that P-gp inhibition strongly correlates with the presence of 
diketomorpholine scaffold and the activity was lost with the diketopiperazine analogue. Also of a 
note, synthetic diketomorpholine analogues were non cytotoxic to parenteral cells and 5.5c was the 
most active compound and non-cytotoxic in the same time followed by 5.5e and 5.5f as well as the 
two natural products, shornephine A (5.16) and 15b-β-hydroxy-5-N-acetylardeemin (5.17). 
 
 
Figure 5.45. Diagram showed the hydrolysis of the synthetic products to give the acid form that has the following 
molecular weights (5.6c) m/z 321[M+H], (5.6e) m/z  316[M+H] and (5.6f) m/z  312[M+H] 
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5.3 Conclusion 
Chemical analysis of fungal isolate (CMB-M081F), isolated from a sediment sample collected near 
Shornecliff, Queensland, Australia, yielded the new DKM shornephine A (5.16), its methanolysis 
artifact seco-shornephine A (5.15), and two known and one new DKP, 15b-β-hydroxyl-5-N-
acetyladreemin (5.17), 5-N-acetyladreemin (5.18) and 15b-β-methoxy-5-N-acetyladreemin (5.19) 
respectively. Two of these metabolites 5.16 and 5.19 were inhibitors of P-glycoprotein, a critical 
determinant in many multidrug-resistant cancers, responsible for efflux of many clinically 
important chemotherapeutics. These results directed us to the synthesis of additional 
diketomorpholines (DKMs), to probe the structure activity relationship (SAR) associated with the 
P-gp inhibitors pharmacophore. To achieve these objectives, we applied a new method for the 
synthesis of DKMs using microwave approach, to prepare 14 DKMs analogues, three of which 
exhibited P-gp inhibitory properties comparable with that of the positive control verapamil. 
Although the DKMs inhibitors were effective in the P-gp inhibitor assay; they were less effective in 
a reversal multidrug resistance assay (MDR). The failure to reverse multidrug resistance was 
attributed to poor in vivo stability, and prompted consideration to enhance stability, including a 
closer analysis of the natural product shornephine A (5.16) 
5.4 Future work 
Curiously, and contrary to our experience with shornephine A (5.16), prior published DKM natural 
products were not prone to methanolysis. Given the ease with which shornephine A (5.16) 
undergoes solvolysis, and being keen to explain how prior published DKM natural products 
avoided this fate, we noted that the latter fall into two distinct structural groups – inclusive of a 
common structural feature that differentiates them from shornephine A (5.16). The first, consisting 
of DKMs incorporating a tryptophan moiety (eg. mollenines, javanicunines and PF1233 A and B), 
all possess a fused A – D heterocyclic scaffold in common with the ardeemins 5.17 – 5.19. 
Importantly, this heterocyclic scaffold features fully substituted DKM amide nitrogen. The second, 
comprising all other known DKM natural products, features an N-methylated DKM amide. Based 
on these observations we speculate that N-substitution (heterocycle or methylation) stabilizes the 
DKM lactone towards solvolysis, greatly simplifying isolation, characterization and structure 
elucidation, compared to 5.16 which features a free 2-NH. This hypothesis may also explain the 
historic biodiscovery bias, which has failed to document more unstable (reactive) DKMs such as 
5.16.  
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5.5 Experimental section 
5.5.1 Isolation and identification of strain CMB-M081F  
The marine derived fungus strain CMB-M81F was isolated from a marine sediment sample 
collected from Shonecliff, Australia. The fresh sediment sample was transferred to the laboratory in 
a sealed 50 mL Falcon tube at room temperature (24 h), where it is stored in the dark at −30 °C for 
one week. Approximately, 1 g of the thawed terrestrial sample was suspended in 8 mL sterile 0.9% 
saline solution and then subjected to heat-shock at 60 °C for 30 min after which 100 µL was serially 
diluted to 10-1, 10-2 and 10-3 and transferred into 1000 µL sterile saline solution by means of sterile 
micro titre pipette. Furthermore, 50 µL from each diluted portion was dispersed across agar plates 
comprising into agar medium in artificial ocean sea salt (3.3%, 25 mL), starch (1%), yeast extract 
(0.4%), peptone (0.2%) and agar (2%) and 0.0005% rifampicin); incubated at 27 °C for 4 weeks. 
The resulting agar plate was incubated at 27 °C for three weeks. Pure strains of individual colonies 
were obtained by standard microbiological techniques, and were grown to dense colonies on a 
single agar plate.  
 
5.5.2 Chemical profiling:  
A single colony of CMB-M81F was sub-sampled into agar medium in artificial ocean sea salt 
(3.3%, 25 mL), starch (1%), yeast extract (0.4%), peptone (0.2%) and agar (2%) and incubated at 
27 °C for 4 weeks. The agar plate was soaked into EtOAC (100 mL), and shake on the rotary shaker 
at 100 rpm overnight. The organic phase was concentrated in vacuo to yield an extract that was 
subsequently analysed by HPLC-DAD-ESI(±)MS and NMR. 
5.5.3  Analytical cultivation and chemical analysis 
A single colony of strain CMB-M81F was used to inoculate a seed culture composed of M1 agar 
medium in seawater including artificial ocean seawater (3.3%, 100 mL), starch (1%), yeast extract 
(0.4%), peptone (0.2%) and agar (2%), which was cultivated for a period of 4 weeks. After the 
initial cultivation timeline the whole agar plates were extracted with EtOAc, which was then dried 
in vacuo yielding a crude extract of 50.1 mg that was subsequently analysed by HPLC-DAD-MS 
with conditions set as follows (Zorbax C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min, gradient from 
90 – 10 % H2O/MeCN (isocratic 0.05% formic acid) over 15 min. Peaks with the following 
retention times The crude extract was then resuspended in MeCN and analysed by HPLC-DAD-
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MS. Peaks with the following retention times tR = 11.1, 12.2, 12.4 and 12.8 min exhibited the 
following m/z [M+H]+ 435 (5.16), 485 (5.17), 469 (5.18) and 499 (5.19) 
5.5.4 Large-scale cultivation and extraction of strain CMB-M81F:  
A single colony of CMB-M81F was sub-sampled onto ten seawater M1 agar plates (300 mL of 
Ocean Nature seawater, 1% starch, 0.4% yeast extract and 0.2% peptone) with dimensions 150 × 
120mm and incubated at 27 °C for 4 weeks. The resulting agar plates were sliced up and soaked in 
EtOAc (500 mL) for 24 h and the organic phase concentrated in vacuo to yield an extract (60.2 mg). 
The extract was sequentially triturated with 8 mL each of hexane and CH2Cl2 to afford, after 
concentration in vacuo, 2 and 60 mg fractions, respectively. The DCM fraction was analysed by 
HPLC-DAD-ESI(±)MS and NMR which was found to be rich in the secondary metabolites, was 
subsequently subjected to semi-preparative reversed-phase HPLC (Zorbax C8 250 × 9.4 mm, 5 µm 
column, 3 mLmin-1 gradient elution from 10% H2O/MeCN to 100% MeCN over 30 min with a hold 
at 100% MeCN for 5 min), to yield shornephine A (5.16) (tR = 23.9 min, 2 mg, 1.8%), 15b-β-
hydroxy-5-N-acetylardeemin (5.17) (tR = 25.5 min, 1.5 mg, 2.2%), 5-N-acetylardeemin (5.18) (tR = 
27.0 min, 1.9 mg, 2.5%) and 15b-β-methoxy-5-N-acetylardeemin (5.19) (tR = 28.0 min, 1.5 mg, 
3.0%). [Note - % yields are determined on a mass-to-mass basis against the weight of EtOAc crude 
extract]. 
5.5.5 Cell Lines and Cell Culture 
Two cancer cell pairs were employed. One pair includes parental cell line SW620 (American Type 
Culture Collection, Manassasm VA, CCL-227) and subline SW620 Ad300. SW620 is a human 
colon cell line that was originated from a lymph node metastasis in the patient with primary 
adenocarcinoma of the colon. The multi-drug resistant (MDR) cell line, SW620 Ad300, which 
over-expresses Permeable-glycoprotein (P-gp), was selected from SW620 by growth in the 
presence of increasing concentrations of doxorubicin. SW620 and SW620 Ad300 were grown in 
RPMI medium 1640 as adherent mono-layer in flasks supplemented with 10% foetal bovine serum, 
0.1 mM non-essential amino acids (NEAA), 2 mM L-glutamine, 100 unit/mL penicillin and 100 
µg/mL streptomycin in a humidified incubator containing of 5% CO2 at 37 °C. After SW620 Ad300 
exhibited stable phenotype of P-gp, the cells were maintained in 300 ng/mL doxorubicin. Another 
cancer cell pair includes KB-3-1 and KB-V1. These human cervix cancer cells were grown in 
DMEM as adherent mono-layer in flasks supplemented with 10% foetal bovine serum, 0.1 mM 
NEAA, 2 mM L-glutamine and 100 unit/mL penicillin and 100 µg/mL streptomycin in a humidified 
incubator containing of 5% CO2 at 37 °C. KB-3-1 is the parental cancer cell line and sensitive to 
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anticancer agent, the sub line, KB-V1 was vinblastine selected from KB-3-1 and is maintained in 
0.1 µg/mL vinblastine. These two cell lines were kindly provided from Dr. M.M. Gottesman in NIH 
(Bethesda, MD). The cytototxic drug was routinely removed from the sub-line cells 2 weeks in 
advance before any assay was performed. 
 
5.5.6 MDR Reversal (Vinblastine, doxorubicin and taxol) Assay 
Reversal of resistance of SW620 Ad300 cells to anti-cancer drug (doxorubicin, vinblastine or taxol) 
assay was performed as described for the standard cytotoxicity assay (above). Instead of measuring 
the cytotoxicity of dioxomorpholines, this assay was applied to measure the cytotoxicity of 
vinblastine, doxorubicin and taxol against SW620 Ad300, in the presence or absence of natural and 
synthetic compounds at concentrations that were non-cytotoxic to SW620 Ad300. The amount of 
medium containing cells per well was adjusted to 160 µL at the beginning and the addition 20 µL of 
either PBS, compound (designated concentration) or verapamil (10 µM) was dispensed to the well 1 
h before addition of an anticancer drug (doxorubicin, vinblastine or taxol) dilution series. 
Gain in sensitivity (GS) was calculated according to GS=IC50 of vinblastine, doxorubicin and taxol 
without dioxomorplines/IC50 of vinblastine or doxorubicin or taxol with dioxomorpholines (test 
concentration in µM is shown in parentheses). The IC50 value without dioxomorpholines for 
vinblastine was 0.38 µM, doxorubicin 3.59 µM and taxol 14.7 µM, verapamil 2.5 µM was used as a 
positive control (GS = 6.23) 
5.5.7 Flow Cytometry (Calcein AM assay) 
The flow cytometry assay was based on that described previously.209 Briefly, cells that overexpress 
P-gp (SW620 Ad300) were harvested with trypsin, resuspended in completed medium to give a 
final concentration of 50 × 104 cells/mL. Cells were then washed twice with cold PBS and pre-
incubated with tested compound (20 µM) or verapamil (20 µM) for 30 min at 37 °C under 5% CO2. 
Subsequently, cells were incubated with 2.5 µM calcein AM (calcein acetoxymethyl ester) for 1 h 
before measurement followed by washing twice with cold PBS. Samples were then analysed on a 
BD FACSCantoTM II flow cytometer (Becton Dickinson, San Jose, CA). Calcein fluorescence was 
detected with a 488 nm argon laser and a 530 nm band pass filter. The data were analysed by using 
FCSexpress 3 (De Novo Software, Los Angeles, CA). 10000 events were collected from each 
sample. Inhibition was evaluated using the following equation: FAR (fluorescence arbitrary ratio) = 
calcein fluorescence intensity (Geo mean) in the presence of tested compounds at 20 µM /calcein 
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fluorescence intensity (Geo mean) in the presence of PBS. Verapamil at 20 µM was used as 
positive control (FAR=43.1) Reversal MTT assay 
 
5.5.8 Mosher ester derivatives of shornephine A (5.17) 
Mosher ester derivatives were prepared according to protocol published by Hoye et al.199 
Shornephine A (50 µg) (5.16) was transferred into 2 mL glass vial with a Teflon-coated magnetic 
stir bar, to this was added 200 µL 6 M HCl and the reaction were heated overnight at 110 °C. The 
solution was dried down under N2 and Teflon magnetic stir bar was added to the vial. Briefly, to a 
stirred solution of (S)-(+)-phenyllactic acid (1 eq in 150 µL dry DCM) in a 2 mL vial, (R)-(+)-
MTPA-OH (3 eq in 150 µL dry DCM) or (S)-(−)-MTPA-OH (3 eq in 150 µL dry DCM) was added, 
followed by DCC (3 eq in 100 µL dry DCM) and DMAP (3 eq in 100 µL dry DCM). The reaction 
was left overnight at room temperature, after which it was filtered and dried under N2 at 40 °C. The 
product was dissolved in MeOH and was analysed with HPLC-ESIMS, 60 – 15% H2O/MeCN, 
0.05% HCO2H using Zorbax Eclipse XDB C8 column. Amount of compounds derivatized: (+)-
shornephine A (5.16), 0.1 mg (0.23 µmol) 
seco-Shornephine A (5.14): pale yellow oil; [α]23D −73 (c 0.08, CHCl3); UV (MeOH) λmax (log ε) 
218 (4.36), 248 (3.89), 306 (3.96); NMR (600 MHz, CDCl3) see Table 5.1; HRESI(+)MS m/z 
489.2015 [M+Na]+ (calcd for C26H30N2O6Na 489.2009). 
 
Shornephine A (5.16): pale yellow oil; [α]22D +21.8 (c 0.05, CHCl3); NMR (600 MHz, CDCl3) see 
Table 5.2; HRESI(+)MS m/z 457.1731 [M+Na]+ (calcd for 457.1734)  
  
15b-β-hydroxyl-5-N-acetyladreemin (5.17): pale yellow oil; [α]22D −18.7  (c 0.09, CHCl3); NMR 
(600 MHz, CDCl3) see Table 5.4; HRESI(+)MS m/z 507.2016 [M+Na]+ (calcd for C28H28N4O4Na 
507.2003)  
 
5-N-acetyladreemin (5.18): pale yellow oil; [α]23D −20.7 (c 0.05, CHCl3); NMR (600 MHz, CDCl3) 
see Table 5.6; HRESI(+)MS m/z 491.2050 [M+Na]+ (calcd for C28H28N4O3Na 491.2054) 
 
15b-β-methoxy-5-N-acetyladreemin (5.19): pale yellow oil; [α]23D −16.0 (c 0.07, MeOH); UV 
(CDCl3) λmax (log ε) 208 (4.03), 223 (4.06), 262 (3.59), 274 (3.57), 303 (3.17); NMR (600 MHz, 
CDCl3) see Table 5.7; HRESI(+)MS m/z 521.2163 [M+Na]+ (calcd for 521.2159) 
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 (3S,6S)-3-benzyl-6-phenylmorpholine-2,5-dione (5.5a): white oil (3 mg, 75%); [α]D22 −73.9 (c 
0.04, CHCl3); HRMS calculated for C17H16N1O3 282.1125, found 282.1117.  1H NMR (600 MHz, 
CDCl3) see Figure 5.33 and Table 5.11.  
 
(3S,6S)-3,6-dibenzylmorpholine-2,5-dione (5.5b): white crystals (2.5 mg, 72%); [α]D22 − 446.1 (c 
0.05, CHCl3); HRMS calculated for C18H18N1O3 296.1281, found 296.1277. 1H NMR (600 MHz, 
CDCl3) and 13C NMR (150 MHz, CDCl3) see Figure 5.34 and Table 5.12.  
 
(3S,6S)-3-((1H-Indol-3-yl)methyl)-6-phenylmorpholine-2,5-dione (5.5c): colourless oil (4 mg, 
75%); [α]D22 −4.2 (c 0.14, CHCl3); HRMS calculated for C19H16N2NaO3 343.1053, found 343.1055. 
1H NMR (600 MHz, CDCl3) and 13C NMR (150 MHz, CDCl3) see Figure 5.35 and Table 5.13.  
 
(3S,6S)-3-((1H-Indol-3-yl)methyl)-6-benzylmorpholine-2,5-dione (5.5d): colourless oil (4 mg, 
75%); [α]D22 −75.6 (c 0.05, CHCl3); HRMS calculated for C20H19N2O3 335.1390, found 335.1376. 
1H NMR (600 MHz, CDCl3) and 13C NMR (150 MHz, CDCl3) see Figure 5.36 and Table 5.14.  
 
(3S,6S)-3-(4-Hydroxybenzyl)-6-phenylmorpholine-2,5-dione (5.5e): colourless oil (2.5 mg, 69%); 
[α]D22 +2.1 (c 0.11, CHCl3); HRMS calculated for C17H16N1O4 298.1074, found 298.1072.1H NMR 
(600 MHz, CDCl3) and 13C NMR (150 MHz, CDCl3) see Figure 5.37 and Table 5.15.  
 
(3S,6S)-6-Benzyl-3-(4-hydroxybenzyl)morpholine-2,5-dione (5.5f): colourless oil (3.1 mg, 65%); 
[α]D22 −89.4 (c 0.1, CHCl3); HRMS calculated for C18H17N1NaO4 334.1050, found 334.1044.1H 
NMR (600 MHz, CDCl3) and 13C NMR (150 MHz, CDCl3) see Figure 5.38 and Table 5.16.  
 
(3S,6S)-3-Methyl-6-phenylmorpholine-2,5-dione (5.5g): colourless oil (2.5 mg, 62%); [α]D22 +28.5 
(c 0.05, CHCl3); HRMS calculated for C11H12NO3 206.0812, found 206.0819. 1H NMR (600 MHz, 
CDCl3) and 13C NMR (150 MHz, CDCl3) see Figure 5.39 and Table 5.17.  
 
(3S,6S)-6-Benzyl-3-methylmorpholine-2,5-dione (5.5h): colourless oil (3.1 mg, 69%); [α]D22 +85.4 
(c 0.05, CHCl3); HRMS calculated for C12H14NO3 220.0968, found 220.0976. 1H NMR (600 MHz, 
CDCl3) and 13C NMR (150 MHz, CDCl3) see Figure 5.40 and Table 5.18.  
 
cyclo-(L-Trp-L-Phe) (5.28): This compound was synthesised as reported208 in quantitative yield to 
afford pale yellow oil; (45 mg, 98.6%), [α]23D −20.7 (c 0.05, CHCl3); ESIMS, m/z 334 [M+H] 1H 
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NMR (600 MHz, DMSO-d6); 10.87 (1H, s), 7.88 (1H, br s), 7.68 (1H, br s), 7.47 (1H, d, 7.8), 7.30 
(1H, d, 8.1), 7.15 (2H, m), 7.05 (1H, t, 7.5), 6.97 (1H, d, 7.5), 6.95 (1H, d, 7.5), 6.69 (1H, d, 7.5), 
3.95 (1H, br s), 3.83 (1H, br s), 2.79 (1H, dd, 14.4, 4.2), 2.51 (1H, d, 6.1), 2.45 (1H, dd, 13.4, 4.7), 
1.84 (1H, dd, 13.4,7.1); 13C (150 MHz, DMSO d6); 168.8, 168.1, 138.5, 138.0, 131.7, 130.1, 130.0, 
129.5, 128.3, 126.4, 122.8, 120.7, 120.4, 113.3, 110.8, 81.2, 80.9, 80.7, 57.6, 57.2, 31.7 
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6 Chapter 6: Desotamides: New cyclic hexapeptides with 
inhibitory activity against Mycobacterium bovis 
6.1 Introduction 
As part of an ongoing collaboration between the Capon research group and the Australian microbial 
biodiscovery company, Microbial Screening Technologies (MST), we routinely receive novel 
microbial metabolites for spectroscopic analysis, structure elucidation and biological evaluation. 
This chapter describes one study, involving known and new examples of a rare class of cyclic 
hexapeptides, the desotamides. 
6.2 History 
To date the scientific literature records only one natural product characterized as a desotamide, first 
reported in 1997, by Miao et al.210 from a soil isolate of Streptomyces sp. Structure elucidation was 
achieved by NMR analysis including HSQC, COSY, HMBC, TOCSY and NOE, and the absolute 
configuration assigned by Marfey analysis and total synthesis of the two stereoisomers. Desotamide 
has not been reported to exhibit any biological activity.  
6.3 Desotamides from MST 
Studies into the secondary metabolites produced by Streptomyces sp. (MST-1150688), led MST 
researchers to isolate a selection of peptidic metabolites collectively identified as “desotamides”, as 
outlined in Scheme 6.1. 
6.4 Desotamides 
The desotamides metabolites were provided from Microbial Screening technology (MST) for 
structure elucidation and biological assay. Primary screening on HPLC-DAD-MS showed the 
presence of interesting metabolites as shown in Figure 6.1 and Figure 6.2. 
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Scheme 6.1. Isolation scheme for desotamide (6.01 −  6.06). (a) rotatory evaporation. (b) diluted to 2L with H2O and 
purified using C18. (c) 500 mg sub-sample LH-20, 2.5 × 100 cm CH2Cl2/MeOH ratio 50:50. (d) mega preparative 
HPLC, LUNA 65% MeOH, 0.01% TFA, 60 mL/min. (e) preparative HPLC, LUNA 55% MeOH, 0.01% TFA, 10 
mL/min. (f) preparative HPLC, LUNA 50% MeOH, 0.01% TFA, 10 mL/min.  
 
 
Figure 6.1. Desotamides (6.01 - 6.06). *Marfey’s analysis of 6.02 and 6.06 is still under progress 
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Figure 6.2. HPLC-DAD (254 nm) chromatogram and UV-vis spectrum from analytical gradient H2O/MeCN with 
0.05% HCO2H using Zorbax C8 of the crude extract from Streptomyces sp. (MST-1150688) of the desotamides (6.01 – 
6.06) 
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6.4.1 Desotamide (6.01) 
 
HRESI(+)MS analysis of desotamide (6.01) returned an adduct ion [M+Na]+ corresponding to a 
molecular formula (C35H52N8O7, Δmmu −0.6). Careful analysis of the 1D and 2D NMR (DMSO-d6) 
data for 6.01 suggested a cyclohexapeptide structure inclusive of a Trp residue. A C3 Marfey’s 
analysis of 6.01 supported this hypothesis, and detected the presence of L-Trp, L-Leu, D-Leu, L-
allo-Ile, L-Asn and Gly (Figure 6.3 and Figure 6.4), while a literature search suggested that 6.01 
[α]22D – 29.3 (c 0.05, MeOH) was the known microbial cyclohexapeptide desotamide [α]23D –6.7 (c 
0.35, MeOH) (Table 6.2). Desotamide was first reported in 1997 by Miao et al.210 from a soil 
isolate of Streptomyces sp. To confirm the structure assignment, Miao et al. synthesized five closely 
related co-metabolites. To confirm our reisolation of desotamide (6.01), a full spectroscopic and 
Marfey’s analysis was carried out (Figure 6.3, Figure 6.4, Figure 6.5, Table 6.1 and Table 6.2). 
6.4.1.1 C3 Marfey’s analysis 
A Marfey’s analysis was performed according to the method described by Miao et al.173,210, 6.01 
was subjected to acid hydrolysis using 6 M HCl/5% thioglycolic acid, derivatized with D-FDAA, 
and subjected to HPLC analysis, using our modified C3 Marfey’s analysis which enable the 
differentiation between D-Ile from D-allo-Ile, or L-Ile from L-allo-Ile45 to determine the absolute 
stereochemistry of the amino acids. Absolute configuration of 6.01 was determined by comparing 
the retention times of standard amino acids with the hydrolysate of 6.01. The amino acids of 6.02 
was confirmed to be L-Trp, L-Leu, D-Leu, L-allo-isoLeu, L-Asn and Gly consistent with the 
reported desotamide (Figure 6.3 and Figure 6.4). 
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Figure 6.3. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) L-allo-Ile + L-FDAA 
(tR = 35.0 min), (b) L-allo-Ile + D-FDAA (tR = 43.5 min), (c) L-Asn + D-FDAA (tR = 13.7 min), (d) D-Asn + D-FDAA 
(tR = 13.1 min), (e) D-Leu + D-FDAA (tR = 36.3 min), (f) L-Leu + D-FDAA (tR = 44.3 min), (g) L-Trp + L-FDAA (tR = 
34.1 min) and (h) L-Trp + D-FDAA (tR = 38.2 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 
mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
 
 
Figure 6.4. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of desotamide (6.01). Identity of amino 
acids was confirmed by retention time and molecular weight. (a) Co-injection of hydrolysate of 6.01 (200 µg) with L-
Asn, Gly, D -Leu, L-Leu, L-Trp, L-allo-Ile + D-FDAA, (b) Gly + D-FDAA, (c) L-Asn + D-FDAA, (d) L-allo-Ile + D-
FDAA, (e) D-Leu + D-FDAA, (f) L-Leu + D-FDAA and (g) L-Trp + D-FDAA. HPLC conditions, Zorbax, SB-C3 
column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic 
acid) over 55 min. 
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Figure 6.5.1H NMR (600 MHz, DMSO-d6) and UV-vis (inset) spectra of desotamide (6.01) 
 
Figure 6.6. 1H NMR (600 MHz, DMSO-d6) spectrum of desotamide (6.01) 
 
Figure 6.7. 1H NMR (600 MHz, DMSO-d6) spectrum of desotamide (6.01) 
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Figure 6.8. 1H NMR (600 MHz, DMSO-d6) spectrum of desotamide (6.01) 
 
The C3 Marfey’s analysis unambiguously confirmed the presence of all the amino acid residues and 
allowed the assignment of allo-Ile without the need for the synthesis of different stereoisomers – as 
shown in the literature. To assist positioning these residues in 6.01 it was necessary to assign key 
1D NMR resonances, and identify key 2D NMR correlations linking adjacent amino acids. 
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and C-10a, and (iii) 6-NH and H-8 to C-6a 
 
Figure 6.9. Key 2D NMR correlations of desotamide (6.01) 
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L-Leu and D-Leu: As NMR cannot distinguish between amino acid enantiomers, the following 
assignments of NMR resonances to Leu residues merely characterizes the two independent Leu 
residues, but does not go to the issue of assignment of their absolute configuration. 
Leucine #2:  COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to 
H2-3 to H-4 to H3-5/H3-6, while HMBC correlations linked H-2 to C-1 
Leucine #3: As above COSY NMR (DMSO-d6) correlation established the sequence 1-NH to H-2 
to H2-3 to H-4 to H3-5/H3-6, while HMBC correlation linked 2-NH to C-1 (Figure 6.10). 
 
Figure 6.10. Key 2D NMR correlations of desotamide (6.01) 
L-allo-isoleucine #4: Our C3 Marfey’s analysis has the ability to distinguish between allo-isoleucine 
and isoleucine. Analysis of the COSY NMR (DMSO-d6) data of 6.01 identified the sequence 2-NH 
to H-2 to H-3/H3-3 to H2-4 to H3-5, while HMBC correlations linked H-2 to C-1 (Figure 6.11). 
 
Figure 6.11. Key 2D NMR correlations of desotamide (6.01) 
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Figure 6.12. Key 2D NMR correlations of desotamide (6.01) 
 
Gly #6: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2, while 
HMBC correlations linked 2-NH and H2-2 to C-1 (Figure 6.13). 
 
Figure 6.13. Key 2D NMR correlations of desotamide (6.01) 
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Figure 6.14. ROESY (600 MHz, DMSO-d6) spectrum showing key correlations of desotamide (6.01)  
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Table 6.1. NMR (600 MHz, DMSO-d6) data of desotamide (6.01) 
# Pos. δH, mult (J in Hz)a δCa COSY 1H-13C HMBC ROESY 
Trp. 1  171.4    
 2 4.35b 54.3 3   
 3 a 3.12, dd (14.6, 10.1) 27.0 3b, 2, 2-NH 1, 2, 4, 5, 10a  
  b 2.96, dd (14.6, 10.1)  3a, 2, 2-NH 2, 4, 5, 10a  
 4  109.4    
 5 7.11, d (1.8) 123.1 6 3, 4, 6a, 10a  2, 3 
 6a  135.6    
 7 7.31, d (8.0) 110.9 8 10, 10a 6-NH 
 8 7.04, t (8.0) 120.5 7, 9 6a, 10  
 9 6.96, t (8.0) 117.9 8, 10 7, 10a  
 10 7.49, d (8.0) 118.2 9 4, 8, 6a, 10a 2, 3 
 10a  126.7    
 2-NH 8.29, d (8.6)  2 1, 2, 3 2-Gly,2- Leu2 
 6-NH 10.81, s  5 4, 5, 6a, 10a 5 
Gly. 1  168.9    
 2 a 3.88, dd (15.8, 6.5) 42.9 2b, NH 1 2-NH-Trp 
  b 3.26, dd (15.8, 6.5)  2a, NH 1 2-NH-Trp 
 NH 7.94, t (5.9)  2a,b  2-Asn,NHAsn 
Asn. 1  171.2    
 2 4.55, m 48.9 2-NH, 3 1, 3 NH-Gly 
 3 a 2.80, dd (16.2, 5.5) 36.5 2, 3b 1, 2  
  b 2.61, dd (16.2, 5.5) 36.5 2, 3a 1, 2  
 4  172.0 3a,b   
 2-NH 7.57, d (8.6)  2 1, 3 2-allo-Ile, NH-Ile 
 NH2 7.62, br s   4 3 
allo-Ile 1  170.9    
 2 4.18, dd (7.8, 4.3) 56.1 2-NH 1, 3, 6-Me 3-Me,NH-Asn 
 3 2.01, m 34.9 2, 6-Me, 4 6-Me, 5-Me  
 4 1.17-1.23, m 25.3 3, 5 2  
 5-Me 0.81b 11.1 4   
 6-Me 0.81b 14.3 3   
 2-NH 8.24, d (8.6)  2 1  
Leu#1 1  173.1    
 2 4.35b, m 51.3 3, NH 1, 4 NH-Leu#1 
 3 1.53, m 39.3 2, 5/6-Me   
 4 1.53b 23.7 3, 5/6-Me 2, 5/6-Me  
 5-Me 0.82b 22.1c  3, 4  
 6-Me 0.82b 22.1c  3, 4  
 2-NH 8.29, d (8.6)   1, 2, 3 NH-Leu#2 
Leu#2 1  172.2    
 2 4.35b, m 50.3 3, NH 1  
 3 1.43, m 41.3 4 2  
 4 1.53b, m 24.1 3, 5-Me 2  
 5-Me 0.88b, d (6.9) 22.1c 6-Me 3  
 6-Me 0.87b, d (6.9) 22.1c 5-Me 3  
 2-NH 7.62b   2 4, NH-Leu#1 
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonances 
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Table 6.2. NMR (DMSO-d6) data comparison of experimental and literature210 data of desotamide (6.01)  
# Pos.  δH, mult (J in Hz)a (experimental) δc δH, mult (J in Hz)b (literature) δc 
Trp. 1  171.4  170.9 
 2 4.35b 54.3 4.36, m 55.4 
 3 a 3.12, dd (14.6, 10.1) 27.0 3.31, dd (14.7, 5.0) 27.3 
  b 2.96, dd (14.6, 10.1)  2.96, dd (14.7, 10.1)  
 4  109.4  110.0 
 5 7.11, br s 123.1 7.11, s 123.5 
 6a  135.6  136.1 
 7 7.31, d (8.0) 110.9 7.30, d (8.1) 111.3 
 8 7.04, t (8.0) 120.5 7.04, t (7.7) 120.9 
 9 6.96, t (8.0) 117.9 6.96, t (7.7) 118.3 
 10 7.49, d (8.0) 118.2 7.49, d (7.7) 118.1 
 10a  126.7  127.1 
 2-NH 8.29, d (8.6)  8.24, d (8.3)  
 6-NH 10.81, s  10.76, s  
Gly. 1  168.9  169.1 
 2 a 3.88, dd (15.8, 6.5) 42.9 3.89, dd (15.8, 6.2) 43.3 
  b 3.26, dd (15.8, 5.4)  3.28, dd (15.8, 4.6)  
 NH 7.94, t (5.9)  7.90, t (5.5)  
Asn. 1  171.2  171.0 
 2 4.55, m 48.9 4.56, m 49.4 
 3 a 2.80, dd (16.2, 5.5) 36.5 2.79, dd (16.0, 5.5) 36.9 
  b 2.61, dd (16.2, 5.5)  2.61, dd (16.0, 5.5)  
 4  172.0  172.0 
 2-NH 7.57, d (8.6)  7.59, d (8.4)  
 NH2 7.62, br s  7.56, s  
Ile 1  170.9  171.0 
 2 4.18, dd (7.8, 4.3) 56.1 4.16, dd (7.5, 4.5) 56.6 
 3 2.01, m 34.9 2.00, h (7.0) 35.2 
 4 1.17-1.23, m 25.3 1.2, m 25.6 
 5-Me 0.81c 11.1 0.82, t (7.0) 11.5 
 6-Me 0.81c 14.3 0.81, t (7.0) 14.5 
 NH 8.24, d (8.6)  8.19, d (7.5)  
Leu#1 1  173.1  173.3 
 2 4.35, m 51.3 4.34, m 51.8 
 3 1.53, m 39.3 1.45, m 39.3 
 4 1.53c 23.7 1.54, m 24.2 
 5-Me 0.88c 22.1d 0.82, d (7.0) 22.1d 
 6-Me 0.88c 22.1d 0.82, d (7.0) 22.4d 
 2-NH 7.09, br s  8.20, d (6.0)  
Leu#2 1  172.2  171.9 
 2 4.35, m 50.3 4.35, m 50.8 
 3 1.53, m 41.3 1.45, m 41.4 
 4 1.53 24.1 1.54, m 24.4 
 5-Me 0.88c 22.1d 0.88, d (7.0) 22.5d 
 6-Me 0.87c 22.1d 0.88, d (7.0) 22.6d 
 2-NH 7.64, d (7.6)  7.65, d (7.8)  
*(a) 1H NMR at 600 MHz. (b)1H NMR at 400 MHz. (c) Overlapping resonances. (d) Interchangeable resonances 
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6.4.2 Desotamide B (6.02)  
 
HRESI(+)MS analysis of 6.02 returned an adduct ion [M+Na]+ consistent with a molecular formula 
C35H52N8O7 (Δmmu +1.6). Examination of the NMR (DMSO-d6) data (Table 6.3 and Figure 6.16) 
revealed a close similarity to desotamide (6.01). As the ESI(+)MS data (m/z, 695, M+H+) was the 
same as 6.01, the structure elucidation was performed using 2D NMR spectra including HSQC, 
COSY and HMBC correlation outline in Figure 6.16 and Table 6.3. NMR data showed the presence 
of Trp, Leu, Ile × 2, Asn and Gly residues. A C3 Marfey’s analysis is still under investigation to 
prove the presence of the amino acid residues and determine the absolute stereochemistry of the 
amino acids. The sequence of amino acid residues is tentatively proposed as indicated, but will be 
addressed towards the end of this chapter. 
 
Figure 6.15. Key 2D NMR correlations for amino acids residues of desotamide B (6.02) 
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Figure 6.16. 1H NMR (600 MHz, DMSO-d6) of desotamide B (6.02) 
 
Figure 6.17. 1H NMR (600 MHz, DMSO-d6) comparison of desotamide (6.01) (blue) and desotamide B (6.02) (red) 
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Table 6.3. NMR (600 MHz, DMSO-d6) data of desotamide B (6.02) 
# Pos. δH, mult (J in Hz)a δCa COSY 1H-13C HMBC ROESY 
Trp. 1  170.6    
 2 4.36b, m 54.9 2-NH, 3a,b    
 3 a 3.11, dd (15.1, 10.3) 27.2 2, 3b 1, 4, 5  
  b 2.96, dd (15.1, 10.3)  2, 3a 1, 4, 5  
 4  109.9    
 5 7.12, brd 123.1 6 3, 4, 6a  
 6a  135.8   6a 
 7 7.31, d (7.8) 111.1 8 10, 10a   
 8 7.04, t (7.8) 120.7 7, 9 6a, 10  
 9 6.96, t (7.8) 118.2 8, 10 4, 10a  
 10 7.49, d (7.8) 117.9 9 4, 6a, 8, 10a 3a,b 
 10a  126.7    
 2-NH 8.34, d (5.9)  2 1-Gly 2-Leu 
 6-NH 10.81, s  5 4, 5, 6a, 10a  5, 7 
Gly. 1  168.3    
 2 a 3.83, dd (16.1, 5.3) 43.0 2b, 2-NH 1, 1-Asn  
  b 3.27, dd (16.1, 5.3)  2a, 2-NH 1, 1-Asn  
 2-NH 7.96, t (5.3)  2a,b 1, 1-Asn 2-NH-Asn 
Asn. 1  171.4    
 2 4.55, m 48.8 3a,b, 2-NH 1-Ile, 3 NH-Gly 
 3 a 2.83, dd (16.5, 5.4) 36.6 2, 3b 2, 4  
  b 2.62, dd (16.5, 5.4)  2, 3a 2, 4  
 4  171.1    
 2-NH 7.61b  2 1  
 NH2 7.60, s   4  
Ile#1 1  171.5    
 2 4.17, dd (8.5, 6.1) 57.7 2-NH, 3 1, 3, 5/6 2-NH-Trp 
 3 1.77b, m 34.6 2, 6-Me, 4   
 4 1.10b, m 24.8  5/6-Me  
 5-Me 0.82b 11.6c    
 6-Me 0.87b 14.5c    
 2-NH 8.21, d (7.8)  2   
Ile#2 1  172.3    
 2 4.23, dd (7.8, 4.1) 55.9 2-NH, 3 1, 5/6  
 3 2.02, m 34.9 2, 6   
 4 a 1.08 - 1.21, m 25.4 5 5/6  
 5-Me 0.82b 10.8c    
 6-Me 0.83b 14.4c    
 2-NH 8.23b  2  2-NH-Ile2 
Leu 1  171.8    
 2 4.43, dd (14.0, 7.2) 50.6 3a,b, 2-NH 1, 3  
 3 a 1.54b, m 41.5 2, 4 5/6-Me  
  b 1.43b, m  2, 4 1, 5/6-Me  
 4 1.43b, m 24.1 3a,b, 4/5-Me 1, 5/6-Me  
 5-Me 0.90, d 22.1 4   
 6-Me 0.83, d 22.4 4   
 2-NH 8.26, d (8.5)  2  2-NH-Trp 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonances 
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Table 6.4. NMR (600 MHz, DMSO-d6) comparison of desotamide (6.01) and desotamide B (6.02) 
Desotamide B (6.02) Desotamide  (6.01) 
# Pos. δH, mult (J in Hz)a δCa # Pos. δH, mult (J in Hz)a δCa 
Trp. 1  170.6 Trp. 1  170.9 
 2 4.36b, m 54.9  2 4.36, m 55.4 
 3 a 3.11, dd (14.9, 4.7) 27.2  3 3.31, dd (14.7, 5.0) 27.3 
  b 2.96, dd (15.1, 10.3)    2.96, dd (14.7, 10.1)  
 4  109.9  4  110.0 
 5 7.12, brd 123.1  5 7.11, s 123.5 
 6a  135.8  6a  136.1 
 7 7.31, d (7.8) 111.1  7 7.30, d (8.1) 111.3 
 8 7.04, t (7.8) 120.7  8 7.04, t (7.7) 120.9 
 9 6.96, t (7.8) 118.2  9 6.96, t (7.7) 118.3 
 10 7.49, d (7.8) 117.9  10 7.49, d (7.7) 118.1 
 10a  126.7  10a  127.1 
 2-NH 8.34, d (5.9)   2-NH 8.24, d (8.3)  
 6-NH 10.81, s   6-NH 10.76, s  
Gly. 1  168.3 Gly. 1  169.1 
 2 a 3.83, dd (16.1, 5.3) 43.0  2 a 3.88, dd (15.8, 6.5) 43.3 
  b 3.27, dd (16.1, 5.3)    b 3.26, dd (15.8, 6.5)  
 2-NH 7.96, t (5.3)   NH 7.94, t (5.9)  
Asn. 1  171.4 Asn. 1  171.2 
 2 4.55, m 48.8  2 4.55, m 48.9 
 3 a 2.83, dd (16.5, 5.4) 36.6  3 a 2.80, dd (16.2, 5.5) 36.5 
  b 2.62, dd (16.5, 5.4)    b 2.61, dd (16.2, 5.5)  
 4  171.1  4  172.0 
 2-NH 7.61b   2-NH 7.57, d (8.6)  
 NH2 7.60, s   NH2 7.62, br s  
Ile#1 1  171.5 allo-Ile 1  170.9 
 2 4.17, dd (8.5, 6.1) 57.7  2 4.18, dd (7.8, 4.3) 56.1 
 3 1.77b, m 34.6  3 2.01, m 34.9 
 4 1.10b, m 24.8  4 1.17-1.23, m 25.3 
 5-Me 0.82b 11.6c  5-Me 0.81b 11.1 
 6-Me 0.87b 14.5c  6-Me 0.81b 14.3 
 2-NH 8.21, d (7.8)   NH 8.24, d (8.6)  
Leu 1  171.8 Leu1 1  173.1 
 2 4.43, dd (14.0, 7.2) 50.6  2 4.35b, m 51.3 
 3 a 1.54b, m 41.5  3 1.53, m 39.3 
  b 1.43b, m      
 4 1.43b, m 24.1  4 1.53b 23.7 
 5-Me 0.90, d 22.1  5-Me 0.82b 22.1c 
 6-Me 0.83, d 22.4  6-Me 0.82b 22.1c 
 2-NH 8.26, d (8.5)   2-NH 8.29, d (8.6)  
Ile#2 1  172.3 Leu2 1  172.2 
 2 4.23, dd (7.8, 4.1) 55.9  2 4.35b, m 50.3 
 3 2.02, m 34.9  3 1.43, m 41.3 
 4 a 1.08 - 1.21, m 25.4  4 1.53b, m 24.1 
 5-Me 0.82b 10.8c  5-Me 0.88b, d (6.9) 22.1c 
 6-Me 0.83b 14.4c  6-Me 0.87b, d (6.9) 22.1c 
 2-NH 8.23b   2-NH 7.64, d (7.6)  
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonances 
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6.4.3 Desotamide C (6.03)  
 
HRESI(+)MS analysis of desotamide C (6.03) returned an adduct ion [M+Na]+ consistent with the 
molecular formula (C35H50N8O7, Δmmu +0.9), UV-vis shows that 6.03 and 6.01 have Trp-residue. 
NMR (600 MHz, DMSO-d6) comparison for both 6.01 and 6.03 suggested replacement of a Leu 
residue in 6.01 with a Val residue in 6.03 (Figure 6.27). A C3 Marfey’s analysis of 6.03 confirmed 
this hypothesis, revealing the presence of L-Trp, L-Leu, D-Val, L-allo-Ile, L-Asn and Gly residues 
(Figure 6.18 and Figure 6.19). While the NMR comparisons between 6.01 and 6.03 (Figure 6.27) 
suggested a very similar amino acid sequence, to be confident of this required assignment of the 1D 
NMR data, and careful consideration of the 2D NMR correlations. Following the strategy outlined 
previously for desotamide (6.01), it was possible to fully assign the data to the respective amino 
acids, as indicated in Table 6.5, and as illustrated in Figure 6.26. Of particular importance, 
diagnostic HMBC correlations permitted unambiguous assignment of the 13C NMR resonances for 
all amide carbonyls. The sequence of amino acid residues is tentatively proposed as indicated, but 
will be addressed towards the end of this chapter. 
 
6.4.3.1 C3 Marfey’s analysis of 6.03 
Employing the C3 Marfey’s method as previously described, 6.03 was subjected to acid hydrolysis 
using 6 M HCl/5% thioglycolic acid, derivatized with D-FDAA, and subjected to HPLC analysis to 
determine the absolute stereochemistry of the amino acids. Absolute configuration of 6.03 amino 
acid residues was determined by comparing the retention times of derivatized standard amino acids 
with the derivatized hydrolysate of 6.03. The amino acid residues of 6.03 were confirmed to be L-
Trp, L-Leu, L-Leu, L-allo-Ile, D-Val, L-Asn and Gly (Figure 6.18 and Figure 6.19). 
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Figure 6.18. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of standard amino acids reacting with 
D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) L-allo-Ile + L-FDAA (tR = 
35.0 min), (b) L-allo-Ile + D-FDAA (tR = 43.5 min), (c) D-Val + D-FDAA (tR = 38.4 min), (d) L-Val + D-FDAA (tR = 
38.0 min), (e) L-Trp + L-FDAA (tR = 34.1 min) and (f) L-Trp + D-FDAA (tR = 38.2 min) (g) D-Asn + D-FDAA (tR = 
13.2 min), (h) L-Asn + D-FDAA (tR = 13.7 min), (i) D-Leu + D-FDAA (tR = 36.3 min) and (j) L-Leu + D-FDAA (tR = 
44.4 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µM), 1 mL/min, gradient of 15 – 60% 
MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
 
Figure 6.19. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of desotamide C (6.03). Identity of 
amino acids was confirmed by retention time and molecular weight. (a) Co-injection of hydrolysate of 6.03 (200 µg) 
with L-Asn, Gly, D-Val, L-Leu, L-Trp, L-allo-Ile + D-FDAA, (b) L-Asn + D-FDAA, (c) L-allo-Ile + D-FDAA, (d) D-Val 
+ D-FDAA, (e) L-Leu + D-FDAA, (f) L-Trp + D-FDAA and (g) Gly + D-FDAA. HPLC conditions, Zorbax, SB-C3 
column (150 × 4.6 mm, 5 µM), 1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% 
formic acid) over 55 min. 
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Six amino acids fragments: 
L-Tryptophan #1: Analysis of the COSY NMR (DMSO-d6) data of 6.03 revealed diagnostic 
correlation sequences consistent with the structure fragment (i) H-7 to H-8 to H-9 to H-10, (ii) 2-
NH to H-2 to H2-3, and (iii) H-5 to 6-NH.  Key HMBC correlation permitting assignment of the 
quaternary carbons included (i) 2-NH to C-1, (ii) H2-3 to C-5 and C-4, and (iii) 6-NH and H-8 to C-
6a (Figure 6.20). 
 
Figure 6.20. HMBC (600 MHz, DMSO d6) spectrum with key correlations (Trp) of desotamide C (6.03) 
 
L-Leucine #2:  COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to 
H2-3 to H-4 to H3-5/H3-6, while HMBC correlations linked H-2 and 2-NH to C-1 (Figure 6.21). 
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Figure 6.21. HMBC (600 MHz, DMSO d6) spectrum with key correlations of desotamide C (6.03) 
 
D-Valine #3:  COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to 
H-3 to H3-4/H3-5, while HMBC correlations linked 2-NH to C-1 (Figure 6.22). 
 
Figure 6.22. HMBC (600 MHz, DMSO-d6) spectrum with key correlations (Val) of desotamide C (6.03) 
 
L-allo-isoleucine #4: Analysis of the COSY NMR (DMSO-d6) data for 6.03 identified the sequence 
2-NH to H-2 to H-3/H3-3 to H2-4 to H3-5, while HMBC correlations linked 2-NH to C-1 (Figure 
6.23). 
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Figure 6.23. HMBC (600 MHz, DMSO d6) spectrum with key correlations (Ile) of desotamide C (6.03) 
 
 
L-Asn #5: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to H2-
3, while HMBC correlations linked H2-3 to C-4 and 2-NH and H-2 to C-1 (Figure 6.24). 
 
Figure 6.24. HMBC (600 MHz, DMSO-d6) spectrum with key correlations (Asn) of desotamide C (6.03) 
 
Gly #6: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2, while 
HMBC correlations linked H2-2 to C-1 (Figure 6.25). 
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Figure 6.25. HMBC (600 MHz, DMSO-d6) spectrum with key correlations (Gly) of desotamide C (6.03) 
 
 
 
 
 
Figure 6.26. 1H NMR (600 MHz, DMSO-d6) and UV-vis (inset) spectra of desotamide C (6.03) 
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Figure 6.27. 1H NMR (600 MHz, DMSO-d6) comparison of desotamide (6.01) (blue) and desotamide C (6.03) (red) 
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Table 6.5. NMR (600 MHz, DMSO-d6) data of desotamide C (6.03) 
# Pos. δH, mult (J in Hz)a δCa COSY 1H-13C HMBC ROESY 
Trp. 1  169.9    
 2 4.38, m 55.8 2-NH, 3a/b   
 3 a 3.11, dd (14.4, 9.0) 28.3 2 5, 4  
  b 2.96, dd (14.4, 9.0)  2 2, 4  
 4  110.8    
 5 7.10, d (1.8) 124.3 6-NH 4, 10a, 6a  
 6a  136.6    
 7 7.30, d (8.0) 112.2 8 10a , 10  
 8 7.04, t (7.7) 121.9 9, 7 10, 6a  
 9 6.96, t (7.7) 119.2 10, 8 10, 10a, 6a, 7  
 10 7.49, d (7.7) 119.1 9 8, 6a 2-Trp 
 10a  127.7    
 2-NH 8.26, d (9.0)  2 1 2a-Gly 
 6-NH 10.81, s  5 5, 4, 10a, 6a  
Gly. 1  168.9    
 2 a 3.83, dd (16.3, 5.3) 44.1 2b 1  
  b 3.25, dd (16.3, 5.3)  2a 1  
 2-NH 7.97, t (5.3)  2a/b  2-Asn 
Asn. 1  172.0    
 2 4.57, m 49.7 2-NH, 3a/b 1 2-NH Gly 
 2-NH 7.62b  2 1  
 3 a 2.84, dd (16.3, 5.5) 37.8 2 4  
  b 2.61, dd (16.3, 5.5)  2 1  
 4  172.8    
 NH2 7.60b     
allo-Ile 1  173.3    
 2 4.24, dd (8.1, 3.6) 56.8 2-NH, 3 1, 3  
 3 1.88, m 29.3 4   
 4 1.18-1.22, m 26.4 3 2 6-Me 
 5-Me 0.91b 14.9 6-Me   
 6-Me 0.91b 12.9    
 2-NH 8.21, d (8.1)  2 1 3-Ile 
Leu1 1  171.6    
 2 4.42, m 51.5 2-NH, 3a/b 1  
 3 a 1.54, m 42.5 3b, 4 5/6-Me  
  b 1.43b, m 42.5 3a, 4 5/6-Me  
 4 1.44b 24.9 3a/b, 5-Me   
 5-Me 0.91b 22.9c 4   
 6-Me 0.86b 23.5c    
 2-NH 7.62b  2 1  
Val 1  172.3    
 2 4.04, dd (9.0, 6.7) 56.8 2-NH, 3 1, 3, 4/5-Me  
 3 1.87, m 29.3 2, 4/5-Me   
 4-Me 0.82b 19.8    
 5-Me 0.89b 19.8    
 2-NH 8.42, d (6.7)  2 1 NH-Ile 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonances 
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Table 6.6. NMR (600 MHz, DMSO-d6) comparison of both desotamide (6.01) and desotamide C (6.03) 
Desotamide C (6.03) Desotamide (6.01) 
# Pos. δH, mult (J in Hz)a δCa # Pos. δH, mult (J in Hz)a δCa 
Trp. 1  169.9 Trp. 1  170.9 
 2 4.38, m 55.8  2 4.36, m 55.4 
 3 a 3.11, dd (14.4, 4.9) 28.3  3 3.31, dd (14.7, 10.1) 27.3 
  b 2.96, dd (14.4, 4.9)    2.96, dd (14.7, 10.1)  
 4  110.8  4  110.0 
 5 7.10, d (1.8) 124.3  5 7.11, s 123.5 
 6a  136.6  6a  136.1 
 7 7.30, d (8.0) 112.2  7 7.30, d (8.1) 111.3 
 8 7.04, t (7.7) 121.9  8 7.04, t (7.7) 120.9 
 9 6.96, t (7.7) 119.2  9 6.96, t (7.7) 118.3 
 10 7.49, d (7.7) 119.1  10 7.49, d (7.7) 118.1 
 10a  127.7  10a  127.1 
 2-NH 8.26, d (9.0)   2-NH 8.24, d (8.3)  
 6-NH 10.81, s   6-NH 10.76, s  
Gly. 1  168.9 Gly. 1  168.9 
 2 a 3.83, dd (16.3, 5.3) 44.1  2 a 3.88, dd (15.8, 6.5) 42.9 
  b 3.25, dd (16.3, 5.3)    b 3.26, dd (15.8, 6.5)  
 2-NH 7.97, t (5.3)   NH 7.94, t (5.9)  
Asn. 1  171.8 Asn. 1  171.2 
 2 4.57, m 49.7  2 4.55, m 48.9 
 2-NH 7.62b   2-NH 7.57, d (8.6)  
 3 a 2.84, dd (16.3, 5.5) 37.8  3 a 2.80, dd (16.2, 5.5) 36.5 
  b 2.61, dd (16.3, 5.5)    b 2.61, dd (16.2, 5.5)  
 4  172.0  4  172.0 
 NH2 7.62b   NH2 7.62, br s  
allo-Ile 1  173.3 allo-Ile 1  170.9 
 2 4.24, dd (8.1, 3.6) 56.8  2 4.18, dd (7.8, 4.3) 56.1 
 3 2.03, m 36.0  3 2.01, m 34.9 
 4 1.18-1.22, m 26.4  4 1.17-1.23, m 25.3 
 5-Me 0.81b 14.9c  5-Me 0.81b 11.1 
 6-Me 0.82b 12.9c  6-Me 0.81b 14.3 
 2-NH 8.21, d (7.9)   NH 8.24, d (8.6)  
Leu1 1  171.6 Leu1 1  173.1 
 2 4.42, m 51.5  2 4.35b, m 51.3 
 3 a 1.54, m 42.5  3 1.53, m 39.3 
  b 1.43b, m 42.5     
 4 1.44b 24.9  4 1.53b 23.7 
 5-Me 0.91b 22.9c  5-Me 0.82b 22.1c 
 6-Me 0.86b 23.5c  6-Me 0.82b 22.1c 
 2-NH 7.62b   NH 8.29, d (8.6)  
Val 1  173.3 Leu2 1  172.2 
 2 4.04, dd (9.0, 6.7) 56.8  2 4.35b, m 50.3 
 3 1.83, m 29.3  3 1.43, m 41.3 
 4-Me 0.82b 19.8c  4 1.53b, m 24.1 
 5-Me 0.81b 19.8c  5-Me 0.88b, d (6.9) 22.1c 
 2-NH 8.42, d (6.7)   6-Me 0.87b, d (6.9) 22.1c 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonances 
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6.4.4 Desotamide D (6.04)  
 
HRESI(+)MS analysis of desotamide D (6.04) returned an adduct ion [M+Na]+ consistent with the 
molecular formula (C34H50N8O7, Δmmu +1.2) suggestive of an analogue of desotamide (6.01) as 
both of them has similar UV. A C3 Marfey’s analysis of 6.04 confirmed this hypothesis, revealing 
the presence of L-Trp, L-Leu, L-Val, L-Asn and Gly residue. While the NMR comparisons between 
6.01 and 6.03 to 6.04 suggested a very similar amino acid sequence. To be confident of this 
assignment required careful consideration of the 2D NMR correlations. Following the strategy 
outlined previously for desotamide (6.01), it was possible to fully assign the data to the respective 
amino acids, as indicated in Table 6.7 and as illustrated in Figure 6.30. Of particular importance, 
diagnostic HMBC correlations permitted unambiguous assignment of the 13C NMR resonances for 
all amide carbonyls. The sequence of amino acid residues is tentatively proposed as indicated, but 
will be addressed towards the end of this chapter. 
 
6.4.4.1 C3 Marfey’s analysis of 6.04 
Employing a C3 Marfey’s analysis as previously described, 6.04 was subjected to acid hydrolysis 
using 6 M HCl/5% thioglycolic acid, derivatized with D-FDAA, and subjected to HPLC analysis to 
determine the absolute stereochemistry of the amino acids. Absolute configuration of 6.04 was 
determined by comparing the retention times of derivatized standard amino acids with the 
derivatized hydrolysate of 6.04. The amino acids of 6.04 were confirmed to be L-Trp, L-Leu, L-Val, 
L-Asn and Gly as shown in Figure 6.28 and Figure 6.29. 
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Figure 6.28. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of derivatized standard amino acids 
reacting with D-FDAA. Identity of derivatized amino acids was confirmed by retention time and molecular weight. (a) 
L-Trp + D-FDAA (tR = 38.2 min), (b) L-Trp + L-FDAA (tR = 34.1 min), (c) L-Val + D-FDAA (tR = 38.0 min), (d) D-Val 
+ D-FDAA (tR = 38.4 min), (e) D-Asn + D-FDAA (tR = 13.2 min), (f) L-Asn + D-FDAA (tR = 13.7 min), (g) D-Leu + D 
-FDAA (tR = 36.3 min) and (h) L-Leu + D-FDAA (tR = 44.4 min). HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 
mm, 5 µM), 1 mL/min, gradient of 15 - 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min 
 
 
Figure 6.29. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of desotamide D (6.04). Identity of 
amino acids was confirmed by retention time and molecular weight. (a) Co-injection of hydrolysate of 6.04 (300 µg) 
with L-Asn, Gly, L-Val, L-Leu, L-Trp, Gly + D-FDAA, (b) L-Asn + D-FDAA, (c) L-Val + D-FDAA, (d) L-Leu + D-
FDAA, (e) L-Trp + D-FDAA and (f) Gly + D-FDAA. HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µM), 
1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min. 
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Six amino acids fragments: 
L-Trptophan #1: Analysis of the COSY NMR (DMSO-d6) data of 6.04 revealed diagnostic 
correlation sequences consistent with the structure fragment (i) H-7 to H-8 to H-9 to H-10, (ii) 2-
NH to H-2 to H2-3, and (iii) 6-NH to H-5.  Key HMBC correlation permitting assignment of the 
quaternary carbons included (i) 2-NH to C-1 and (ii) 6-NH and H-8 to C-6a (Figure 6.30). 
 
Figure 6.30. HMBC (600 MHz, DMSO-d6) spectrum with key correlations (Trp) of desotamide D (6.04) 
 
Leucine #2 and 3:  From the Marfey’s analysis, the presence of only L-Leu residue was proved, 
which contributes to both Leu #2 and #3 and can explain the overlapping of the signals due to 
similarity of two Leu residues as L configuration. COSY NMR (DMSO-d6) correlations readily 
identified the sequence 2-NH to H-2 to H2-3 to H-4 to H3-5/H3-6, while HMBC correlations linked 
2-NH to C-1 (Figure 6.31). 
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Figure 6.31. HMBC (600 MHz, DMSO-d6) spectrum with key correlations of desotamide D (6.04) 
 
 
L-Val #4: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to H-3 
to H3-4 and H3-5, while HMBC correlations linked H-2 to C-1 to C-4 and C-5.  
 
Figure 6.32. HMBC (600 MHz, DMSO-d6) spectrum with key correlations (Val) of desotamide D (6.04) 
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L-Asn #5: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to H2-
3, while HMBC correlations linked H2-3, NH2 to C-4, H-2 to C-1, 2-NH. 
 
Figure 6.33. HMBC (600 MHz, DMSO-d6) spectrum with key correlations (Asn) of desotamide D (6.04) 
 
Gly #6: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H2-2, while 
HMBC correlations linked H2-2 and NH to C-1 and linking H2-2. 
 
Figure 6.34. HMBC (600 MHz, DMSO-d6) spectrum with key correlations (Gly) of desotamide D (6.04) 
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Figure 6.35. 1H NMR (600 MHz, DMSO-d6) of desotamide D (6.04) 
 
Figure 6.36. 1H NMR (600 MHz, DMSO-d6) comparison of desotamide (6.01) (blue) and desotamide D (6.04) (red) 
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Table 6.7. NMR (600 MHz, DMSO-d6) data of desotamide D (6.04) 
# Pos. δH, mult (J in Hz)a δCa COSY 1H-13C HMBC ROESY 
Trp. 1  170.9    
 2 4.34b, m 56.1 2-NH, 3a,b   
 3 a 3.12, dd (14.3, 5.6) 28.1 2, 3b 4, 5, 10a  
  b 2.96, dd (14.3, 5.6)  2, 3a 4, 5, 10a  
 4  110.7    
 5 7.12, brd 124.1 6-NH 4, 6a, 10a   
 6a  136.5    
 7 7.31, d (7.8) 112.0 8 10a, 10  
 8 7.05, brd 121.6 7, 9 6a, 10  
 9 6.96, t (7.8) 119.1 8, 10 7, 10a   
 10 7.49, d (7.8) 118.8 9 4, 8, 6a  
 10a  128.2    
 2-NH 8.30, d (8.1)  2 1  
 6-NH 10.82, s  5 5, 4, 6a, 10a  
Gly. 1  169.9    
 2 a 3.87, d (16.1, 5.6) 43.8 2b 1  
  b 3.34c  2a 1  
 2-NH 7.88, t (5.6)    2-Asn 
Asn. 1  171.3    
 2 4.48, brd 50.2 2-NH, 3,b 1 2-NH-Gly 
 3 a 2.77, d (15.8) 37.3 2, 3b 4  
  b 2.63, d (15.8)  2, 3a   
 4  171.8    
 2-NH 7.64b   1-Val 2-Val 
 NH2 7.57, s   4  
Leu1 1  173.7d    
 2 4.34b, m 51.9d 2-NH, 3a,b 5/6-Me  
 3 a 1.54b 42.1 2, 3b, 4 1  
  b 1.45b  2, 3a, 4 1  
 4 1.45b 24.8d 3a,b, 5/6-Me   
 5-Me 0.83b 17.8d 4 2  
 6-Me 0.84b 20.1d 4   
 2-NH 8.20, d (5.8)  2   
Leu2 1  173.7d    
 2 4.34b, m 51.9d 2-NH, 3a,b 1, 5/6-Me NH-Val 
 3 a 1.53b 40.5 2, 3b, 4   
  b 1.44b  2, 3a, 4   
 4 1.45b 25.2d 3a,b, 5/6-Me   
 5-Me 0.83b 17.8d 4 2  
 6-Me 0.84b 20.1d 4   
 2-NH 7.64b  2   
Val 1  170.8    
 2 3.99, t (7.8) 59.6 2-NH, 3 1, 3, 4/5-Me NH-Asn 
 3 2.18, q (6.3) 29.4 2, 4/5-Me   
 4-Me 0.88 17.4 3   
 5-Me 0.85 22.1 3   
 2-NH 8.25, d (7.8)  2  2-Leu 
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Obscured by solvent. (d) Interchangeable resonances 
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Table 6.8. NMR (600 MHz, DMSO-d6) comparison of desotamide (6.01) and desotamide D (6.04) 
Desotamide D (6.04) Desotamide (6.01) 
# Pos. δH, mult (J in Hz)a δCa # Pos. δH, mult (J in Hz)a δCa 
Trp. 1  170.9 Trp. 1  170.9 
 2 4.34b, m 56.1  2 4.36, m 55.4 
 3 a 3.12, dd (14.3, 5.6) 28.1  3 3.31, dd (14.7, 5.0) 27.3 
  b 2.96, dd (14.3, 5.6)    2.96, dd (14.7, 10.1)  
 4  110.7  4  110.0 
 5 7.12, brd 124.1  5 7.11, s 123.5 
 6a  136.5  6a  136.1 
 7 7.31, d (7.8) 112.0  7 7.30, d (8.1) 111.3 
 8 7.05, brd 121.6  8 7.04, t (7.7) 120.9 
 9 6.96, t (7.8) 119.1  9 6.96, t (7.7) 118.3 
 10 7.49, d (7.8) 118.8  10 7.49, d (7.7) 118.1 
 10a  128.2  10a  127.1 
 2-NH 8.30, d (8.1)   2-NH 8.24, d (8.3)  
 6-NH 10.82, s   6-NH 10.76, s  
Gly. 1  169.9 Gly. 1  168.9 
 2 a 3.87, dd (16.1, 6.1) 43.8  2 a 3.88, dd (15.8, 6.5) 42.9 
  b 3.34c    b 3.26, dd (15.8, 6.5)  
 2-NH 7.88, t (6.1)   NH 7.94, t (6.5)  
Asn. 1  171.3 Asn. 1  171.2 
 2 4.48, brd 50.2  2 4.55, m 48.9 
 3 a 2.77, d (15.4) 37.3  3 a 2.80, dd (16.2, 5.5) 36.5 
  b 2.63, d (15.4)    b 2.61, dd (16.2, 5.5)  
 4  171.8  4  172.0 
 2-NH 7.64b   2-NH 7.57, d (5.5) 2-NH 
 NH2 7.57, s   NH2 7.62, br s  
Val 1  170.8 allo-Ile 1  170.9 
 2 3.99, t (7.8) 59.6  2 4.18, dd (8.6, 4.3) 56.1 
 3 2.18, q (7.8) 29.4  3 2.01, m 34.9 
 4-Me 0.88b 17.4  4 1.17-1.23, m 25.3 
 5-Me 0.85b 22.1  5-Me 0.81b 11.1 
 2-NH 8.25, d (7.8)   6-Me 0.81b 14.3 
     2-NH 8.24, d (8.6)  
Leu1 1  173.7d Leu1 1  173.1 
 2 4.34b, m 51.9d  2 4.35b, m 51.3 
 3 a 1.54b 42.1  3 1.53, m 39.3 
  b 1.45b      
 4 1.45b 24.8d  4 1.53b 23.7 
 5-Me 0.83b 17.8d  5-Me 0.82b 22.1d 
 6-Me 0.84b 20.1d  6-Me 0.82b 22.1d 
 2-NH 8.20, d (5.8)   2-NH 8.29, d (8.6)  
Leu2 1  173.7d Leu2 1  172.2 
 2 4.34b, m 51.9d  2 4.35b, m 50.3 
 3 a 1.53b 40.5  3 1.43, m 41.3 
  b 1.44b      
 4 1.45b 25.2d  4 1.53b, m 24.1 
 5-Me 0.83b 17.8d  5-Me 0.88b, d (6.9) 22.1d 
 6-Me 0.84b 20.1d  6-Me 0.87b, d (6.9) 22.1d 
 2-NH 7.64b   2-NH 7.62b  
(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Obscured by solvent. (d) Interchangeable resonances 
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6.4.5 Desotamide E (6.05)  
 
HRESI(+)MS analysis of desotamide E (6.05) returned a quasi-molecular ion [M+H]+ consistent 
with the molecular formula (C38H59N9O7, Δmmu +2.2) suggestive of an analogue of desotamide 
(6.01) as both of them has similar UV. A C3 Marfey’s analysis of 6.05 confirmed this hypothesis, 
revealing the presence of L-Trp, L-Leu, L-Leu, L-allo-Ile, L-Asn and L-Orn residues. While the 
NMR comparisons between 6.01 and 6.05 suggested a very similar amino acid sequence, to be 
confident of this required assignment of the 1D NMR data, and careful consideration of the 2D 
NMR correlations. Following the strategy outlined previously for desotamide (6.01), it was possible 
to fully assign the data to the respective amino acids, as indicated in Table 6.9, Table 6.10 and as 
illustrated in Figure 6.44 and Figure 6.45. Of particular importance, diagnostic HMBC correlations 
permitted unambiguous assignment of the 13C NMR resonances for all amide carbonyls. The 
sequence of amino acid residues is tentatively proposed as indicated, but will be addressed towards 
the end of this chapter. 
Ornithine is a nonessential amino acid and is manufactured by the body. The amino acid, arginine, 
is metabolized during urea production as it acts as a precursor of citrulline, proline and glutamic 
acid. Ornithine plays an important role in the urea cycle and is the precursor of the amino acids 
citrulline, glutamic acid, and proline. Another primary role of ornithine is being an intermediate in 
arginine biosynthesis, although this is due to its participation in the urea cycle (responsible for the 
production of urea). Ornithine is not directly incorporated into proteins and enzymes and does not 
have a codon in the genetic code.211  
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6.4.5.1 C3 Marfey’s analysis of 6.05 
Employing the C3 Marfey method as previously described, 6.05 was subjected to acid hydrolysis 
using 6 M HCl/5% thioglycolic acid, derivatized with D-FDAA, and subjected to HPLC analysis to 
determine the absolute stereochemistry of the derivatized amino acids. Absolute configuration of 
6.05 was determined by comparing the retention times of standard amino acids with the derivatized 
hydrolysate of 6.05. The amino acids of 6.05 were confirmed to be L-Trp, L-Leu, L-Orn, L-Asn, L-
allo-Ile and Gly as shown in Figure 6.37 and Figure 6.38. 
 
Figure 6.37. HPLC trace (340 nm) from HPLC-DAD-MS C3 Marfey’s analysis of the standard amino acids reacting 
with D-FDAA. Identity of amino acids was confirmed by retention time and molecular weight. (a) L-allo-Ile + D-FDAA 
(tR = 43.0 min), (b) L-allo-Ile + D-FDAA (tR = 35.0 min), (c) L-Leu + D-FDAA (tR = 44.3 min), (d) D-Leu + D-FDAA 
(tR = 36.3 min), (e) L-Trp + D-FDAA (tR = 38.2 min), (f) L-Trp + L-FDAA (tR = 34.1 min), (g) L-Asn + D-FDAA (tR = 
13.7 min), (h) D-Asn + D-FDAA (tR = 13.1 min) and (i) L-Orn + D-FDAA (tR = 36.2 min). HPLC conditions, Zorbax, 
SB-C3 column (150 × 4.6 mm, 5 µm), 1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% 
formic acid) over 55 min. * excess Marfey reagent. ** di-substituted derivatized L-Orn + D-FDAA (tR = 35.7 min) 
 
As expected Marfey reagent reacted with each γ and α amino group of L-Orn to afford two 
derivatized L-Orn m/z 385 [M+H] with retention times 6.7 and 10.4 min. Also, Marfey reagent 
reacted with both γ and α amino group of L-Orn to afford derivatized L-Orn m/z 637 [M+H] with 
retention time 35.7 min 
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Figure 6.38. HPLC trace (340 nm) from HPLC-DAD-MS Marfey’s analysis of desotamide E (6.05). Identity of amino 
acids was confirmed by retention time and molecular weight. (a) Co-injection of hydrolysate of 6.05 (300 µg) with L-
Asn, L-allo-Ile, L-Orn, L-Leu, L-Trp + D-FDAA, (b) L-allo-Ile + D-FDAA, (c) L-Orn + D-FDAA, (d) L-Asn + D-FDAA, 
(e) L-Leu + D-FDAA and (f) L-Trp + D-FDAA and. HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 µm), 1 
mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) over 55 min.* excess 
Marfey reagant 
 
Six amino acids fragments: 
L-Trptophan #1: Analysis of the COSY NMR (DMSO-d6) data of 6.05 revealed diagnostic 
correlation sequences consistent with the structure fragment (i) H-4′ to H-5′ to H-6′ to H-7′, (ii) 2-
NH to H-2 to H2-3, and (iii) 5-H to 6-NH.  Key HMBC correlation permitting assignment of the 
quaternary carbons included (i) 2-NH to C-1, (ii) H2-3 to C-4 and C-5 and (iii) 6-NH and H-8 to C-
6a (Figure 6.39). 
 
Figure 6.39. HMBC (600 MHz, DMSO-d6) spectrum with the key correlations (Trp) of desotamide E (6.05)  
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L-Leucine #2 and 3:  From the Marfey’s analysis, we proved the presence of only L-Leu residue, 
which contributes to both Leu #2 and #3 and can explain the overlapping of the signals due to 
similarity of two Leu residues as L configuration. COSY NMR (DMSO-d6) correlations readily 
identified the sequence 2-NH to H-2 to H2-3 to H-4 to H3-5/H3-6, while HMBC correlations linked 
2-NH to C-1 (Figure 6.40).  
 
Figure 6.40. HMBC (600 MHz, DMSO-d6) spectrum with the key correlations of desotamide E (6.05)  
 
L-allo-Ile #4: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to 
H-3 to H3-6 to H2-4 to H3-5, while HMBC correlations linked H-2 and 2-NH to C-1 (Figure 6.41). 
 
Figure 6.41. HMBC (600 MHz, DMSO-d6) spectrum with the key correlations (allo-Ile) of desotamide E (6.05) 
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L-Asn #5: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to H-
3, while HMBC correlations linked H-2 to C-1, H2-3 and NH2 to C-4 (Figure 6.42). 
 
Figure 6.42. HMBC (600 MHz, DMSO-d6) spectrum with the key correlations (Asn) of desotamide E (6.05) 
 
L-Orn #6: COSY NMR (DMSO-d6) correlations readily identified the sequence 2-NH to H-2 to H2-
3 to H2-4 to H2-5, while HMBC correlations linked 2-NH to C-1 (Figure 6.43).  
 
 
Figure 6.43. HMBC (600 MHz, DMSO-d6) spectrum with the key correlations (Orn) of desotamide E (6.05) 
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Figure 6.44. 1H NMR (600 MHz, DMSO-d6) of desotamide E (6.05) 
 
Figure 6.45. 1H NMR (600 MHz, DMSO-d6) spectra comparison of desotamide E (6.05) (red) and deostamide (6.01) 
(blue) 
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Table 6.9. NMR (600 MHz, DMSO-d6) data of desotamide E (6.05) 
# Pos. δH, mult (J in Hz)a δCa COSY 1H-13C HMBC ROESY 
Trp. 1  171.0    
 2 4.28b, m 55.8 2-NH, 3a,b 1  
 3 a 3.18, dd (14.8, 5.1) 27.9 2, 3b 5  
  b 2.95, dd (14.8, 10.1) 27.9 2, 3a 5  
 4  110.4    
 5 7.12, d (2.0) 124.3 6-NH 3, 4, 6a, 10a  
 6a  136.5    
 7 7.32, d (7.3) 112.1 8 1-Orn, 10a  
 8 7.05, t (7.3) 121.7 7, 9 6a, 10   
 9 6.97, t (7.3) 119.2 8, 10 7, 10a  
 10 7.51b 118.9 9 4, 6a, 8  
 10a  127.6    
 2-NH 8.42, d (5.1)  2 1-Orn, 3 2-Orn 
 6-NH 10.81, s  5 5, 4, 6a, 10a   
Orn 1  170.0    
 2 4.16b, m 51.5 2-NH  2-NH-Trp 
 3a 1.40b, m 22.8    
 3b 1.28b, m     
 4 1.20b, m 25.4    
 5 1.20b, m 25.4    
 2-NH 7.66, d (7.3)  2  2-Asn 
 NH2 c     
Asn. 1  170.8    
 2 4.62, dd (14.1, 6.4) 50.1 2-NH, 3 1, 3 2-NH-Orn 
 3 a 2.64b, m 37.8 2 4  
  b 2.63b, m     
 4  171.2    
 2-NH 7.56, br  2   
 NH2 7.33, s  4 3 2-Asn 
Leu#1 1  171.6    
 2 4.28b, m 52.6 2-NH, 3   
 3 a 1.48b, m 41.9 2, 4   
  b 1.39b, m  2, 4   
 4 1.55b, m 24.7c 3   
 5-Me 0.86b 24.1c    
 6-Me 0.90b 23.9c    
 2-NH 8.42, d (5.5)  2 1 2-Leu#2 
Leu#2 1  170.6    
 2 4.44, dd (15.1, 7.3) 50.9 2-NH, 3a,b 1, 3 NH-Ile 
 3 a 1.45b, m 39.2 2, 3b,    
  b 1.36b, m  2, 3a, 4   
 4 1.47b, m 24.9c 3, 5/6-Me   
 5-Me 0.85b 21.8c 4   
 6-Me 0.89b 22.0c 4   
 2-NH 7.52, brd  2   
allo-Ile 1  174.1    
 2 4.16b, m 56.7 2-NH, 3 1  
 3 2.04, m 36.1 4   
 4 a 1.52b, m 26.1 3   
  b 1.43b, m  3   
 5-Me 0.80 11.1    
 6-Me 0.84 14.1    
 2-NH 8.31, d (7.6)  2 1 2-Leu#2 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonaces. (d) Not observed 
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Table 6.10. NMR (600 MHz, DMSO-d6) comparison of both desotamide E (6.05) and desotamide (6.01) 
Desotamide E (6.05) Desotamide (6.01) 
# Pos. δH, mult (J in Hz)a δCa # Pos. δH, mult (J in Hz)a δCa 
Trp. 1  171.0 Trp. 1  170.9 
 2 4.28b, m 55.8  2 4.36, m 55.4 
 3 a 3.18, dd (14.8, 10.1) 27.9  3 3.31, dd (14.7, 10.1) 27.3 
  b 2.95, dd (14.8, 10.1) 27.9   2.96, dd (14.7, 10.1)  
 4  110.4  4  110.0 
 5 7.12, d (2.0) 124.3  5 7.11, s 123.5 
 6a  136.5  6a  136.1 
 7 7.32, d (7.3) 112.1  7 7.30, d (8.1) 111.3 
 8 7.05, t (7.3) 121.7  8 7.04, t (7.7) 120.9 
 9 6.97, t (7.3) 119.2  9 6.96, t (7.7) 118.3 
 10 7.51b 118.9  10 7.49, d (7.7) 118.1 
 10a  127.6  10a  127.1 
 2-NH 8.42, d (5.1)   2-NH 8.24, d (8.3)  
 6-NH 10.81, s   6-NH 10.76, s  
Orn 1  170.0 Gly. 1  168.9 
 2 4.16b, m 51.5  2 a 3.88, dd (15.8, 6.5) 42.9 
 3 a 1.40b, m 22.8   b 3.26, dd (15.8, 6.5)  
  b 1.28b, m   NH 7.94, t (5.9)  
 4 1.20b, m 25.4     
 5 1.20b, m 25.4     
 2-NH 7.66, d (7.3)      
 NH2 d      
Asn. 1  170.8 Asn. 1  171.2 
 2 4.62, dd (14.1, 6.4) 50.1  2 4.55, m 48.9 
 3 a 2.64b, m 37.8  3 a 2.80, dd (16.2, 5.5) 36.5 
  b 2.63b, m    b 2.61, dd (16.2, 5.5)  
 4  171.2  4  172.0 
 2-NH 7.56, br   2-NH 7.57, d (8.6)  
 NH2 7.33, s   NH2 7.62, br s  
allo-Ile 1  174.1 allo-Ile 1  170.9 
 2 4.16b, m 56.7  2 4.18, dd (7.8, 4.3) 56.1 
 3 2.04, m 36.1  3 2.01, m 34.9 
 4 1.43-1.52, m 26.1  4 1.17-1.23, m 25.3 
 5-Me 0.80 11.1  5-Me 0.81b 11.1 
 6-Me 0.84 14.1  6-Me 0.81b 14.3 
 2-NH 8.31, d (7.6)   NH 8.24, d (8.6)  
Leu#1 1  171.6 Leu#1 1  173.1 
 2 4.28b, m 52.6  2 4.35b, m 51.3 
 3 a 1.48b, m 41.9  3 1.53, m 39.3 
  b 1.39b, m      
 4 1.55b, m 24.7c  4 1.53b 23.7 
 5-Me 0.86b 24.1c  5-Me 0.82b 22.1c 
 6-Me 0.90b 23.9c  6-Me 0.82b 22.1c 
 2-NH 8.42, d (5.5)   2-NH 8.29, d (8.6)  
Leu#2 1  170.6 Leu#2 1  172.2 
 2 4.44, dd (15.1, 7.3) 50.9  2 4.35b, m 50.3 
 3  1.35-1.45b, m 39.2  3 1.43, m 41.3 
 4 1.47b, m 24.9c  4 1.53b, m 24.1 
 5-Me 0.85b 21.8c  5-Me 0.88b, d (6.9) 22.1c 
 6-Me 0.89b 22.0c  6-Me 0.87b, d (6.9) 22.1c 
 2-NH 7.52, brd   2-NH 7.64, d (7.6)  
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonaces. (d) Not observed 
 
 
Chapter 6. Desotamides: New cyclic hexapeptides with inhibitory activity against Mycobacterium bovis  
314 
 
6.4.6 Desoatmide F (6.06)  
HRESI(+)MS analysis of desotamide F (6.06) returned a quasi-molecular ion [M+H]+ 
corresponding to a molecular formula (C39H59N6O8, Δmmu –1.9). Analysis of the NMR data 
suggested that the allo-Ile in 6.05 had been replaced by a Val in 6.06. The structure elucidation was 
performed using 2D NMR spectra including HSQC, COSY and HMBC correlation outline in 
Figure 6.46, Figure 6.47 and Table 6.11. From the NMR analysis, we predict the presence of Trp, 
Leu (× 2), Val, Asn and Orn residues, however, these assignments will be confirmed by C3 
Marfey’s analysis which still under investigation. The sequence of amino acid residues is 
tentatively proposed as indicated, but will be addressed towards the end of this chapter. 
 
 
Figure 6.46. Key 2D NMR correlations of desotamide F (6.06) 
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Figure 6.47. 1H NMR (600 MHz, DMSO-d6) spectrum of desotamide F (6.06) 
 
Figure 6.48. 1H NMR (600 MHz, DMSO-d6) spectra comparison of 6.05 (blue) and 6.06 (red) 
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Table 6.11. NMR (600 MHz, DMSO-d6) data of desotamide F (6.06) 
# Pos. δH, mult (J in Hz)a δCa COSY 1H-13C HMBC ROESY 
Trp. 1  170.7    
 2 4.27, m 54.5 2-NH, 3a,b 3, 4, 6a, 10a  
 3 a 3.22, dd (14.4, 10.6) 26.8 2, 3b 2, 4, 5  
  b 2.90, dd (14.4, 10.6) 26.8 2, 3a 2, 4, 5  
 4  109.7    
 5 7.31, br 123.2 6-NH 3, 4, 6a, 10a  
 6a  135.6    
 7 7.31, d (7.4) 111.1 8 10, 10a  
 8 7.04, t (7.4) 120.6 7, 9 6a, 10  
 9 6.96, t (7.4) 118.1 8, 10 7, 10a  
 10 7.50, d (7.4) 117.8 9 4, 8, 6a  
 10a  126.5    
 2-NH 8.33b  2  NH-Leu, 2-Orn 
 6-NH 10.81, s  5 5, 4, 6a, 10a  
Asn 1  170.2    
 2 4.57, dd (13.6, 6.2) 49.1 1, 3   
 3 2.55, d (6.2) 37.0 2, 4   
 4  170.3    
 2-NH 7.39, br    2-Asn, NH-Val 
 NH2 6.95, s   3  
Orn 1  170.3    
 2 4.02, t (7.2)  2-NH, 3 1 NH-Trp 
 3 2.55, d (6.7) 40.8 2 2, 4  
 4 1.38b 26.9    
 5 1.38b 26.9    
 2-NH 7.40, br  2  3, 2-Asn 
 NH2 d     
Leu#1 1  170.5    
 2 4.43, dd (14.8, 7.4) 50.4 2-NH, 3 1, 3, 5/6  
 3 a 1.51b, m 41.6    
  b 1.44b, m     
 4 1.56b, m 23.6    
 5-Me 0.89b, m 22.2c    
 6-Me 0.84b, m 22.1c    
 2-NH 7.47b  2  NH-Leu#2 
Leu#2 1  172.7    
 2 4.32, dd (14.3, 6.6) 51.3 2-NH, 3 1  
 3 a 1.40b 39.3 2 3  
  b 1.46b     
 4 1.46b, m 24.1    
 4-Me 0.86b, m 22.4c    
 5-Me 0.85b, m 22.0c    
 2-NH 8.29b  2 2, 3 NH-Leu#1 
Val 1  171.4    
 2 3.99, dd (7.8, 4.5) 58.2 2-NH, 3 1, 4/5-Me  
 3 2.24, m 28.5 2   
 4-Me 0.86b, m 16.7 3   
 5-Me 0.89b, m 18.9 3   
 2-NH 8.33b  2  NH-Asn, NH-Leu#2 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonances. (d) not observed 
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Table 6.12. 1H NMR (600 MHz, DMSO-d6) comparison of desotamide E (6.05) and desotamide F (6.06) 
Desotamide E (6.05) Desotamide F (6.06) 
# Pos. δH, mult (J in Hz)a δCa # Pos. δH, mult (J in Hz)a δCa 
Trp. 1  171.0 Trp. 1  170.7 
 2 4.28b, m 55.8  2 4.27, m 54.5 
 3 a 3.18, dd (14.6, 10.1) 27.9  3 a 3.22, dd (14.4, 10.6) 26.8 
  b 2.95, dd (14.6, 10.1) 27.9   b 2.90, dd (14.4, 10.6) 26.8 
 4  110.4  4  109.7 
 5 7.12, d (2.0) 124.3  5 7.31, brd 123.2 
 6a  136.5  6a  135.6 
 7 7.32, d (7.3) 112.1  7 7.31, d (7.4) 111.1 
 8 7.05, t (7.3) 121.7  8 7.04, t (7.4) 120.6 
 9 6.97, t (7.3) 119.2  9 6.96, t (7.4) 118.1 
 10 7.51b 118.9  10 7.50, d (7.4) 117.8 
 10a  127.6  10a  126.5 
 2-NH 8.42, d (5.1)   2-NH 8.33b  
 6-NH 10.81, s   6-NH 10.81, s  
Orn 1  170.0 Orn 1  170.3 
 2 4.16b, m 51.5  2 4.02, t (6.7)  
 3 1.28-1.40b, m 22.8  3 2.55, d (6.7) 40.8 
 4 1.20b, m 25.4  4 1.38b 26.9 
 5 1.20b, m 25.4  5 1.38b 26.9 
 2-NH 7.66, d (7.3)   2-NH 7.40, brd  
 NH2 d   NH2 d  
Asn. 1  170.8 Asn 1  170.2 
 2 4.62, dd (14.1, 6.4) 50.1  2 4.57, dd (13.6, 6.2) 49.1 
 3 2.63-2.64b, m 37.8  3 2.55, d (6.2) 37.0 
 4  171.2  4  170.3 
 2-NH 7.56, br   2-NH 7.39, brd  
 NH2 7.33, s   NH2 6.95, s  
allo-Ile 1  174.1 Val 1  171.4 
 2 4.16b, m 56.7  2 3.99, dd (7.8, 4.5) 58.2 
 3 2.04, m 36.1  3 2.24, m 28.5 
 4 1.43-1.52, m 26.1  4-Me 0.86b, m 16.7 
 5-Me 0.80 11.1  5-Me 0.89b, m 18.9 
 6-Me 0.84 14.1  2-NH 8.33b  
 2-NH 8.31, d (7.6)      
Leu#1 1  171.6 Leu#1 1  170.5 
 2 4.28b, m 52.6  2 4.43, dd (14.8, 7.4) 50.4 
 3 a 1.48b, m 41.9  3 a 1.51b, m 41.6 
  b 1.39b, m    b 1.44b, m  
 4 1.55b, m 24.7c  4 1.56b, m 23.6 
 5-Me 0.86b 24.1c  5-Me 0.89b, m 22.2c 
 6-Me 0.90b 23.9c  6-Me 0.84b, m 22.1c 
 2-NH 8.42, d (5.5)   2-NH 7.47b  
Leu#2 1  170.6 Leu#2 1  172.7 
 2 4.44, dd (15.1, 7.3) 50.9  2 4.32, dd (14.3, 6.6) 51.3 
 3  1.35-1.45b, m 39.2  3 a 1.40b 39.3 
 4 1.47b, m 24.9c  4 b 1.46b  
 5-Me 0.85b 21.8c  5-Me 1.46b, m 24.1 
 6-Me 0.89b 22.0c  6-Me 0.86b, m 22.4c 
 2-NH 7.52, br   2-NH 0.85b, m 22.0c 
*(a) 13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Interchangeable resonances. (d) not observed 
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6.4.7 Amino acid residues correlations for deostamides (6.01 – 6.06) 
Based on the data listed above including HMBC (Figure 6.49) and ROSEY (Figure 6.50) 
correlations and NMR comparison with known desotamide (6.01), we could acknowledge that 2D 
NMR data does not permit unambiguous sequence assigned for some correlations. Based on the 
biosynthetic grounds for the desotamides, it is obvious that all of them share Trp, Leu and Asn 
residues, and that they only differ in three amino acid residues A, B and C (Figure 6.51) in which it 
ranges from Ile, Leu, Val, Gly and Orn (arginine through arginase produces ornithine). In most 
cases, the amino acids codes for these amino acids can undergo slight variation in one code to give 
a rise to another amino acid, for example, Ile (ATT, ATC, ATA), while Leu (CTT, CTC, CTA).   
 
 
Figure 6.49. HMBC (600 MHz, DMSO-d6) correlations for amide/carbonyl of the amino acid residues of six 
desotamides (6.01 – 6.06)  
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Figure 6.50. ROESY (600 MHz, DMSO-d6) correlations of amino acid residues of desotmaides (6.01 – 6.06) 
 
Figure 6.51. Proposed sequence homology based on biosynthetic grounds 
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6.4.8 Biological screening 
6.4.8.1 Antimicrobial and cytotoxicity assay 
The desotamides (6.01 - 6.06) have been screened against the in-house biological assays, 
antibacterial, antifungal (Figure 6.52 and Table 6.13) and cytotoxic assay (Figure 6.53). The 
desotamides (6.01 – 6.06), displayed no antibiotic activity against the Gram negative bacteria 
Escherichia coli (ATCC 11775) and Pseudomonas aeruginosa (ATCC 10145), but moderate 
antibacterial activity against the Gram positive bacteria Bacillus subtilis (ATCC 6633 and ATCC 
6051), while desotamide B (6.02) and F (6.06) exhibit antibacterial activity against  Staphylococcus 
aureus (ATCC 9144 and ATCC 25923) (Table 6.13 and Figure 6.52). Likewise, these same 
compounds failed to exhibit cytotoxicity (IC50 >30 µM) against the human colon cancer cell line 
SW620, lung cancer cell line NCIH460 (Figure 6.53). 
 
Table 6.13. Antibacterial and antifungal screening results 
 Staphylococcus aureus 
ATCC 25923 
Staphylococcus aureus 
ATCC 9144 
Bacillus subtilis 
ATCC 6051 
Bacillus subtilis 
ATCC 6633 
Compounds MIC 
(µM) 
IC50 
(µM) 
MIC 
(µM) 
IC50 
(µM) 
MIC 
(µM) 
IC50 
(µM) 
MIC 
(µM) 
IC50 
(µM) 
desotamide  
(6.01) 
-- -- -- -- 15 7.5 15 7.5 
desotamide B 
(6.02) 
15 7.5 15 9 3.7 1.5 3.7 1.8 
desotamide C 
(6.03) 
-- -- -- -- 15 7.5 15 7.5 
desotamide D 
(6.04) 
-- -- -- -- 15 7.5 15 7.5 
desotamide E 
(6.05) 
-- -- -- -- 7.5 3.5 7.5 3.5 
desoatmide F 
(6.06) 
3.7 0.9 3.7 0.8 15 9.2 15 12.0 
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Figure 6.52. Antimicrobial assay screening graphs of desotamides (6.01 - 6.06) 
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Figure 6.53. Cytotoxicity assay of the desotamides (6.01 −  6.06) against (a) SW620 (human colon cancer cell line), (b) 
NCIH460 (lung cancer cell line) 
 
6.4.8.2 Activity against Mycobacterium bovis (BCG) 
The early bactericidal activity of the desotamides (6.01 – 6.06) prompted us to further test their 
activity against Mycobacterium bovis. In collaboration with Dr Antje Blumenthal (Diamantina 
Institute, The University of Queensland) we conducted preliminary studies using the vaccine strain 
Mycobacterium bovis, Bacille Calmette Guerin and observed that desotamide E (6.05) and F (6.06) 
inhibited mycobacterial growth and showed bactericidal activity in vitro with IC50 2.79 and 3.09 
µM respectively.   
Mycobacterium bovis, Bacille Calmette Guerin (BCG) (strain Pasteur, ATCC) was grown until 
early-mid log phase in 7H9 liquid medium (Difco) containing 0.2% glycerol, 0.05% Tween80, 
0.5% BSA, 0.2% dextrose, and 0.085% sodium chloride. Single cell suspensions of independent 
cultures were prepared by centrifuging the bacterial cultures for 10 min, at room temperature, 130 x 
g and then diluted to an optical density (OD; 600 nm) of 0.02. Bacterial growth in the presence of 
desotamides (6.01 – 6.06) (200 µl aliquots) was monitored in 96 well plates by OD measurements. 
To analyse bacterial survival, serial dilutions of culture material were plated on Middlebrook 7H10 
plates supplemented with 10% oleic acid/albumin/dextrose catalase (OADC; Middlebrook) and 
0.5% glycerol. Plates were incubated at 37 °C for 3 weeks and colonies enumerated to calculate 
colony forming units (CFU). Isoniazid (INH) was used as a positive control (20 µg/mL in 10% 
DMSO) (Figure 6.54 and Figure 6.55). 
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Figure 6.54. Inhibition of M. bovis, BCG growth by desotamides 6.05 and 6.06  in vitro. 
 
 
Figure 6.55. Desotamide E (6.05) has bactericidal activity against M. bovis, BCG in vitro. CFU determined on d7 post 
exposure to desotamide. *n.d. = not detectable, dotted line = indicates the bacterial number present in the culture at the 
beginning of the experiment on d0 
 
6.4.9 Conclusion for the desotamides 
The desotamides compounds were provided from Microbial Screening Technology (MST) in 
Sydney for structure elucidation and biological analysis. This chapter reports the identification of 
one known desotamide (6.01) and five new desotamides B – F (6.02 – 6.06). The desotamides 
exhibited moderate antibacterial activity S. aureus (ATCC 25923 and 9144) and B. subtilis (ATCC 
6051 and 6633) with MIC ranging from 7.5 to 15 µM and IC50 ranging from 3.5 to 7.5 µM and 
were tested for their activity against Mycobacterium bovis. Desotamide E and F (6.05 and 6.06) 
exhibited good anti-BCG activity.  Likewise, these same compounds failed to exhibit cytotoxicity 
(IC50 >30 µM) against the human colon cancer cell line SW620 and lung cancer cell line 
(NCIH460). These results suggest that 6.05 and 6.06 may be potent inhibitors of Mycobacterium 
desotamide D (6.04)
desotamide E (6.05)
desotamide C (6.03)
desotamide     (6.01)
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tuberculosis pharmacophore with minimal (low) mammalian cytotoxicity. The SAR by co-
metabolites study further demonstrates the critical importance of the L-Orn residue for anti-TB 
activity, and suggests that all L-cyclohexapeptides is preferred. 
 
6.4.10 Future work for the desotamides 
C3 Marfey’s analysis for both desotamide B (6.02) and desotamide F (6.06) to assign the absolute 
stereochemistry of the amino acids residues, C3 Marfey analysis for D-Orn to confirm the presence 
of L-Orn as well as finishing the antibacterial screening assay against Mycobacterium bovis and 
macrophage screening assay. Further studies will also be directed at the synthesis of analogues with 
L-Orn is replaced by L-Lys, or L-Arg to further probe optimize and document the antibacterial 
desotamide pharmacophore. 
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6.5 Experimental section 
Desotamide (6.01): white powder; [α]22D –29.3 (c 0.05, MeOH); 1H NMR (600 MHz, DMSO-d6) 
see Figure 6.5 and Table 6.1; HRESI(+)MS m/z 719.3857 (calcd for C35H52N8O7Na, 719.3851). 
 
Desotamide B (6.02): white powder; [α]22D +20.2 (c 0.01, MeOH); 1H NMR (600 MHz, DMSO-
d6) see Figure 6.16 and Table 6.3; HRESI(+)MS m/z 719.3835 (calcd for C35H52N8O7Na, 
719.3851). 
 
Desotamide C (6.03): white powder; [α]22D +80.2 (c 0.05, MeOH); 1H NMR (600 MHz, DMSO-
d6) see Figure 6.26 and Table 6.5. HRESI(+)MS m/z 705.3686 (calcd for C34H50N8O7Na, 
705.3695). 
 
Desotamide D (6.04): white powder; [α]22D +95.7 (c 0.05, MeOH); 1H NMR (600 MHz, DMSO-
d6) see Figure 6.35 and Table 6.7; HRESI(+)MS m/z 705.3683 (calcd for C34H50N8O7Na, 
705.3695). 
 
Desotamide E (6.05): white powder; [α]22D + 78.8 (c 0.05, MeOH); 1H NMR (600 MHz, DMSO-
d6) see Figure 6.44 and Table 6.9; HRESI(+)MS m/z 705.3673 (calcd for C34H50N8O7Na, 
705.3695). 
 
Desotamide F (6.06): white powder; [α]22D + 20.2 (c 0.01, MeOH); NMR (600 MHz, DMSO-d6) 
see Figure 6.47 and Table 6.11; HRESI(+)MS m/z 740.4473 (calcd for C37H58N9O7, 740.4454). 
6.5.1 Marfey analysis for desotamides 
Marfey’s analysis were prepared according to the method described210. About 200 µg of desotamide 
(6.01 - 6.02) mixed with 100 µL of 5% thioglycolic acid/6 M HCl. The mixture was degassed with 
N2 and heated at 110 °C overnight in tightly capped vial. The vial was left to cool, and then the 
solvent was removed under N2. The remaining residue was mixed with 50 µL D-FDAA solution (10 
mg/mL in acetone) and 100 µL 1 M NaHCO3 solution. The mixture was heated at 60 °C for 5 min 
in a tightly capped vial. After cooling, 50 µL of 2 M HCl and 500 µL of 1:1 MeCN/H2O were 
added. The mixture was analysed using HPLC conditions, Zorbax, SB-C3 column (150 × 4.6 mm, 5 
µM), 1 mL/min, gradient of 15 – 60% MeOH/H2O (isocratic 5% MeCN containing 1% formic acid) 
over 55 min.45 
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7 Chapter 7. Aranciamycins: New Anthraquinones antibiotics 
7.1 Introduction 
During our screening for microbial metabolites with antibacterial activity, we tested a crude extract 
from CMB-M448 and detected antibacterial activity against Gram-positive bacteria Bacillus subtilis 
(ATCC 6051 and 6633). Large-scale cultivation yielded two known metabolites aranciamycin A 
(7.01) and aranciamycin (7.02) as well as two new metabolites aranciamycin I (7.03) and 
aranciamycin J (7.04). This chapter provides a brief account of the isolation, structure elucidation 
and antimicrobial assessment of these metabolites. 
7.2 Results and discussion 
7.2.1 Analytical cultivation and chemical analysis 
 
Figure 7.1. Solid phase culture of Streptomyces sp. (CMB-M448) 
 
Streptomyces sp. (CMB-M448) was obtained from our in house marine microbial library. The crude 
extracts revealed interesting metabolites and antibacterial activity. A single colony of CMB-M448 
was sub-sampled into seawater medium (100 mL of Ocean Nature seawater, 1% starch, 0.4% yeast 
extract and 0.2% peptone) and incubated at 27 °C for 10 d at 190 rpm. The culture was extracted 
with EtOAc (100 mL), and the organic phase concentrated in vacuo to yield an extract (12.7 mg) 
that was subsequently analysed by HPLC-DAD-MS with conditions set as follows (Zorbax C8 
column, 150 × 4.6 mm, 5 µm, 1 mL/min, gradient from 90 − 10 % H2O/MeCN, with an isocratic 
0.05% formic acid modifier, over 15 min, with a hold at 100% MeCN for 5 min). Peaks with the 
following retention times tR = 8.1, 8.4, 6.8 and 6.9 min exhibited the following m/z [M−H]− 499 
(7.01), 543 (7.02), 485 (7.03) and 513 (7.04) as shown in Figure 7.2. 
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Figure 7.2. HPLC-DAD chromatogram from analytical gradient H2O/MeCN with 0.05% HCO2H using Zorbax C8 at 
254 nm of the crude extract from Streptomyces sp. (CMB-M448) 
 
7.2.2 Preparative cultivation 
A seed culture was prepared by inoculating Streptomyces sp. (CMB-M448) in liquid M1 media (50 
mL) containing 1% starch, 0.4% yeast extract, 0.2% peptone and Ocean Nature seasalt (3.3%). 
Aliquots of the seed culture (5 mL) were transferred to six 3 L Fernbach flasks, each containing the 
same M1 liquid media (500 mL), and the flasks were shaken at 190 rpm for 10 d at 27 °C. The 
resulting cultures were extracted with EtOAc (400 mL) and the combined organic phase 
concentrated in vacuo to yield an extract (80.5 mg). The extract was sequentially triturated with 
hexane (8 mL), DCM (8 mL) and MeOH (8 mL) to afford, after concentration in vacuo, hexane (3 
mg), CH2Cl2 (4.2 mg) and MeOH (45 mg) soluble fractions. The MeOH fraction, rich in the target 
metabolites 7.01 − 7.04, was subjected to semi-preparative reversed-phase HPLC (Zorbax C8 
column, 250 × 9.4 mm, 5 µm, 3 mL/min gradient elution 90 − 10% H2O/MeCN over 30 min) to 
yield aranciamycin I (7.03) (tR = 11.8 min, 0.8 mg, 0.8%), aranciamycin J (7.04) (tR = 12.2 min, 1.8 
mg, 0.8%), aranciamycin A (7.02) (tR = 16.1 min, 1.1 mg, 0.7%) and aranciamycin (7.01) (tR = 15.5 
min, 1.0 mg, 1%) (Scheme 7.1). A UV-Vis λmax 440 nm common to all of 7.01 − 7.04 (Figure 7.3) 
was suggestive of a quinone chromophore. 
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Scheme 7.1. Isolation scheme of the microbial metabolites, 7.01 - 7.04. (a) Trituration [hexane (-1-1), CH2Cl2 (-1-2) 
and MeOH (-1-3)], (b) Semi-preparative HPLC: Zorbax C8, 90 −  10% H2O/MeCN, 3 mL/min, 30 min 
 
 
 
Figure 7.3. UV-vis (DAD) at 254 nm of aranciamycin A (7.01) 
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7.2.2.1 Aranciamycin A (7.01) 
 
HRESI(+)MS data of 7.01 revealed an adduct ion (M+Na)+ indicative of a molecular formula 
C26H28O10 (Δmmu −0.5). The 1H NMR (DMSO d6) data of 7.01 (Figure 7.5 and Table 7.1) revealed 
resonances attributed to an anthraquinone fragment, with analysis of 2D NMR data (HSQC, COSY 
and HMBC) as outlined in Figure 7.4. A literature search suggested that 7.01 was the known 
microbial anthraquinone aranciamycin A,212 first isolated in 2007 from S. diastatochromogenes 
TE6028 through cloning and expression of aranciamycin gene cluster. To our knowledge, 
aranciamycin A was identified through spectroscopic analysis and although no optical properties 
(i.e [α]D) have been reported of 7.01, our reisolated sample exhibited an [α]D +119 (c 0.10, MeOH) 
 
 
 
Figure 7.4. Key 2D NMR (600 MHz, DMSO-d6) correlations of aranciamycin A (7.01) 
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Figure 7.5. 1H NMR (600 MHz, DMSO-d6) of aranciamycin A (7.01) 
 
 
 
 
 
 
 
 
 
 
  
Figure 7.6. UV-vis (DAD) at 254 nm of aranciamycin A (7.01) 
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Table 7.1. NMR (600 MHz, DMSO-d6) data of aranciamycin A (7.01) 
Pos δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1 7.71, d, (7.8) 119.1 2 3, 4a, 12  
2 7.80, dd, (8.0, 8.0) 136.8 1, 3 4, 12a  
3 7.38, d, (8.0) 123.8 2 1, 4a  
4  160.8    
4a  115.7    
5  b    
5a  113.4    
6  161.0    
6a  130.9    
7 4.93, dd, (7.8, 5.5) 72.2 8α/β 1′, 6, 6a, 9, 10a 1′, 8α/β 
8 α 2.14, dd, (13.8, 7.8) 42.7 7, 8β 6, 6a, 9, 9-Me, 10 5′, 7 
 β 1.98, dd, (13.8, 7.8)  7, 8α 6a, 7, 9, 10 5′, 7 
9  67.0    
10 α 2.98, d, (16.9) 44.4 10β 6a, 8, 9, 9-Me, 10a, 11 11 
 β 2.78, d, (16.9)  10α 6a, 8, 9, 9-Me, 10a, 11 11 
10a  146.8    
11 7.45, s 119.6 13 5a, 6a, 10, 12 10α/β 
11a  b 12   
12  180.9    
12a  132.9    
1′ 5.19, s 100.1 2′ 2′, 3′, 5′ 2′, 7 
2′ 3.26, m 80.9 1′, 3′ 2′-OMe, 3′, 4′ 1′ 
3′ 3.38, m 70.2 2′, 3′-OH, 4′   
4′ 3.17, m 71.6 3′, 4′-OH, 5′  5′-Me 
5′ 3.58, m 69.1 4′, 5′-Me 4′ 5′-Me 4′-OH, 9-Me 
5′-Me 1.18, d, (6.1) 17.7 5′ 4′, 5′ 4′, 5′ 
9-Me 1.28, s 28.3  8, 9, 10 5′ 
2′-OMe 3.40, s 57.9  2′  
3′-OH 4.58, d, (5.6)  3′ 3′, 4′  
4′-OH 4.81, d, (5.2)  4′ 4′, 5′ 5′ 
9-OH 4.75, s   8, 9, 9-Me, 10  
 *(a) assignments supported by HSQC. (b) signals not observed 
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Table 7.2. NMR and 13C (600 MHz, DMSO-d6) comparison of experimental and literature212 data of aranciamycin A 
(6.08) 
Pos δH, mult, (J in Hz) (experimental) δCa δH, mult, (J in Hz) (literature) δCa 
1 7.71, d, (7.8) 119.1 7.66, d (7.7) 118.9 
2 7.80, dd, (8.0, 7.8) 136.8 7.75, dd (8.2, 7.7) 137.0 
3 7.38, d, (8.0) 123.8 7.33, d (8.2) 124.6 
4  160.8  161.6 
4a  115.7  116.1 
5  b  191.4 
5a  113.4  113.6 
6  161.0  162.0 
6a  130.9  131.4 
7 4.93, dd, (6.0, 5.5) 72.2 4.92, dd (5.6, 5.1) 72.5 
8 α 2.14, dd, (13.8, 7.8) 42.7 α 2.11, dd (13.8, 6.1) 43.1 
 β 1.98, dd, (13.8, 7.8)  β 1.97, dd (13.8, 5.1)  
9  67.0  67.3 
10 α 2.98, d, (16.9) 44.4 α 2.94, d (16.4) 44.4 
 β 2.78, d, (16.9)  β 2.75, d (16.4)  
10a  146.8  146.7 
11 7.45, s 119.6 7.39, s 119.6 
11a  b  131.8 
12  180.9  181.4 
12a  132.9  133.4 
1′ 5.19, s 100.1 5.20, s 100.1 
2′ 3.26, m 80.9 3.25a 80.8 
3′ 3.38, m 70.2 3.37, m 70.4 
4′ 3.17, m 71.6 3.17, m 72.0 
5′ 3.58, m 69.1 3.57, dq (9.2, 6.1) 69.3 
5′-Me 1.18, d, (6.1) 17.7 1.17, d (6.1) 17.8 
9-Me 1.28, s 28.3 1.27, s 28.4 
2′-OMe 3.40, s 57.9 3.39, s 58.4 
3′-OH 4.58, d, (5.6)  4.51, br d (5.1)  
4′-OH 4.81, d, (5.2)  4.76, br d (5.1)  
9-OH 4.75, s  4.69, br s  
  *(a) assignments supported by HSQC. (b) signals not observed 
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7.2.2.2 Aranciamycin (7.02)  
 
HRESI(+)MS data of 7.02 revealed a quasi-molecular ion (M+H)+ indicative of a molecular 
formula C27H26O12 (Δmmu –0.3).  The 1H NMR (CDCl3) data of 7.02 (Figure 7.8 and Table 7.3) 
were very similar to 7.01 with the exception that 7.02 featured an oxidized C-8 bearing an 8-OMe 
(δH 3.55, δC 60.2). The structure elucidation of 7.02 was further supported by 2D NMR data 
(HSQC, COSY and HMBC) as outlined in Figure 7.7. A literature search suggested that 7.02 was 
the known microbial metabolite anthraquinone aranciamycin213,214 first reported in 1970 from 
Streptomyces echinatus 215 then in 1993, Schmidt et al., were able to crystalize aranciamycin 216to 
confirm the absolute stereochemistry that was reported in 1970. Aranciamycin (7.02) was re-
isolated again from Streptomyces sp. associated with a marine sponge, Haliclona sp. This 
assignment was further confirmed by a measuring the [α]D +161 (c 0.10, MeOH) of 7.02 compared 
to [α]23D +140 (c 0.1, MeOH) for the reported aranciamycin.213 
 
 
 
Figure 7.7. Key 2D NMR (600 MHz, DMSO-d6) correlations of aranciamycin (7.02) 
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Figure 7.8. 1H NMR (600 MHz, CDCl3) spectrum of aranciamycin (7.02) 
 
 
 
 
 
 
 
 
 
 
  
Figure 7.9. UV-vis (DAD) at 254 nm of aranciamycin (7.02) 
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Table 7.3. NMR (600 MHz, CDCl3) data of aranciamycin (7.02) 
Pos δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC 
1 7.88, d (7.9) 120.8 2 3, 4a, 12 
2 7.74, dd (8.2, 7.9) 138.3 1, 3 4, 12a 
3 7.34, d (8.2) 125.2 2 4a 
4  163.1   
4a  115.2   
5  193.1   
5a  118.5   
6  162.6   
6a  133.1   
7 5.20, br s 72.1 8 1′, 6, 6a, 8, 9, 10a 
8 3.77, br s 85.6 7 7, 6a, 9, 8-OMe, 10 
9  76.6   
10  198.5   
10a  135.9   
11 8.41, s 117.7  5a, 6a, 12 
11a  133.4   
12  180.4   
12a  133.5   
1′ 5.64, s 100.6  3′, 5′ 
2′ 3.52b, m 80.1 3′ 2′-OMe 
3′ 3.54b, m 71.5 2′, 4′  
4′ 3.45, dd (9.7, 6.2) 73.4 3′, 5′  
5′ 3.82, dq (9.7, 6.2) 69.5 4′, 5′-Me  
5′-Me 1.39, d (6.2) 17.6 5′  
9-Me 1.52, s 22.9  9 
2′-OMe 3.56, s 58.9  2′ 
8-OMe 3.55, s 60.2  8 
3′-OH c    
4′-OH c    
4-OH 11.85, s   5a, 6a, 6 
6-OH 12.85, s   3, 4a, 4 
*(a) assignments supported by HSQC, (b) signals are overlapping, (c) not observed 
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Table 7.4. NMR (600 MHz, DMSO-d6) data of aranciamycin (7.02) 
Pos δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC 
1 7.73, d, (7.3) 119.2 2 3, 4a, 12 
2 7.82, dd, (8.3, 7.3) 137.3 1, 3 4, 12a 
3 7.40, d, (8.3) 124.4 2 1, 4, 4a 
4  161.5   
4a  116.1   
5  b   
5a  118.7   
6  161.4   
6a  133.0   
7 5.09, d, (2.3) 71.4 8 1′, 6, 6a, 8, 9, 10a 
8 3.62, d, (2.3) 85.8 7 6a, 7, 8-OMe, 9, 9-Me, 10 
9  76.1   
10  198.7 10β  
10a  135.3   
11 8.03, s 114.5 13 5a, 6a, 10, 12 
11a  b   
12  180.5   
12a  133.0   
1′ 5.46, s 100.5 2′ 2′, 3′, 5′ 
2′ 3.33, dd, (3.2, 1.6) 80.4 1′, 3′ 2′-OMe, 3′, 4′ 
3′ 3.41, m 70.2 2′, 4′  
4′ 3.24, ddd, (9.1, 9.0, 6.2) 71.8 3′, 5′ 3′, 5′-Me 
5′ 3.66, dq, (9.1, 6.2) 70.0 4′, 5′-Me 4′ 
5′-Me 1.26, d, (6.2) 17.6 5′ 4′, 5′ 
9-Me 1.40, s 23.1  8, 9, 10 
2′-OMe 3.44, sa 58.3  2′ 
3′-OH 4.71, s  3′  
4′-OH 4.94, d, (5.6)  4′  
8-OMe 3.45, s 59.5  8 
9-OH 5.68, s  9-Me 8, 9, 9-Me, 10 
 *(a) assignments supported by HSQC. (b) signals not observed 
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Table 7.5. NMR (600 MHz, CDCl3) comparison of experimental and literature213 data of aranciamycin (7.02)  
Pos. δH, mult, (J in Hz) (experimental) δCa δH, mult, (J in Hz) (literature)  δC 
1 7.88, d (7.9) 120.8 7.90, dd (8.2, 1.1) 121.1 
2 7.74, dd (8.2, 7.9) 138.3 7.76, t (8.2) 138.5 
3 7.34, d (8.2) 125.2 7.36, dd (8.2, 1.1) 125.3 
4  163.1  163.2 
4a  115.2  115.9 
5  193.1  193.2 
5a  118.5  118.9 
6  162.6  162.6 
6a  133.1  133.6 
7 5.20, br s 72.1 5.23, d (2.3) 72.2 
8 3.77, br s 85.6 3.79, d (2.3) 85.8 
9  76.6  77.0 
10  198.5  199.1 
10a  135.9  136.3 
11 8.41, s 117.7 8.42, s 118.0 
11a  133.4  133.6 
12  180.4  180.7 
12a  133.5  133.9 
1′ 5.64, s 100.6 5.66, d (1.3) 100.7 
2′ 3.52b, m 80.1 3.53, dd (3.6, 1.3) 80.2 
3′ 3.54b, m 71.5 3.54, m 71.7 
4′ 3.45, dd (9.7, 5.6) 73.4 3.45, t (9.6) 73.6 
5′ 3.82, dq (9.7, 6.2) 69.5 3.83, dq (9.6, 6.1) 69.7 
5′-Me 1.39, d (6.2) 17.6 1.40, d (6.1) 178.6 
9-Me 1.52, s 22.9 1.53, s 23.1 
2′-OMe 3.56, s 58.9 3.56, s 59.1 
8-OMe 3.55, s 60.2 3.57, s 60.3 
3′-OH c  c  
4′-OH c  c  
4-OH 11.85, s  11.86, s  
6-OH 12.85, s  12.85, s  
*(a) assignments supported by HSQC. (b) Overlapping resonaces. (c) signals not observed 
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7.2.2.3 Aranciamycin I (7.03) 
 
 
HRESI(+)MS analysis of 7.03 revealed a quasi-molecular ion (M+H)+ indicative of a molecular 
formula C25H26O10 (Δmmu –0.2). The NMR (DMSO-d6) data (Figure 7.11 and Table 7.6) for 7.03 
was very similar to 7.01 and 7.02 (Figure 7.13 and Table 7.7). A comprehensive analysis of the 1D 
and 2D NMR (DMSO d6) was supportive of 7.03 being a new member of the aranciamycin 
structure class, attributed the structure and trivial name aranciamycin I (7.03). The absolute 
configuration of aranciamycin I (7.03) was proposed on the basis it is being a co-metabolite with 
aranciamycin (7.02), both of which exhibit similar specific rotations; 7.02, [α]D +145 (c 0.1, 
MeOH); 7.03, [α]D +139 (c 0.1, MeOH). The configuration of the anomeric proton was determined 
by its small vicinal coupling constant with H-2′ (J1′2′ = 1.1 Hz), which is only reasonable for an 
equatorial position. The orientation of H-4′ (δH 3.23) was proven by its large antiperiplanar 
coupling to H-5′ (δH 3.60, m) (J4′5′ = 9.3 Hz). 
 
 
 
Figure 7.10. Key 2D NMR (600 MHz, DMSO-d6) correlations of aranciamycin I (7.03) 
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Figure 7.11. 1H NMR (600 MHz, DMSO-d6) of aranciamycin I (7.03) 
 
 
 
 
 
 
 
  
Figure 7.12. UV-vis (DAD) at 254 nm of aranciamycin I (7.03) 
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Figure 7.13. 1H NMR (600 MHz, DMSO-d6) spectra showing the comparisons between (a) 7.03, (b) aranciamycin 
(7.02) and (c) aranciamycin A (7.01) 
Table 7.6. NMR (600 MHz, DMSO-d6) data of aranciamycin I (7.03) 
Pos δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1 7.71, d, (7.4) 119.0 2 3, 4a, 12  
2 7.80, t, (7.4) 137.2 1, 3 4, 12a  
3 7.38, d, (8.6) 124.1 2 1, 4a  
4  160.9    
4a  115.6    
5  c    
5a  113.4    
6  161.0    
6a  130.9    
7 4.92, t (6.4) 71.8 8α/β 1′, 6, 6a, 9, 10a  
8 α 2.13, dd, (13.5, 6.4) 42.8 7, 8β 6a, 7, 9-Me, 10a  
 β 1.99, dd, (13.5, 6.4)  7, 8α 6a, 7, 9, 10 5′ 
9  67.0    
10 α 2.98, d, (17.4) 44.1 10β 6a, 8, 9, 9-Me, 10a, 11 11 
 β 2.77, d, (17.4) 44.1 10α 6a, 8, 9, 9-Me, 10a, 11 11 
10a  146.9    
11 7.46, s 119.8 13 5a, 6a, 10, 12 10α/β 
11a  c    
12  180.9    
12a  132.9    
1′ 5.04, d (1.1) 103.2 2′ 3′, 4′, 5′  
2′ 3.61b, m 70.4 1′, 2′-OH, 3′   
3′ 3.30, dd (9.3, 5.4) 70.3 2′, 3′-OH, 4′ 4′  
4′ 3.23, ddd (9.3, 9.3, 5.4) 71.5 3′, 4′-OH, 5′ 3′, 5′, 5′-Me  
5′ 3.60, d (9.3) 69.0 4′, 5′-Me  8β 
5′-Me 1.19, d (9.3) 17.5 5′ 4′, 5′  
9-Me 1.28, s 28.4  8, 9, 10  
2′-OH 4.74b, d (4.8)  2′   
3′-OH 4.45, d (5.8)  3′ 3′  
4′-OH 4.75b, d (5.4)  4′   
9-OH 4.73, s   8, 9, 9-Me, 10  
*(a) assignments supported by HSQC.  (b) Overlapping resonances. (c) signals not observed 
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Table 7.7. NMR (600 MHz, DMSO-d6) data comparison of aranciamycin I (7.03), aranciamycin (7.02) and 
aranciamycin A (7.01) 
Pos δH, mult, (J in Hz) (7.03) δCa δH, mult, (J in Hz) (7.02) δCa δH, mult, (J in Hz) (7.01) δCa 
1 7.71, d, (7.4) 119.0 7.73, d, (7.3) 119.2 7.71, d, (7.8) 119.1 
2 7.80, t, (7.4) 137.2 7.82, dd, (8.3, 7.3) 137.3 7.80, dd, (8.0, 8.0) 136.8 
3 7.38, d, (8.6) 124.1 7.40, d, (8.3) 124.4 7.38, d, (8.0) 123.8 
4  160.9  161.5  160.8 
4a  115.6  116.1  115.7 
5  c  c  c 
5a  113.4  118.7  113.4 
6  161.0  161.4  161.0 
6a  130.9  133.0  130.9 
7 4.92, t (6.4) 71.8 5.09, d, (2.3) 71.4 4.93, dd, (6.0, 5.5) 72.2 
8 α 2.13, dd, (13.5, 6.4) 42.8 3.62, d, (2.3) 85.8 2.14, dd, (13.8, 6.0) 42.7 
 β 1.99, dd, (13.5, 6.4)    1.98, dd, (13.8, 6.0) 42.7 
9  67.0  76.1  67.0 
10 α 2.98, d, (17.4) 44.1  198.7 2.98, d, (16.9) 44.4 
 β 2.77, d, (17.4) 44.1   2.78, d, (16.9) 44.4 
10a  146.9  135.3  146.8 
11 7.46, s 119.8 8.03, s 114.5 7.45, s 119.6 
11a  c  b  b 
12  180.9  180.5  180.9 
12a  132.9  133.0  132.9 
1′ 5.04, d (1.1) 103.2 5.46, s 100.5 5.19, s 100.1 
2′ 3.61b, m 70.4 3.33, dd, (3.2, 1.6) 80.4 3.26, m 80.9 
3′ 3.30, dd (9.3, 5.4) 70.3 3.41, m 70.2 3.38, m 70.2 
4′ 3.23, ddd (9.3, 9.3, 5.4) 71.5 3.24, ddd, (9.1, 9.0, 5.6) 71.8 3.17, m 71.6 
5′ 3.60, d (9.3) 69.0 3.66, dq, (9.1, 6.2) 70.0 3.58, m 69.1 
5′-Me 1.19, d (9.3) 17.5 1.26, d, (6.2) 17.6 1.18, d, (6.1) 17.7 
9-Me 1.28, s 28.4 1.40, s 23.1 1.28, s 28.3 
2′-OH 4.74b, d (4.8)  3.44, sa 58.3 3.40, s 57.9 
3′-OH 4.45, d (5.8)  4.71, s  4.58, d, (5.6)  
4′-OH 4.75b, d (5.4)  4.94, d, (5.6)  4.81, d, (5.2)  
8-OMe 4.73, s  3.45, s 59.5   
9-OH 7.71, d, (7.4)  5.68, s  4.75, s  
*(a) assignments supported by HSQC. (b) Overlapping resonances. (c) signals not observed 
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7.2.2.4 Arancimaycin J (7.04) 
 
 
HRESI(+)MS analysis of 7.04 revealed a quasi-molecular ion (M+H)+ indicative of a molecular 
formula C26H26O11(Δmmu −0.3). The 1H NMR (DMSO-d6) data of 7.04 were very similar that 
recorded for aranciamycin (7.02), with the only significant difference being the absence of 8-OMe 
moiety and the appearance of an H2-8 methylene. A comprehensive analysis of the 1D and 2D 
NMR (DMSO d6) was supportive of 7.04 being a new member of the aranciamycin structure class, 
attributed the structure and trivial name aranciamycin J (7.04) The absolute configuration of 
aranciamycin J (7.04) was proposed on the basis it is being a co-metabolite with aranciamycin 
(7.02), both of which exhibit similar specific rotations; 7.02, [α]D +145 (c 0.1, MeOH); 7.04, [α]D 
+136 (c 0.1, MeOH), establishing the 7R, 8S, 9S configuration in addition to the sugar component 
2-O-methyl-α-L-rhamnose.216 
 
Figure 7.14. Key 2D NMR (600 MHz, DMSO-d6) correlations of aranciamycin J (7.04) 
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Figure 7.15. 1H NMR (600 MHz, DMSO-d6) of aranciamycin J (7.04) 
 
 
 
 
 
 
 
 
Figure 7.16. UV-vis (DAD) at 254 nm of aranciamycin J (7.04) 
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Figure 7.17. 1H NMR (600 MHz, DMSO-d6) comparison of aranciamycian J (7.04) in blue and aranciamycin (7.02) in 
red. The spectra highlights the replacement of OMe with H-8 methylene  
Table 7.8. NMR (600 MHz, DMSO-d6) data of aranciamycin J (7.04) 
Pos δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC ROESY 
1 7.76, dd (7.5, 1.1) 120.0 2 3, 4a, 12  
2 7.85, dd (8.3, 7.5) 138.2 1, 3 4, 12a  
3 7.43, dd (8.3, 1.1) 125.1 2 1, 4, 4a  
4  161.8    
4a  116.8    
5  c    
5a  118.9    
6  c    
6a  136.4    
7 5.16, dd (5.3, 3.5) 70.2 8α/β 1′, 9 8α/β 
8 α 2.52, d (5.3) 41.8 7, 8β 9, 9-Me, 10 7 
 β 2.26, dd (14.6, 5.3)  7, 8α 6a, 9, 10 5′, 7 
9  72.5    
10  199.7   11 
10a  c    
11 8.10, s 116.2 13 5a, 6a, 10, 12 9-Me 
11a  c    
12  181.2    
12a  133.9    
1′ 5.29, d, (1.4) 100.7 2′ 2′, 5′  
2′ 3.28, dd, (3.2, 1.4) 81.2 1′, 3′ 2′-OMe, 3′, 4′  
3′ 3.40, mb 70.9 2′, 3′-OH, 4′   
4′ 3.20, ddd, (9.6, 9.4, 6.2) 72.4 3′, 4′-OH, 5′   
5′ 3.64, dq, (9.6, 6.2) 70.1 4′, 5′-Me 4′ 8β 
5′-Me 1.21, d, (6.2) 18.3 5′ 4′, 5′  
9-Me 1.43, s 26.0  8, 9, 10  
2′-OMe 3.41, s 58.9  2′  
3′-OH 4.64, d, (5.8)  3′  9-OH 
4′-OH 4.87, d, (5.8)  4′  9-OH 
9-OH 5.67, s   8, 9, 9-Me 3′-OH, 4′-OH 
 *(a) assignments supported by HSQC. (b) Overlapping resoances. (c) signals not observed 
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Table 7.9. NMR (600 MHz, DMSO-d6) data comparison of aranciamycin J (7.04) and aranciamycin (7.02)  
Pos δH, mult, (J in Hz) (7.04) δCa δH, mult, (J in Hz) (7.02) δCa 
1 7.76, dd (7.5, 1.1) 120.0 7.73, d, (7.3) 119.2 
2 7.85, dd (8.3, 7.5) 138.2 7.82, dd, (8.3, 7.3) 137.3 
3 7.43, dd (8.3, 1.1) 125.1 7.40, d, (8.3) 124.4 
4  161.8  161.5 
4a  116.8  116.1 
5  c  c 
5a  118.9  118.7 
6  c  161.4 
6a  136.4  133.0 
7 5.16, dd (5.3, 3.5) 70.2 5.09, d, (2.3) 71.4 
8 α 2.52, d (5.3) 41.8 3.62, d, (2.3) 85.8 
 β 2.26, dd (14.6, 5.3)    
9  72.5  76.1 
10  199.7  198.7 
10a  c  135.3 
11 8.10, s 116.2 8.03, s 114.5 
11a  c  b 
12  181.2  180.5 
12a  133.9  133.0 
1′ 5.29, d, (1.4) 100.7 5.46, s 100.5 
2′ 3.28, dd, (3.2, 1.4) 81.2 3.33, dd, (3.2, 1.6) 80.4 
3′ 3.40b, m 70.9 3.41, m 70.2 
4′ 3.20, ddd, (9.4, 9.4, 6.2) 72.4 3.24, ddd, (9.1, 9.0, 6.2) 71.8 
5′ 3.64, dq, (9.4, 6.2) 70.1 3.66, dq, (9.1, 6.2) 70.0 
5′-Me 1.21, d, (6.2) 18.3 1.26, d, (6.2) 17.6 
9-Me 1.43, s 26.0 1.40, s 23.1 
2′-OMe 3.41, s 58.9 3.44, s 58.3 
3′-OH 4.64, d, (5.8)  4.71, s  
4′-OH 4.87, d, (5.8)  4.94, d, (5.6)  
8-OMe   3.45, s 59.5 
9-OH 5.67, s  5.68, s  
*(a) assignments supported by HSQC. (b) Overlapping resonances. (c) signals not observed 
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7.2.3 Antimicrobial assay 
Arancimycins (7.01 – 7.04) were screened against different Gram-negative and Gram-positive 
bacteria (see General experimental part) and they showed inhibitory effect against B. subtilis 
(ATCC 6051 and 6633) (Figure 7.18 and Table 7.10).  
 
 
Figure 7.18. Antimicrobial assay of aranciamycins (7.01 – 7.04) 
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Table 7.10. Antibacterial and antifungal screening results of aranciamycins (7.01 – 7.04) 
 Escherichia coli ATCC 
11775 
Pseudomonas 
aeruginosa ATCC 
10145 
Bacillus subtilis ATCC 
6051 
Bacillus subtilis 
ATCC 6633 
Compounds MIC 
(µM) 
IC50 (µM) MIC 
(µM) 
IC50 (µM) MIC 
(µM) 
IC50 (µM) MIC 
(µM) 
IC50 
(µM) 
 Aranciamycin A 
(7.01) 
-- -- -- -- 7.1 2.3 7.0 2.0 
 Aranciamycin  
(7.02) 
-- -- -- -- 7.0 2.2 6.5 2.0 
Aranciamycin I 
(7.03) 
-- -- -- -- 3.5 1.5 7.5 3.1 
Aranciamycin J 
(7.04) 
-- -- -- -- 7.0 2.0 3.7 2.5 
 
7.3 Conclusion for the aranciamycins 
Aranciamycins belong to the anthracycline group of microbial natural products. Anthracyclines 
have contributed as effective antitumor drugs such as doxorubicin and danunorubicin, as well as 
antibiotics such as tetracycline and tigecycline. The known auranciamycins illustrated in Figure 
7.19 are uniquely isolated from Streptomyces sp.216 217 showed a potent antibacterial activity. 
Most there great antitumor activity, many side effects are observed during the treatment. In order to 
overcome this problem, combinatorial biosynthesis where found to be the most promising tool to 
overcome the toxicity and increase the effectivety. Therefore, new arancimycin analogs have been 
generated by combinatorial biosynthesis to give the next generation of different aranciamycins 
analogues (7.05 – 7.13) through the expression of the aranciamycin biosynthetic gene cluster in 
Streptomyces diastatochromogenes Tü6028.217 Also, it was found that aranciamycin analogues 
(7.08 – 7.13) inhibits collagenase, the metalloprotease that cleaves collagen, and plays an important 
role in the organism by connecting its connective tissue.214 Then synthetic studies were directed at 
the synthesis of aranciamycinone and its analogues (7.05 – 7.07)218(Figure 7.19). 
 
In our study, aranciamyins 7.01 – 7.04 were isolated from marine derived Streptomyces sp. (CMB-
M0448) including two new aranciamycins (7.03 and 7.04) providing an excellent opportunity for 
antibiotic SAR analysis. In the event, this analysis revealed significant antibacterial SAR tolerance 
for C-10 methyelene; C-8 methoxy versus methyelen, and C-2′ hydroxyl versus methoxy. By 
screening these metabolites in our in house antibacterial activity and they showed antibacterial 
effect against B. subtilis (ATCC 6051 and 6633) (IC50 = 3.5 µM)  
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Figure 7.19. Aranciamycins structures 
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7.4 Experimental section 
7.4.1 Analytical cultivation and chemical analysis 
A single colony of CMB-M448 was sub-sampled into seawater medium of Ocean Nature seawater 
(80 mL, 3.3%), starch (1%), yeast extract (0.4%) and peptone (0.2%) and incubated at 27 °C for 10 
d at 190 rpm. The culture was extracted with EtOAc (100 mL), and the organic phase concentrated 
in vacuo to yield an extract (12.7 mg) that was subsequently analysed by HPLC-DAD-MS with 
conditions set as follows (Zorbax C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min, gradient from 90 − 
10 % H2O/MeCN, with an isocratic 0.05% formic acid modifier, over 15 min, with a hold at 100% 
MeCN for 5 min). Peaks with the following retention times tR = 8.1, 8.4, 6.8 and 6.9 min exhibited 
the following m/z [M−H]− 499 (7.01), 543 (7.02), 485 (7.03) and 513 (7.04) 
7.4.2 Preparative cultivation 
A seed culture was prepared by inoculating Streptomyces sp. (CMB-M448) in liquid M1 media (50 
mL) containing 1% starch, 0.4% yeast extract, 0.2% peptone and Ocean Nature seasalt (3.3%). 
Aliquots of the seed culture (5 mL) were transferred to six 3 L Fernbach flasks, each containing the 
same M1 liquid media (500 mL), and the flasks were shaken at 190 rpm for 10 d at 27 °C. The 
resulting cultures were extracted with EtOAc (400 mL) and the combined organic phase 
concentrated in vacuo to yield an extract (80.5 mg). The extract was sequentially triturated with 
hexane (8 mL), CH2Cl2 (8 mL) and MeOH (8 mL) to afford, after concentration in vacuo, 3, 4.2 and 
45 mgs respectively. The MeOH fraction, rich in the target metabolites 7.01 − 7.04, was subjected 
to semi-preparative reversed-phase HPLC (Zorbax C8 column, 250 × 9.4 mm, 5 µm, 3 mL/min 
gradient elution 90 − 10% H2O/MeCN over 30 min) to yield aranciamycin I (7.03) (tR = 11.8 min, 
0.8 mg, 0.8%), aranciamycin J (7.04) (tR = 12.2 min, 1.8 mg, 0.8%), aranciamycin A (7.02) (tR = 
16.1 min, 1.1 mg, 0.7%) and aranciamycin (7.01) (tR = 15.5 min, 1.0 mg, 1%).  
 
Aranciamycin A (7.01); Orange solid; [α]D +119 (c 0.10, MeOH); UV (MeOH) λmax (log ε) 228 
(4.28), 258 (4.10), 289 (3.70), 432 (3.78); NMR (600 MHz, DMSO-d6) see Table 7.1; 
HRESI(+)MS m/z 523.1580 (calcd for C26H28O10Na, 523.1575). 
 
Aranciamycin (7.02): Orange solid; [α]D +161 (c 0.13, MeOH); UV (MeOH) λmax (log ε) 237 
(4.39), 260 (4.21), 435 (3.84); NMR (600 MHz, CDCl3) see Table 7.3; HRESI(+)MS m/z 567.1476 
(calcd for C27H28O12Na, 567.1473). 
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Aranciamycin I (7.03): Orange solid; [α]D +139 (c 0.10, MeOH); UV (MeOH) λmax (log ε) 228 
(4.37), 258 (4.18), 432 (3.86); NMR (600 MHz, DMSO-d6) see Table 7.6; HRESI(+)MS m/z 
509.1421 (calcd for C25H26O10Na, 509.1418) 
 
Aranciamycin J (7.04): Orange solid; [α]D +150 (c 0.10, MeOH); UV (MeOH) λmax (log ε) 240 
(4.32), 261 (4.15), 435 (3.87); NMR (600 MHz, DMSO-d6) see Table 7.8; HRESI(+)MS m/z 
537.1368 (calcd for C26H26O11Na, 537.1367). 
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8 Chapter 8. Citrinaline X and the importance of 
physicochemical characterization 
8.1 Introduction 
Natural products containing nitro groups have been isolated from different plants, fungi, bacteria 
and mammals. These compounds exhibit structural diversity and a wide range of biological 
activities, including antibiotic, antitumor as well as cell signalling properties.219 There are different 
biosynthetic pathways leading to the incorporation of nitro groups such as, direct nitration, as 
demonstrated for the nitroaromatics pyrrolnitrin and aureothin, the sugar D-rubranitrose, and the 
antibiotic pyrrolomycins antibiotics (8.01 – 8.09) produced by Pseudomonas sp. and Myxococcus 
fulvus220,221 as shown in Figure 8.1 and the gene cluster prnD responsible for utilizing molecular 
oxygen as a co-substrate, leading to oxidation of the aryl amino group to a nitro through an aryl 
hydroxylamine and aryl nitroso species.222 Aureothin and its analogues (8.10 – 8.14) (Figure 8.2) 
isolated from Streptomyces luteoreticuli and Streptomyces griseus were assembled by polyketide 
synthase (PKS) in which the gene cluster aurF encodes for a monooxygenase that utilizes 
molecular oxygen to catalyse the oxidation of 4-aminobenzoic acid to 4-nitrobenzoic acid, as a 
polyketide starter unit.223 
 
Figure 8.1. Structures of pyrrolomycin analogues 
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Figure 8.2. Structures of aureothin derivatives 
 
Fungi have proved to be an important source of bioactive and structurally diverse natural products. 
The first known paraherquamides A (8.15) was isolated in 1980 from Penicillium paraherquei, 224 
since then several analogues of the paraherquamides family characteristic with oxindole moiety as 
potent anthelmintics have been isolated from other Penicillium sp. For example, in 1981 Yamazaki 
et al., isolated paraherquamides B-G (8.16 – 8.22) with a characteristic oxindole moiety as potent 
anthelmintics (Figure 8.3).225 In 1990, Ostlind et al. expanded on the anthelmintic properties of 
paraherquamide against Trichostrongylus cloubriformis.226 Most recently a semi-synthetic 
paraherquamide, 2-deoxy-paraherquamide (derquantel) (8.23), was marketed by Pfizer Animal 
Health as a new generation animal health anthelmintic which induces paralysis by acting as 
selective and competitive cholinergic antagonists.227 
 
Figure 8.3. Structures of the paraherquamides derivatives 
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The paraherquamides are closely related to the marcfortines (8.24)228 and brevianamides (8.25) 
from various Penicillium sp. In 2002, Qian et al., isolated closely related antitumor agents, 
stephacidin A (8.26), and avrainvillamide (8.27)229 from Aspergillus sp. (Figure 8.4). 
 
Figure 8.4. Structures of marcfortine A, brevianamide B, stephacidin A and avrainvillamide 
 
Recently, Pimenta et al.230 using an innovative procedure to optimize cultivation conditions that 
enhanced secondary metabolite production, isolated the new nitro diketopiperazines analogue 
citrinalines A (8.28) and B (8.29) from Penicillium citrinum. 
 
 
 
This chapter describes our further contribution to the citrinalines structure class, including 
citrinaline X. In the course of investigating the citrinalines we had cause to examine their likely 
biosynthesis and explore stereochemical intricacies, leading to a rearrangement of the structure for 
citrinaline B (8.29). 
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8.2 Results and discussion 
8.2.1 Isolation and taxonomy 
Penicillium sp. (CMB-TF438) was isolated from a terrestrial soil sample collected from North 
Stradbroke Island. The soil sample was added to sterile buffer solution (10 mL), shaken vigorously 
and heat shocked at 55 ˚C for 8 min. An aliquot of the supernatant (50 µL) was dispersed across a 
solid phase agar isolation plate (ISP-2 media) and incubated at 27 ˚C for 2 – 6 weeks. The plate was 
monitored on a regular basis for microbial growth. A pure culture was obtained for strain CMB-
TF438 by repeated, single colony transfer on solid media. The 16S rRNA gene sequence 
(Appendix) showed 96% homology with other members of the genus Penicillium by the use of the 
BLAST database. 
 
Figure 8.5. Pencillium sp. (CMB-TF438) 
 
8.2.2 Analytical cultivation and chemical analysis 
A single colony of Penicillium sp.  (CMB-TF438) was used to inoculate a seed culture on ISP-2 
agar media, which was cultivated for a period of 10 days at 26 °C. After incubation the agar was 
sliced and soaked in 75% EtOAc:MeOH (50 mL) for 1 h. and the decanted organic crude extract 
dried in vacuo to yield a crude extract (10.2 mg) which was resuspended in MeOH (1 mg/mL) and 
analysed by HPLC-DAD-MS. The analysis revealed peaks attributed to the new metabolite (tR = 7.8 
min, m/z 453 (M−H)-, 8.30) and the very well known citrinin (tR = 9.1 min, m/z 254 (M+H), 8.31) 
(Figure 8.6). *Noting the presence of other isomers of citrinaline X (8.30). 
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Figure 8.6. HPLC (254 nm) chromatogram from analytical gradient H2O/MeCN plus 0.05% HCO2H using Zorbax C8, 
of the crude extract from Penicillium sp. cultivated on ISP-2 agar medium. *citrinaline X isomers 
 
8.2.3 Preparative cultivation and isolation 
Fifty petri dishes containing ISP-2 agar were inoculated with Penicillium sp. (CMB-TF0438) and 
incubated at 26 °C for 10 d. The agar was extracted with EtOAc (250 mL/10 plates), and the 
combined organic layer concentrated in vacuo to yield an EtOAc extract (95 mg). The EtOAc 
extract was sequentially triturated with hexane (8 mL), CH2Cl2 (8 mL) and MeOH (8 mL), which 
were concentrated under N2 to yield 10, 19.5, and 60 mgs respectively. The MeOH soluble material 
was further fractionated by semi-preparative reversed phase HPLC (Zorbax 5 µm C18, 250 × 9.4 
mm column, 3 mL/min gradient elution from 90 – 40% H2O/MeCN over 30 min, with isocratic 
0.01% TFA modifier) to afford citrinaline X (8.30) (tR= 19 min, 3 mg, 3.1%) and citrinin (8.31) 
(tR= 25 min, 5 mg, 5.2%). [Note - % yields are determined on a mass-to-mass basis against the 
weight of EtOAc crude extract] (Scheme 8.1)* The minor metabolites were not isolated at this time, 
but will be discussed at the end of the chapter. 
 
Scheme 8.1. Isolation scheme of crude extract Penicillium sp. (CMB-TF438). (a) Trituration [hexane (-1-1), CH2Cl2 (-
1-2) and MeOH (-1-3)], (b) Semi-preparative HPLC: Zorbax C8, 90 – 40% H2O/MeOH plus 0.01% TFA, 3 mL/min, 30 
min 
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8.2.3.1 Structural elucidation of citrinaline X (8.30) 
 
HRESI(–)MS analysis of 8.30 revealed a quasi molecular ion [M-H]- indicative of a molecular 
formula (C25H32N3O5, Δmmu +0.5). The 1D and 2D NMR (MeOH, d4) data for 8.30 revealed a 
number of diagnostic resonances and correlations that could be assembled into significant structure 
fragments (Figure 8.7 and Table 8.1). These included COSY correlations (i) a sequence from H-9 to 
H-10, HMBC correlations from H-10 to C-12, C-8, C-7, C-11 and C-1), (ii) HMBC correlations 
from H-9 to C-6, C-7, C-8 and C-11, (iii) HMBC correlations from H3-24, H3-25 and H2-5 to C-4 
(δc 80.4), all of which were suggestive of fragment A (Figure 8.7). Likewise, (iv) a COSY 
correlation sequence from H-14 to H2-15 to H-16 to H2-19 (inclusive of H2-17 and H2-18 due to 
overlapping), (v) HMBC correlations from H2-23 to C-2 (δc 185.4), C-11 (δc 121.8), to C-1 (δc 
59.4), to C-13 (δc 47.7) and C-22 (δc 93.9), together with (vi) HMBC correlations from H-14, H3-26 
and H3-27 to C-13, and H2-15 to C-17/18, were suggestive of planar fragment B (Figure 8.7 and 
Figure 8.8). ROESY correlations from H-14 to H-15b; and H-16 to H-15a, support the proposition 
that H-14 and H-16 were trans to each other (Figure 8.9 and Figure 8.10). 
 
To establish the relative configuration for citrinaline X (8.30) required consideration of the ROESY 
NMR data (Figure 8.9 and Figure 8.10). Correlations from H3-27 to both H-14 and H-15b, and from 
H-14 to H-15b (not H-15a), established that all were positioned on a common (α) face, while 
correlation from H-16 to H-15a (but not H-15b) suggested that these protons occupied the opposite 
(β) face of the molecule (Figure 8.11a). Likewise, correlations from H-10 to H3-26 and H-23a 
confirmed that these moieties occupied the same (β) face as H-16 and H-15a (Figure 8.11b). 
Finally, a correlation from H-23b to H-21b required that they occupied the same (α) face, while 
correlation from H-21a to H-19a was consistent with placement on the opposite (β) face (Figure 
8.11b). These ROESY observations established the relative configuration about C-1, C-14, C-16 
and N-20 to be the same as that reported (and confirmed by X-ray analysis) for citrinaline A (8.28). 
Citrinaline X (8.30) did not possess NMR (600 MHz, MeOH-d4) data in common with citrinaline A 
(8.28) (Table 8.2), nor did it co-elute on HPLC (Figure 8.12) this necessitated the configuration 
about C-22 in 8.30 was opposite to that in 8.28 (with a α disposed NO2 moiety). Supportive of this 
hypothesis, careful comparison of the 1D NMR (600 MHz, MeOH-d4) data for 8.30 and 8.28 
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established that differences were localized about C-9 and C-10 (Figure 8.15 and Figure 8.17), and 
C-23 and C-26 (Figure 8.16), fully consistent with inversion of the configuration about C-22. 
 
 
Figure 8.7. Key correlations of citrinaline X (8.30) showing the assigned fragments 
 
 
Figure 8.8. HMBC (600 MHz, MeOH-d4) spectrum with key correlation for citrinaline X (8.30) - fragment B 
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Figure 8.9. ROESY (600 MHz, MeOH-d4) spectrum of citrinaline X showing key correlations from H-10 to H-23a to 
H3-26 (8.30) 
   
 
 
Figure 8.10. ROESY (600 MHz, MeOH-d4) spectrum of citrinaline X (8.28) 
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Figure 8.11. Energy minimized molecular model (Chem, 3D, MM2) structure (a) and (b) of citrinaline X (8.30) 
showing key ROESY correlations 
 
Figure 8.12. The chromatogram of citrinaline X (8.30) and citrinaline A (8.28) using HPLC-DAD-MS 90 – 0% 
H2O/MeCN (0.05% HCO2H modifier) over 15 min at 254 nm (DAD) 
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As citrinaline X (8.30) and citrinaline A (8.28) generate almost identical CD spectra (Figure 8.13), 
we infer that they both possess the same absolute configuration about C-1 – the only chiral centre 
positioned in proximity to the UV chromophore. Hence we propose that citrinaline X (8.30) in the 
C-22 epimer of citrinaline A (8.28), as shown. Having completed our structure elucidation of 8.30, 
we were surprised to learn (personal correspondence) that the published structure for citrinaline B 
(8.29) was to be corrected to one identical to that proposed for citrinaline X (8.30).  
 
 
 
Figure 8.13. CD spectrum of citrinaline X (8.30) and citrinaline A (8.28) in MeCN at concentration 0.8 mg/mL, speed 
200 nm/min, cell length 0.01 cm 
 
In the absence of an authentic sample of citrinaline B (8.29), we could not make a direct 
comparison, but we were concerned as the [α]D for 8.30 (–10) did not match that reported for 8.29 
(+20). To resolve this issue, an authentic sample of citrinaline X (8.30) was forwarded to Dr David 
Williams at the University of British Columbia, for direct HPLC (co-injection) comparison with an 
authentic sample of citrinaline B (8.29). 
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Figure 8.14. 1H NMR (600 MHz, MeOH-d4) and UV-vis (inset) spectra of citrinaline X (8.30) 
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Table 8.1. NMR data (600 MHz, MeOH-d4) of citrinaline X (8.30) 
Pos. δH, mult (J in Hz)a δCa COSY ROESY 
1H-13C HMBC 
1  59.4    
2  185.4    
3-NH      
4  80.4    
5 a 2.79, d (16.7) 49.3  24/25 24/25 
 b 2.75, d (16.7)     
6  194.8    
7  106.7    
8  160.8    
9 6.63, d (8.4) 111.7 10  6, 8, 7, 11 
10 7.46, d (8.4) 134.4 9 23a, 26 1, 8, 7, 11, 12 
11  121.8    
12  143.7    
13  47.7    
14 3.05, dd (14.1, 3.7) 47.1 15a, b 17b/18b, 15b, 21b, 23b, 27 13, 26 
15 a 2.55, ddd (14.1, 13.9, 6.3) 21.7 14, 15b, 16 16, 26 13, 16, 17 
 b 1.97, dd (14.1, 6.3)  14, 15a 27 14, 22 
16 4.21, br s 63.0 17a/18a, 17b/18b 15a  
17 a 2.34b, m 27.7    
 b 2.18b, m     
18 a 2.32b, m 20.9    
 b 2.20b, m     
19 a 3.60b, m 57.1  21a  
 b 3.36c     
20      
21 a 4.07, br d (13.3) 57.8 19b, 21b 19a  
 b 3.55, d (13.3)  21a 14, 23b  
22  93.9    
23 a 3.39, d (16.4) 42.1 23b 10 1, 2, 11, 13, 22 
 b 2.47, d (16.4)  23a 14, 21b 1, 2, 11, 13, 21 
24-Me 1.46, s 26.9  5a/b 4, 5, 25 
25-Me 1.45, s 26.9  5a/b 4, 5, 26 
26-Me 0.75, s 20.6  10, 15a 4, 5, 27 
27-Me 0.94, s 23.8  14, 15b 4, 5, 26 
(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) Obscured by the solvent. (d) Interchangeable resonances 
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Table 8.2. NMR and 13C (600 MHz, MeOH-d4) comparison of citrinaline X (8.30) and citrinaline A (8.28) 
 citrinaline X (8.30)  citrinaline A (8.28)  
Pos. δH, mult (J in Hz)a δCa δH, mult (J in Hz)a δCa 
1  59.4   
2  185.4   
3-NH     
4  80.4   
5 a 2.79, d (16.7) 49.3 2.79, d (16.7) 49.2 
 b 2.75, d (16.7)  2.75, d (16.7)  
6  194.8   
7  106.7   
8  160.8   
9 6.63, d (8.4)  111.7 6.58, d (8.4) 111.1 
10 7.46, d (8.4) 134.4 7.33, d (8.4) 133.8 
11  121.8   
12  143.7   
13  47.7   
14 3.05, dd (14.1, 3.7) 47.7 3.06, dd (14.1, 3.4) 47.7 
15 a 2.55, ddd (14.1, 13.9, 6.3)  21.7   
 b 1.97, dd (14.1, 6.3)  1.75, dd (14.1, 3.4) 22.0 
16 4.21, br s 63.0   
17 a 2.34b, m 27.7 b  
 b 2.18b, m    
18 a 2.32b, m 20.9 b  
 b 2.20b, m    
19 a 3.60b, m 57.1 c  
 b 3.36c  c  
20     
21 a 4.07, br d (13.3) 57.8 c  
 b 3.55, d (13.3)  c  
22  93.9  c 
23 a 3.39, d (16.4)  42.1 3.10b 43.7 
 b 2.47, d (16.4)  2.50, d (16.4)  
24-Me 1.46, s 26.9 1.46, s 26.5 
25-Me 1.45, s 26.9 1.44, s 26.5 
26-Me 0.75, s 20.6 0.83, s 22.4 
27-Me 0.94, s 23.7 0.91, s 23.6 
*(a)13C assignments obtained from gHSQC and gHMBC data. (b) Overlapping resonances. (c) signals not observed  
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Figure 8.15. Comparison of 1H NMR (600 MHz, MeOH-d4) spectra of (A) citrinaline X (8.28) and (B) citrinaline A 
(8.30) 
 
Figure 8.16. 1H -13C HSQC (600 MHz, MeOH-d4) comparison of both citrinaline X (8.28) (red-CH2 and blue-CH/CH3) 
and citrinaline A (8.30) (black-CH2 and green-CH/CH3).*ΔδC = δC (citrinaline X, 8.30) - δC (citrinaline A, 8.28) 
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Figure 8.17. 1H-13C HSQC (600 MHz, MeOH-d4) comparison of both citrinaline X (8.28) (blue) and citrinaline A 
(8.30). *ΔδC = δC (citrinaline X, 8.30) - δC (citrinaline A, 8.28). *ΔδH = δH (citrinaline X, 8.30) - δH (citrinaline A, 8.28) 
 
8.2.4 Highlight- Plausible Biosynthesis of citrinaline X 
It seems very likely that the biosynthesis of the citrinalines proceeds through an intermediate 
similar to that of paraherquamide F (8.21) with hydrolysis of the lactam heterocycle accompanied 
by decarboxylation and oxidation of the NH2 to a NO2 moiety (Figure 8.18). 
 
Figure 8.18 A plausible biosynthetic route to the citrinaline X (8.30) 
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8.2.5 Citrinin (8.31) 
 
HRESI(+)MS analysis of 8.31 revealed a quasi-molecular ion (M+H)+ indicative of a molecular 
formula C13H14O5 (Δmmu +1.4). The UV-vis and the NMR (CDCl3) spectra were very 
characteristic for citrinin. The structure elucidation was further supported by 2D NMR data, 
including HSQC, COSY and HMBC. On searching the literature, 8.31 was confirmed to be the well 
known fungal metabolite citrinin, previously isolated from the Penicillium janthinellum. This 
assignment was further confirmed by comparing the [α]22D –20.1 (c 0.10, CHCl3) for 8.31 to the 
reported [α]21D – 17.4 (c 0.10, CHCl3) of citrinin.231  
 
 
Figure 8.19. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 
citrinin (8.31) 
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Table 8.3. NMR data (600 MHz, CDCl3) of citrinin (8.31) 
Pos. δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1 8.10, s 139.1 -- 3, 8a 
2     
3 4.67, dd (14.4, 7.2) 82.2 4, 9 1, 10 
4  2.89, dd (14.4, 7.2) 34.1 3, 10 1, 5, 8a, 9 
5  123.3   
6  177.2   
7  102.2   
8  184.1   
8a  107.4   
8b  163.3   
9 1.41, d (7.2) 18.5 3 3, 4 
10 1.31, d (6.7) 18.2 4 1, 3, 4 
11 1.81, s 9.4  1, 5 
OH 15.70, s    
12-COOH 14.91, s 174.5   
*(a)13C assignments obtained from gHSQC and gHMBC data.  
 
Table 8.4. 1H NMR (CDCl3) data comparison of experimental and published data105,232 of citrinin (8.31) 
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (published) 
1 8.10, s 8.25, s 
3 4.67, dd (14.4, 7.2) 4.80, q (6.7) 
4  2.89, dd (14.4, 7.2) 2.98, q (7.1) 
9 1.41, d (7.2) 1.35, d (6.7) 
10 1.31, d (6.7) 1.23, d (7.1) 
11 1.81, s 2.02, s 
OH 15.70, s 15.90, s 
12-COOH 14.91, s 15.31, s 
*measured in (a) (600 MHz, CDCl3), (b) (400 MHz, CDCl3) 
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8.3 Diketopiperazines stimulates the production of microbial metabolites 
Fungal secondary metabolites are often coded by gene clusters encoded on chromosomal DNA. It 
has been observed that activation (transcription) of gene clusters can be influenced by unique low 
molecular weight compounds, transfer RNA, sigma factors and gene products formed during post-
exponential development,233 as well as nutrient and environmental factors.234 These events can 
generate signals that affect regulatory pathways resulting in chemical differentiation and 
morphogenesis. In many secondary metabolites pathway, primary metabolites play a critical role. 
235For example, tryptophan is a substrate/precursor for dimethylallyltryptophan synthase in ergot 
alkaloid biosynthesis,236 as is leucine for bacitracin237, methionine for cephalosporin in 
Cephalosporium acremonium238, lysine for cephamycin in Streptomyces clavuligerus,239 valine for 
tylosin in Streptomyces fradiae240 and phenylacetate for penicillin G in Penicillium chrysogenum. 
Likewise glycine, phenylalanine, tyrosine and arginine are essential for the biosynthesis of 
vancomycin.233 
 
Diketopiperazines (DKPs) are a widely explored class of bioactive dipeptides.241 Interest in DKPs is 
evident from significant bioactivities including plant-growth promotion242, antimicrobial activity 
243, quorum-sensing signaling244,245, antitumor activity246, antiviral activity246, and inhibition against 
aflatoxin production 247. A parallel study in my PhD (Chapter 4) described the importance of a DKP 
as a regulator of bNOS and heronapyrrole biosynthesis. Likewise, another aspect of my research 
(chapter 5) studied a novel class of fungal diketomorpholines (DKMs) as inhibitors of P-gp 
mediated drug efflux. During that study, we had caused to synthesize cyclo-(L-Trp-L-Phe) (5.28) 
(see Chapter 5). As the DKP cyclo-(L-Trp-L-Phe) (5.28) is a well known fungal metabolite with no 
attributed biology, we were keen to determine if this DKP has the potential to regulate fungal 
secondary metabolism, much as modulated in chapter 4. To test this hypothesis, 5.28 and DKPs 
(4.39a – f) listed in Chapter 4 were tested against 20 different fungal and bacterial strains. Of 
significance to this current chapter, 5.28 activated silent secondary metabolism in Penicillium sp. 
(CMB-TF438), while simultaneously suppressed citrinaline X and citrinin biosynthesis. 
 
Penicillium sp. (CMB-TF438) was cultivated on two different media; ISP-2 with and without the 
addition of 5.28. The presence of 5.28 (10 µM) inhibited the production of all citrinalines and 
citrinin, and activated the production of another two metabolites (Figure 8.20). Large-scale 
cultivation and isolation yielded janthinone (8.32) and citrinolactone B (8.33), which was 
determined to be non-cytotoxic in antibacterial and antifungal assays against E.coli (ATCC 11775), 
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S. aureus (ATCC 25923 and ATCC 9144), B. subtilis (ATCC 6051 and ATCC 6633) and C. 
albicans (ATCC 90028). 
 
 
Figure 8.20. Chromatogram of Penicillium sp. (CMB-TF438) using HPLC-DAD-MS 90 – 0% H2O/MeCN (0.05% 
HCO2H modifier) over 15 min and detecting at 254 nm (DAD) with and without the addition of 10 µM cyclo-(L-Trp-L-
Phe) (5.28) on ISP-2 agar medium. 
 
 
8.3.1 cyclo-(L-Trp-L-Phe) and the secondary metabolites production of CMB-TF438  
In conclusion, that cyclo-(L-Trp-L-Phe) (5.28) (Chapter 4) has such a dramatic effect on the 
metabolite profile of Penicillium sp. (CMB-TF438) is noteworthy. Future studies within our group 
will attempt to; 
(a) Assess this effect over a range of concentrations. 
(b) Apply 5.28 to other Penicillium sp. known to produce citrinin, to establish if the effect is 
strain limited, or whether it is linked to specific polyketide synthases. 
(c) Monitoring the production levels of metabolites produced by Penicillium sp. (CMB-TF438) 
in the presence and absence of 5.28, overtime (daily for 24 days), to determine if 5.28 
activated silent metabolism, or alternatively accelerates the development of the culture.  
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8.3.1.1 Janthinona (8.32) 
 
 
HRESI(+)MS analysis of 8.32 revealed an adduct ion (M+Na)+ indicative of molecular formula 
C16H12O5 (Δmmu +0.9). The NMR (CDCl3) (Figure 8.21 and Table 8.5) showed the presence of 
five aromatic protons (δH 6.74, H-2; δH 6.62, H-4; δH 7.51, H-5; δH 7.72, H-6; and δH 7.28, H-7) in 
addition to the presence of a methoxy (δH 4.01) and a deshielded OH/NH (δH 12.13). The structure 
elucidation was further supported by 2D NMR data, including HSQC, COSY and HMBC (Table 
8.5). On searching the literature, 8.32 was consistent with the known fungal metabolite janthinona 
isolated from Penicillium janthinellum.232 
 
 
 
Figure 8.21.1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 
janthinona (8.32) 
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Table 8.5. NMR (600 MHz, CDCl3) data of janthinona (8.32) 
Pos.  δH, mult (J in Hz)a δCa COSY 
1H-13C HMBC 
1 12.13, s    
2 6.74, s 107.4 11-Me  
3  b   
4 6.62, s 112.4 11-Me 2 
4a  149.9   
5 7.51, d (8.3) 119.8 6 7 
5a  133.6   
6 7.72, t (8.3) 135.3 5, 7 5a, 7, 8 
7 7.28, d (8.3) 122.9 6 5 
8  155.9   
8-OMe 4.01, s 53.5  9 
8a  120.2   
9  170.3   
9a  b   
10  b   
11-Me 2.41, s 22.9  2, 4, 4a 
(a)13C assignments obtained from gHSQC and gHMBC data. (b) signals not observed 
 
 
Table 8.6. NMR (CDCl3) data comparison of experimental and literature232 data of janthinona (8.32)  
Pos δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (published) 
1 12.13, s c 
2 6.74, s 6.74, d (1.8) 
4 6.62, s 6.62, d (1.8) 
5 7.51, d (8.3) 7.51, dd (8.2, 2.0) 
6 7.72, t (8.3)  
7 7.28, d (8.3) 7.30, dd (7.3, 2.0) 
8-OMe 4.01, s 4.03, s 
11-Me 2.41, s 2.43, br s 
*measured (a) (600 MHz, CDCl3), (b) (400 MHz, CDCl3), (c) (signal not observed) 
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8.3.1.2 Citrinolactone B (8.33) 
 
HRESI(+)MS analysis of 8.33 returned a quasi-molecular ion (M+Na)+ indicative of formula 
C13H12O4 (Δ mmu +0.3). The NMR and 13C (DMSO-d6) spectra (Figure 8.22 and Table 8.7) showed 
one methyl, two aliphatic methylenes, two aromatic protons, six aromatic quaternary carbons, one 
carbonyl and one OH group. The structure elucidation was further supported by 2D NMR data, 
including HSQC, COSY and HMBC. On searching the literature, 8.33 was confirmed to be 
citrinolactone B, first isolated from Penicillium citrinum.248 This assignment was further supported 
by comparison of the [α]23D +20 (c 0.1, MeOH) of 8.33 with the reported [α]20D +86 (c 0.7, EtOAc) 
of citrinolactone B.248 
 
 
 
Figure 8.22. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 
citrinolactone B (8.33) 
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Table 8.7. NMR (600 MHz, DMSO-d6) data of citrinolactone B (8.33) 
Pos.  δH, mult (J in Hz)a δCa COSY ROESY 
1H-13C HMBC 
1  172.8    
2  b    
3  b    
4  b    
4a  147.9    
5 6.67, s 112.8 12  7, 12 
6  147.1    
7 6.94, s 107.8 12  5, 7, 12 
8  160.4    
8-OH 12.73, s    5, 7, 8 
8a  b    
9 5.08, d (6.6) 69.4 9-OH  1 
9-OH 5.21, d (6.6)  9 10a  
10 a 3.11, m 29.9 10a, 11b 9-OH 1 
 b 2.80, m  10b, 11a  1 
11 a 2.32, m 31.1 10b   
 b 1.56, m  10a   
12 2.37, s 21.7   4a, 5, 7 
*(a)13C assignments obtained from gHSQC and gHMBC data. (b) signals not observed 
 
Table 8.8. NMR (CDCl3) data comparison of experimental and published data248 of citrinolactone B (8.33) 
Pos. δH, mult, (J in Hz)a (experimental) δH, mult, (J in Hz)b (published) 
5 6.61, s 6.61, d (0.5) 
7 6.70, s 6.69, d (0.5) 
9 5.43, br  5.43, dd (14.0, 3.8) 
10a 2.49, m 2.77, m 
10b 2.03, m 2.03, m 
11a 3.09, m 3.11, m 
11b 2.82, m 2.83, m 
12-Me 2.37, s 2.39, m 
8-OH c 12.32, s 
*measured in (a) (600 MHz, CDCl3), (b) (500 MHz, CDCl3), (c) (signal not observed) 
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8.3.2 Biological assays 
The natural products, janthinona (8.32) and citrinolactone X (8.33) were tested in antimicrobial and 
cytotoxicity assays (see General experimental part). For the antimicrobial assay, the compounds 
were evaluated for the growth inhibitory against Staphylococcus aureus (ATCC 25923 and 9144), 
Bacillus subtilis (ATCC 6051 and 6633), Escherichia coli (ATCC 11775), Pseudomonas 
aeruginosa (ATCC 10145) and Candida albicans (ATCC 10231) as shown in Figure 8.24 and for 
cytotoxic assay, the compounds were also tested against two different cell lines, AGS (human 
stomach adrenocarcinoma) and HT 29 (human colon adrenocarcinoma) as shown in Figure 8.23. 
The compounds were tested in two fold dilution starting from 30 µM to 0.1 µM in 1% DMSO. 
These compounds did not show any biological activity. 
 
Figure 8.23. Graphs showing the cytotoxic activity of citrinaline X (8.30) and citrinaline A (8.28) against (a) human 
gastric cell line (AGS) and (b) colonadenocarcinoma (HT-29) cells as measured by plate reader spectrophotometer at 
OD600 with IC50 for citrinaline X (8.30) = 27.1±0.1 and 29.5±0.1 µM respectively 
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Figure 8.24. Graphs showing the antibacterial and antifungal activity of 8.30, 8.32 and 8.33 as measured by plate reader 
spectrophotometer at OD600 
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8.4 Conclusion 
This chapter outlines the isolation of citrinaline X (8.30) as a new DKP metabolite from a terrestrial 
Penicillium sp. (CMB-TF438) together with the well-known fungal metabolite citrinin (8.31). The 
structure of citrinaline X was established by analysis of spectroscopic data using both 1D and 2D 
NMR data. During this study, citrinaline A and B were published by Pimenta et al. Further analysis 
of NMR data for 8.30 confirmed that it was the C-22 epimer of citrinaline A (8.28). A comparison 
between authentic sample citrinaline A (8.28) and citrinaline X (8.30) confirmed that citrinaline X 
(8.30) was not citrinaline A (8.28). We note from private communication that the published 
structure for citrinaline B (8.29) is to be revised, to be identical with that we now propose of 8.30. 
However, we also note that these two compounds citrinaline B (8.29) and citrinaline X (8.30) 
possess opposite [α]D measurements. To resolve this matter, the sample of 8.30 had been forward to 
collaborate for direct HPLC comparison with 8.29. Although these results are pending, we strongly 
suspect the 8.30 and 8.29 are not the same, and that the proposed structure revision to 8.29 may 
required close inspection. 
 
No biological activity has been reported for citrinaline A.230 Also, citrinaline X was inactive in 
antimicrobial assay against Staphylococcus aureus (ATCC 25923 and 9144), Bacillus subtilis 
(ATCC 6051 and 6633), Escherichia coli (ATCC 11775), Pseudomonas aeruginosa (ATCC 10145) 
and Candida albicans (ATCC 10231) as well as against different cell line in the cytotoxic assay. In 
the same time, DKP cyclo-(L-Trp-L-Phe) was synthesized and added at different concentrations to 
Penicillium sp. (CMB-TF438) at 10 µM, it completely inhibited the production of citrinaline X and 
citrinin and activates the production of another metabolites, which where purified and the structures 
were solved to afford two known metabolites, janthinona (8.32) and citrinolactone B (8.33).  
8.5 Future work 
We hypothesize that cyclo-(L-Trp-L-Phe), which is present in many fungal metabolites, plays a role 
in the activation of secondary metabolites that may have in the future an important biological 
activity (see p.371).  
 
 
Chapter 8. Citrinaline X and the importance of physicochemical characterization 
 379 
8.6 Experimental section 
8.6.1 Isolation and identification of strain CMB-TF0438:  
The terrestrial derived fungus strain CMB-TF0438 was isolated from a terrestrial sample collected 
from North Stradbroke Island, Queensland. The fresh terrestrial sample was transferred to the 
laboratory in a sealed 50 mL Falcon tube at room temperature (24 h), where it is stored in the dark 
at −30 °C for one week. Approximately, 1 g of the thawed terrestrial sample was suspended in 8 mL 
sterile 0.9% saline solution and then subjected to heat-shock at 60 °C for 30 min after which 100 µL 
was serially diluted to 10-1, 10-2 and 10-3 and transferred into 1000 µL sterile saline solution by 
means of sterile micro titre pipette. Furthermore, 50 µL from each diluted portion is dispersed 
across agar plates comprising (25 mL of 0.4% yeast extract, malt extract 1%, glucose 0.4%, agar 
2% and 0.0005% rifampicin). The resulting agar plate was incubated at 27 °C for three weeks. Pure 
strains of individual colonies were obtained by standard microbiological techniques, and were 
grown to dense colonies on a single agar plate.  
 
8.6.2 Chemical profiling:  
A single colony of Penicillium sp. (CMB-TF0438) was sub-sampled into distilled water agar 
medium (25 mL of distilled water, 0.4% yeast extract, malt extract 1%, glucose 0.4%, agar 2%) and 
incubated at 27 °C for 10 d. The agar plate was soaked with EtOAc (100 mL), and shaken on the 
rotary shaker at 100 rpm overnight. The organic phase was concentrated in vacuo to yield an extract 
that was subsequently analysed by HPLC-DAD-ESI(±)MS and NMR. 
8.6.3 Large-scale cultivation and extraction of strain CMB-TF0438:  
A seed culture was prepared by inoculating a 25 mL agar plate containing (15 mL distilled water 
containing 0.4% yeast extract, malt extract 1%, glucose 0.4%, agar 2%) with 50 µL from the frozen 
culture followed by incubating the plate for 10 d at 27 °C. A loop of the seed culture was 
transferred to 30 agar plates with dimensions 150 × 120mm, and the plates were incubated for 10 d 
at 27 °C. The resulting cultures were sliced and soaked in 400 mL EtOAc and shake on the rotary 
shaker at 100 rpm overnight. The organic layer was concentrated in vacuo to yield an extract (190 
mg). The extract was sequentially triturated with 25 mL each of hexane, CH2Cl2 and MeOH to 
afford 10 mg, 19.5 mg and 151.4 mg fractions, respectively. Each fraction was analysed by HPLC-
DAD-MS and NMR. The MeOH fraction, which was found to be rich in the secondary metabolites, 
was subsequently subjected to semi-preparative reversed-phase HPLC (Zorbax C18 250 × 9.4 mm, 5 
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µm column, 3 mL/min gradient elution from 70 – 10% H2O/MeCN over 30 min with constant 
0.01% TFA with a hold at 100% MeCN for 5 min), to yield citrinlaine X (8.30) (tR = 19 min, 3 mg, 
3.1%) and citrinin (8.31) (tR= 25 min, 5 mg, 5.2%). [Note - % yields are determined on a mass-to-
mass basis against the weight of EtOAc crude extract]. 
8.6.4 Large-scale cultivation and extraction of CMB-TF0438 in the presence of 8.32 
A seed culture was prepared by inoculating a 80 mL ISP-2 broth containing (80 mL distilled water 
containing 0.4% yeast extract, malt extract 1%, glucose 0.4%) followed by incubating for 10 d at 27 
°C. Seed culture (5 mL) was transferred to 400 mL ISP-2 broth containing 8.32 (10 µM) and 
incubated for 10 d at 27 °C. The broth was extracted with 2 × 400 mL EtOAc. The organic layer 
was concentrated in vacuo to yield an extract (190 mg). The extract was sequentially triturated with 
8 mL each of hexane, CH2Cl2 and MeOH to afford 2 mg, 40 mg and 3 mg fractions, respectively. 
Each fraction was analysed by HPLC-DAD-MS and NMR. The CH2Cl2 fraction, which was found 
to be rich in the secondary metabolites, was subsequently subjected to semi-preparative reversed-
phase HPLC (Zorbax C8 250 × 9.4 mm, 5 µm column, 3 mL/min gradient elution from 90 − 10% 
H2O/MeCN over 30 min with constant 0.01% TFA with a hold at 100% MeCN for 5 min), to yield 
janthinona (8.33) (tR = 15 min, 1.5 mg, 3.1%) and citrinolactone B (8.34) (tR= 22 min, 1 mg, 5.2%). 
[Note - % yields are determined on a mass-to-mass basis against the weight of EtOAc crude 
extract]. 
 
Citrinaline X (8.30): pale yellow powder [α]D –8.1 (c 0.01, CHCl3). UV (MeOH) λmax (logε): 206 
(3.94), 228 (3.75, 259 (3.59), 352 (3.20) nm. IR (film) νmax: 3348, 2946, 2833, 2360, 1449 cm-1. 
NMR (600 MHz, MeOH-d4) see Table 8.1; HRESI(+)MS m/z 454.2331 [M+H] (Δmmu +0.5) 
(calcd for C25H32N3O5 454.2336) 
 
Citrinin (8.31): yellowish brown oil; 1H NMR (600 MHz, DMSO-d6) see Table 8.3; HRESI(+)MS 
m/z 251.090 [M+H]+ (calcd for C13H14O5 251.0914). 
 
Janthinona (8.32): yellow oil; 1H NMR (600 MHz, CDCl3); see Table 8.5; HRESI(+)MS m/z 
307.0577 [M+Na]+ (calcd for C22H17O7Na 307.0586). 
 
Citrinolactone B (8.33): colourless oil; [α]22D + 20.2 (c 0.01, MeOH); see Table 8.7; HRESI(+)MS 
m/z 255.0625 [M+H]+ (calcd for C22H17O7Na 255.0628). 
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9 Chapter 9. Additional Microbial Chemical Diversity 
9.1 Introduction 
A diverse range of known secondary metabolites was isolated from various strains obtained from 
diverse locations around coastal areas of Australia. This chapter describes in brief an overview of 
known secondary metabolites from different strains. All analytical cultivation procedures were 
performed in which a single colony of the microbes was used to inoculate a seed culture composed 
of M1 media (100 mL in a 250 mL Schott flask). The strain was shaken at 190 rpm for 7 d at 27 °C, 
extracted with EtOAc (2 × 50 mL per flask), and the crude extract was redissolved in MeOH 
generating a concentration of 1 mg/mL and analysed by HPLC-DAD-ESI(±)MS (Zorbax C8 
column, 150 × 4.6 mm, 5 µm, 1 mL/min, gradient from 90 – 0% H2O/MeCN (isocratic 0.05% 
formic acid) over 15 min, with a hold at 100% MeCN for 5 min). Large-scale cultivation was 
performed using two 2-L Erlenmeyer flasks containing M1 broth (400 mL) were inoculated with 
seed culture (5 mL) of the microbe. The flasks were incubated at 27 °C on a rotary shaker at 190 
rpm for 7 d, extracted with EtOAc (2 × 300 mL per flask),  
9.2 Streptomyces sp. (CMB-M0137) 
A previous PhD student isolated Streptomyces sp. (CMB-M0137) from a marine sediment sample 
collected from Queensland, Australia. Analytical cultivation yielded peaks with the retention times 
tR = 10.2 min and 11.4 min, which exhibited the following m/z [M+H]+ 507 (9.01), 271 (9.02). 
Large-scale cultivation yielded a crude extract (60 mg). The crude extract was sequentially 
triturated with hexane and CH2Cl2 (10 mL aliquots), which were concentrated in vacuo, to yield 
15.3 and 35 mg respectively (Scheme 9.1).  
 
 
Scheme 9.1. Isolation scheme of crude extract from CMB-M0137 (a) Trituration [hexane (-1-1) and CH2Cl2 (-1-2)], (b) 
Semi-preparative HPLC: Zorbax C8, 90 – 10% H2O/MeOH, 3 mL/min, 30 min. 
 
crude extract
60 mg
-1-1
15.3 mg
-1-2
35 mg
-1-2-1
1.5 mg
9.01
(a)
(b)
-1-2-2
2.3 mg
9.02
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9.2.1 Streptonigrin (9.01) 
HRESI(+)MS analysis of 9.01 revealed a quasi-molecular ion [M+H]+ corresponding to a molecular 
formula (C25H22N4O8, Δmmu –0.6). On searching the literature, 9.01 was determined to be 
consistent with the known bacterial metabolite streptonigrin. Analysis of all the NMR (600 MHz, 
CDCl3) data with comparison to literature data (Figure 9.1, Table 9.1 and Table 9.2) confirmed that 
9.01 was streptonigrin. Herlt et al. isolated streptonigrin from Streptomyces sp. as a novel 
heterocyclic compound with antibacterial and antifungal activity.249 
 
 
Figure 9.1. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 
streptonigrin (9.01) 
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Table 9.1. NMR (600 MHz, CDCl3) data of streptonigrin (9.01) 
 
(a) assignments supported by HSQC and HMBC, (b) signals not observed 
 
Table 9.2. 1H NMR (600 MHz, CDCl3) comparison of experimental and literature250 data of streptonigrin (9.01) 
 250
 
*(a) assignments supported by HSQC, (b) signals not observed 
Pos !H, mult, (J in Hz) !C
a COSY 1H – 13C HMBC 
1     
2  144.8   
3 8.50, d (8.3) 134.8 4 7, 8a 
4 8.72, d (8.3) 125.8 3 2, 4a 
4a  126.5   
5  179.9   
6  137.5   
7  b   
8  b   
8a  159.7   
1"  
b   
2"  134.5   
3"  139.6   
4"  132.2   
5"  147.4   
6"  136.8   
7"  113.6   
8" 
 b   
9"  136.8   
10"  159.6   
11" 6.70, d (8.3) 105.6 12" 7", 9" 
12" 6.82, d (8.3) 125.4 11" 5", 10" 
6-OMe 4.13, s 60.9  6 
7-NH2/NH 5.75, s   5 
8"-OH 5.92, s    
2"-COOH 
b    
3"-Me 2.52, s 17.8  2", 3", 4" 
9"-OMe 3.98, s 56.6  10" 
10"-OMe 4.02, s 62.1  6" 
 
Pos !H, mult, (J in Hz) (experimental) !H, mult, (J in Hz) (literature) 
3 8.50, d (8.3) 8.48, d (8.4) 
4 8.72, d (8.3) 8.69, d (8.4) 
11" 6.70, d (8.3) 6.68, d (8.5) 
12" 6.82, d (8.3) 6.80, d (8.5) 
6-OMe 4.13, s 4.10, s 
7-NH2/NH 5.75, s 5.12, br s 
8"-OH 5.92, s 5.95, br s 
2"-COOH 
b 12.39, br s 
3"-Me 2.52, s 2.50, s 
9"-OMe 3.98, s 3.95, s 
10"-OMe 4.02, s 3.99, s 
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9.2.2 1-N-methylalbonourisin (9.02) and lansai D (9.03) 
 
ESI(+)MS data for 9.02 revealed a m/z 271[M+H]+ consistent with 1-N-methylalbonourisin. On 
searching the literature, 9.02 was determined to be consistent with the known bacterial metabolite 
(3Z, 6E)1-N-methylalbonourisin. Analysis of all the NMR (600 MHz, CDCl3) data with comparison 
to literature data (Figure 9.2 and Table 9.3) confirmed that 9.02 was 1-N-methylalbonourisin. 1-N-
methylalbonourisin was isolated from the culture of first isolated from Streptomyces sp.251 and then 
was reisolated from Micromonospora sp.250. Lansai D (9.03) is similar 1-N-methylalbonourisin but 
with (3E, 6E).252 Our molecule was a mixture of 1-N-methylalbonourisin and lansai D. We 
hypothesize that 9.03 during handling and isolation procedures can undergo double isomerization to 
give the more stable analogue 9.02. Wang et al isolated 9.03 using TFA, while Tuntiwachwuttikul 
et al. isolated 9.03 only with EtOAc and MeOH. 
 
 
 
 
Figure 9.2. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 
1-N-methylalbonourisin (9.02) (blue) and lansai D (9.03) 
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Table 9.3. NMR (600 MHz, DMSO-d6) data of 1-N-methylalbonourisin (9.02) and lansai D (9.03) 
 
  *(a) assignments supported by HSQC and HMBC, (b) Overlapping resonances 
Pos !H, mult, (J in Hz) (9.02) !C
a (9.02) !H, mult, (J in Hz) (9.03) !C
a (9.03) 
1-Me 3.16, s 29.9 3.10, s 29.0 
2  159.7  158.2 
3  129.5  128.3 
4-NH 10.23, s  10.67, s  
5  156.8  156.6 
6  128.7  128.3 
7 6.69, s 114.8 6.45, s 119.8 
8  129.5  130.3 
9, 13 7.57, d (7.8) 129.1  129.9 
10, 11, 12 7.38, t (7.8) 128.5  127.6 
14 5.53,d (9.3) 132.3 5.49, d (9.3) 131.6 
15 3.64, m 26.1 3.71, m 29.9 
16 1.03, d (3.3)b 22.9b 1.03, d (3.3)b 22.9b 
17 1.02, d (3.1)b 22.9b 1.02, d (3.1)b 22.9b 
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9.3 Streptomyces sp. (CMB-TB376) 
Streptomyces sp. (CMB-TB376) was isolated from a terrestrial sample collected from North 
Stradbroke Island, Queensland, Australia. Analytical cultivation yielded peaks with the retention 
times tR = 6.2 min and 8.3 min exhibited the following m/z [M+H]+ 394 (9.04), 393. Large-scale 
cultivation yielded a crude extract (30 mg), which was sequentially triturated with hexane, CH2Cl2 
and MeOH (10 mL aliquots), concentrated in vacuo, to yield 4, 3 and 20 mg respectively (Scheme 
9.2). 
  
 
Scheme 9.2. Isolation scheme of crude extract from CMB-TB385 (a) Trituration [hexane (-1-1), CH2Cl2 (-1-2) and 
MeOH (-1-3)], (b) Semi-preparative HPLC: Zorbax-C18, 60 – 10% H2O/MeCN, isocratic 0.01% TFA, 3 mL/min, 30 
min. 
9.3.1 Undecyl prodigiosin (9.04) 
HRESI(+)MS analysis of 9.04 revealed an adduct molecular ion [M+Na]+ corresponding to a 
molecular formula (C25H35N3O1, Δ mmu –1.8). On searching the literature, 9.04 was determined to 
be consistent with the known bacterial metabolite undecyl prodigiosin. Analysis of all the NMR 
(600 MHz, DMSO-d6) data with comparison to literature data (Figure 9.3, Table 9.4 and Table 9.5) 
confirmed that 9.04 was undecyl prodigiosin. Wasserman et al. isolated undecyl prodigiosin from 
Streptomyces longisporus ruber sp.253,254  
 
 
Figure 9.3. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H at 254 nm) spectra of 
undecyl prodigiosin (9.04) 
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Table 9.4. NMR (600 MHz, DMSO-d6) data of undecyl prodigiosin (9.04) 
Pos δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC 
1  149.2   
2 6.13, br 110.1 3  
3 6.58, br 118.3 2  
4  c   
5     
6 6.63, s 114.0  8 
7  c   
8  160.2   
9 5.98, br 95.8   
10  c   
11     
12  123.4   
13 7.09, br 121.9   
14 6.21, br 109.5  12 
15 6.72, br 111.8 16  
16-NH 11.71, br  15  
8-OMe 3.84, s 57.9  6 
1′ 2.75, t (7.8) 27.5 2′ 1 
2′ 2.17, m 26.9 1′, 3′  
3′ 1.97, m 26.1 2′, 4′  
4′ 1.63, m 25.2 3′, 5′  
5′ 1.47, m 24.2 4′  
6′-10′ 1.30b 21.6   
11′-Me 0.84, t (6.1) 13.5   
*(a)assignments supported by HSQC and HMBC, (b) Overlapped resonances, (c) signals not observed 
 
Table 9.5. 1H NMR comparison (CDCl3) of experimental and literature122 data of undecyl prodigiosin (9.04) 
Pos δH, mult, (J in Hz) (experimental) δH, mult, (J in Hz) (literature) 
2 6.10, d (3.4) 6.18, d (3.7) 
3 6.79, d (3.4) 6.81, d (3.7) 
6 6.99, s 6.98, s 
9 6.02, s 6.08, s 
13 7.31, br 7.32, brs 
14 6.38, dd (3.1, 2.0) 6.37, dd (3.5, 2.5) 
15 6.99, dd (3.1, 2.0) 6.97, dd (3.7, 1.1) 
8-OMe 4.03, s 4.01, s 
1′ 2.88, m 2.79, m 
2′-10′ 1.21 – 1.39, m 1.25 – 1.35, m 
11′-Me 0.88, t (6.2) 0.87, t (6.6) 
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9.4 Streptomyces sp. (CMB0-TB385) 
Streptomyces sp. (CMB-TB385) was isolated from a terrestrial sample collected from New South 
Wales, Australia. Analytical cultivation yielded peaks with the following retention times tR = 9.1 
min and 15.6 min exhibited the following m/z [M+H]+ 193 (9.05), 364 (9.06). Large-scale 
cultivation yielded a crude extract (30 mg), which was sequentially triturated with hexane, CH2Cl2 
and MeOH (10 mL aliquots), concentrated in vacuo, to yield 1, 10 and 32.3 mg respectively 
(Scheme 9.3). 
 
 
Scheme 9.3. Isolation scheme of crude extract from CMB-TB385 (a) Trituration [hexane (-1-1), CH2Cl2 (-1-2) and 
MeOH (-1-3)], (b) Semi-preparative HPLC: Zorbax C8, 90 – 10% H2O/MeOH, 3 mL/min, 30 min. 
 
9.4.1 6,8-dihydroxy-3-methylisocoumarin (9.05) 
HRESI(+)MS analysis of 9.05 revealed an adduct molecular ion [M+H]+ corresponding to a 
molecular formula (C10H8O4, Δmmu –0.1). On searching the literature, 9.05 was determined to be 
consistent with the known bacterial metabolite 6,8-dihydroxy-3-methylisocoumarin. Analysis of all 
the NMR (600 MHz, DMSO-d6) data with comparison to literature data (Figure 9.4, Table 9.6 and 
Table 9.7) confirmed that 9.05 was 6,8-dihydroxy-3-methylisocoumarin. Mehdi et al., isolated 6,8-
dihydroxy-3-methylisocoumarin from Streptomyces sp.255  
crude extract
50.3 mg
-1-1
1 mg
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Figure 9.4. 1H NMR (600 MHz, DMSO-d6) of 6,8-dihydroxy-3-methylisocoumarin (9.05) 
Table 9.6. NMR (600 MHz, DMSO-d6) data of 6,8-dihydroxy-3-methylisocoumarin 9.05 
Pos δH, mult, (J in Hz) δCa 
1H – 13C HMBC 
1  166.2  
2    
3  155.6  
4 6.44, s 102.6 4a 
4a  141.2  
5 6.29, s 100.9  
6  166.2  
7 6.26, s 103.7 6 
8  b  
7,8-OH 10.91, brs   
9-Me 2.18, s 18.4 1, 3 
(a)assignments supported by HSQC, (b) Overlapped resonances 
 
Table 9.7. 1H NMR (DMSO-d6) comparison of experimental and literature255 data of 9.05 
Pos δH, mult, (J in Hz) (experimental)a δH, mult, (J in Hz) (literature)b 
4 6.44, s 6.47, s 
5 6.29, s 6.33, s 
7 6.30, s 6.30, s 
7,8-OH 10.91, br s c 
9-Me 2.18, s 2.22, s 
(a) measured 600 MHz, (b) 300 MHz, (c) not observed 
9.4.2 Trindoline (9.06) 
HRESI(+)MS analysis of 9.06 revealed an adduct molecular ion [M+Na]+ corresponding to a 
molecular formula (C24H17N3O1, Δmmu –0.1). On searching the literature, 9.06 was determined to 
be consistent with the known bacterial metabolite trindoline. Analysis of all the NMR (600 MHz, 
DMSO-d6) data with comparison to literature data (Figure 9.5, Table 9.8 and Table 9.9) confirmed 
that 9.06 was trindoline. Kobayashi et al., isolated trindoline from Vibrio sp. as new antibiotic 
indole dimer.256  
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Figure 9.5. 1H NMR (600 MHz, DMSO-d6) of trindoline (9.06) 
Table 9.8. NMR (600 MHz, DMSO-d6) data of trindoline (9.06) 
Pos δH, mult, (J in Hz) δCa COSY 
1H – 13C HMBC 
1 10.57, s   3 
2  c   
3  56.2   
3a  136.2   
4 7.23b, m 128.2 5 7a 
5 6.91, t (7.3) 122.0 4, 6  
6 7.19, d (2.6) 121.3 5, 7  
7 6.99, d (7.8) 121.5 6 3a 
7a  142.1   
1′, 1′′ 10.94, s  2′/2′′  
2′, 2′′ 6.82, d (2.4) 124.8 1′/1′′ 3′a/3′′b, 4′/4′′ 
3′, 3′′  117.3   
3′a, 3′′b  126.2   
4′, 4′′ 7.22b, m 125.5 5′/5′′  
5′, 5′′ 6.79, t (8.1) 118.8 4′/4′′, 6′/6′′  
6′, 6′′ 6.96, t (7.8) 110.2 5′/5′′, 7′/7′′  
7′, 7′′ 7.33, d (8.1) 112.1 6′/6′′ 7′a/7′′a 
7′a, 7′′a  140.1   
  *(a) assignments supported by HSQC and HMBC, (b) Overlapping resonances, (c) signals not observed 
 
Table 9.9. NMR comparison (MeOH-d4) of experimental and literature256 data of trindoline (9.06) 
 
*(a) measured at 600 MHz, (b) measured at 500 MHz 
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9.5 Streptomyces sp. (CMB-TB350) 
Streptomyces sp. (CMB-TB350) was isolated from a terrestrial sample collected from North 
Stradbroke Island, Queensland, Australia. A single colony of strain CMB-TB350 was used to 
inoculate a seed culture composed of ISP-2 media. Analytical cultivation yielded peaks with 
retention times tR = 11.1 min and 13.2 min exhibited the following m/z [M+2H]2+ 649 (9.07). 
Large-scale cultivation, yield a crude extract (45 mg), which was sequentially triturated with hexane 
and CH2Cl2 (10 mL aliquots), concentrated in vacuo, to yield 12, and 25.4 mg respectively (Scheme 
9.4). 
 
 
Scheme 9.4. Isolation scheme of crude extract from CMB-TB350 (a) Trituration [hexane (-1-1) and CH2Cl2 (-1-2)], (b) 
Semi-preparative HPLC: Zorbax-C8, 90 – 10% H2O/MeCN (isocratic 0.01% TFA), 3 mL/min, 30 min. 
9.5.1 Actinomycin Z (9.07) 
ESI(+)MS analysis of 9.07 revealed a molecular ion m/z 649 [2M+2H]+. On searching the literature, 
9.07 was determined to be consistent with the known bacterial metabolite actinomycin Z1. Analysis 
of all the NMR (600 MHz, CDCl3) data with comparison to literature data (Figure 9.6, Table 9.10 
and Table 9.11) confirmed that 9.07 was actinomycin Z1. Lackner et al., isolated actinomycin Z1 
from Streptomyces fradiae sp. as new antibiotic.257  
 
Figure 9.6. 1H NMR (600 MHz, CDCl3) of actinomycin Z1 (9.07) 
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Table 9.10. NMR (600 MHz, CDCl3) data of actinomycin Z1 (9.07) 
 
*(a) assignments supported by HSQC and HMBC, (b) Overlapped resonances, (c) signals not observed 
# Pos. !H, mult (J in Hz)
a 
       "-ring                             #-ring 
!C
a COSY HMBC 
Thr 1   168.3/170.1   
 2 4.65, d (9.0) 5.01, m 55.2 3 1, 4 
 3 5.24, dd (9.0, 3.1) 5.10, m 77.6 4  
 4 1012, d (6.0) 3.66b, m 17.2 3 2 
 NH 7.14, d (6.0) c    
 OH c c    
Val 1   172.3/173.4   
 2 3.42b, m 3.82b, m 57.6/57.8 3 1 
 3 2.11, m 2.18, m 32.9 2  
 3-Me 0.90, m 0.91, d (6.1) 18.9 3  
  1.12, d (6.5) 1.12, d (6.1)    
 NH 8.16, d (6.5) c    
3-OH-5-Me-Pro 1   171.3/169.2   
 2 5.91, d (9.1) 6.14, d (6.5) 66.3 3  
 3 3.95b, m 2.32 c, m 77.2 2 1 
   3.92c, m    
 4 a 2.11b, m  40.2   
  b 2.17b, m     
 5 4.70, d (4.5) 4.52, dd (7.2, 2.3) 55.4 5-Me  
 5-Me 1.48, br d 1.58d 17.8 5  
 OH c c    
Sar 1   167.8   
 2 a 3.59c, m 3.62c, m 71.7  1 
  b 4.62, d (6.1) 4.52, d (16.5)    
 N-Me 2.87, s 2.86, s 22.1   
Me Val 1   166.8   
 2 2.68 c, m 3.21c 52.3 3 3 
 3 2.67 c, m 1.31, d (6.1)  2 1 
 3-Me 0.72, d (6.1)  36.1 3  
  0.93, d (6.1)     
 N-Me 2.84, s 2.87, s 29.2   
Chrom. 4-Me 2.12, s  33.1   
 6-Me 2.51, s  36.1  8 
 7 7.35, d (7.6)  122.6 8  
 8 7.51, d (7.6)  125.9 7  
 NH2 
c     
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Table 9.11. 1H NMR (CDCl3) comparison of experimental and literature257 data of actinomycin Z1 (9.07)  
 
*(a) assignments supported by HSQC and HMBC, (b) Overlapping resonances, (c) signals not observed 
# Pos. !H, mult (J in Hz)
a experimental 
       "-ring                             #-ring 
!H, mult (J in Hz)
a literature 
       "-ring                             #-ring 
Thr 1     
 2 4.65, d (9.0) 5.01, m 4.62, dd, br 2.01, dd br 
 3 5.24, dd (9.0, 3.1) 5.10, m 52.4, dq (10.1, 3.2) 5.10, m 
 4 1012, d (6.0) 3.66b, m 1.12, d (6.4) 3.69, m 
 NH 7.14, d (6.0) c 7.18, brs 8.13, d (6.2) 
 OH c c  3.22, s 
Val 1    3.83, dd (9.9, 6.2) 
 2 3.42b, m 3.82b, m 3.44, dd (9.9, 6.9) 2.18, m 
 3 2.11, m 2.18, m 2.11, m 0.92, d (6.2) 
 3-Me 0.90, m 0.91, d (6.1) 0.90, d (6.2) 1.15, d (6.6) 
  1.12, d (6.5) 1.12, d (6.1) 1.12, d (6.3)  
 NH 8.16, d (6.5) c 8.15, d (6.9) 8.30, brs 
3-OH-5-Me-Pro 1     
 2 5.91, d (9.1) 6.14, d (6.5) 5.86, s 6.42, dd (11.0, 2.0) 
 3 3.95b, m 2.32 c, m 4.16, dd (11.3, 5.2) 2.32, d (17.6) 
   3.92c, m  3.93, dd (17.6, 11.0) 
 4 a 2.11b, m  2.11, m  
  b 2.17b, m  2.18, m  
 5 4.70, d (4.5) 4.52, dd (7.2, 2.3) 4.71, m 4.55,q (7.1) 
 5-Me 1.48, br d 1.58d 1.49, d (5.8) 1.59, d (7.1) 
 OH c c 4.46, m  
Sar 1     
 2 a 3.59c, m 3.62c, m 3.61, d (17.5) 3.65, d (17.5) 
  b 4.62, d (6.1) 4.52, d (16.5) 4.73, d (17.5) 4.56, d (17.5) 
 N-Me 2.87, s 2.86, s 2.88, s 2.85, s 
Me Val 1     
 2 2.68 c, m 3.21c 2.69, d (9.3) 3.22, q (6.9) 
 3 2.67 c, m 1.31, d (6.1) 2.64, m 1.32, d (6.9) 
 3-Me 0.72, d (6.1)  0.73, d (6.7)  
  0.93, d (6.1)  0.94, d (6.4)  
 N-Me 2.84, s 2.87, s 2.88, s 2.89, s 
Chrom. 4-Me 2.12, s  1.93, s  
 6-Me 2.51, s  2.51, s  
 7 7.35, d (7.6)  7.34, d (7.6)  
 8 7.51, d (7.6)  7.48, d (7.6)  
 NH2 
c  7.20 + 8.10 br  
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10   Chapter 10. Microbial Community isolation and analysis 
10.1 Introduction 
Soil microbes play an important role in various aspects of terrestrial ecosystems. In order to access 
these microbial communities, terrestrial soil/sediment samples collected from different regions in 
Australia were used to inoculate solid phase culture media, and facilitate the recovery of pure 
isolates using standard microbiological techniques. 
 
10.2 Sampling 
A total of 120 (~ 5 g) sediment samples were collected during the period from January 2009 to 
December 2009, from different environments in Australia, to maximize access to a diversity of soil 
microorganisms. Samples were collected in sterile 50 mL falcon tubes, and debris/plant residues 
removed by manual inspection.  
10.3 Transportation and storage conditions 
Environmental factors such as freezing, thawing and moisture can have a great impact on microbial 
cell wall and may cause cell lysis for microbes with fragile cell structures. Hence, the transportation 
and storage conditions can impact on microbial community diversity. We employed transportation 
and storage methods designed to minimize the loss of microbial diversity. Samples were rapidly 
transferred to the laboratory in sealed containers and processed immediately after arrival (or stored 
at −32 °C freezer).  
 
10.4 Isolation of microbes 
The samples were processed by two different methods;  (1) stamping and (2) dilution and heat-
shock; and were inoculated into different isolation media (M1, LB, YPD, M7, ISP-2, MH, mannitol 
and TSA)  (Table 10.1).  
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10.4.1 Stamping 
In the stamping method a sediment sample (1 g) was placed aseptically in a sterile petri dish, dried 
(approx. 24 h) in a laminar flow hood, and then inoculated onto agar media by stamping 8 to 9 
times in a circular way to give a serial dilution effect.258,259 
 
Figure 10.1. Schematic demonstration of stamping technique. Figure from Tresner et al. 259 
 
10.4.2 Dilution and heat-shock 
In the dilution and heat-shock, sterile brine (9 mL) was added to a soil sample (1 g), which was 
shaken well. The resulting suspension was heated at 55 °C for 30 min with vigorous shaking on a 
water bath. The supernatant from this heat-shock processing was diluted serially (10-1 to 10-6) by 
transferring 1 mL into 9 mL sterile brine solution. Furthermore, 50 µL from each diluted portion 
was dispersed across a culture plate (Petri dish) containing one of several defined media by means 
of disposable sterile rods (Scheme 10.1). 
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Scheme 10.1. Schematic demonstration of heat shock and dilution technique. 
 
For both methods, culture plates were grown for 1 − 5 weeks in an incubator set at 26.5 − 30° C, 
with periodic inspection to note for significant growth. Standard microbiological technique of 
sampling and replating was used to acquire pure isolates of individual colonies. Actinomycetes 
usually appeared between one and six weeks of incubation. The pure actinomycetes colony was 
considered the colony with tough leathery texture, dry or folded appearance, and branching 
filaments with or without aerial mycelia (Scheme 10.2).  
 
Scheme 10.2. Schematic demonstration for the microbial isolation from sediment samples 
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Table 10.1. Summary for the description of the different isolation media  
 
All the isolation media were supplemented with either the antifungal cycloheximide (100 µg/mL) 
(10.01) for actinomycetes selection, and either of the antibacterials rifampin (5 µg/mL) (10.02) or 
novobiocin sodium salt (25 µg/mL) (10.03) for fungal selection.  
                   
 
# Description 
Media 1 
(LB) 
LB agar: comprising H2O (1 L), casein peptone (10 g), yeast extract (5 g), NaCl (5 g) and 
agar (15 g). 
 
Media 2 
(Manniol 
agar) 
Mannitol agar: comprising H2O (1 L), peptone (3 g), yeast extract* (5 g), D-mannitol (25 g) 
and agar* (15 g). 
Media 3 
(YPD) 
YPD agar: comprising H2O (1 L), yeast extract* (10 g), peptone* (20 g), D-glucose* (20 g) 
and agar (20 g). 
Media 4 
(M1) 
M1 agar: comprising H2O (1 L), yeast extract (4 g), peptone (2 g) and agar (18 g). 
Media 5 
(M7) 
M7 agar: comprising H2O (1 L), D-mannitol (0.5 g), tryptone (0.1 g) and agar (8 g). 
Media 6 
(ISP-2) 
ISP-2: comprising H2O (1 L), yeast extract (4 g), malt extract (10 g), D-glucose (4 g) and 
agar (20 g).  
Media 7 
(Muller 
Hinton) 
Muller Hinton agar: comprising H2O (1 L), beef extract powder (2 g), acid digest casein 
(17.5 g), starch (1.5 g) and agar (17 g). 
Media 8 
(Tryptic 
soy) 
Tryptic soy agar: comprising pancreatic digest of casein (15 g), papaic digest of soybean (5 
g), NaCl (5 g) and agar (15 g). 
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Figure 10.2. Example for antimicrobial screening for the microbial crude extracts against (a) Bacillus subtilis (ATCC 
6051) and (b) Candida albicans (ATCC 10231). Control is either Bacillus subtilis (ATCC 6051) or Candida albicans 
(ATCC 10231) in the presence of 1% DMSO, negative control is media only. 
10.5 Primary cultivation and preservation of pure microbial isolates 
All pure isolates were cultured in 100 mL shaken flasks at 150 rpm for 7 − 10 d, or in a micro-
bioreactor (1.5 mL). After cultivation, sample of each isolates were preserved in 20% aqueous 
glycerol and stored at −80 °C, while the remaining cultures were extracted with equal volumes of 
EtOAc and the organic layer were concentrated to dryness by rotary evaporation, and the resulting 
crude extracts weighed and redissolved at 1 mg/mL in MeOH prior to HPLC-DAD-MS analysis. 
Crude extracts were stored at −30 °C for future bioassay. 
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Scheme 10.3. Scheme for the purification, chemical and biological profiling of microbes 
 
10.6 Cultivation of isolates for chemical profiling 
10.6.1 Actinomycetes 
Actinomycetes isolates were prioritized for detailed chemical investigation depending on their 
chemical (secondary metabolite) profile, morphological appearance and biological activity.  A 
primary culture of each isolate was started using the total volume of a cryo-preserved stock vial as a 
seed culture in a 100 mL shake flask. Isolates were then cultured at 150 rpm for 7 − 10 d, after 
which the culture was extracted with EtOAc (100 mL). The EtOAc fraction was dried using the 
rotary evaporation, and analysed by HPLC-DAD-MS (Zorbax C8 analytical column, 150 × 4.6 mm, 
5 µm, 15 min eluting gradient with 1.0 mL/min 90% H2O/MeCN to MeCN with a constant 0.05% 
HCO2H/MeCN modifier), followed by 5 min hold, monitoring at 210 and 254 nm. The crude 
extracts were stored at −32 °C in 96-well microtiter plate for further investigation 
 
10.6.2 Fungi 
The fungal colony was inoculated from the cryo-preserved stock into agar-based media. After 5 − 
10 d, the agar plates were cut from the culture plates into 1.5 cm cubes. These cubes were used to 
inoculate the broth media. Cultivation conditions and media used were identical to those used for 
actinomycetes. The crude extracts were stored at −32 °C in 96-well microtiter plate for further 
investigation. 
10.7 Biological assays 
The crude extract from either actinomycetes or fungi were screened for their antibacterial activity 
against the Gram negative Escherichia coli (ATCC 11775) and Pseudomonas aeruginosa (ATCC 
10145), and the Gram positive bacteria Staphylococcus aureus (ATCC 25923 and ATCC 9144) and 
Bacillus subtilis (ATCC 6051 and ATCC 6633) and the fungi Candida albicans (ATCC 10231), 
Chapter 10. Microbial Community isolation and analysis 
402 
 
Candida parapsilosis (ATCC 22019) and Candida krusei (ATCC 6258); Cytotoxicity was 
measured against different cancer cell lines including human gastric cancer cell line (AGS), human 
colon cancer cell line (HT29), Hela cancer cell line and human neuroblastoma cancer cell line (SH-
SY5Y). The microbial crude extracts were prioritized depending on their biological activity. 
10.8 Isolation of secondary metabolites 
Isolates were prioritized based on chemical profiling and the biological activity. High priority 
isolates were cultivated on a large scale (400 mL × 6) to facilitate isolation and structural 
elucidation of secondary metabolites. 
 
10.8.1 Cultivation of actinomycetes on large scale-broth based media 
An aliquot (5 mL) from a seed culture was used to inoculate six 2 L Erlenmeyer flasks containing 
350 − 400 mL of water − based media, and the resulting culture was shaken at 190 rpm for 7 – 10 d. 
After the cultivation period, the culture was extracted with EtOAc (400 mL × 3) and the EtOAc 
fraction dried using rotary evaporation. The resulting EtOAc soluble residue was sequentially 
triturated into hexane, CH2Cl2 and MeOH fractions (8 mL each), and prioritized for futher chemical 
fractionation on the basis of HPLC-DAD-MS and NMR data.  
 
10.8.2 Cultivation of actinomycetes on large scale-agar based media 
As some of the actinomycetes do not produce secondary metabolites when grown in liquid media, 
they were cultured on agar−based media in large petri dishes (145 × 20 mm) for 7 − 10 d at 26.5 °C. 
After the cultivation period, the agar media was sliced into 1.5 cm3 cubes, extracted with EtOAc 
(400 mL × 2), dried by rotary evaporation. The resulting crude extracts from EtOAc fraction were 
dried using the rotary evaporation and sequentially triturated into hexane, CH2Cl2 and MeOH 
fractions (8 mL each). Fractions were prioritized for further chemical fractionation based on HPLC-
DAD-MS and NMR analysis. 
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11   Chapter 11. List of Publications during Candidature 
 
During my PhD studies and as a member of microbial biodiscovery team, I screened pure 
compounds and crude extracts (marine or microbial) from Capon group members against different 
G-ve and G+ve bacteria and fungi as a drug discovery paradigm. The outcomes of these screening 
assays are outlined in the publications listed in the preliminary pages. 
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12   General Experimental Details 
12.1 Chiroptical measurements  
Chiroptical measurements ([α]D) were obtained on a JASCO P-1010 intelligent remote module type 
polarimeter, in a 100 × 2 mm cell, at 22 °C, unless otherwise specified. Optical rotations were 
recorded at the sodium D line (589 nm) with values reported in degL/gdm, and concentrations in 
g/100 mL. 
 
12.2 High Performance Liquid Chromatography (HPLC) 
HPLC was performed using an Agilent 1100 Series separations module equipped with Agilent 1100 
Series diode array and/or multiple wavelength detectors and Agilent 1100 Series fraction collector, 
controlled using ChemStation Rev.9.03A and Purify version A.1.2 software. 
12.3 Ultraviolet-visble  
Ultraviolet-visble (UV-vis) absorption spectra were obtained using a Varian CARY 50 UV-visible 
spectrophotometer with 1 cm quartz cells. 
12.4 NMR  
1D and 2D NMR spectra were acquired on the following systems: Bruker Avance DRX600 
spectrometer with SEI 1H/13C/Z-GRD 5 mm probe and 900 MHz Bruker Avance III with a TCI 
1H/13C/15N/Z-GRD cryoprobe, in the solvents indicated and referenced to residual signals in 
deuterated solvents. 
12.5 Electrospray ionization mass spectra  
Electrospray ionization mass spectra (ESIMS) were acquired using Agilent 1100 Series separations 
module equipped with an Agilent 1100 Series LC/MS single quadrupole mass detector in both 
positive and negative ion modes under the following conditions (Zorbax C8 column, 150 × 406 mm, 
eluting with 1.0 mL/min 90% H2O/MeCN to MeCN (with isocartic 0.05% HCO2H modifier) over 
15 min, then held for 5 min with detection at 210 and 254 nm). 
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12.6 High-resolution mass spectra 
High-resolution ESIMS measurements were obtained on a Bruker micrOTOF mass spectrometer by 
direct infusion in MeCN at 3 µL/min using sodium formate clusters as an internal calibrant. 
12.7 Antibacterial assay:  
The bacterium to be tested was streaked onto a tryptic soy agar plate and was incubated at 37 °C for 
24 h. One colony was then transferred to fresh tryptic soy broth (15 mL) and the cell density was 
adjusted to 104 – 105 cfu/mL. The compounds to be tested were dissolved in DMSO and diluted 
with H2O to give 300 µM stock solutions (10% DMSO). The stock solutions were then serially 
diluted with 10% DMSO to give final concentrations of 30 µM to 0.01 µM in 1% DMSO. An 
aliquot (20 µL) of each dilution was transferred to a 96-well microtiter plate and freshly prepared 
microbial broth (180 µL) was added to each well. The plates were incubated at 37 °C for 24 h and 
the optical density of each well was measured spectrophotometrically at 600 nm using POLARstar 
Omega plate (BMG LABTECH, Offenburg, Germany). Each test compound was screened against 
the Gram-negative bacteria Escherichia coli (ATCC 11775) and Pseudomonas aeruginosa (ATCC 
10145) and the Gram-positive bacteria Staphylococcus aureus (ATCC 9144 and ATCC 25923) and 
Bacillus subtilis (ATCC 6633 and ATCC 6051). The IC50 value was calculated as the concentration 
of the compound or anticancer drug required for 50% inhibition of the cancer cells using Prism 5.0 
from GraphPad Software Inc. (La Jolla, CA). 
12.8 Antifungal assay 
The fungus to be tested was streaked onto a Sabouraud agar plate and was incubated at 26.5 °C for 
48 h. One colony was then transferred to fresh Sabouraud broth (15 mL) and the cell density was 
adjusted to 104˗105 cfu/mL. Test compounds were dissolved in DMSO and diluted with H2O to give 
a 300 µM stock solution (10% DMSO). The stock solution was then serially diluted with 10% 
DMSO to give final concentrations of 30 µM to 0.01 µM in 1% DMSO. An aliquot (20 µL) of each 
dilution was transferred to a 96-well microtiter plate and freshly prepared microbial broth (180 µL) 
was added to each well. The plates were incubated at 26.5 °C for 48 h and the optical density of 
each well was measured spectrophotometrically at 600 nm using POLARstar Omega plate (BMG 
LABTECH, Offenburg, Germany). Each test compound was screened against the fungus Candida 
albicans (ATCC 90028). The IC50 value was calculated as the concentration of the compound or 
anticancer drug required for 50% inhibition of the cancer cells using Prism 5.0 from GraphPad 
Software Inc. (La Jolla, CA). 
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12.9 Cytotoxicity assay 
The cytotoxicity MTT assay was used to evaluate the cytotoxicity of compounds against cancer 
cell. This assay was modified slightly from that previously described.209 Briefly, cells (2,000/well in 
180 µL of RPMI 1640 supplemented with 10% FBS for SW620 and NCIH-460 or DMEM 
supplemented with 10% FBS for both AGS and HT-29 cells 3,000/well in 180 µL of DMEM 
supplemented with 10% FBS) were seeded evenly in a 96-well micro-plate, and the plate was 
incubated for 18 hours (37 °C; 5% CO2) to allow cells to attach. Compounds to be tested were 
dissolved in 5% DMSO (v/v) and diluted from 300 µM-100 nM. Aliquots (20 µL) of each dilution 
(or of 5% aqueous DMSO for control wells) were added to the plate in duplicate. After 68 hours of 
incubation (37 °C; 5% CO2), a solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma Chemical CO., St Louis, Mo, USA) in PBS was added to each well to a final 
concentration of 0.4 mg/mL and the plate was incubated for a further 4 hours (37 °C; 5% CO2). 
After that, medium was carefully aspirated and precipitated formazan crystals were dissolved in 
DMSO (100 µL/well). Finally, the absorbance of each well at 570 nm was measured with a 
PowerWave XS Microplate Reader from Bio-Tek Instruments Inc. (Vinooski, VT). The IC50 value 
was calculated as the concentration of the compound required for 50% inhibition of the cancer cells 
using Prism 5.0 from GraphPad Software Inc. (La Jolla, CA). 
 
12.10 Chemicals 
Chemicals were purchased from Merck, Sigma, Aldrich or Fluka. Solvents used for purification by 
HPLC were HPLC grade, and were filtered through an Alltech 0.45 µm polytetrafluoroethylene 
(PTFE) filter before use. Water for HPLC was filtered through a Millipore filtration system. 
Analytical grade solvents were used for solvent extractions. Substructure, and all other literature 
searches were carried out using Antibase 2002 and Scifinder. 
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14  Appendix 
Taxonomic identifucation of Aspergillus sp. (CMB-M0423) 
DNA extraction was performed using cetyltrimethylammonium bromide (CTAB) protocol.260 
Mycelia of the fungus cultivated on M1 broth (approximately 200 – 500 mg) were frozen with 
liquid N2 and ground to a fine paste in a morter and pestle in 500 µL CTAB buffer. The 
CTAB/mycelia mixture was incubated for 15 min at 55 °C in a recirculating water bath. The 
mixture was centrifuged for 5 min at 12000 g and the supernatant was transferred to a clean 
microcentrifuge tube. An aliquot (1 mL) of phenol:chloroform:isoamyl alcohol (25:24:1) was 
added, the tube was centrifuged at 12000 g for 1 min and the upper aqueous layer was transferred to 
clean microcentrifuge tube. To the tube, ammonium acetate (7.5 M, 150 µL) was added followed by 
ice cold absolute ethanol (1 mL) and the tube was incubated at –20 °C for 1 h. The tube was 
centrifuged at 13000 g for 30 min, the supernatant was removed and the DNA pellet was washed 
twice with ice cold 70% ethanol. Finally, the DNA was resuspended in distilled water (70 µL). 
Amplification and sequencing of fungal DNA:  
The 18S RNA genes were amplified from genomic DNA by PCR using primers ITS 1 (5′-
TCCGTAGGTGAACCTGCGG-3′) and ITS 4 (5′-TCCTCCGCTTATTGATATGC-3′) 
purchased from Sigma˗aldrich.261 
PCR was performed on 1 µL (1 to 5 ng) of template DNA in a total reaction volume of 50 µL 
consisting of 10 mM Tris-HCl (pH 8.3) (5 µL), 50 mM MgCl2 (1.5 µL), 10 µM 
deoxyribonucleoside triphosphates (2 µL), 10 µM ITS 1 primer (1.6 µL), 10 µM ITS 4 primer (1.6 
µL) Taq DNA polymerase (1.25 U) (0.5 µL) and water (36.8 µL). PCR was carried out under the 
following conditions: initial denaturation, 95 °C, 3 min; 35 cycles of denaturation (94 °C, 30 s), 
annealing (55.9 °C, 30 s), and extension (72 °C, 30 s); and final extension, 72.5 °C, 5 min. A 
negative control was performed with each test run by replacing the template DNA with sterilized 
water in the PCR mixture. PCR products were purified with PCR purification kit (Qiagen, Victoria, 
Australia). Amplification products were examined by agarose gel electrophoresis. The 18S rRNA 
gene sequence showed 98% homology with other members of the genus Aspergillus by the BLAST 
database. 
 ITS4 sequence 
CGGGCTTCCTACCTGATCCGAGGTCACCTGGAAAAACAAGTTGCAAAAAAATTGCGTCGGCAGGCG
CCGGCCGGGCCTACGGAGCGGAAGACGAAGCCCCATACGCTCGAGGACCGGACGCGGTGCCGCCGC
TGCCTTTCGGGCCCGTCCCCCGGGAGCCGGGGGACGAGGGCCCAACACACAAGCCGGGCTTGAGGG
CAGCAATGACGCTCGGACAGGCATGCCCCCCGGAATACCAGGGGGCGCAATGTGCGTTCAAAGACT
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CGATGATTCACTGAATTCTGCAATTCACATTAGTTATCGCATTTCGCTGCGTTCTTCATCGATGCC
GGAACCAAGAGATCCATTGTTGAAAGTTTTAACTGATTGCAAAGAATCACACTCAGACTGCAAGCT
TTCAGAACAGGGTTCATGTTGGGGTCTCCGGCGGGCACGGGCCCGGGGGCGAGTCGCCCCCCGGCG
GCCAGCAACGCTGGCGGGCCCGCCGAAGCAACAAGGTACAATAGTCACGGGTGGGAGGTTGGGCCA
TAAAGACCCGCACTCGGTAATGATCCTTCCGCAGGTTCACCCTACGGAAG 
 
ITS1 sequence 
GGGGTTTGAATGGGGGTCTTTATGGCCACCTCCCCCCGTGACTATTGTACCTTGTTGCTTCGGCGG
GCCCGCCACCCTAGCTAGGCGCCGGGGGGCGACTCGCCCCCGGGGCCGTGCCCGCTGGAAACAAAA
CATGAACCTAGATCTGAATGCTTGCAAACTGAAAAGATTCTTTACAATCAGTTAAAACTTTCT 
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Taxonomic fungal DNA of CMB-M81F 
18S rRNA Gene Sequence 
TGGCTTCCTTGCGATTCTCGCCGATCTTCCTTCCTTGCGTTACTAAGATCTACCGACTTAATTCAT
CCAGGCGACCGGCTAAATGTTGTGGGACGAAGAGGGTAAGTTGTTTTTGTTGCCCTAATTTTTACT
ATGATATGACACTTATTTCGCGATTCATGTTCTTTTTTCTCCTGTATAAACTTGTGATTGTCGGTT
GCATGTGGACTTTTCCATTGAGGGGACTTGTGGTCTTCCTCCCCCGGTGAATGGCGTGAGTAGCTT
GCGTTCTCATATTCCCCTTCTTCATCGTCAACTCCTGCCCCCTCAACCCCAATTTCTCCACTCCCA
GAGCCTTATTGACATGATTTTACGTTTAATTCGCCCGTTTGTTGAACAACGTAACAAAAAAAACGA
TGTTCTATTGCAGGAGATTTGTAAGCGCTACTGTTTTCGCATTATTCCCGAGAAATTTTCCGAAAT
ACAGGAGAATGACATCGGATTTTACTAAGTGGGTTCGTAAATGAAGGAGTTTAAGGAATATCCTCC
GCCATAGATCGTTAAGCCTG 
 
Blast Search 
 
 
Taxonomic fungal DNA of CMB-TF438 
18S rRNA Gene Sequence 
GAAATCGGTTCGTCAGTCCGACTTTACATCATTTGAGAAGCGGTGAGATCGGAAGTTCTATCTTCT
ATAGGGGGGAGGTAGAGGGCGAGGATGCCGGAAGTCAACAAGGTTCACCCATCGAATTGGAATTTC
GGGATAAGACTCATACTGAAACTTCATGATCCTTTTATGTGGGCCCCTAGCGAACGCGGGGCCCGC
GTGTGTATATACCGTCGGGCAACACGGGTGGGAGGTTGGGCCCCGAGGGGCCCGCACTCGGTAATG
ATCCTTCCGCACGTTCACCTATGGAAGTTCTCGAAAGAGAGGGGGCCCCTCGGGGCCTCTCCATCA
ACATGTGCTCTTGAATTACGTTTATCGACCTAATACCTTCTGTTCACTCTTATTAAAGCTCGCACT
TTACACTTTGTCATAGGCCCTTTCCTCTTTCCTCCCATGGTACTCAAAATCTTCAAAGATTCTATT
TTTGATTTTCTTTTTTTTTTATATGTTAAGCTATAATGCATTTATAAATTTTCTCCTACTTCAATT
TTAGTCCAATCA 
Blast Search 
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